Conditions: Highly Drug-resistant Focal Epilepsy
Keywords: UCB0942 Treatment-resistant focal epilepsy Partial seizures Seizure therapy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 55
Healthy volunteers: no

Brief summary:
This study is to assess the efficacy, safety, and tolerability of the investigational drug UCB0942in adult subjects with drug-resistant focal epilepsy across multiple centers in Europe.

Detailed description:
The study will include a Screening Visit, a Prospective Outpatient Baseline Period (2 to 3 weeks), an Inpatient Period (3 weeks), an Outpatient Period (8 weeks of treatment and 2 weeks of taper), and a Safety Follow-Up Period (4 weeks). The total study duration after screening will be 19 to 20 weeks. Approximately 6 months after the last visit subjects will be asked to return for an additional visit.

Arms:
arm 1: UCB0942/UCB0942 arm 2: Placebo/UCB0942 (after 2-week inpatient period, placebo subjects will receive the experimental medicine, UCB0942).

Interventions: intervention 1: UCB0942 intervention 2: UCB0942 intervention 3: Placebo
Intervention descriptions: intervention 1: Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 200 mg Route of Administration: Oral use intervention 2: Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 100 mg Route of Administration: Oral use intervention 3: Pharmaceutical form: Film-coated tablet Route of administration: Oral use

Protocol document:
Prot_000.pdf: 
UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 1 of 125
PROTOCOL EP0069 AMENDMENT 4.0
A DOUBLE-BLIND, RANDOMIZED, 
PLACEBO-CONTROLLED STUDY OF THE EFFICACY, 
SAFETY/TOLERABILITY, AND PHARMACOKINETIC 
PROFILE OF UCB0942 IN ADULT PATIENTS WITH HIGHLY 
DRUG-RESISTANT FOCAL EPILEPSY
PHASE 2A
EudraCT Number: 2014-003330-12
Sponsor:
UCB Biopharma SPRL
Allée de la Recherche 60
B-1070 Brussels
BELGIUM
Protocol/Amendment number
Date
Type of 
amendment
Final Protocol
18 Mar 2015
Not applicable
Protocol Amendment 0.1 (
27 Jul 2015
Nonsubstantial
Protocol Amendment 1.0
16 Sep 2015
Substantial
Protocol Amendment 2.0
19 Nov 2015
Substantial
Protocol Amendment 3.0
13 May 2016
Substantial
Protocol Amendment 4.0
10 Oct 2016
Nonsubstantial
Confidential Material
Confidential
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.
REDACTED 
mber
mber
DA
COPY
ssels
ssel
GIUM
GIUM
This document cannot be 
o
be used 
me
me
l Am
l Am
ed to 
end
end
o support
nt 1.0
nt 1.
dment
dment
pp
s
any
1 (
1 (
0
any marketing 
r
ke
m
authorization 
M
ut
ut
ut
ut
application and any extensions or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 2 of 125
STUDY CONTACT INFORMATION
Sponsor
UCB Biopharma SPRL
Allée de la Recherche 60
B-1070 Brussels
BELGIUM
Coordinating Investigator
Name:
Prof. 
Affiliation:
Address:
Phone:
Coordinating Investigator 
Name:
Prof. Dr. 
Affiliation:
Address:
Phone:
Early Development Lead/New Medicines Therapeutic Area Specialist
Name:
, MD
Address:
UCB Biopharma SPRL
Chemin du Foriest
B-1420 Braine-l'Alleud
BELGIUM
Phone:
Sponsor Study Physician
Name:
, MD
Address:
UCB Biopharma SPRL
Chemin du Foriest
B-1420 Braine-l'Alleud
BELGIUM
Phone:
RED
R
ACTED 
EDAC
R
COPY 
OP
OPY
This document
Spo
Spo
cannot
Phon
Phon
t
n
be 
b
used to supp
UC
U
supp
pp
su
t
port any
d/N
d/N
a
mark
ar
Ne
N
eting 
ting
rketin
authorization 
at
application 
n
lic
a
and 
d any extensions s
sio
or 
o variations 
v
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 3 of 125
Exploratory Project Manager
Name:
Address:
UCB Biopharma SPRL
Chemin du Foriest
B-1420 Braine-l'Alleud
BELGIUM
Phone:
Clinical Trial Biostatistician
Name:
Address:
UCB BIOSCIENCES Inc.
8010 Arco Corporate Drive
Raleigh, NC  27617
UNITED STATES
Phone:
Clinical Monitoring Contract Research Organization
Name:
PRA Health Sciences
Address:
Phone:
Fax:
REDACTED 
ED
ED
RED CTED
DACT
COPY
Org
Org
OP
This document cannot be used to support any marketing 
tin
ar
tin
arketi
authorization 
at
au horiza
application 
ati
anizat
niza
a
and 
a
any extensions s
sio
or 
o variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 4 of 125
SERIOUS ADVERSE EVENT REPORTING
Serious adverse event reporting (24h)
Fax
Europe and Rest of the World: +32 2 386 24 21
Email
Global: DSICT@ucb.com (for interventional clinical studies)
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 5 of 125
TABLE OF CONTENTS
LIST OF ABBREVIATIONS..................................................................................................10
1
SUMMARY.....................................................................................................................13
2
INTRODUCTION ...........................................................................................................14
2.1
General background...............................................................................................14
2.2
Phase 1 experience.................................................................................................16
2.2.1
Adverse event profile...................................................................................16
2.2.2
Psychiatric adverse events ...........................................................................16
2.2.3
Drug-drug interactions.................................................................................17
2.3
Rationale for this study..........................................................................................17
3
STUDY OBJECTIVES....................................................................................................17
3.1
Primary objective...................................................................................................17
3.2
Secondary objectives .............................................................................................17
3.3
Exploratory objectives ...........................................................................................17
4
STUDY VARIABLES.....................................................................................................18
4.1
Efficacy variables...................................................................................................18
4.1.1
Primary efficacy variable.............................................................................18
4.1.2
Secondary efficacy variables .......................................................................18
4.1.3
Exploratory efficacy variables.....................................................................18
4.2
Pharmacokinetic variables .....................................................................................18
4.3
Exploratory variables.............................................................................................19
4.4
Safety variables......................................................................................................20
5
STUDY DESIGN.............................................................................................................21
5.1
Study description ...................................................................................................21
5.1.1
Study duration per subject ...........................................................................23
5.1.2
Planned number of subjects and sites ..........................................................23
5.1.3
Anticipated regions and countries................................................................23
5.2
Schedule of study assessments...............................................................................24
5.3
Schematic diagram.................................................................................................34
5.4
Rationale for study design and selection of dose...................................................34
6
SELECTION AND WITHDRAWAL OF SUBJECTS...................................................35
6.1
Inclusion criteria ....................................................................................................35
6.2
Exclusion criteria ...................................................................................................36
6.3
Withdrawal criteria ................................................................................................38
6.3.1
Potential drug-induced liver injury IMP discontinuation criteria................40
7
STUDY TREATMENTS.................................................................................................41
7.1
Description of investigational medicinal products ................................................41
7.2
Treatments to be administered...............................................................................41
7.2.1
Test study medication..................................................................................41
7.2.2
Reference product........................................................................................41
7.3
Packaging...............................................................................................................41
REDACTED
........
......
........
.....
......
......
.
COPY 
......
.....
s......
s.....
This document
6
cannot 
6.2
6.2
be
ECT
CT
used 
ma
ma
ationa
iona
IO
IO
o
atic
atic
support 
u
pated 
pated
of stu
of stu
d
any 
n n 
mber
mber
marketing 
.......
....
........
....
per s
per
authorization
.......
.....
........
........
........
.......
.......
application 
.......
......
......
..... .
.......
.....
and 
.........
any 
......
....
extensions 
..
......
.....
.....
.....
......
.....
or
.....
....
variations 
.16
.16
......1
.....
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 6 of 125
7.4
Labeling .................................................................................................................42
7.5
Handling and storage requirements .......................................................................42
7.6
Drug accountability................................................................................................42
7.7
Procedures for monitoring subject compliance......................................................43
7.8
Concomitant medications/treatments.....................................................................43
7.8.1
Permitted concomitant treatments (medications and therapies) ..................43
7.8.2
Prohibited concomitant treatments (medications and therapies) .................43
7.8.3
Rescue medication.......................................................................................43
7.9
Blinding..................................................................................................................44
7.9.1
Procedures for maintaining and breaking the treatment blind.....................44
7.9.1.1
Maintenance of study treatment blind................................................44
7.9.1.2
Breaking the treatment blind in an emergency situation....................44
7.9.1.3
Breaking the treatment blind for taper of dose during the study .......44
7.10
Randomization and numbering of subjects............................................................44
8
STUDY PROCEDURES BY VISIT ...............................................................................45
8.1
Screening and Baseline Period...............................................................................45
8.1.1
Screening (Visit 1, Day -1)..........................................................................45
8.1.2
Baseline Period (Visit 2, Day BL1 to BL14-21) .........................................46
8.2
Inpatient Period (3 weeks) .....................................................................................46
8.2.1
Titration Week (Visit 3, Day T1 to Day T7) ...............................................46
8.2.2
Maintenance-Dose Week (Visit 4, Day MD1 to Day MD7) .......................47
8.2.3
Transition-to-Outpatient Week (Visit 5, Day TTO1 to Day TTO7)............48
8.3
Outpatient Period (14 weeks).................................................................................49
8.3.1
Outpatient Maintenance Period (Visit 6 to Visit 15, Day OP1 to Day 
OP57)...........................................................................................................49
8.3.2
Taper Period (Visit 15 to Visit 17, Day OP57 to TOO14) ..........................51
8.3.3
Safety Follow-Up (Visit 18 to 20, Day SFU7, SFU14, and SFU28)...........52
8.3.4
Echocardiography follow up........................................................................52
8.4
Withdrawal Visit....................................................................................................52
8.5
Unscheduled Visit..................................................................................................53
8.6
Open-label extension study (EP0073) ...................................................................53
9
ASSESSMENT OF EFFICACY......................................................................................53
9.1
Seizure frequency...................................................................................................53
9.1.1
Video monitoring.........................................................................................54
9.2
Seizure Severity Questionnaire..............................................................................54
9.3
Quality of Life Inventory in Epilepsy-31-P...........................................................54
9.4
Diary Addendum....................................................................................................55
10
ASSESSMENT OF PK AND EXPLORATORY VARIABLES ....................................55
10.1
Pharmacokinetic parameters..................................................................................55
10.2
Exploratory parameters..........................................................................................55
10.3
Sampling procedures..............................................................................................56
REDACTED
ay
ay T
y
ek (V
ek (V
atient 
atient 
weeks
weeks
COPY 
1 to
 t
......
.....
T1
T1
This document cannot 
SE
SE
.1
be 
Op
ESS
ESS
used
ched
ched
pen
pen
to 
aw
d
support 
ollo
ollo
ocardio
cardi
wal V
al V
any
d (V
d (V
ow
ow
marketing 
ks)s).....
.....
enance
nance
........
....
isi
authorization 
.......
1 to D
to D
Visit 4
sit 4
Week
Wee
application 
.....
....
.........
.......
L14
L14-2
.
and 
......
....
any
............
extensions
........
......
n......
......
ng th
ng th
or
.....
....
variations 
43
43
.....44
...44
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 7 of 125
10.4
Bioanalytical methods............................................................................................56
10.5
Pharmacokinetic/pharmacodynamic relationships.................................................56
11
ASSESSMENT OF SAFETY..........................................................................................56
11.1
Adverse events.......................................................................................................56
11.1.1
Definition of adverse event..........................................................................56
11.1.2
Procedures for reporting and recording adverse events...............................57
11.1.3
Description of adverse events......................................................................57
11.1.4
Follow up of adverse events ........................................................................57
11.1.5
Rule for repetition of an adverse event........................................................57
11.1.6
Pregnancy.....................................................................................................57
11.1.7
Overdose of investigational medicinal product ...........................................58
11.1.8
Safety signal detection.................................................................................58
11.1.9
Safety Review Group...................................................................................59
11.2
Serious adverse events...........................................................................................59
11.2.1
Definition of serious adverse event .............................................................59
11.2.2
Procedures for reporting serious adverse events..........................................60
11.2.3
Follow up of serious adverse events............................................................61
11.3
Adverse events of special interest..........................................................................61
11.4
Immediate reporting of adverse events..................................................................61
11.5
Anticipated serious adverse events........................................................................61
11.6
Laboratory measurements......................................................................................62
11.6.1
Evaluation of PDILI.....................................................................................62
11.6.1.1
Consultation with the Medical Monitor and local hepatologist.........66
11.6.1.2
Immediate action: determination of IMP discontinuation .................66
11.6.1.3
Testing: identification/exclusion of alternative etiology ...................66
11.6.1.4
Follow-up evaluation .........................................................................68
11.7
Other safety measurements....................................................................................68
11.7.1
Vital signs ....................................................................................................68
11.7.2
Electrocardiograms ......................................................................................68
11.7.3
Echocardiograms .........................................................................................69
11.7.4
Physical examination...................................................................................69
11.7.5
Assessment of suicidality.............................................................................69
11.7.6
Psychiatric and cognitive assessments.........................................................70
11.7.7
Withdrawal monitoring................................................................................70
12
STUDY MANAGEMENT AND ADMINISTRATION.................................................70
12.1
Adherence to protocol............................................................................................70
12.2
Monitoring .............................................................................................................70
12.2.1
Definition of source data..............................................................................70
12.2.2
Source data verification ...............................................................................71
12.3
Data handling.........................................................................................................71
12.3.1
Case Report form completion......................................................................71
REDACTED
nts
nts....
......
.....
I.....
.....
on wi
on wi
COPY
......
....
nts
nts....
This document 
12
12
cannot
11.7
1.7
11
11
be 
7.4.4
7 5
7
used
Ec
E
4
to
Elec
Elec
support
measu
eas
al signs
l sign
ctro
ctr
any
w-up
up
ur
marketing
with th
ith th
action:
ction
identi
ident
authorization 
.......
......
....
......
.....
......
....
h
application
ts....
s...
.......
....
..........
........
.
and 
......
....
any
.....
... ...
extensions
.....
... .....
...........
......
....
or
....
....
variations 
57
57
.....57
...57
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 8 of 125
12.3.2
Database entry and reconciliation................................................................71
12.3.3
Database lock...............................................................................................71
12.3.4
Subject Screening and Enrollment log/Subject Identification Code list......72
12.4
Termination of the study........................................................................................72
12.5
Archiving and data retention..................................................................................72
12.6
Audit and inspection ..............................................................................................72
12.7
Good Clinical Practice...........................................................................................73
13
STATISTICS ...................................................................................................................73
13.1
Definition of analysis sets......................................................................................73
13.2
General statistical considerations...........................................................................74
13.3
Planned efficacy analyses ......................................................................................74
13.3.1
Analysis of the primary efficacy variable....................................................74
13.3.2
Secondary efficacy analyses ........................................................................74
13.3.3
Exploratory efficacy analyses......................................................................75
13.4
Planned safety and population PK analyses...........................................................75
13.4.1
Safety analyses.............................................................................................75
13.4.2
PK analyses..................................................................................................76
13.4.2.1
Non-compartmental PK analysis .......................................................76
13.4.2.2
Population PK analysis ......................................................................76
13.4.2.3
Population PK-PD analysis................................................................76
13.5
Handling of protocol deviations.............................................................................77
13.6
Handling of dropouts or missing data....................................................................77
13.7
Planned interim analyses and data monitoring ......................................................77
13.8
Determination of sample size.................................................................................78
14
ETHICS AND REGULATORY REQUIREMENTS......................................................78
14.1
Informed consent ...................................................................................................78
14.2
Subject identification cards....................................................................................79
14.3
Subject compensation ............................................................................................79
14.4
Independent Ethics Committees ............................................................................79
14.5
Subject privacy.......................................................................................................80
14.6
Protocol amendments.............................................................................................80
15
FINANCE, INSURANCE, AND PUBLICATION.........................................................80
16
REFERENCES ................................................................................................................81
17
APPENDICES .................................................................................................................82
17.1
Protocol Amendment 1.0 .......................................................................................82
17.2
Protocol Amendment 2.0 .......................................................................................91
17.3
Protocol Amendment 3.0 .......................................................................................94
17.4
Protocol Amendment 4.0 .....................................................................................118
18
DECLARATION AND SIGNATURE OF INVESTIGATOR .....................................122
19
DECLARATION AND SIGNATURE OF COORDINATING INVESTIGATOR 
(
).................................................................................................................123
analy
naly
ons.....
ns.....
missin
missin
es an
es an
COPY 
alalys
ys
......
.....
ysi
This document 
17
cannot
NAN
NAN
REF
REF
A
be 
Pro
Pr
N
used
bject 
ject 
rototo
to
nde
nde
support
ificati
ficat
ompens
mpen
ent
ent
any 
......
......
ioi
marketing
nd dat
nd da
e size
size
OR
ORY R
Y
authorization 
.......
sis......
.........
.......
ng data
g dat
application 
.....
....
.......
....
.......
...
.
and 
......
....
any 
......
.....
extensions
........
......
........
......
......
....
or
.....
....
variations 
73
73
.....73
...73
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 9 of 125
20
DECLARATION AND SIGNATURE OF COORDINATING INVESTIGATOR......124
21
SPONSOR DECLARATION ........................................................................................125
LIST OF TABLES
Table 5‒1: Dose titration to UCB0942 400mg bid.................................................................22
Table 5‒2: Taper from UCB0942 400mg bid to UCB0942 200mg bid .................................22
Table 5‒3: Dose taper from UCB0942 400mg bid.................................................................23
Table 5-4: Schedule of study assessments .............................................................................25
Table 5‒5: Schedule of study assessments, Inpatient Period..................................................31
Table 7‒1: Description of investigational medicinal product.................................................41
Table 11‒1:
Anticipated SAEs for the epilepsy population.............................................61
Table 11‒2:
Laboratory measurements............................................................................62
Table 11‒3:
Required investigations and follow up for PDILI .......................................64
Table 11‒4:
PDILI laboratory measurements..................................................................67
Table 11‒5:
PDILI information to be collected...............................................................68
LIST OF FIGURES
Figure 5‒1: Study design..........................................................................................................34
REDACTED
F F
F F
......
...
COPY 
FIG
FIG
This document cannot be used to support any marketing authorization 
GUR
GUR
......
....
application 
.......
......
.......
.....
and 
......
....
any 
......
.....
extensions 
.....
........
......
......
.....
or 
....
variations 
23
23
......2
....2
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 10 of 125
LIST OF ABBREVIATIONS
50%RR
50% responder rate
75%RR
75% responder rate
AE
adverse event
AED
antiepileptic drug
ALP
alkaline phosphatase
ALT
alanine aminotransferase
ANCOVA
analysis of covariance
ANOVA
analysis of variance
AST
aspartate aminotransferase
BMI
body mass index
BP
blood pressure
BPRS
Brief Psychiatric Rating Scale
BRV
brivaracetam
BUN
blood urea nitrogen
cBZR
benzodiazepine-binding site
CDMS
clinical data management system
CI
confidence interval
CIWA-B
Clinical Institute Withdrawal Assessment-Benzodiazepines
CNS
central nervous system
CPMP
Committee for Proprietary Medicinal Products
CRO
contract research organization
C-SSRS
Columbia-Suicide Severity Rating Scale
CT
computed tomography
CV
coefficient of variation
CYP
cytochrome P450
DAP
data analysis plan
DNA
deoxyribonucleic acid
DS
Drug Safety
ECG
electrocardiogram
eCRF
electronic Case Report form
EEG
electroencephalogram
EPM
Exploratory Project Manager
ES
Enrolled Set
REDACTED 
g
ement
emen
rval
val
titute 
titute 
COPY 
site
site
This document 
DS
DS
cannot 
NA
be used to support 
trara
Colum
Colum
co
co
any 
act re
ct re
marketing 
Wit
Wit
ous s
us sy
ee for
e fo
authorization 
nt sy
systst
thth
application and any extensions or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 11 of 125
EudraCT
European Union Drug Regulating Authorities Clinical Trials
FAS
Full Analysis Set
GABA-A
gamma-aminobutyric acid receptor type A
GCP
Good Clinical Practice
GMP
Good Manufacturing Practice
HBsAg
hepatitis B surface antigen
HCV-Ab
hepatitis C antibody
HIV-1/2Ab
human immunodeficiency virus-1/2 antibody
ICF
Informed Consent form
ICH
International Conference on Harmonisation
IEC
Independent Ethics Committee
ILAE
International League Against Epilepsy 
IMP
investigational medicinal product
IRT
interactive response technology
LEV
levetiracetam
MedDRA
Medical Dictionary for Regulatory Activities
MINI
Mini International Neuropsychiatric Interview
MMSE
mini-mental state examination
MRI
magnetic resonance imaging
mRNA
messenger ribonucleic acid
MTD
maximum tolerated dose
NCA
non-compartmental analysis
OLE
open-label extension
PDILI
potential drug-induced liver injury
PI
Principal Investigator
PK
pharmacokinetic(s)
PPS
Per-Protocol Set
QOLIE-31-P
Quality of Life Inventory in Epilepsy-31-P
QTcB
QT interval corrected for heart rate using Bazett’s formula
QTcF
QT interval corrected for heart rate using Fridericia’s formula
RS
Randomized Set
SAE
serious adverse event
SD
standard deviation
SFU
Safety Follow Up
SAP
Statistical Analysis Plan
europ
euro
exam
exam
onanc
onanc
bo
b
COPY 
egulat
egul
ps
This document
QTc
QTc
Q
cannot 
LIE
LIE-3
-3
B
be used to support
pen
en-lala
pote
pote
any
ompa
ompa
b
marketing 
ce 
onucle
nucle
tolera
toler
t
authorization 
ator
tor
sychia
chia
minati
minati
 ima
ima
application 
ory
ry A
y
and any extensions or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 12 of 125
SOP
Standard Operating Procedure
SRG
Safety Review Group
SS
Safety Set
SSQ
Seizure Severity Questionnaire
SV2
synaptic vesicle glycoprotein 2 (also known as SV2A)
ULN
upper limit of normal
VNS
vagus nerve stimulation
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 13 of 125
1
SUMMARY
UCB0942 is a new chemical entity with selective affinity for synaptic vesicle glycoprotein 2 
(SV2) and for the benzodiazepine-binding site (cBZR) on the gamma-aminobutyric acid 
receptor type A (GABA-A). UCB0942 has shown superior efficacy in several preclinical 
models of epilepsy.
EP0069 is a Phase 2A, double-blind, randomized, placebo-controlled, multicenter study that 
will test the potential efficacy, safety/tolerability, and pharmacokinetic (PK) profile of 
UCB0942 in adult subjects with highly drug-resistant focal epilepsy. Randomization will be 
in a 1:1 ratio. 
The primary objective of the study is to evaluate the efficacy of UCB0942 administered 
concomitantly with each subject’s current, stable antiepileptic drug (AED) regimen in 
subjects who have 4 or more focal seizures with or without secondary generalization per 
week and who have failed to achieve seizure control with ≥4 AED regimens of adequate dose 
and duration. In this protocol, unless otherwise specified, “focal seizures” refers to partial-
onset seizures of type IA1, IB, and IC, but does not include type IA2, IA3, or IA4 seizures.
The secondary objectives are to evaluate the safety and tolerability of UCB0942 and to 
evaluate the steady-state PK of UCB0942 and its metabolites.
This study consists of:
!
A 4-week prescreening Historical Baseline Period for study eligibility purposes
!
A Screening Visit followed by a 2- to 3-week postscreening Prospective Outpatient 
Baseline Period (Day BL1 to Day BL14-21)
!
A 3-week Inpatient Period which consists of:
∀
An Inpatient Titration Week (Day T1 to Day T7)
∀
An Inpatient Maintenance-Dose Week (Day MD1 to Day MD7)
∀
An Inpatient Transition-to-Outpatient Week (Day TTO1 to Day TTO7)
!
An open-label Outpatient Maintenance Period of 8 weeks (Day OP1 to Day OP57)
!
A Tapering Period of 2 weeks (Day TOO1 to Day TOO14)
!
A Safety Follow-Up (SFU) Period of 4 weeks (Day SFU1 to Day SFU28)
!
An echocardiogram during dosing and after the last dose (the SFU7 echocardiogram). 
The echocardiogram will be repeated at 6 months (±1 month) after the last dose in the 
following subjects:
∀
Subjects who complete this study but do not enter the OLE study
∀
Subjects who withdraw from the Outpatient Period 
∀
Subjects who withdraw from the Inpatient Period and have an abnormal SFU7 
echocardiogram
Titration to UCB0942 400mg bid will occur over the course of 1 week in the clinical unit. 
For subjects in the active arm, doses will be titrated to UCB0942 400mg bid during the first 
inpatient week. For subjects who initially received placebo, doses will be titrated to 
UCB0942 400mg bid during the last week of the Inpatient Period. Dose reductions will be 
allowed during titration and maintenance in the Inpatient Period, but this should be discussed 
wee
wee
14
14-21
-21
consi
cons
k (D
k (D
COPY 
eriod
eriod
ek
ek
This document cannot
lowin
owin
∀
be
choc
choc
used 
low
ow
cardio
ardio
to
ow-U
-U
support 
tient 
ent 
od of 2
d of 2
U
any 
n-
n-toto
M
marketing
Day
Day T
y
Dose 
Dose
-O
authorization 
f
posts
posts
1)
sts of
ts of
application 
for stu
or stu
and 
y of U
of U
any 
 r
IA3, o
A3, 
extensions 
en in
en in
ization
zation
s of a
of a
refe
refe
or 
red 
ed 
variations 
e
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 14 of 125
with the Sponsor Study Physician unless this is not possible due to the circumstances. 
Multiple adjustments (tapering or increase) of the dose are allowed during the Outpatient 
Maintenance Period (minimum 100mg bid and maximum 400mg bid); however, any change 
of dose in the Outpatient Maintenance Period should first be discussed with the Sponsor 
Study Physician.
The total duration for subject participation in the study will be up to 20 weeks, plus an
echocardiographic follow-up visit 6 months after the last dose of study medication. The total 
duration of exposure to UCB0942 is 13 weeks in EP0069. Subjects who experience 
substantial benefit from UCB0942 with acceptable tolerability according to the subject and 
Investigator, will have the opportunity to continue taking UCB0942 in an open-label 
extension (OLE) study. Each subject’s decision to enter the OLE study will be in 
consultation with their neurologist and taking into account the potential risks and benefits of 
continuing to take UCB0942 and the potential risks and benefits of other treatment options. 
Subjects who enter the OLE study will not have a Tapering Period at the end of the 
Outpatient Maintenance Period. The OLE study is described in a separate protocol (EP0073).
The primary efficacy measure is the 75% responder rate (75%RR, proportion of subjects who 
achieve ≥75% reduction in focal seizure frequency) during the Inpatient Period compared to 
the 2-week Prospective Outpatient Baseline Period.
Secondary efficacy variables include:
!
Median percent reduction in weekly focal seizure frequency from the Prospective
Outpatient Baseline Period to the Inpatient Period and the End of Treatment.
!
Seizure-free rate during the Inpatient Period, the last 4 weeks of the Outpatient
Maintenance Period, and at the End of Treatment.
!
The 75%RR during the last 4 weeks of the Outpatient Maintenance Period and at the End
of Treatment.
!
Percentage of seizure-free days during the Inpatient and Outpatient Periods.
The exploratory efficacy variables are detailed in Section 4.1.3.
Plasma concentrations of UCB0942, and its identified metabolites 
, will be determined from blood samples obtained in the study in order to 
investigate the PK of UCB0942 and its major metabolites.
Blood samples for deoxyribonucleic acid (DNA), messenger ribonucleic acid (mRNA), and 
lipidomics/proteomics/additional blood biomarkers will be collected during the study for 
exploratory biomarker studies.
The safety of participating subjects will be closely monitored. Assessment of specific 
domains of psychiatric and cognitive symptoms will be performed by a staff member trained 
in the identification of psychiatric symptoms.
Other safety variables are detailed in Section 4.4.
2
INTRODUCTION
2.1
General background
In Europe and North America there are 350,000 to 500,000 (3 to 4 million worldwide) 
patients with focal epilepsy who have not been able to achieve freedom from disabling 
seizures despite sequential and/or combination treatment with several of the available AEDs. 
Despite the introduction of 12 new AEDs over the last 2 decades, the proportion of patients 
REDACTED COPY
ure f
ure f
Period
Perio
eriod,
eriod
of Tre
of Tre
eeks o
eeks o
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
d
benefit
benef
ment op
ment o
d of the
of th
e proto
proto
oportio
portio
atient P
tient
requen
equen
od and t
d and 
, the la
the l
reatmen
eatme
of the O
of the
ys durin
dur
ables a
bles
f UCB0
UCB
ll be d
l be d
of UC
UCB
for 
for deo
de
proteom
oteo
ory
ry biom
bi
y
afet
afety o
y
omains 
main
in the
in th
O


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 15 of 125
with epilepsy who are unable to achieve complete control of their seizures has only decreased 
minimally, from 36% to 34% (Brodie et al, 2012), highlighting the large unmet medical need 
and the fact that recently-developed AEDs have not been able to meet this medical need. 
Patients with focal epilepsy who have failed to achieve seizure control with 2 or more AED 
regimens are defined as drug-resistant by the International League Against Epilepsy (ILAE; 
Kwan et al, 2010). It is important to highlight that there is a continuum of degrees of drug 
resistance within the patient population classified as drug-resistant according to ILAE 
criteria. When a patient with focal epilepsy has failed to achieve seizure freedom after the 
second AED regimen, he or she has less than 10% chance of achieving complete seizure 
control with subsequent AED regimens (Steinhoff, 2014; Beyenburg et al, 2012; Chung et al, 
2010; Schiller and Najjar, 2008; Mohanraj and Brodie, 2006). The likelihood of achieving 
complete seizure control diminishes as the number of failed AED regimens increases. Thus, 
when a patient with focal epilepsy has not been able to control their seizures despite 
treatment with 5 or more AED regimens, the likelihood of achieving complete seizure control 
with another AED regimen is 1-6% (Schiller and Najjar, 2008; Mohanraj and Brodie, 2006; 
UCB internal data on lacosamide and brivaracetam [BRV]). In addition, high-seizure 
frequency also correlates with reduced likelihood of achieving seizure freedom. For instance, 
patients who have failed 3 or 4 AED regimens but who have daily seizures have only a 2% 
chance of becoming seizure free with subsequent AEDs. In this study, to ensure that subjects 
who participate have a very low likelihood of benefiting from existing treatments, we will 
combine 2 criteria to identify the target population: failure to control seizures despite 
treatment with at least 4 AED regimens and having at least 4 seizures per week on average. 
This group of patients will be referred to as having “highly drug-resistant focal epilepsy.”
Resective surgery is an option for some patients with drug-resistant focal epilepsy. The ILAE 
recommends that patients be evaluated for surgery after failing to achieve seizure freedom 
with the second AED regimen; however, in most places patients are referred for surgery only 
after failing multiple AED regimens. Therefore, the patients who in practice are evaluated for 
and undergo surgery are similar to the highly drug-resistant population as defined above. Due 
to various factors (limited number of epilepsy surgery centers, inability to localize the seizure 
focus during work-up, contraindications to surgery, etc) fewer than 1% of patients with drug-
resistant focal epilepsy undergo epilepsy surgery. Therefore, the vast majority of patients 
with highly drug-resistant focal epilepsy have no treatment options (pharmacological or 
surgical) that can provide complete seizure control or even substantial reduction in the 
number of seizures.
UCB0942 has shown superior efficacy in several preclinical models of epilepsy. UCB0942 is 
superior to levetiracetam (LEV) and BRV in 10 animal models of focal and generalized
epilepsy, indicating that it has broad antiseizure effects. In the rat amygdala kindling model –
a model of drug-resistant focal epilepsy – UCB0942 is superior to 12 other AEDs tested thus 
far: LEV, BRV, phenytoin, phenobarbital, carbamazepine, lacosamide, valproate, retigabine, 
perampanel, clobazam, diazepam, clonazepam, and the combination of LEV or BRV with 
diazepam. In this model of drug-resistant focal epilepsy, UCB0942 was the only compound 
that produced complete seizure suppression in all animals at a plasma exposure equivalent to 
the plasma exposure achieved in humans taking UCB0942 400mg bid. Other AEDs produced
seizure suppression in this model, but only at plasma exposures that are unattainable in 
humans. Based on its superior preclinical efficacy profile, UCB0942 may show efficacy in 
patients with focal epilepsy who continue to suffer from frequent seizures despite having 
attempted to achieve seizure control with multiple AED regimens (patients with highly drug-
resistant focal epilepsy).
REDACTED COPY 
fail
fa
ving at
ving a
having
aving
patient
patien
d for s
d for s
wever,
wever
ns T
ns T
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
et al
et al,
eving
ving 
ses. Th
es. T
spite 
pite
te seiz
e sei
and Br
nd B
n, high
, high
ure free
e fre
y seizu
seiz
is stud
is stu
om exi
om ex
re to c
e to 
t least 
least
g “high
“hig
nts with
s wit
surgery
urger
, in mo
in m
Theref
There
the hig
the h
ber of e
er of
ainindica
di
ndergo 
dergo
ant foc
ant fo
rovide 
vide
es.
es.
s sho
show
o levet
o leve
sy, indi
, ind
odel of
del o
ar: LEV
r: LE
peram
per
did


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 16 of 125
If seizure freedom or a substantial reduction in seizure frequency could be achieved in these 
patients, their quality of life would dramatically improve, and this improvement is expected 
to outweigh the potential risks associated with the administration of UCB0942.
Preclinical experience with UCB0942 is described extensively in the Investigator’s Brochure.
2.2
Phase 1 experience
UCB0942 has completed Phase 1 development with a total of 145 subjects exposed to single 
doses up to UCB0942 490mg and multiple doses up to UCB0942 400mg bid for up to 
14 days, including 20 subjects with epilepsy at 400mg bid. There were no clinically
significant changes in laboratory tests or vital signs thought to be related to UCB0942 during 
Phase 1 development, although transient, minor reductions in systolic and diastolic blood 
pressure were seen (consistent with the known effects of benzodiazepine drugs). There were 
no clinically significant changes attributed to UCB0942 in 12-lead ECGs; however, 
4 subjects had treatment-emergent rhythm disturbances (atrial and ventricular ectopy). These 
were asymptomatic and were assessed by an external cardiologist expert in electrophysiology 
as unlikely to be related to UCB0942.
2.2.1
Adverse event profile 
The safety findings to date suggest that the adverse event (AE) profile in subjects receiving 
single and repeated doses of UCB0942 is related mostly to the central nervous system (CNS). 
At UCB0942 300mg bid and above the AEs tend to be of slightly greater severity and 
persistence than at doses below UCB0942 300mg bid. In broad terms, the AEs are consistent 
with the AEs associated with established SV2 and GABA-A targeting AEDs, and common 
CNS AEs include headache, nausea, somnolence, fatigue, dizziness, balance disorder, 
disturbance in attention, and memory impairment. Modeling of the relationship between dose 
or plasma exposure, time, and AEs showed that 1) headache, fatigue, somnolence, balance 
disorder, and disturbance in attention are dose-dependent AEs; 2) tolerance develops for 
disturbance in attention and balance disorder; 3) tolerance does not seem to develop for 
fatigue, somnolence, and headache; and 4) titration will reduce the likelihood that a subject 
experiences most of these AEs. 
2.2.2
Psychiatric adverse events
In the multiple ascending dose study, 1 healthy volunteer had a “delirious syndrome” with 
prominent psychotic symptoms, and in a subsequent Phase 1 study, 1 healthy volunteer had 
“mania-like symptoms.” Both of these AEs were classified as serious adverse events (SAEs)
because the subjects required hospitalization. After these psychiatric SAEs occurred, close 
psychiatric monitoring was implemented. Therefore, when 2 other healthy volunteers began 
to develop “hypomania” and “aggressive state,” respectively, the symptoms were discovered 
early, and discontinuation of UCB0942 prevented the development of these symptoms into 
more severe psychiatric symptoms. Based on this, it appears that close psychiatric monitoring 
during the first 2 weeks of dosing, and tapering and discontinuation of the drug in subjects 
who start to develop psychiatric AEs, will reduce the risk that subjects develop more severe 
psychiatric AEs or psychiatric SAEs. Therefore, in this study, daily psychiatric monitoring 
will be performed in all subjects for the first 2 weeks after dosing starts, and weekly 
thereafter. In addition, to further reduce the risk that participating subjects develop 
psychiatric AEs, subjects with a history of psychosis, schizophrenia, bipolar disorder, or 
severe unipolar depression will be excluded from this study. Lastly, based on the fact that 
titration has been shown to reduce the incidence of other AEs and increase the general 
tolerability of UCB0942, titration may also reduce the risk of psychiatric AEs.
REDACTED COPY 
be
b
g bid.
g bid.
and G
and G
olence
olenc
mpairm
pairm
howed
howed
on ar
on ar
d
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
uring
ring
ood 
od 
here w
ere w
ver,
ver,
ar ectop
ecto
n elect
n elec
) profil
 profi
the cen
he ce
f slight
sligh
. In bro
n bro
GABA
GABA
e, fatig
e, fati
ment.
ment. M
d that 1
d that
re dose
e dos
disord
disord
he; and
; an
s. 
c adv
c ad
ing do
ng do
c sym
ym
ptoms
ptom
ubjects
ubject
c monit
mon
lop “h
op “h
y, and 
and d
more se
ore s
durin
duri
wh
w


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 17 of 125
2.2.3
Drug-drug interactions
A drug-drug interaction study in subjects with epilepsy showed that carbamazepine – a strong 
cytochrome P450 (CYP) 3A4 inducer – reduced UCB0942 plasma exposure by >85%. 
Therefore, subjects on carbamazepine or other strong CYP3A4 inducers (eg, phenytoin, 
phenobarbital, or primidone) will not be enrolled in this study because the plasma exposure 
may be too low to produce any therapeutic benefit.
2.3
Rationale for this study
This is a Phase 2A efficacy, safety, and tolerability study.
Based on the preclinical results in 10 animal models of focal and generalized epilepsy, and 
the precedented mechanisms of action, it is almost certain that UCB0942 will have 
antiseizure effects in humans. The rationale for the current study is to test whether UCB0942 
has unprecedented efficacy in a very severe patient population, namely in subjects with focal 
epilepsy who continue to suffer from frequent, almost-daily seizures despite having attempted 
to achieve seizure control with multiple AED regimens. In this study the efficacy of 
UCB0942 400mg bid in subjects with such highly drug-resistant focal epilepsy will be 
assessed for the first time. In this protocol, “focal seizures” refers to partial-onset seizures of 
type IA1, IB, and IC, but does not include type IA2, IA3, or IA4 seizures.
Based on analysis of similar subjects in UCB’s lacosamide and BRV databases, the placebo 
response is very low (after 2 weeks of treatment <7% achieved ≥75% reduction in seizure 
frequency and <2% were seizure free, and after 12 weeks of treatment <4% maintained ≥75% 
reduction in seizure frequency and 0% were seizure free); however, the placebo arm is 
necessary to confirm that the placebo response is equally low in the current target population 
and in the setting of this study (ie, inpatient) and to avoid a false positive study due to an 
apparent seizure frequency reduction from the Prospective Outpatient Baseline Period to the 
Inpatient Treatment Period.
3
STUDY OBJECTIVES
3.1
Primary objective
The primary objective is to evaluate the efficacy of UCB0942 administered concomitantly 
with each subject’s current, stable AED regimen in subjects who have 4 or more focal 
seizures with or without secondary generalization per week and who have failed to achieve 
seizure control with ≥4 AED regimens of adequate dose and duration. 
3.2
Secondary objectives
The secondary objectives are to:
!
Evaluate the safety and tolerability of UCB0942
!
Evaluate the PK of UCB0942 and its metabolites
3.3
Exploratory objectives
The exploratory objectives are to:
!
Identify genetic polymorphisms, gene expression patterns, plasma proteins, plasma lipids,
or other plasma substances that predict or are associated with disease etiology, drug 
response, or tolerability
!
Use video recordings, when available, to explore the effect of UCB0942 on seizure type, 
seizure severity, seizure duration, and duration of the postictal period
REDACTED
e
onse i
onse i
ient)
ent)
from 
from
COPY 
% 
%
2 wee
2 we
izure
zure
This document
E
3
cannot 
Evalua
valua
Ev
Ev
be
ndary
ndary
used 
Sec
Sec
to
thth ≥
support
o ev
 ev
rent, st
ent, s
hout se
out se
≥4
any 
ect
ec
valu
val
marketing 
CTIVE
TIV
ctive
tiv
authorization 
e
e free
free
s equa
s equa
and to
nd to
the
the P
application 
4 se
se
and BR
and B
hieved 
eved
ks of 
ks of
and
o par
o par
eizu
eizu
any 
e
epile
epile
rtit
xtensions
r UC
UC
ects
ects w
e havi
havi
ffica
ffica
or 
B
variations 
and 
nd 
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 18 of 125
!
To assess motivations, hopes and impact of seizures using a Diary Addendum
4
STUDY VARIABLES
4.1
Efficacy variables
4.1.1
Primary efficacy variable
Seizure frequency will be determined using subject diary cards. The subject will be instructed 
as to how to complete the diary, and the procedure for completing the diary will be identical 
during the Outpatient and Inpatient Periods.
The primary outcome measure is the 75%RR. In the active group, this is defined as the 
proportion of subjects with a 75% or greater reduction in focal seizure frequency during the 
last 2 weeks of the Inpatient Period compared to the 2-week Prospective Outpatient Baseline
Period. In the placebo group, the 75%RR is defined as the proportion of subjects with a 75% 
or greater reduction in focal seizure frequency during the first 2 weeks of the Inpatient Period 
(the 2 weeks on placebo) compared to the Prospective Outpatient Baseline Period.
4.1.2
Secondary efficacy variables
The secondary efficacy variables are:
!
Median percent reduction in weekly focal seizure frequency from the Prospective 
Outpatient Baseline Period to the Inpatient Period and the End of Treatment.
!
Seizure-free rate during the Inpatient Period, the last 4 weeks of the Outpatient 
Maintenance Period, and at the End of Treatment.
!
The 75%RR during the last 4 weeks of the Outpatient Maintenance Period and at the End 
of Treatment.
!
Percentage of seizure-free days during the Inpatient and Outpatient Periods.
4.1.3
Exploratory efficacy variables
Exploratory efficacy variables are as follows:
!
Median seizure frequency by seizure type (IA1, IB, IC) per study period: Prospective 
Outpatient Baseline, Titration Inpatient, 1-week Maintenance Inpatient, Transition to 
Outpatient, Outpatient Maintenance, and overall on-treatment period.
!
The 50% responder rate (50%RR) during the Inpatient Period and during the Outpatient 
Maintenance Period.
!
Seizure Severity Questionnaire (SSQ, Cramer et al, 2002), change from Baseline to the 
end of the Inpatient Period and the end of the Outpatient Maintenance Period.
!
Changes in average seizure severity as calculated by the percentage of seizures that are 
type IC.
!
Change from Baseline in score (subscale and total) of the Quality of Life Inventory in 
Epilepsy-31-P (QOLIE-31-P, Cramer et al, 2003)
4.2
Pharmacokinetic variables
Plasma concentrations of UCB0942, 
 will be used 
to calculate the following PK parameters:
!
AUCτ:
area under the plasma concentration-time curve over a dosing interval
REDACTED 
ea
of the O
of the 
s durin
s durin
COPY 
the la
the la
atmen
tmen
This document
t
cannot
d of t
of t
Cha
Cha
be
e Se
e Se
h
used 
po
po
nce
ce P
to
onde
ond
support
ncy
c
Titrat
itra
atient
tient M
any 
y b
y by
marketing
ing th
ng t
acy
cy v
y
a
re as f
e as
authorization 
as
ntnt.
Outpa
Outpa
the
the
application 
ncy
cy from
fr
the En
the E
st 4 w
t 4 w
and any extensions 
nt B
t B
ts with
s with
e Inpat
 Inpa
e Peri
Peri
or 
ng g
Bas
as
variations 
g the
the
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 19 of 125
!
Cmax:
maximum observed plasma concentration
!
tmax:
time of occurrence of Cmax
!
t½:
apparent terminal elimination half-life
!
Ctrough:
measured concentration at the end of the dosing interval at steady state
4.3
Exploratory variables
!
Blood samples for DNA, mRNA, and lipidomics/proteomics/additional blood biomarkers
will be collected during the study:
∀
DNA: One tube for DNA isolation will be collected at the beginning of the Inpatient 
Period of the study. The DNA may be used to assess known variants associated with 
drug-resistant epilepsy or AED resistance and may be used for further genetic 
analyses relating to epilepsy and drug response.
∀
mRNA: One tube will be collected on the day before the first dose of 
UCB0942/placebo, and 1 tube will be collected on the last day of the Inpatient 
Maintenance-Dose Week. The mRNA samples may be used to identify gene 
expression patterns that are associated with disease etiology, that predict (Baseline 
sample), or that are associated with (posttreatment sample) drug response.
∀
Lipidomics/proteomics/additional blood biomarkers: One tube will be collected on 
the day before the first dose of UCB0942 or placebo, and 1 tube will be collected on 
the last day of the Inpatient Maintenance-Dose Week. These samples may be used for 
additional blood biomarker analysis.
All subjects will be asked to provide specific consent for these samples. Refusal to provide 
consent for the collection of samples for DNA, mRNA, and lipidomics/proteomics will not 
disqualify the subject from participating in the study.
Single archive blood samples (for potential background AED assay) will be collected at the 
start of titration, the end of the Inpatient Period, and at the end of the Outpatient Maintenance 
Period (before last dose of IMP). These samples will be collected just before the morning 
dose of IMP and stored for up to 1 year after the study ends.
!
At the discretion of the Investigator, sites may or may not perform video or 
video-electroencephalogram (EEG) monitoring during parts of the Inpatient Period or 
during the whole Inpatient Period, depending on the infrastructure of each site, to assess 
seizure type, severity, duration, and the duration of the postictal period. The video data 
will not be used to corroborate or supplement the diary data and shall not influence the 
diary seizure capture by the subject.
!
Responses to open questions in the Diary Addendum, including:
∀
Reason for participation in the study
∀
Hopes for this new treatment and fulfillment of hopes during the study
∀
Baseline and change from Baseline in the impact of seizures on the patient’s life
The subject will be instructed to leave any questions blank that he/she does not feel 
comfortable answering. 
REDACTED 
ecific 
ecific
for D
for D
pating
pating
COPY
or pla
or pl
e-Do
Do
This document canno
ry se
se
y
Resp
Resp
be
ot be
ot be
eiz
eiz
us
y
ed
whol
hol
pe, se
pe, se
y
e u
e
to 
nce
ole
ole
support
r up
up
f the
the I
epha
epha
any
MP). T
P). 
p to
p to
marketing
g in t
g in 
potenti
otent
npatien
npatie
Th
T
authorization
se W
e W
 conse
cons
DNA, 
NA, 
th
application
g
mple) d
mple) 
rkers
kers:
cebo
cebo
We
W
and
to i
o 
gy, , thth
any 
f the
f th
iden
ide
extensions 
netic
etic
of 
of 
or
ed w
d w
variations 
tient 
tient
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 20 of 125
4.4
Safety variables
The safety of participating subjects will be closely monitored. Psychiatric assessment will be 
performed by a staff member trained in the identification of psychiatric symptoms, and the 
assessments will be performed using the Brief Psychiatric Rating Scale (BPRS; Overall and 
Gorham, 1962), which assesses various psychiatric domains including:
!
Changes in mood and symptoms of depression or mania
!
Changes in thinking and perception, and other symptoms of psychosis
!
Changes in behavior
Other safety variables are:
!
Adverse events reported by the subject and/or caregiver or observed by the Investigator or 
inpatient staff
!
Serious adverse events
!
Subject withdrawals or premature UCB0942 tapering due to AEs
!
Changes in clinical laboratory test parameters
!
Changes in vital sign parameters – pulse rate, blood pressure, and respiratory rate
!
Changes in 12-lead electrocardiogram (ECG) parameters
!
Changes in 2-dimensional Doppler echocardiography from Baseline to after Baseline 
(during dosing, after the last dose, and 6 months after last dose), with diastolic 
measurements as well as atrial volumes to identify any subtle valvular changes and to 
assess for pericardial effusions
!
Changes in physical examination (including body weight) and neurological examination 
findings
!
Changes in memory or cognition as assessed with the mini-mental state examination 
(MMSE; Folstein et al, 1975)
!
Changes indicative of a hypersensitivity reaction including an AE or laboratory value (as 
defined below) suggestive of internal organ involvement (including but not limited to 
hepatitis, nephritis, pneumonitis, carditis, colitis, encephalitis, pancreatitis, myositis, 
arthritis, or hematologic system involvement) combined with at least 1 of the following: 
fever, rash, lymphadenopathy, or eosinophilia
∀
Treatment-emergent abnormal laboratory value criteria suggestive of internal organ 
involvement or eosinophilia:
◦
Eosinophils % ≥10%
◦
Eosinophils absolute ≥0.5G/L
◦
Neutrophils absolute <1.5G/L
◦
Platelets ≤100G/L
◦
ALT ≥2x ULN
◦
AST ≥2x ULN
!
Any indication of withdrawal symptoms using the Clinical Institute Withdrawal 
Assessment-Benzodiazepines (CIWA-B; Busto et al, 1989)
REDACTED
mon
mo
es to i
es to i
on
on (in
(in
COPY 
aram
ara
diogra
diogr
onth
ont
This document cannot
invo
invo
be
eatm
eatm
used 
hem
em
h, l, lym
ym
to
iti
mat
mat
support
f a hy
a hy
ggestiv
gesti
is, pn
s, pn
any 
75)
75)
yp
marketing 
nclud
clu
ition a
tion 
authorization
aphy
aph
ths aft
hs aft
identi
denti
udid
application 
sure
ure, an
eters
ers
hy
hy frf
and any extensions
nvesti
vesti
or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 21 of 125
!
Changes in suicidality using the Columbia-Suicide Severity Rating Scale (C-SSRS)
5
STUDY DESIGN
5.1
Study description
EP0069 is a Phase 2A, double-blind, randomized, placebo-controlled, multicenter study that 
will test the potential efficacy, safety/tolerability, and PK profile of UCB0942 in adult 
subjects with highly drug-resistant focal epilepsy. UCB0942 400mg bid will be administered 
as add-on to each subject’s concomitant AED regimen.
Screening assessments will be conducted after subjects have understood the risks and 
potential benefits of the study and signed the written Informed Consent form (ICF). Only 
subjects who fulfill all eligibility criteria will be enrolled.
This study consists of:
!
A 4-week prescreening Historical Baseline Period for study eligibility purposes
!
A Screening Visit followed by a 2- to 3-week postscreening Prospective Outpatient 
Baseline Period (Day BL1 to Day BL14-21)
!
A 3-week Inpatient Period, which consists of:
∀
An Inpatient Titration Week (Day T1 to Day T7)
∀
An Inpatient Maintenance-Dose Week (Day MD1 to Day MD7)
∀
An Inpatient Transition-to-Outpatient Week (Day TTO1 to Day TTO7)
!
An open-label Outpatient Maintenance Period of 8 weeks (Day OP1 to Day OP57)
!
A Tapering Period of 2 weeks (Day TOO1 to Day TOO14)
!
A Safety Follow-Up Period of 4 weeks (Day SFU1 to Day SFU28) 
!
An echocardiogram during dosing and after the last dose (the SFU7 echocardiogram). 
The echocardiogram will be repeated at 6 months (±1 month) after the last dose in the 
following subjects:
∀
Subjects who complete this study but do not enter the OLE study
∀
Subjects who withdraw from the Outpatient Period 
∀
Subjects who withdraw from the Inpatient Period and have an abnormal SFU7 
echocardiogram
UCB0942 doses for placebo subjects will be titrated to UCB0942 400mg bid during the 
Inpatient Transition-to-Outpatient Week (Day TTO1 to Day TTO7). After the Inpatient 
Period, all subjects will continue in an open-label Outpatient Maintenance Period and a final 
Tapering Period of 2 weeks (Day TOO1 to Day TOO14). Doses for subjects continuing in the 
OLE study will not be tapered but will follow the schedule of safety and efficacy assessments 
as outlined in the OLE study protocol. Safety follow up will consist of 2 required visits, 1 and 
4 weeks after the last dose of IMP (Day SFU7 and Day SFU28), and 1 optional visit 2 weeks 
after the last dose of IMP (Day SFU14). For details of the study assessments, refer to 
Table 5-4. For a general presentation of the study design refer to Figure 5‒1.
Dosing in the Inpatient Period
Titration Week (first week of the Inpatient Period
REDACTED 
W
e Peri
Peri
ay
ay TO
4 w
4 w
COPY
ay MD
M
Week
eek
This document
e
Tape
Tape
O
cannot 
42 2 
tient T
ent T
riod, 
iod, 
be 
do
used
s wh
wh
cardio
ardio
to 
ho 
h
support 
omplet
mple
o with
with
any 
e r
marketing 
eeks 
eeks (
osing
ing an
repea
repe
authorization 
k (Day
Da
iod of
od of
OO1 t
application 
D1 to
1 to D
and any
ctive
ctiv
extensions 
purpo
urpo
or variations 
ly y 
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 22 of 125
The objective of the Titration Week is to achieve the maximum UCB0942 dose of 400mg bid 
in as many of the subjects randomized to UCB0942 as possible while minimizing tolerability 
issues. During the Titration Week the dose for subjects randomized to UCB0942 will be 
titrated to UCB0942 400mg bid following the schedule in Table 5‒1. The UCB0942 dose 
will be titrated to 400mg bid in a double-blinded fashion (ie, it will also appear that subjects 
randomized to placebo are being titrated). If, in the opinion of the Investigator, the Subject 
will be unable to titrate to the maximum dose of IMP due to intolerance of a lower dose, the 
Investigator should discuss this immediately with the Sponsor Study Physician, unless the 
subject’s condition warrants immediate unblinding, and time does not allow discussion with 
the Sponsor. Unblinding may be required depending on the plan agreed upon by the 
Investigator and Sponsor Study Physician before dose tapering to UCB0942 200mg bid or 
100mg bid. If unblinding reveals that the Subject is randomized to placebo, then further 
dosing with IMP will cease until the Transition-to-Outpatient Week (third week of the 
Inpatient Period), at which time, the Subject will titrate UCB0942 according to Table 5‒1.All 
other assessments will continue as planned.
Table 5‒1:
Dose titration to UCB0942 400mg bid
Day T1a
Day T2
Day T3
Day T4
Day T5
Day T6
Day T7
Day MD1
AM
0
100mg
100mg
200mg
200mg
300mg
300mg
400mg
PM
100mg
100mg
200mg
200mg
300mg
300mg
400mg
400mg
AM=morning dose; PM=evening dose 
a In placebo-arm subjects the same schedule is used from Day TTO1 to TTO7.
Maintenance-Dose Week (second week of the Inpatient Period)
If a subject is not tolerating the maximum dose of IMP well during the 
Maintenance-Dose Week such that the Investigator believes a dose reduction is necessary, 
then then the Investigator should contact the Sponsor Study Physician to discuss the situation 
and agree upon a course of action. If a dose reduction is agreed, unblinding will be required. 
If the subject is randomized to UCB0942, the dose can be tapered from UCB0942 400mg bid
to UCB0942 200mg bid. The taper from UCB0942 400mg bid to UCB0942 200mg bid will
occur over 3 days (see Table 5‒2) Dose tapering to UCB0942 100mg bid may also be 
permitted after discussion with the Sponsor’s Study Physician. If it is revealed that the 
Subject is randomized to placebo, then further dosing with IMP will cease until the 
Transition-to-Outpatient Week (third week of the Inpatient Period), at which time, the 
Subject will titrate UCB0942 according to Table 5‒1. All other assessments will continue as 
planned.
Table 5‒2:
Taper from UCB0942 400mg bid to UCB0942 200mg bid
Taper Day 1
Taper Day 2
Taper Day 3
Taper Day 4 onwards
AM
300mg
300mg
200mg
200mg
PM
400mg
300mg
300mg
200mg
AM=morning dose; PM=evening dose
Transition-to-Outpatient Week (third week of the Inpatient Period)
The objective of the Transition-to-Outpatient Week is to achieve the maximum UCB0942 
dose of 400mg bid in as many of the subjects randomized to placebo (now switching to 
REDACTED
from 
from
of the 
f the 
imum
imum
t the
t the
COPY 
g
Y
PY
D
This document t
me
me
me
me
cannot 
able
ble 5
c
be used
Outpa
utpa
titrat
itrat
to
ized
ized
t
support 
The
he
Table
able 5
ssion w
ssion 
d to
d t
any
 UC
UC
e tap
e ta
marketing
m 
e Inve
Inve
ontact t
ntact
n. If a 
n. If 
CB
CB
authorization 
Day TT
ay TT
e Inpat
Inpa
dose
dose
application 
Da
g
30
30
n
ati
00mg
0mg
ca
pp
and 
ay T
ay T
d any extensions
rth
of the
f the
o Tab
Tab
or 
her 
er 
variations 
d or 
or 
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 23 of 125
UCB0942) as possible while minimizing tolerability issues. The UCB0942 dose will be 
titrated to 400mg bid in a double-blinded fashion (ie, it will also appear that subjects 
randomized to UCB0942 are being titrated) following the schedule in Table 5‒1. If, in the 
opinion of the Investigator, the Subject will be unable to titrate to the maximum dose of IMP 
due to intolerance of a lower dose, the Investigator should discuss this with the Sponsor 
Study Physician. Unblinding may be required depending on the plan agreed upon by the 
Investigator and Sponsor Study Physician.
Dosing in the Outpatient Maintenance Period and Tapering Period
During the Outpatient Maintenance Period, Subjects will continue to administer UCB0942 at 
the final Inpatient Period dose. Multiple adjustments (tapering or increase) of the dose are 
allowed during the Outpatient Maintenance Period (minimum 100mg bid and maximum 
400mg bid); however, any change of dose in the Outpatient Maintenance Period should first 
be discussed with the Sponsor Study Physician. 
At the end of the Outpatient Maintenance Period, or at the time a subject is withdrawn from 
the study, UCB0942 will be tapered following the schedule in Table 5‒3. If the subject is not 
taking a dose of UCB0942 other than 400mg bid, then the Investigator should contact the 
Sponsor Study Physician to discuss the appropriate tapering schedule.
Table 5‒3:
Dose taper from UCB0942 400mg bid
Day
TOO1 to TOO4
TOO5 to TOO8
TOO9 to TOO12
TOO13 and TOO14
AM
300mg
200mg
100mg
PM
300mg
200mg
100mg
100mg
AM=morning; PM=evening dose
In order to provide an ongoing assessment of the safety of subjects as the study progresses, a 
Safety Review Group (SRG) comprising appropriate Sponsor study team members and the 
Investigator(s) at each site will meet regularly to review appropriate safety data (see 
Section 11.1.9).
5.1.1
Study duration per subject
The total duration of the study after Screening is 20 weeks for each subject, including the 
Prospective Outpatient Baseline Period (2 to 3 weeks), the Inpatient Period (3 weeks), the 
Outpatient Period (8 weeks of treatment and 2 weeks of taper), and a SFU Period (4 weeks).
In addition, there is an echocardiography visit at 6 months after the last dose. The total 
duration of exposure to UCB0942 during this study is 13 weeks.
The end of the study is defined as the date of the last visit of the last subject in the study.
5.1.2
Planned number of subjects and sites
Subjects with highly drug-resistant focal epilepsy will be enrolled at 
 sites in order 
to provide 46 evaluable subjects, ie, 46 subjects who complete the Inpatient Period. Subjects 
who drop out before Visit 6 (eg, during the Inpatient Period) for reasons other than safety or 
tolerability will be replaced. First subject, first visit is planned for Q2 2015.
5.1.3
Anticipated regions and countries
The study is planned to be performed in The 
 
 
REDACTED 
D
CT
essm
essm
COPY
TOO
TO
OP
CO
This document 
.1
Su
Su
cannot 
nd of 
d of
.2
.2
be
f ex
f ex
used
od (
here i
here 
to
tien
tien
(8
suppor
uratio
rati
the stu
he st
ent B
nt B
any 
ion
io
marketing
ment o
ment o
rising a
ising 
meet re
meet r
authorization 
ati
ori
hor
or
or
application 
O9 to T
9 to 
lic
a
and 
tor 
or 
dule.
ule.
any 
. IfIf
sho
sh
extensions
shoul
houl
s with
with
f t
f t
or 
um
um
variations 
2 at 
 at 
arere
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 24 of 125
5.2
Schedule of study assessments
The schedule of study assessments is presented in Table 5-4, and a detailed schedule of 
assessments for the Inpatient Period is presented in Table 5‒5.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 25 of 125
Table 5-4:
Schedule of study assessments
Assessments
Baseline
Period
Inpatient Period
Outpatient Period
Period
Screeninga/
Baseline
Titration
Mainte-
nance
Transition 
to 
Outpatient
Outpatient Maintenance Period
Taper/Safety Follow-Up Period
Duration
1 day
2 weeksb
1 week
1 week
1 week
8 weeks
Up to 2
weeks
4 weeks
Visit
V1
V2
V3
V4
V5
V6
V7
V8
V9
V10
V11
V12
V13
V14
V15
V16
V17
V18
V19
V20
Study days
-1
BL1 to 
BL14/21
T1 to T7
MD1 to 
MD7
TTO1 to 
TTO7
OP
3
OP
5
OP
8
OP
15
OP
22
OP
29
OP
36
OP
43
OP
50
OP
57c
TOO
7
TOO
14
SFU
7
SFU
14d
SFU
28
(±2)
(±2) (±2)
(±2)
(±2)
(±2)
(±2)
(±2)
(±2)
(±2) (±2)
(±1)
(±1)
(±2)
(±2)
Written informed 
consent
X
Demographic data
X
Habits and lifestyle
X
X
General 
medical/medication/
procedures history
X
X
Review historic 
seizure count
X
Verification of 
inclusion/exclusion 
criteria
X
X
Admission to clinic
X
Discharge from 
clinic
Xe
Withdrawal criteria
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Physical 
examinationf
X
X
X
X
X
X
X
X
X
X
REDACTED 
D
T D
CT
CT
CTE
CT
DA
ED
COPY 
(±
(
PY
PY
PY
COPY
C
This document cannot
an ot 
ot be 
X
be used 
ed
X
se
to 
o support 
por
pp
s
any y marketing 
ke
g
ke
ke
ke
ke
authorization 
t
at
at
atio
at
ori
ho
ut
application 
OP
OP
29
29
at
(±2)
(±2)
a
p
a
pp
ap
and
V1
V1
d
an
an
an
an
a
any 
a
extensions 
ns
ex
or variations 
on
va
thereof. 
1


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 26 of 125
Table 5-4:
Schedule of study assessments
Assessments
Baseline
Period
Inpatient Period
Outpatient Period
Period
Screeninga/
Baseline
Titration
Mainte-
nance
Transition 
to 
Outpatient
Outpatient Maintenance Period
Taper/Safety Follow-Up Period
Duration
1 day
2 weeksb
1 week
1 week
1 week
8 weeks
Up to 2
weeks
4 weeks
Visit
V1
V2
V3
V4
V5
V6
V7
V8
V9
V10
V11
V12
V13
V14
V15
V16
V17
V18
V19
V20
Study days
-1
BL1 to 
BL14/21
T1 to T7
MD1 to 
MD7
TTO1 to 
TTO7
OP
3
OP
5
OP
8
OP
15
OP
22
OP
29
OP
36
OP
43
OP
50
OP
57c
TOO
7
TOO
14
SFU
7
SFU
14d
SFU
28
(±2)
(±2) (±2)
(±2)
(±2)
(±2)
(±2)
(±2)
(±2)
(±2) (±2)
(±1)
(±1)
(±2)
(±2)
Neurological 
examinationf
X
X
X
X
X
X
X
X
X
X
Psychiatric and 
cognitive 
assessmentsg
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
CIWA-Bh
X
X
X
X
X
X
Vital signs (BP, 
pulse, and 
respiratory rate)i
X
X
X
X
X
X
X
X
X
X
X
X
Body weight and 
heightj
X
X
X
X
X
X
12-lead ECGi
X
X
X
X
X
X
X
X
Echocardiogramk
X
X
X
Clinical laboratoryl
X
X
X
X
X
X
X
X
Video or video-
EEG monitoringm
X
X
X
Pregnancy testn
X
X
X
X
X
X
X
REDACTED 
D
X
D
ED CT D
ED
ED
ED
ED
COPY 
(±
(
PY
PY
PY
COPY
This document t cannot 
ot
no
c
be
X
used 
d
ed
u
to support 
por
X
po
po
po
po
s
any 
X
ny marketing 
g
tin
ke
authorization 
at
X
at
at
at
ho
at
au
application 
OP
OP
29
29
at
(±2)
(±2)
a
p
a
pp
ap
and
V1
V1
d
an
an
an
an
a
any 
a
extensions 
ns
ex
or variations 
on
va
thereof. 
1


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 27 of 125
Table 5-4:
Schedule of study assessments
Assessments
Baseline
Period
Inpatient Period
Outpatient Period
Period
Screeninga/
Baseline
Titration
Mainte-
nance
Transition 
to 
Outpatient
Outpatient Maintenance Period
Taper/Safety Follow-Up Period
Duration
1 day
2 weeksb
1 week
1 week
1 week
8 weeks
Up to 2
weeks
4 weeks
Visit
V1
V2
V3
V4
V5
V6
V7
V8
V9
V10
V11
V12
V13
V14
V15
V16
V17
V18
V19
V20
Study days
-1
BL1 to 
BL14/21
T1 to T7
MD1 to 
MD7
TTO1 to 
TTO7
OP
3
OP
5
OP
8
OP
15
OP
22
OP
29
OP
36
OP
43
OP
50
OP
57c
TOO
7
TOO
14
SFU
7
SFU
14d
SFU
28
(±2)
(±2) (±2)
(±2)
(±2)
(±2)
(±2)
(±2)
(±2)
(±2) (±2)
(±1)
(±1)
(±2)
(±2)
Serologyo
X
Screening for drug 
and alcohol usep
X
X
X
X
Randomizationq
X
Administration of 
IMP
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Sample for
UCB0942, 
 
plasma 
concentrations
Xr
Xs
Xs
Xs
Xs
Xs
Xs
Xs
Xs
Xs
Xs
Sample for DNA
X
Sample for mRNA/ 
lipidomics/ 
proteomics
X
X
SSQ (Baseline 
version)
X
X
X
X
X
X
X
X
QOLIE-31-Pt
X
X
X
X
X
CT D
CT
CT
CT
ED CT
ED
ED
ED
ED
COPY 
(±
(
PY
PY
PY
OPY
CO
C
This document 
en
en
en cannot 
ot
an
be 
b
used
ed to 
to support 
por
su
any marketing 
X
ke
g
ke
ke
ket
ke
authorization 
on
o
at
ho
ho
hor
ho
X
au
application 
OP
OP
29
29
at
(±2)
(±2)
a
p
a
pp
ap
and
V1
V1
d
an
an
an
an
a
any 
a
extensions 
ns
ex
or variations 
on
va
thereof. 
1


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 28 of 125
Table 5-4:
Schedule of study assessments
Assessments
Baseline
Period
Inpatient Period
Outpatient Period
Period
Screeninga/
Baseline
Titration
Mainte-
nance
Transition 
to 
Outpatient
Outpatient Maintenance Period
Taper/Safety Follow-Up Period
Duration
1 day
2 weeksb
1 week
1 week
1 week
8 weeks
Up to 2
weeks
4 weeks
Visit
V1
V2
V3
V4
V5
V6
V7
V8
V9
V10
V11
V12
V13
V14
V15
V16
V17
V18
V19
V20
Study days
-1
BL1 to 
BL14/21
T1 to T7
MD1 to 
MD7
TTO1 to 
TTO7
OP
3
OP
5
OP
8
OP
15
OP
22
OP
29
OP
36
OP
43
OP
50
OP
57c
TOO
7
TOO
14
SFU
7
SFU
14d
SFU
28
(±2)
(±2) (±2)
(±2)
(±2)
(±2)
(±2)
(±2)
(±2)
(±2) (±2)
(±1)
(±1)
(±2)
(±2)
C-SSRS (Screening/
Baseline version)
X
C-SSRS (Since last 
visit)
X
X
X
X
X
X
X
Dispense IMPu
X
X
X
X
X
X
X
IMP returnv
X
X
X
X
X
Dispense/return
diary card 
X
Xw
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Diary Addendumx
X
1
Concomitant 
medications/ 
procedures
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
AED archive 
sample
X
X
X
AE reporting
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
REDACTED 
D
CT D
AC
ED C
RE
COPY 
(±
(
PY
PY
PY
COPY
C
This document cannot be
X
b
used 
ed
us
to 
to support 
rt 
por any marketing 
g
e
g
X
et
ke
m
authorization 
t
at
at
atio
ho
at
tho
ho
ho
ho
a
application 
OP
OP
29
29
at
(±2)
(±2)
a
p
a
pp
ap
and
V1
V1
d
an
an
an
an
a
any 
a
extensions 
ns
ex
or variations 
on
va
thereof. 
1


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 29 of 125
Table 5-4:
Schedule of study assessments
Assessments
Baseline
Period
Inpatient Period
Outpatient Period
Period
Screeninga/
Baseline
Titration
Mainte-
nance
Transition 
to 
Outpatient
Outpatient Maintenance Period
Taper/Safety Follow-Up Period
Duration
1 day
2 weeksb
1 week
1 week
1 week
8 weeks
Up to 2
weeks
4 weeks
Visit
V1
V2
V3
V4
V5
V6
V7
V8
V9
V10
V11
V12
V13
V14
V15
V16
V17
V18
V19
V20
Study days
-1
BL1 to 
BL14/21
T1 to T7
MD1 to 
MD7
TTO1 to 
TTO7
OP
3
OP
5
OP
8
OP
15
OP
22
OP
29
OP
36
OP
43
OP
50
OP
57c
TOO
7
TOO
14
SFU
7
SFU
14d
SFU
28
(±2)
(±2) (±2)
(±2)
(±2)
(±2)
(±2)
(±2)
(±2)
(±2) (±2)
(±1)
(±1)
(±2)
(±2)
AE=adverse event; AED=antiepileptic drug; BL=Baseline; BP=blood pressure; BPRS=Brief Psychiatric Rating Scale; CIWA-B=Clinical Institute Withdrawal 
Assessment-Benzodiazepines; C-SSRS=Columbia-Suicide Severity Rating Scale; DBP=diastolic blood pressure; DNA=deoxyribonucleic acid; 
ECG=electrocardiogram; EEG=electroencephalogram; HBsAg=hepatitis B surface antigen; HCV-Ab=hepatitis C antibody; HIV-1/2Ab=human 
immunodeficiency virus-1/2 antibody; IMP=investigational medicinal product; IRT=interactive response technology; MD=Maintenance Dose; MINI=Mini 
International Neuropsychiatric Interview; MMSE=mini-mental state examination; mRNA=messenger ribonucleic acid; OLE=open-label extension; 
OP=Outpatient; PR=pulse rate; QOLIE-31-P=Quality of Life Inventory in Epilepsy-31-P; SBP=systolic blood pressure; SFU=Safety Follow-Up Visit; 
SSQ=Seizure Severity Questionnaire; T=Titration; TOO=Taper of Outpatient; TTO=Transition to Outpatient
a If a subject fails screening, a rescreening is allowed if deemed appropriate by the Investigator.
b Baseline Period of at least 2 weeks and no more than 3 weeks.
c Day OP57 is the same day as Day TOO1.
d SFU14 is optional, only if deemed necessary by the Investigator. Additional assessments can be added if necessary.
e On Day TTO7 after completing all assessments, subjects will be discharged.
f Physical examination (complete) and neurological examination at Screening and on Days MD1, TTO7, OP22, OP57, TOO14, SFU7, SFU14 (if deemed 
necessary by the Investigator), and SFU28. Physical examination (focused, or as per center policy) and neurological examination on Day T1.
g MINI at Screening; BPRS and MMSE at every visit. During the first week after discharge psychiatric symptoms will be assessed during each visit, using the 
BPRS and MMSE, and by phone, using the BPRS only, on the other days. 
h CIWA-B will be performed before the evening dose on the last day before discharge from the inpatient unit.
i Vital signs include PR, respiratory rate, SBP, and DBP. In addition, at Day T1, MD7, and TTO7 body temperature should be measured; on Day T1 this should 
be prior to first administration of UCB0942. Obtain vital signs and a 12-lead ECG once in the morning, unless otherwise noted. 
j Height at Screening only.
k In addition to the echocardiogram during dosing and after the last dose (SFU7), the echocardiogram will be repeated at 6 months (±1 month) after the last dose 
in the following subjects: 1) Subjects who complete this study but do not enter the OLE study, 2) Subjects who withdraw from the Outpatient Period, and 3) 
REDACTED
rface 
rface
uct; IR
uct; IR
minatio
minatio
ry in E
ry in E
Outpat
Outpat
pr
p
COPY 
(±
(
PY
RS=Bri
RS=B
DBP=
DBP=
PY
PY
This document cannot 
iogram
ogram
: 1)
1) Su
S
be
UCB
UCB
used
evenin
venin
te, SB
e, SB
0
to
y
BPR
BPR
support
cts
examin
amin
ical exa
cal ex
y visit. 
visit.
RS
any
igato
igat
 will 
will 
marketing
tient;
ent
opriate 
priate 
or
or
authorization
ef
=diasto
=diast
ntigen
tigen
T=inte
inte
on; 
on; mR
mR
pile
pileps
ps
t; T
t; T
application 
OP
OP
29
29
at
(±2)
(±2)
a
p
a
f Psyc
Psyc
l
pp
and
V1
V1
d
an
an
an
an
a
any 
a
extensions 
ns
ex
or variations 
on
va
thereof. 
1


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 30 of 125
Subjects who withdraw from the Inpatient Period and have an abnormal SFU7 echocardiogram. Please note that the during dosing time point of Day OP22 for 
the echocardiogram has a time window of ±1 week instead of ±2 days and the Day SFU7 echocardiogram has a time window of ±1 week instead of ±1 day.
l Clinical chemistry, hematology, and urinalysis.
m At the discretion of the Investigator, sites may or may not perform video or video-EEG monitoring during parts of the Inpatient Period or during  the whole 
Inpatient Period.
n Urine or serum pregnancy test.
o Serology to include HIV-1/2Ab, HBsAg, and HCV-Ab.
p The drug screen will include amphetamines, benzodiazepines, barbiturates, cocaine, cannabinoids, methadone, opiates, and alcohol. Use of AED from one of 
the classes mentioned will be allowed if allowed by inclusion and exclusion criteria.
q Randomization on Day T1 before first IMP administration using IRT.
r Obtain blood samples for measurement of plasma concentration of UCB0942 and metabolites on Day MD1 and MD7, at the following times: predose (within 
5min of dosing), then at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, and 12h postdose. Time windows for postdose samples are as follows: ±5min for the 0.5h, 1h, 1.5h, 
2h, 3h, and 4h samples; ±10min for the 6h, 8h, and 12h samples. The 12h sample must be obtained prior to the pm dose. 
s Obtain blood samples for measurement of trough levels of UCB0942 and metabolites just prior to the morning dose of UCB0942. If a predose sample is not 
possible prior to the morning dose a sample can be taken just prior to the evening dose of UCB0942. If no sample can be taken just prior to dosing, a postdose 
sample will be taken and the actual dosing and sampling times will be recorded. 
t The QOLIE-31-P will be completed by all subjects prior to any other study procedures at the visit. At Day T1, QOLIE-31-P will be assessed in the morning 
before randomization.
u For the Outpatient Period, medication will be dispensed on Days TTO7, OP15, OP29, OP43, and OP57.
v Medication should be presented at each visit for check on compliance.
w During the Baseline Period the subjects should be called at least once to check on the completion of the diary card.
x The subject will be instructed to leave any questions blank that he/she does not feel comfortable answering.
y Collect at Day OP57 or at Early Withdrawal. 
REDACTED 
OP15,
OP15,
e.
nce to 
nce to
he/she
he/she
COPY
se of
se 
cedure
cedur
This document cannot be used to support any marketing 
does 
does
authorization
es at t
es at t
OP29
OP29
check 
heck 
application
tdose
dos
ed prior
d prio
or to the
or to th
UCB0
CB094
9
h
and 
MD1 a
MD1 a
se s
se s
any extensions 
en
piates
iates
or
nt Pe
t Pe
variations 
on
me poin
e poin
 week
eek
thereof. 
1


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 31 of 125
Table 5‒5:
Schedule of study assessments, Inpatient Period
Period
Titration 
Maintenance
Transition to Outpatient
Visit
Visit 3
Visit 4
Visit 5
Study days
T1 T2
T3
T4 T5
T6 T7
MD1
MD2
MD3
MD4
MD5
MD6
MD7
TTO1 TTO2
TTO3
TTO4
TTO5
TTO6 TTO7
Admission to clinica
X
Discharge from clinic
Xb
Habits and lifestyle
X
General Medical/Medication/ 
procedures history
X
Verification of inclusion/
exclusion criteria
X
Withdrawal criteria
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Physical/Neurological 
examination (complete)
Xc
X
X
Psychiatric assessment 
(BPRS)
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Cognitive assessment 
(MMSE)
X
X
X
X
X
X
X
CIWA-B
Xd
Vital signs (BP, pulse, and 
respiratory rate)e
X
X
X
X
X
X
X
X
Body temperaturef
X
X
X
Body weight
X
X
12-lead ECGe
X
X
X
X
X
X
Clinical laboratoryg
X
X
X
Video or video-EEG 
monitoringh
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Pregnancy testi
X
D
X
CT
DAC
RE
R
COPY 
PY
X
OP
C
This document 
en cannot
X
nn
X
ca
c
be 
be
b
used 
X
s d
s
us
to 
to support 
o t
or
s ppo
sup
s
any y
a
marketing 
X
g
in
rk
ma
m
authorization
X
itititio
h
ati
X
ho
th
application 
io
at
pp
ap
and 
d
an
any 
a
extensions 
TO2
O2
on
io
en
ext
e
or
nsiti
nsit
o variations 
on
tion
io
va
thereof. 
1


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 32 of 125
Table 5‒5:
Schedule of study assessments, Inpatient Period
Period
Titration 
Maintenance
Transition to Outpatient
Visit
Visit 3
Visit 4
Visit 5
Study days
T1 T2
T3
T4 T5
T6 T7
MD1
MD2
MD3
MD4
MD5
MD6
MD7
TTO1 TTO2
TTO3
TTO4
TTO5
TTO6 TTO7
Screening for drugs and 
alcohol
X
Randomizationj
X
Administration of IMPk
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Sample for UCB0942, 
 
 plasma 
concentrations
X
X
Sample for DNA
X
Sample for mRNA
X
X
Sample for lipidomics
X
X
Sample for proteomics
X
X
SSQ (Baseline version)m
X
X
X
X
QOLIE-31-Pm
X
C-SSRS (since last visit)
X
X
X
X
Diary card completion
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Dispense IMPn
X
X
X
X
Dispense diary cardn
X
X
X
X
Diary Addendumo
X
Concomitant 
medications/procedures
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
AED archival sample
X
X
AE reporting
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
REDACTED 
D
CT
DAC
DA
DA
DA
RE
R
COPY 
PY
O
This document t cannot 
X
ot
nn
X
n
c n
be 
X
b
used 
d
s d
X
se
us
to 
to support 
X
o t
or
ppo
up
s
any 
X
X
any
a
marketing 
ng
in
ke
ma
m
authorization 
n
ati
ati
ati
ati
ati
ori
th
ut
application 
X
n
pp
io
a
and 
d
X
d 
d any 
ny extensions 
TO2
O2
on
io
en
ext
or
nsiti
nsit
o variations 
on
tion
io
va
thereof. 
1


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 33 of 125
Table 5‒5:
Schedule of study assessments, Inpatient Period
Period
Titration 
Maintenance
Transition to Outpatient
Visit
Visit 3
Visit 4
Visit 5
Study days
T1 T2
T3
T4 T5
T6 T7
MD1
MD2
MD3
MD4
MD5
MD6
MD7
TTO1 TTO2
TTO3
TTO4
TTO5
TTO6 TTO7
AE=adverse event; AED=antiepileptic drug; BP=blood pressure; BPRS=Brief Psychiatric Rating Scale; CIWA-B=Clinical Institute Withdrawal Assessment-
Benzodiazepines; C-SSRS=Columbia-Suicide Severity Rating Scale; DNA=deoxyribonucleic acid; ECG=electrocardiogram; EEG=electroencephalogram;
IMP=investigational medicinal product; IRT=interactive response technology; MD=Maintenance Dose; MMSE=mini-mental state examination; 
mRNA=messenger ribonucleic acid; QOLIE-31-P=Quality of Life Inventory in Epilepsy-31-P; SSQ=Seizure Severity Questionnaire; T=Titration; 
TTO=Transition to Outpatient
a Admission in the morning of Day T1.
b Discharge after completion of all assessments on Day TTO7; pm dose is first outpatient dose.
c Physical examination can be focused on Day T1 if center procedures allow.
d CIWA-B will be performed before the evening dose on the last day before discharge from the inpatient unit.
e Obtain vital signs and a 12-lead ECG once in the morning, unless otherwise noted.
f Body temperature should be measured before the first dose of UCB0942 on Day T1.
g Clinical chemistry, hematology, and urinalysis.
h At the discretion of the Investigator, sites may or may not perform video or video-EEG monitoring during parts of the Inpatient Period or during the whole 
Inpatient Period.
i Urine or serum pregnancy test, female subject only.
j Randomization after completion of all assessments on Day T1 using IRT.
k First administration after randomization in the evening of Day T1 followed by bid dosing.
l Obtain blood samples for measurement of plasma concentration of UCB0942 and metabolites on Day MD1 and MD7, at the following times: predose (within 
5min of dosing), then at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, and 12h postdose. Time windows for postdose samples are as follows: ±5min for the 0.5h, 1h, 1.5h, 
2h, 3h, and 4h samples; ±10min for the 6h, 8h, and 12h samples. The 12h sample must be obtained prior to the pm dose. 
m The QOLIE-31-P and SSQ (Baseline version) will be completed by all subjects prior to any other study procedures at the visit.
n For the Outpatient Period, after completion of all assessments on Day TTO7.
o The subject will be instructed to leave any questions blank that he/she does not feel comfortable answering.
REDACTED
Day 
Day
deo or 
eo or
COPY 
rge from
rge fro
ted.
ed.
T
This document cannot be used to 
es
support
h s
h s
be com
e com
ll assess
asse
stion
tions
any
and 
and 
sampl
am
marketing 
ng IRT.
g IRT
T1 follo
1 foll
ion of U
on of
12
1
authorization 
T1.1.
video
video
application 
m the in
the in
and
ure Se
e S
any 
car
ca
E=min
E=min
eve
ev
exten
Clinica
linica
ardio
rdio
ensions 
TO2
O2
on
io
en
or
nsiti
nsit
o variations 
on
tion
io
va
thereof. 
1


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 34 of 125
5.3
Schematic diagram
Figure 5‒1: Study design
5.4
Rationale for study design and selection of dose
This multicenter, double-blind, randomized, placebo-controlled, parallel-group study will 
assess the safety and efficacy of UCB0942 in the adjunctive treatment of seizures with or 
without secondary generalization in adult subjects with highly drug-resistant focal epilepsy, 
for the first time. The study will have an Inpatient Period to minimize the psychiatric risk to 
subjects during the titration. The Outpatient Maintenance Period is necessary to ensure that 
any efficacy observed is maintained and that subjects do not develop tolerance to UCB0942.
The dose used in this study (UCB0942 400mg bid) was chosen because it is the maximum
tolerated dose (MTD) in Phase 1 studies. This dose is expected to:
1. achieve exposures similar to those that show unprecedented efficacy in the rat amygdala 
kindling model of drug-resistant focal epilepsy,
2. achieve full and constant SV2 occupancy based on modeling predictions, and
3. achieve 10-15% occupancy of the cBZR site on the GABA-A receptor.
Based on previous experience in Phase 1, a dose titration over 1 week was chosen to 
minimize the occurrence of AEs. The titration will be performed during the Inpatient Period 
in all subjects (Section 8.2.1). If a subject does not tolerate UCB0942 400mg bid during the 
Maintenance-Dose Week or later, taper to UCB0942 200mg bid can be started by the 
Investigator.
REDACTED COPY 
This document
k
2
cannot
d d
d do
achie
achie
kiki
be
used
used
os
os
used
bserv
serv
d i
d i
to
e tit
e tit
support
acy
cy
eralizat
raliza
e study
e study
ra
any
d, 
d, ran
ra
y of 
of
y
marketi
study
tudy
nd
eting authorization application and any extensions or 
riations 
vari
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 35 of 125
The SRG will monitor the effectiveness of these strategies in controlling AEs on an ongoing 
basis, as detailed in Section 11.1.9.
6
SELECTION AND WITHDRAWAL OF SUBJECTS
6.1
Inclusion criteria
To be eligible to participate in this study, all of the following criteria must be met:
1. Subject is an adult (18 years of age or more).
2. Subject is able to understand the study and the ICF as assessed by the Investigator.
Subjects with known mental retardation (defined as IQ below 70) are not eligible to 
participate.
3. A written ICF approved by the or Independent Ethics Committee (IEC) is signed and 
dated by the subject, after the Investigator assesses whether the subject is able to 
understand the potential risks and benefits of participating in the study. A separate ICF 
should be signed and dated by the subject to allow for the optional DNA, mRNA, and 
lipidomics/proteomics/additional blood biomarker samples.
4. Subject and/or caregiver is considered reliable and capable of adhering to the protocol 
(eg, able to understand and complete diaries), visit schedule, and the medication intake 
scheme as instructed according to the judgment of the Investigator.
5. Subject is of normal weight as determined by a body mass index (BMI) between 16.0 and 
40.0kg/m2 (exclusive) and with a body weight of at least 50kg (males) or 45kg (females).
6. Subject fulfills ILAE (1989) criteria for focal epilepsy:
∀
clinical semiology should be described and fulfill criteria for focal seizures.
∀
there will have been an electroencephalogram (EEG) reading compatible with focal 
epilepsy in the last 5 years.
∀
the subject has no seizures that are not focal by the new ILAE criteria.
∀
a brain MRI (magnetic resonance imaging) or head CT (computed tomography) to be 
performed before randomization, if no such scan was performed in the last 5 years, 
and a report is available. If a scan was performed within the last 5 years but the 
epilepsy has not been stable since the last scan, a new scan should be obtained.
7. Subject has failed to achieve seizure control with ≥4 appropriately chosen AED regimens 
of adequate dose and duration, including the current treatment, as documented in medical 
records and per Investigator assessment of patient report.
8. Subject is currently treated with a stable dose of at least 1 AED for the 4 weeks prior to 
the Screening Visit (Visit 1) and throughout the duration of the Treatment Period with or 
without additional concurrent vagus nerve stimulation (VNS) or other neurostimulation 
treatments. The VNS must have been in place for at least 12 months with constant 
settings for at least 3 months and the battery life of unit anticipated to extend for the 
duration of study prior to the Screening Visit and throughout the duration of the study.
9. During the 4 weeks prior to Screening (Historical Baseline Period), subject must report to 
have had an average of at least 4 spontaneous and observable focal seizures per week 
(“focal seizures” refers to partial-onset seizures of type IA1, IB, and IC, but does not 
include type IA2, IA3, or IA4 seizures), and cannot have had any seizure-free period 
longer than 3 days (based on Investigator assessment of subject report and seizure diaries
r foca
r foca
escribe
scribe
ctroen
ctroen
COPY
a bod
a bo
ght of 
ght of
l
This document
w
cannot 
ubject
ubject
the S
the S
be
s an
used
fail
ail
ate do
te do
d
to 
led
ed
support 
rand
rand
availab
availa
not be
not b
any
ic res
ic res
dom
do
marketing
ncep
cep
s that 
 that
authorization
f at l
at l
l epile
l epile
ed and
ed and
ph
ph
application 
e,e, and
an
nvestig
vesti
y mass
y mas
leas
lea
and 
adher
adher
d
any 
NA
N
xtensions
ned a
ed a
able to
ble to
A sep
A sep
NA, m
A, m
or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 36 of 125
if available). The cut-off seizure frequency (4 seizures per week) and maximum seizure-
free interval (3 days) must be maintained during the 2-week Prospective Outpatient 
Baseline Period.
10. Subject has clinical laboratory test results within the reference ranges of the laboratory or
isolated test results that are outside the specified ranges and that are deemed as not 
clinically significant by the Investigator.
11. Subject has blood pressure and heart rate within normal range in the supine position after 
5 minutes rest, or the subject has hypertension that is under partial control with a stable 
antihypertensive medication regimen but that the Investigator deems as clinically not 
significant.
12. Female subjects of nonchildbearing potential (premenarcheal, postmenopausal for at least 
2 years, bilateral oophorectomy or tubal ligation, and complete hysterectomy) are eligible. 
Female subjects of childbearing potential are eligible if they use medically accepted 
contraceptive methods. Oral or depot contraceptive treatment with at least ethinylestradiol 
30μg per intake used with an additional barrier contraception method, monogamous 
relationship with vasectomized or female partner, or double-barrier contraception are 
acceptable methods. The subject must understand the consequences and potential risks of 
inadequately protected sexual activity, be educated about and understand the proper use 
of contraceptive methods, and undertake to inform the Investigator of any potential 
change in status. Abstinence will be considered as an acceptable method of contraception 
if the Investigator can document that the subject agrees to be compliant when it is in line 
with the preferred and usual lifestyle of the subject.
13. Male subjects confirm that during the study period and for a period of 3 months after the 
final dose, when having sexual intercourse with a woman of childbearing potential, he 
will use a barrier contraceptive (eg, condom) and that the respective partner will use an 
additional contraceptive method.
6.2
Exclusion criteria
Subjects are not permitted to enroll in the study if any of the following criteria is met:
1. Subject has participated in another study of an investigational medication (or medical 
device) within the last 30 days or is currently participating in another study of an 
investigational medication (or a medical device).
2. Subject has either:
∀
>1.5x upper limit of normal (ULN) of any of the following: 
◦
alanine aminotransferase (ALT)
◦
aspartate aminotransferase (AST)
◦
alkaline phosphatase (ALP)
-OR-
∀
>ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome). 
If subject has elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate 
bilirubin to identify possible undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%). 
he 
stud
study
ercour
ercou
(eg, co
(eg, c
d.d.
COPY
as a
as
ject ag
ect ag
subj
subj
This document cannot 
◦
be
5x u
x 
used
eith
eith
up
up
to 
m
he
h
support
ted in
ed in
last 30
last 3
medica
edic
any
enro
enro
n
marketing 
con
eria
ria
olll
authorization 
gr
g
bject.
ect.
y peri
peri
rse wi
se wi
ndom
ndom
application
and un
nd u
nvestig
nvest
n accep
accep
rees t
ees t
and 
rierer
ences
ences
any
d, m
d, m
r con
r co
extensions
for 
or
y) are 
) are 
y acce
y acc
east e
ast e
mo
or 
r at
r at
variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 37 of 125
For randomized subjects with a baseline result >ULN for ALT, AST, ALP, or total 
bilirubin, a baseline diagnosis and/or the cause of any clinically meaningful elevation 
must be understood and recorded in the Case Report form (CRF). 
If subject has >ULN ALT, AST, or ALP that does not meet the exclusion limit at 
screening, repeat the tests, if possible, prior to dosing to ensure there is no further ongoing 
clinically relevant increase. In case of a clinically relevant increase, inclusion of the 
subject must be discussed with the Medical Monitor.
3. Subject has a known hypersensitivity to any components of UCB0942 formulation or to 
similar drugs (LEV, BRV, or benzodiazepines), or a history of drug or other allergy that, 
in the opinion of the Investigator or UCB Study Physician, contraindicates her/his 
participation.
4. Subject has had significant blood loss or has donated or received 1 or more units (450mL) 
of blood within 30 days prior to UCB0942 administration, or has donated plasma or 
platelets within 14 days prior to UCB0942 administration for this study.
5. Subject tests positive for human immunodeficiency virus-1/2 antibody (HIV-1/2Ab), 
hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCV-Ab).
6. Subject has a medical condition that, in the opinion of the Investigator, could jeopardize 
or would compromise the subject’s safety or his/her ability to participate in this study.
7. Subject has a current or past psychiatric condition that, in the opinion of the Investigator, 
could compromise his/her safety or ability to participate in this study including a history 
of schizophrenia, schizoaffective disorder, bipolar disorder, or severe unipolar depression. 
The presence of potential psychiatric exclusion criteria will be determined based on
screening with the BPRS plus the Mini International Neuropsychiatric Interview (MINI).
8. Subject has a history of status epilepticus or has been hospitalized for status epilepticus 
within the 6-month period prior to Screening Visit.
9. Subject has had EEGs showing a pattern not consistent with a diagnosis of focal epilepsy 
(eg, generalized spike-wave).
10. Subject only has seizures that are uncountable due to clustering.
11. Subject has had pseudoseizures, conversion disorder, or other nonepileptic ictal events 
that, in the opinion of the Investigator, could be confused with seizures.
12. Subject had epilepsy surgery <1 year or an epilepsy dietary therapy initiated < 3 months 
prior to Screening.
13. Subject has taken other (non-AED) prescription, nonprescription, dietary (eg, grapefruit 
or passion fruit), or herbal products that are potent inducers or inhibitors of the CYP3A4 
pathway for 2 weeks (or 5 half-lives, whichever is longer) prior to the Baseline Visit.
14. Subject is currently treated with carbamazepine, phenytoin, primidone, or phenobarbital 
or any other drug known as a strong inducer of CYP3A4 liver enzymes.
15. Subject is taking tiagabine, felbamate, or vigabatrin.
16. Subject is taking benzodiazepines, zolpidem, zaleplon, or zopiclone >3 times per week
for any indication.
17. Subject had intolerable or serious psychiatric side effects with a previous exposure to 
LEV or BRV.
r,r, b
exclus
xclus
Mini I
Mini 
epilep
epilep
tot
COPY
ion t
ion 
o part
o par
bipo
bip
This document 
14.
14
cannot
bject
ect
or pas
r pas
path
pat
be 
Sc
t h
t h
sed
d epi
d epi
cree
cree
to 
nioio
support
ures t
es 
seudos
eudo
on of
n o
any 
e).
e).
s tha
th
marketing
pticu
icu
o Scree
 Scree
ng a pa
g a p
authorization
ticip
cip
olar 
olar d
sion c
on c
nterna
ntern
us
us
application
Inves
Inves
lity to p
ty to 
hat, in t
at, in
ipate
pat
and 
HCV
CV-
st
any
ody
ody (
y
A
extensions 
units (
units (
d plasm
plasm
y.
or variations 
at,
at,
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 38 of 125
18. Subject has past or present substance abuse/dependence that in the opinion of the 
Investigator could threaten the subject’s safety within the study, affect the subject’s 
ability to fully participate in the study, or confound study interpretation.
19. Subject has a lifetime history of suicide attempt (including an actual attempt, interrupted 
attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by 
a positive response (Yes) to either Question 4 or Question 5 of the C-SSRS at Screening.
20. Subject has a clinically significant abnormality on ECG that, in the opinion of the 
Investigator, increases the risks associated with participating in the study. In addition, any 
subject with any of the following findings will be excluded:
∀
QT corrected for heart rate using Bazett’s formula (QTcB) or QT corrected for heart 
rate using Fridericia’s formula (QTcF) interval >450ms
∀
Bundle branch blocks and other conduction abnormalities that are clinically 
significant according to the Investigator and/or with a PR interval ≥220ms
∀
Irregular rhythms other than sinus arrhythmia or occasional, rare supraventricular or 
rare ventricular ectopic beats
∀
In the judgment of the Investigator, T-wave configurations are not of sufficient 
quality for assessing QT interval duration.
21. Subject has a history of unexplained syncope or a family history of sudden death due to 
long QT syndrome.
22. Subject has a clinically significant abnormality on echocardiography at Screening or a 
history of rheumatic heart disease or other known valvular abnormalities.
23. Subjects with a history of hypersensitivity reactions or autoimmune disease.
24. Female subject who is pregnant or breastfeeding.
6.3
Withdrawal criteria
Subjects are free to withdraw from the study at any time, without prejudice to their continued 
care.
Subject may be withdrawn by the Investigator if s/he is noncompliant with the study 
procedures or medications in a way that, in the opinion of the Investigator, may affect the 
study or the safety of the subject, or a subject is unable to manage the completion of the 
diary, or demonstrates a questionable diary.
Subjects must be withdrawn from the study if any of the following events occur:
1. Subject develops a clinically relevant medical condition (or laboratory abnormality) that, 
in the opinion of the Investigator, compromises the subject’s ability to participate or 
safety. Potential drug-induced liver injury IMP discontinuation criteria are described in 
Section 6.3.1. To monitor for hypersensitivity reactions, percent eosinophils >10% or 
absolute eosinophil count ≥0.5G/L or absolute neutrophil count <1.5G/L or absolute 
platelet count ≤100G/L, if in combination with fever, rash, lymphadenopathy, or other 
symptoms/signs suggestive of internal organ involvement (including but not limited to 
hepatitis, nephritis, pneumonitis, carditis, colitis, encephalitis, pancreatitis, myositis, or 
arthritis) will lead to stopping the IMP.
2. UCB or a regulatory agency requests withdrawal of the subject.
REDACTED
mal
mal
ther k
ther k
ensitiv
nsitiv
t or b
t or b
COPY 
a f
a
alit
lit
This document
s
cannot
ubject
bject
in th
in th
sa
be 
must 
must
used
y
onstra
nstra
b
to
y of 
of 
support 
awn by
wn b
ations
ations
th
any
from
ro
marketing
breas
breas
eria
ria
m th
m
authorization 
y on e
y on e
known
nown
vity
ity rere
y
application 
ns 
ns 
mily
ily hih
y
and 
s are
are
any
e sup
e su
extensions 
cally
cally
220m
20m
pr
or 
he
h
variations 
y
hear
hear
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 39 of 125
3. Subject develops psychiatric/mood/behavioral signs or disturbances (see examples in list 
below) that are clinically concerning or that worsen over time. Tapering and 
discontinuation of UCB0942 would be performed in such subjects and they would be 
referred to a mental healthcare professional.
a) Auditory or visual hallucinations
b) Delusions/paranoia/grandeur
c) Disorganized thought process
d) Agitation/aggression/apathy
e) Dysphoria/depression/mood lability/euphoria
f)
Disinhibition
g) Cognitive changes/significant memory impairment
h) Delirium
i)
Aberrant motor behavior
4. Subject requires treatment with a medication that is not permitted (Section 7.8.2) and is 
not allowed after discussion with the UCB Study Physician.
5. Subject becomes pregnant.
6. Subject has active suicidal ideation without specific plan as indicated by a positive 
response (“Yes”) to Question 4 of the “Since Last Visit” version of the C-SSRS. The 
subject should be referred immediately to a Mental Healthcare Professional and may be 
withdrawn from the study based upon the Investigator’s judgment of benefit/risk of 
continuing the subject in the study/on study medication. If the Subject has active suicidal 
ideation with a plan as indicated by a positive response (“Yes”) to Question 5 of the 
“Since Last Visit” version of the C-SSRS, the subject should be referred immediately to a 
Mental Healthcare Professional and must be withdrawn from the study.
7. Subject has a prolongation or worsening of overall seizure duration, frequency, type, or 
pattern considered by the Investigator as persistent and serious enough to warrant 
discontinuation from the study.
In the case of withdrawal or discontinuation during the study or during the echocardiography 
follow-up period, the Investigator should attempt to obtain information on subjects. For 
subjects considered as lost to follow up, the Investigator should make an effort (at least 1 
phone call and 1 written message to the subject), and document his/her effort (date and 
summary of the phone call and copy of the written message in the source documents) to 
complete the final evaluation. All results of these evaluations and observations, together with 
a narrative description of the reason(s) for removing the subject, must be recorded in the 
source documents. The electronic Case Report form (eCRF) must document the primary 
reason for withdrawal or discontinuation.
The Investigator should contact the UCB Study Physician whenever possible to discuss the 
withdrawal of a subject in advance. If this is not possible, the Investigator should contact the
UCB study physician to inform him/her about the subject withdrawal as soon as possible after 
the withdrawal. 
REDACTED
to a M
to a 
n the
n the
y/on s
/on s
y
d b
d by y 
COPY 
pecifi
pecifi
ce La
e La
This document
sour
sour
rere
cannot
ry o
y
plete t
lete t
arrat
arrat
be
and
and
of t
of t
used 
, t, t
dered
dered
d 1
d 1
to 
the
the
support 
he
he
m the s
m the 
awal 
awal
I
any
n or w
or
e Inv
n
marketing
a po
a po
C-SSR
SS
al and 
l and
wo
w
authorization
c
ast Vi
ast V
Menta
Menta
Inves
nves
study
tudy
os
os
application 
n.
c plan
plan
and 
tted (
ted (
any extensions or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 40 of 125
6.3.1
Potential drug-induced liver injury IMP discontinuation criteria
Subjects with potential drug-induced liver injury (PDILI) must be assessed to determine if 
IMP must be discontinued. In addition, all concomitant medications and herbal supplements 
that are not medically necessary should also be discontinued. 
The PDILI criteria below require immediate and permanent discontinuation of IMP: 
!
Subjects with either of the following:
∀
ALT or AST ≥5xULN
∀
ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 
The PDILI criterion below requires immediate discontinuation of IMP:
!
Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without 
clear alternative cause), rash, or eosinophilia (ie, >5%).
If a nondrug-related cause for the symptoms can be confirmed, these subjects may resume 
IMP administration after discussion with the responsible UCB physician, but only when the 
requirements for rechallenge with IMP as provided in Section 11.6.1.2.1 are followed.
The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
investigator. 
!
Subjects with ALT or AST ≥3xULN (and ≥2x baseline) and <5xULN, total bilirubin 
<2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis 
(eg, fatigue, nausea, vomiting, right upper quadrant pain or tenderness).
Evaluation of PDILI must be initiated as described in Section 11.6.1. If subjects are unable to 
comply with the applicable monitoring schedule, IMP must be discontinued immediately.
Investigators should attempt to obtain information on subjects in the case of IMP 
discontinuation to complete the final evaluation. Subjects with PDILI should not be 
withdrawn from the study until investigation and monitoring are complete. All results of 
these evaluations and observations, as well as the reason(s) for IMP discontinuation and 
subject withdrawal (if applicable), must be recorded in the source documents. The CRF must 
document the primary reason for IMP discontinuation.
REDACTED 
d ≥2
d ≥
%), wit
%), wi
t uppe
uppe
teted as
d as
rin
rin
COPY 
nti
nt
≥2x
2x
This document cannot be used to
mary
mary
support
u
bserva
serva
f appli
appl
ry rere
y
any
e fi
e f
ntil in
til in
marketing 
de
de
ng sche
g sche
btain in
tain 
final
fina
authorization 
basel
basel
ith no 
h no 
er qua
r qua
esc
esc
application 
hy
11.6.
11.6
e on IM
on IM
and
se su
e su
ysici
ici
any 
ubje
ubj
extensions 
ptoms
ptoms
vomit
vomi
fever
fever
or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 41 of 125
7
STUDY TREATMENTS
7.1
Description of investigational medicinal products
The details of the active and placebo IMP are displayed in Table 7‒1.
Table 7‒1:
Description of investigational medicinal product
UCB0942
Placebo for UCB0942
Dosage form
Tablets (white, film-coated), in 
2 strengths:
-
100mg
-
200mg
100mg and 200mg tablets have 
the same size and appearance
Tablets (white, film-coated):
Provided in a size and 
appearance matching UCB0942.
Manufacturer
Batch/lot number
Will be assigned according to GMP
Expiry date
Will be assigned according to GMP
GMP=Good Manufacturing Practice
Note: For the Inpatient Period, 1 kit per treatment period and per dose will be packaged. Each kit will contain 
blister packs, each covering 1 week of treatment. For the Outpatient Period, UCB0942 tablets will be 
provided in bottles, containing 37 tablets per bottle, either 200mg tablets for subjects on UCB0942 400mg bid
or UCB0942 200mg bid, or 100mg tablets for subjects who reduce dose to UCB0942 100mg bid. The bottles 
containing 37 UCB0942 100mg tablets will be dispensed for the Taper Period.
7.2
Treatments to be administered
7.2.1
Test study medication
UCB0942 will be supplied by UCB as 100mg and 200mg tablets that are identical in 
appearance.
7.2.2
Reference product
The placebo will be provided as tablets that are identical in appearance to the tablets
containing UCB0942.
7.3
Packaging
All study medication for the double-blind Inpatient Period will be provided in blister packs 
and administered in a double-blind manner. All subjects will be instructed to take tablets 
containing either UCB0942 or placebo twice per day, approximately 12 hours apart. The
blister-packed treatment cards will each provide 7 days’ treatment of active or placebo 
UCB0942. For the open-label Outpatient Maintenance Period, tablets will be provided in 
ACT
ED
COPY
OPY 
COP
This document 
The
The
c
cannot
rance
ance
2.2
.2
be
wil
wil
used 
Tes
Tes
to
eat
eat
support
100mg
00m
100mg t
00mg
tm
tm
any 
of 
of
7 table
table
g t
marketing 
per treat
er trea
tre
tr
eti
authorizatio
Wil
Wi
ho
a
tion 
cation 
n
ti
pplica
app
a
and 
n
a
any extensions 
e
or variations 
0942
0942
tio
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 42 of 125
bottles, with a 2-week supply (see Table 5-4). For the Taper Period, bottles of 100mg tablets 
will be dispensed for 1-2 weeks, depending on dose from which the taper starts.
7.4
Labeling
Clinical drug supplies will be labeled in accordance with the current International Conference 
on Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and Good 
Manufacturing Practice (GMP) and will include any locally required statements. If necessary, 
labels will be translated into the local language.
7.5
Handling and storage requirements
The Investigator (or designee) is responsible for the safe and proper storage of IMP at the 
site. Investigational medicinal product stored by the Investigator is to be kept in a secured 
area with limited access.
Appropriate room temperature storage conditions must be demonstrated by completion of a 
temperature log in accordance with local requirements, including the capture of minimum 
and maximum temperatures reached over a time interval. Temperatures, including minimum 
and maximum recordings, should be documented daily on the log during the site’s days of 
operation. The IMP is to be stored according to the instructions on the label.
In case an out-of-range temperature is noted, it must be immediately communicated to the 
Exploratory Project Manager (EPM) (or designee) before further use of the IMP.
The EPM (or designee) will transmit the out-of-range temperature (copy of the temperature 
log and duration of the out-of-range temperature, if available) to the Drug Supply 
Coordinator. Based on discussion with a UCB Quality Assurance representative, the Drug 
Supply Coordinator will then provide the EPM (or designee) with instructions for the site 
regarding use of the IMP.
The Investigator (or designee) will instruct the subject to store the IMP following the 
instructions on the label.
7.6
Drug accountability
A Drug Accountability form will be used to record IMP dispensing and return information on 
a by-subject basis and will serve as source documentation during the course of the study. 
Details of any IMP lost (due to breakage or wastage), not used, disposed of at the study site, 
or returned to the Sponsor or designee must also be recorded on the appropriate forms. All 
supplies and pharmacy documentation must be made available throughout the study for UCB 
(or designee) to review.
The Investigator (or designee) is responsible for retaining all used, unused, and partially used 
containers of IMP until returned or destroyed.
The Investigator may assign some of the Investigator’s duties for drug accountability at the 
study site to an appropriate pharmacist/designee.
The Investigator must ensure that the IMP is used only in accordance with the protocol.
Periodically, and/or after completion of the clinical phase of the study, all used (including 
empty containers) and unused IMP containers must be reconciled and returned to UCB (or 
designee), preferably in their original package. Investigational medicinal product intended for 
the study cannot be used for any other purpose than that described in this protocol.
REDACTED
CB Q
CB Q
e E
 EPM
PM
inst
inst
COPY 
ange t
ange 
re, if 
e, if 
This document 
he
he
stud
stud
cannot 
esti
sti
iners 
ners
e In
In
be 
)
tiga
tiga
used
harm
arm
to re
to re
to
Spo
po
ma
support 
m
will ser
ill se
ost (du
st (du
onso
on
any 
will 
will
marketing
truct t
truct 
abili
abi
authorization
f av
f avail
ai
Quality
uality
M (or 
M (or 
application 
ediately
diate
further
furthe
emper
mpe
and 
urin
rin
n the 
the 
any
 inc
 inc
ng th
ng
extensions 
omple
omple
ure of
re of
clul
or
ure
ure
variations 
he
he
d
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 43 of 125
7.7
Procedures for monitoring subject compliance
At each visit after where new IMP is dispensed and at the end of the Taper Period (Days 
OP15, OP29, OP43, OP57, and TOO14), subjects must return all unused IMP and empty IMP 
containers. Subjects will be asked to document drug intake on the subject diary throughout 
the Treatment Period. Drug accountability must be done in the subject’s presence in order to 
obtain explanations regarding discrepancies in compliance with the dosing regimen. Drug 
accountability must be recorded on the Drug Accountability form.
If a subject is found to be persistently noncompliant (defined as less than 75% or more than 
125% compliant with the dosage schedule), the Sponsor, in conjunction with the Investigator, 
will make a decision as to whether the subject should be withdrawn from the study.
Timely completion of the subject diary is essential for evaluation of safety and efficacy. A 
caregiver is allowed to help the subject with the completion of the subject diary. Subject diary 
completion will be evaluated at each visit.
7.8
Concomitant medications/treatments
7.8.1
Permitted concomitant treatments (medications and therapies)
The following concomitant medications are permitted during the study:
!
All subjects should continue using their Baseline AED regimen throughout the Inpatient 
Treatment Period. Changes in AEDs during the Outpatient Maintenance Period should be 
discussed with the UCB Study Physician on an individual and case-by-case basis.
!
Oxcarbazepine, eslicarbazepine.
!
Benzodiazepines (as a rescue medication less than or equal to 3 doses within 7 days).
!
Other medication, not mentioned as prohibited, that does not induce CYP3A4 and is
approved by the UCB Study Physician.
7.8.2
Prohibited concomitant treatments (medications and therapies)
The following concomitant medications are prohibited during the study (this is not a 
complete list of prohibited medications):
!
Carbamazepine, phenytoin, phenobarbital, primidone, or other strong CYP3A4 inducers
!
Benzodiazepines taken >3 times per week (see Section 7.8.1)
!
Zolpidem, zaleplon, or zopiclone taken >3 times per week
!
Tiagabine
!
Felbamate
!
Vigabatrin
!
Non-AED CYP3A4 inducers/inhibitors (ie, prescription drugs, nonprescription drugs, 
dietary [eg, grapefruit or passion fruit], or herbal products)
7.8.3
Rescue medication
Benzodiazepines can be used as rescue medication (less than or equal to 3 doses within 
7 days).
REDACTED 
ation l
tion l
d as p
d as p
hy
hysic
sic
COPY 
Ou
O
an ind
an ind
This document 
!
cannot 
elbam
Vigi
be 
bine
bine
used
 zalep
zalep
to 
nes 
nes 
support 
m
hen
enytytoio
take
tak
any
edic
edi
medic
edic
marketing 
pro
cian.
cian.
omita
omita
cati
ca
authorization 
di
less th
less th
ohib
ohib
application 
e st
regimen
egime
atient 
tient M
vidua
vidua
and 
ons
ns
stud
tud
any 
s an
s a
extensions
icac
ac
Subj
Subj
or 
cy
cy
variations 
ator,
tor, 
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 44 of 125
7.9
Blinding
This is a study with a double-blind Inpatient Period and an open-label Outpatient Period. At 
the start of the Titration Period (Day T1) subjects will be randomized to UCB0942 400mg 
bid or placebo in a 1:1 ratio.
The randomization will be stratified for the following LEV prior/current use factor to ensure 
the balance across treatment groups (Placebo, UCB0942 400mg bid):
!
use of LEV (3 levels):
1. LEV prior and current use (concomitant use of LEV at study entry)
2. LEV Prior Use Only=History of prior LEV use and must have discontinued 
4 weeks prior to study entry
3. LEV Naïve=No history of prior LEV use, and no use at study entry
7.9.1
Procedures for maintaining and breaking the treatment blind
7.9.1.1
Maintenance of study treatment blind
All subject treatment details will be allocated and maintained by the interactive response 
technology (IRT). Details of the IRT system will be addressed in a separate randomization 
schedule specification document.
7.9.1.2
Breaking the treatment blind in an emergency situation
In the event of an emergency, it will be possible to determine which treatment arm and dose 
the subject has been allocated to by contacting the IRT. All sites will be provided with details 
of how to contact the system for code breaking at the start of the study. The Medical Monitor 
or equivalent should be consulted prior to unblinding, whenever possible.
The EPM will be informed immediately via the IRT when a code is broken, but will remain 
blinded to specific treatment information. Any unblinding of the IMP performed by the 
Investigator must be recorded in the source documents and on the Study Termination eCRF 
page.
The SRG may also elect to break the blind for individual subjects as part of its review 
process, in order to better assess the significance and response to AEs of concern (see 
Section 11.1.9).
7.9.1.3
Breaking the treatment blind for taper of dose during the study
When the Investigator and Sponsor Study Physician agree that a subject cannot titrate to the 
maximum dose or that a dose reduction is necessary during the Inpatient Period (See 
Section 5.1, the blind will have to be broken, following the procedure described in Section 
7.9.1.2.
7.10
Randomization and numbering of subjects
An IRT will be used for assigning eligible subjects to a treatment regimen based on a 
predetermined production randomization and/or packaging schedule provided by the IRT 
vendor. The randomization schedule will be produced by the IRT vendor. The IRT will 
generate individual assignments for subject kits of study drug, as appropriate, according to 
the visit schedule.
To enroll a subject (Visit 1), the Investigator or designee will contact the IRT and provide 
brief details about the subject to be enrolled. Each subject will receive a 5-digit number 
assigned at Screening that serves as the subject identifier throughout the study. The subject 
REDACTED
ng th
ng t
eaking
eaking
r to un
r to u
iately
iately
COPY
n an
n a
e to d
e to d
he
h
This document
7.10
7.10
A
cannot 
n 5.1
5.1
1.2.2.
0
be
dos
dos
used 
Bre
re
vestig
estig
to
eak
eak
support 
o br
b
ter asse
r ass
any 
reak
rea
marketing 
y via 
via
y
ation. A
ation.
the sou
he so
authorization
deter
eter
e IRT
RT
g at th
at th
unblind
nblind
a t
application
in a 
n a 
emerg
emer
rmi
and
he int
e int
a se
se
any extensions 
ment
ment
or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 45 of 125
number will be required in all communication between the Investigator or designee and the 
IRT regarding a particular subject. Subject numbers and kit numbers will be tracked via the 
IRT. 
To randomize a subject (Visit 3), the Investigator or designee will contact the IRT and 
provide brief details about the subject to be randomized. The IRT will automatically inform 
the Investigator or designee of the subject’s randomization number. The IRT will allocate kit 
numbers to the subject based on the subject number during the course of the study.
After completion of the Inpatient Maintenance Period, doses for subjects receiving placebo 
will be titrated to the Outpatient Maintenance Dose (Day TTO 1 to TTO7). To ensure 
continued blinding all subjects will remain in the clinic for this titration period.
8
STUDY PROCEDURES BY VISIT 
Details of the study assessments to be performed at specific time points prior to and after IMP 
administration are provided in Table 5-4, and an outline of all assessments performed is 
provided in the sections below.
The total blood collection for the study will not exceed 500mL per subject.
8.1
Screening and Baseline Period
8.1.1
Screening (Visit 1, Day -1)
!
Written informed consent
!
Complete medical, medication, and procedure history recording
!
Concomitant and past AEDs
!
Review of historic seizure count (ie, in the preceding 4 weeks)
!
Review of inclusion/exclusion criteria
!
Date of birth, sex, ethnicity, and race
!
Habits and lifestyle
!
Physical examination (complete)
!
Neurological examination
!
Psychiatric and cognitive assessments (MINI, BPRS, and MMSE)
!
Vital signs (blood pressure [BP], pulse, and respiratory rate)
!
Body weight and height
!
12-lead ECG
!
Echocardiogram (this can be done on a different day but must be done before dosing with 
UCB0942)
!
Clinical laboratory (clinical chemistry, hematology, and urinalysis)
!
Urine or serum pregnancy test (female subjects only)
!
Drug and alcohol screening
!
Serology (HIV-1/2Ab, HBsAg, and HCV-Ab)
!
C-SSRS (Screening/Baseline version)
REDACTED 
(ie, in 
(ie, in 
crite
crite
COPY 
ure h
ure h
This document
!
E
cannot 
y w
y w
12-lea
lea
E
be 
wei
wei
used 
nd
nd
ns (
s (blbl
o
d co
d co
support
(com
(com
minati
minat
any 
mp
marketing 
eria
eria
nd race
d rac
authorization
histor
histor
n the p
the p
application and 
ubj
ubj
any 
ject
jec
extensions 
to and
o and
perfor
erfor
or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 46 of 125
!
Diary card dispense
8.1.2
Baseline Period (Visit 2, Day BL1 to BL14-21)
The Baseline Period (Day BL1 to BL14-21) will commence the day after the first day of 
Screening and will start no more than 3 weeks before entry into the clinic for the Inpatient 
Period. 
During the Baseline Period a phone call will be made to the subject to verify completion of 
the diary card and to confirm the T1 admission day.
Screening assessments that cannot be completed on the first screening visit (eg, brain imaging 
with MRI or CT and echocardiogram) can be performed at any time during the Baseline 
Period but must be completed before the first dose of UCB0942.
If a subject fails screening, a rescreening is allowed if deemed appropriate by the 
Investigator.
8.2
Inpatient Period (3 weeks)
Details of the study assessments to be performed at specific time points during the Inpatient 
Period are provided in Table 5‒5.
An outline of all assessments performed is provided in the sections below.
8.2.1
Titration Week (Visit 3, Day T1 to Day T7)
At the discretion of the Investigator, sites may or may not perform video or video-EEG 
monitoring during parts of the Inpatient Period or during the whole Inpatient Period of the 
study, depending on the infrastructure of each site, to provide objective data on seizure type, 
severity, and duration, and on the duration of the postictal period as an exploratory outcome 
measure. The following assessments will be performed at admission to the clinic on Day T1
before administration of IMP:
!
Return of diary cards and seizure count for the Prospective Outpatient Baseline Period to 
verify continued eligibility to participate in the study
!
Dispense of new diary card
!
Habits and lifestyle
!
Concomitant medication/procedures
!
Urine or serum pregnancy test (female subjects only)
!
Drug and alcohol screening
!
Review of inclusion/exclusion criteria
!
Withdrawal criteria assessment
!
Physical examination (focused)
!
Neurological examination
!
Psychiatric monitoring with BPRS
!
Cognitive monitoring with MMSE
!
Vital signs (BP, pulse, temperature, and respiratory rate)
!
Body weight
REDACTED 
od 
od 
ach si
ach s
ion of
ion of
will b
will b
COPY 
o
r may
ma
or d
or d
This document 
!
cannot
eview
view
Wit
Wi
be
and a
and 
used 
rum
um
al
to 
med
ed
support 
dicat
dica
any 
ard
rd
marketing 
re cou
e co
o parti
o par
authorization 
y n
during
uring
ite,
te, toto
f the p
f the p
be per
e per
application
ctions 
tions
ay T7)
T7)
y
notot p
and 
ntnt
any 
s dur
s dur
extensions 
e
or variations 
ging 
ging 
e
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 47 of 125
!
12-lead ECG
!
Blood sample for DNA
!
Blood sample for mRNA
!
Blood sample for lipidomics/proteomics/additional biomarkers
!
Blood sample for AED (archival)
!
SSQ (Baseline version)
!
QOLIE-31-P
!
Diary Addendum (T1)
!
C-SSRS (since last visit)
!
Concomitant AEDs
!
Concomitant medication/procedures
!
AEs
!
Randomization (after all assessments have been done)
Subjects randomized to the active group will be titrated up to UCB0942 400mg bid over 
1 week, as shown in Table 5‒1. Subjects randomized to placebo will do a dummy titration. 
After all admission assessments have been completed, all subjects will be given their first 
100mg dose of IMP (or placebo) in the evening under medical supervision. During the 
double-blind part of the study, subjects in both arms will take the same number of tablets. All 
subjects will continue to record their seizures in subject diaries during the Titration Week.
During the Titration Week the following assessments will be performed as outlined in the 
schedule of assessments (Table 5‒5):
!
Return and dispense of diary card (Day T1)
!
Video or video-EEG monitoring (optional)
!
Withdrawal criteria assessment
!
Psychiatric monitoring with BPRS
!
Cognitive monitoring with MMSE (Days T4 and T7)
!
Vital signs (BP, pulse, and respiratory rate; Days T3, T5, and T7)
!
12-lead ECG (Day T4)
!
Administration of IMP and Baseline AED regimens
!
Concomitant AEDs
!
Concomitant medication/procedures
!
AEs
8.2.2
Maintenance-Dose Week (Visit 4, Day MD1 to Day MD7)
At the end of the Titration Week, subjects continue in the Maintenance-Dose Week, during 
which they will continue to record their seizures in subject diaries.
REDACTED
ng
oth a
oth a
zures 
ures 
wing 
wing 
5):):
COPY 
ed t
ed 
leted,
leted,
g und
und
This document
!
C
cannot 
ead
a
Admi
Admi
C
be 
d E
d E
used 
on
on
ns s (BP
(B
o
nitor
nito
support 
ssess
ess
toring
oring
i
any
torin
tor
sm
marketing 
as
card
ard (D
(D
ing
in
authorization
, a
der m
der m
rms 
rms w
in su
su
sses
sses
application 
to UCB
UC
placebo
laceb
all su
ll su
and any extensions or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 48 of 125
During this period the following assessments will be performed as outlined in the schedule of 
assessments (Table 5‒5):
!
Return and dispense of diary card
!
Video or video-EEG monitoring (optional)
!
Withdrawal criteria assessment
!
Physical examination (complete, Day MD1)
!
Neurological examination (Day MD1)
!
Vital signs (BP, pulse, and respiratory rate; Days MD3 and MD7)
!
Body temperature (Day MD7)
!
12-lead ECG (Days MD1, MD3, and MD7)
!
Clinical laboratory (clinical chemistry, hematology, and urinalysis; Days MD1 and MD7)
!
C-SSRS (since last visit; Days MD1 and MD7)
!
Psychiatric monitoring with BPRS
!
Cognitive monitoring with MMSE (Days MD3 and MD7)
!
Administration of IMP and Baseline AED regimens
!
On Day MD1 and MD7, blood samples for measurement of plasma concentration of 
UCB0942 and metabolites at the following times: predose (within 5min of the morning 
dose), then at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, and 12h postdose. All times relative to 
morning IMP administration time.
!
Blood sample for mRNA (Day MD7)
!
Blood sample for lipidomics/proteomics/additional biomarkers (Day MD7)
!
Concomitant AEDs
!
Concomitant medication/procedures
!
AEs
!
SSQ (Baseline version) for previous week on Day MD1 and MD7
8.2.3
Transition-to-Outpatient Week (Visit 5, Day TTO1 to Day TTO7)
After the end of the Maintenance-Dose Week, subjects will continue to take IMP if this is 
well tolerated (as determined by the Investigator and the subject). If a subject in the active 
arm is not tolerating UCB0942 400mg bid well during the Maintenance-Dose Week, the dose 
can be tapered to UCB0942 200mg bid during the Transition-to-Outpatient Week before 
discharge to the Outpatient Maintenance Period. In this case, the blind will be broken. The 
taper from UCB0942 400mg bid to UCB0942 200mg bid would occur over 3 days (see 
Table 5‒2).
UCB0942 doses for subjects in the placebo arm will be titrated to UCB0942 400mg bid in the 
same way as the doses for subjects in the active arm were titrated during the Titration Week 
(Table 5‒1). If UCB0942 is well tolerated during the titration, subjects in the placebo arm 
will be discharged on UCB0942 400mg bid and followed in the Outpatient Maintenance 
Period. If a subject in the placebo arm cannot tolerate the titration up to UCB0942 400mg 
REDACTED
ng t
ng t
h, 6h,
h, 6h,
MD7
MD7
COPY 
men
me
measu
meas
tim
tim
This document 
can 
an 
disc
disc
t
cannot
lerat
erat
is no
is no
n be
be
be
end o
end 
used
Tran
Tra
to
e ver
ve
support 
on/n/
ersio
rs
any 
/proc
/pro
marketing 
7)
oteomi
oteom
authorization
urem
urem
mes: p
es: p
, 8h, a
8h, a
application 
)
me
me
and any extensions 
ays M
or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 49 of 125
bid, the blind will be broken and the subjects will remain on a tolerable dose (ie, UCB0942 
200mg bid) before starting the Outpatient Maintenance Period.
The entire Inpatient Period will be double-blind (except in cases in which the dose needs to 
be reduced or the taper cannot be completed, as described above); however, subjects and staff 
will know that at discharge all subjects are taking active compound. Therefore, the Outpatient 
Period is open-label.
During the Transition-to-Outpatient Week the following assessments will be performed as 
outlined in the schedule of assessments (Table 5‒5):
!
Return and dispense of diary card
!
Video or video-EEG monitoring (optional)
!
Withdrawal criteria assessment
!
Physical examination (complete; Day TTO7)
!
Neurological examination (Day TTO7)
!
Vital signs (BP, pulse, and respiratory rate; Days TTO4 and TTO7)
!
Body temperature (Day TTO7)
!
Body weight (Day TTO7)
!
12-lead ECG (Day TTO7)
!
Clinical laboratory (clinical chemistry, hematology, and urinalysis; Day TTO7)
!
Administration of IMP and Baseline AED regimens
!
Psychiatric monitoring with BPRS
!
Cognitive monitoring with MMSE (Days TTO4 and TTO7)
!
Withdrawal monitoring with CIWA-B (before evening dose on Day TTO6)
!
SSQ (Baseline version) (Day TTO7)
!
C-SSRS (since last visit; Day TTO7)
!
Blood sample for AED (archival; Day TTO7)
!
Concomitant AEDs
!
Concomitant medication/procedures
!
AEs
Upon release from the clinic subjects will receive IMP for 2 weeks and a diary card for the 
first week of the Outpatient Maintenance Period.
8.3
Outpatient Period (14 weeks)
8.3.1
Outpatient Maintenance Period (Visit 6 to Visit 15, Day OP1 to Day 
OP57)
All subjects will take active UCB0942 during the Outpatient Maintenance Period; however, 
they will not know whether they were taking active or placebo during the Inpatient Period. If 
well tolerated, all subjects will continue to take UCB0942 400mg bid for 8 weeks during the 
Outpatient Maintenance Period. At any time during the Outpatient Maintenance Period, if a 
REDACTED
ema
em
AED
AED
RS
RS
SE
S
COPY 
mato
ato
This document
first 
irst
8
cannot 
s
on re
on re
be 
mita
mit
used
nt AE
A
tant
tant
to 
AED
E
support 
visit;
isit; D
r AED
AED
any
Day
Day T
y
marketing 
E (Day
E (Day
CI
CIWA
W
authorization 
ology
logy
regim
regim
application and
O7
O7)
any extensions or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 50 of 125
subject does not tolerate UCB0942 400mg bid, the Investigator can decide to taper to 
UCB0942 200mg bid as shown in Table 5‒2. During the first week of the Outpatient 
Maintenance Period, all subjects will undergo psychiatric monitoring by phone on the days 
they do not visit the clinic (Days OP1, OP2, OP4, OP6, and OP7) and in person in the clinic 
on Days OP3, OP5, and OP8. Cognitive monitoring with MMSE will take place in the clinic 
on Days OP3, OP5, and OP8. This monitoring is necessary because the subjects initially 
randomized to placebo will be discharged directly after the titration to UCB0942 400mg bid
and psychiatric AEs are most likely to occur in the first 2 weeks of UCB0942 administration.
During the Outpatient Maintenance Period subjects will visit the clinic on the following days 
(±2 days to allow for weekend interruptions):
Day OP3, OP5, OP8, OP15, OP22, OP29, OP36, OP43, OP50, and OP57.
When possible, outpatient clinic visit days will take place in the morning to allow dosing to 
take place in the clinic and collection of a predose blood sample for evaluation of trough PK 
levels at specific visits.
Dose tapering from UCB0942 400mg bid to UCB0942 200mg bid to increase tolerability 
may be implemented for each subject at any time during the 8 weeks of treatment in the 
Outpatient Maintenance Period at the discretion of the Investigator in conjunction with the 
wishes of the subject. Dose tapering to UCB0942 100mg bid may be permitted after 
discussion with the Sponsor’s Study Physician.
During this period the following assessments will be performed according to the schedule of 
assessments (Table 5-4):
!
Return and dispense of diary cards at each visit
!
Return IMP (Days OP15, OP29, OP43, and OP57)
!
Dispense IMP (Days OP15, OP29, OP43, and OP57)
!
Administration of IMP
!
Withdrawal criteria will be assessed at each visit
!
Physical examination (complete; Days OP22 and OP57)
!
Body weight (Days OP22 and OP57)
!
Neurological examination (Days OP22 and OP57)
!
Vital signs (BP, pulse, and respiratory rate; Days OP8, OP22, OP36, and OP57)
!
12-lead ECG (Days OP22 and OP57)
!
Echocardiogram (Day OP22 ±1 week)
!
Clinical laboratory (clinical chemistry, hematology, urinalysis; Days OP8, OP22, and 
OP57)
!
Drug and alcohol screening (Days 22 and OP57)
!
Urine or serum pregnancy test (females only; Days OP8, OP36, and OP57)
!
Obtain blood samples for measurement of plasma concentration of UCB0942 and  
metabolites before morning dose (Days OP3, OP5, OP8, OP15, OP22, OP29, OP36, 
OP43, OP50, and OP57)
each v
each v
OP43,
OP43,
P29,
P29,
COPY 
l be p
l be p
This document
!
C
cannot 
ead
a
Echoc
Echoc
C
be 
d EC
d EC
used 
l ex
e
ns (BP
s (B
o
exam
xam
support
(com
(com
ys OP2
OP
any
as
as
mp
marketing
 OP43
OP4
sses
sse
authorization 
pe
visit
isit
, and 
and 
application 
tor
or
may
may b
y
erform
rform
and
ks of
s of
r in 
in
any
ncrea
ncrea
f tr
f t
extensions 
w dos
w dos
on of t
n of t
or variations 
ys s 
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 51 of 125
!
Psychiatric monitoring with BPRS at the visits (Days OP3, OP5, OP8, OP15, OP22, 
OP29, OP36, OP43, OP50, and OP57) and by phone (Days OP1, OP2, OP4, OP6, and 
OP7)
!
Cognitive monitoring with MMSE at the visits (Days OP3, OP5, OP8, OP15, OP22, 
OP29, OP36, OP43, OP50, and OP57)
!
SSQ (Baseline version) (Days OP22 and OP57)
!
QOLIE-31-P questionnaire (Days OP22, OP36, and OP57)
!
Diary Addendum (OP57)
!
C-SSRS (since last visit; Days OP22 and OP57)
!
Concomitant AEDs recording
!
Concomitant medication/procedures recording
!
AEs recording
!
Decision to continue in the OLE study (Day OP43)
8.3.2
Taper Period (Visit 15 to Visit 17, Day OP57 to TOO14)
All subjects who do not continue into the OLE study (see Section 8.6) will undergo a Taper 
and Safety Follow-Up Period to taper off study medication over a 2-week period (Table 5‒3). 
Subjects will start their taper on Day OP57 (Visit 15) and will return for the Mid Taper Visit 
(Day TOO7) after 1 week and for the End of Taper Visit (Day TOO14) after 2 weeks. 
Changes to concomitant AED(s) are allowed during taper of UCB0942. Subjects can also 
start this taper earlier during the Outpatient Maintenance Period, if they decide to exit the 
study early.
During this period the following assessments will be performed as outlined in the schedule of 
assessments (Table 5-4):
!
Return and dispense of diary cards at each visit
!
Withdrawal criteria will be assessed at each visit
!
Administration of IMP
!
Physical examination (Day TOO14)
!
Neurological examination (Day TOO14)
!
Vital signs (BP, pulse, and respiratory rate) (Day TOO14)
!
12-lead ECG (Day TOO14)
!
Return IMP (Day TOO14)
!
SSQ (Baseline version) (Day TOO14)
!
QOLIE-31-P questionnaire (Day TOO14) 
!
Psychiatric monitoring with BPRS (Days TOO7 and TOO14)
!
Cognitive monitoring with MMSE (Days TOO7 and TOO14)
!
Withdrawal monitoring with CIWA-B (Days TOO7 and TOO14)
!
Concomitant AEDs
REDACTED
a
ed dur
ed du
ent 
ent M
ssess
ssess
COPY 
dica
dic
15) a
aper 
aper 
This document 
!
canno
2-
ot 
lead
lead
Re
Re
be
signs
sign
used 
ical ex
cal ex
to
inat
ina
support 
l b
l 
IMP
MP
ation
tio
any 
y
be as
be a
marketing
sment
smen
ca
card
rd
authorization
an
r Visit
Visit
ring ta
ring ta
Mainte
ainte
application 
57
ection
tion
on ove
ov
nd wi
nd w
and 
to
to
any extensions or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 52 of 125
!
AED archival sample (Day TOO14)
!
Concomitant medication/procedures
!
AEs
8.3.3
Safety Follow-Up (Visit 18 to 20, Day SFU7, SFU14, and SFU28)
Two SFU visits are planned: the first SFU is planned 1 week after the end of the Taper Period
(SFU7) and a final SFU 4 weeks after the end of the Taper Period (SFU28). During these
visits the following assessments will be performed:
!
Return of diary card (Day SFU7, SFU14 [optional], and SFU28), dispense of diary card 
(Day SFU7 and SFU14 [optional])
!
Physical examination
!
Neurological examination
!
Vital signs (BP, pulse, and respiratory rate)
!
Body weight (Day SFU28)
!
12-lead ECG (Day SFU28)
!
Clinical laboratory (clinical chemistry, hematology, and urinalysis)
!
Echocardiogram after last dose and 6 months later (±1 month). For subjects who 
withdraw during the Inpatient Period and for subjects who withdraw during the 
Outpatient Period, see Section 8.4 for echocardiogram requirements following 
withdrawal. 
!
Pregnancy test (urine or serum, females only)
!
SSQ (Baseline version)
!
C-SSRS (since last visit)
!
Psychiatric monitoring with BPRS
!
Cognitive monitoring with MMSE
!
Withdrawal monitoring with CIWA-B
!
Concomitant medication/procedures
!
AEs
If deemed necessary by the Investigator 1 additional SFU visit can be planned one week after 
Day SFU7 (Day SFU14) containing those assessments deemed necessary by the Investigator.
8.3.4
Echocardiography follow up
For subjects who complete this study but do not continue in the OLE study, it is mandatory 
that they have an echocardiogram at 6 months (±1 month) after the last dose of IMP (in 
addition to the echocardiogram at Screening, during dosing, and after the last dose). 
8.4
Withdrawal Visit
In case of early withdrawal of the subject for any reason, all efforts should be taken to have a 
safety follow-up visit as described in Section 8.3.3.
If a complete SFU is not feasible, at least the following assessments will be performed:
REDACTED
hoca
hoc
emales
emale
COPY 
ater 
ater 
or subj
r sub
card
car
This document 
.3
Fo
Fo
cannot 
ed n
d 
SFU
FU7
3.4
.4
be 
nec
nec
used 
m
o
med
med
support
g with
with
itoring
toring
any
h B
h B
h M
h
marketing 
BPR
BP
authorization
ject
ect
rdiogra
diogr
s only
s only
application 
urinal
urina
±1 mo
1 m
ts w
ts w
and any extensions or variations 
ard d 
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 53 of 125
!
Physical examination
!
Neurological examination
!
Vital signs (BP, pulse, and respiratory rate)
!
Body weight
!
12-lead ECG
!
Echocardiogram
∀
Withdrawal during the Inpatient Period: The SFU7 echocardiogram should be 
performed. If there is no abnormality, the echocardiogram does not need to be 
repeated. If there is an abnormality, the echocardiogram should be repeated at 
6 months (±1 month) after the last dose of IMP. 
∀
Withdrawal during the Outpatient Period: The SFU7 echocardiogram should be 
performed, and the echocardiogram should be repeated at 6 months (±1 month) after 
the last dose of IMP. 
!
Clinical laboratory (clinical chemistry, hematology, and urinalysis)
!
Pregnancy test (urine or serum, females only)
!
Diary Addendum
!
C-SSRS 
!
Concomitant medication/procedures
!
AEs
8.5
Unscheduled Visit
At any time, the subject may have an unscheduled clinic visit/phone call if the Investigator or 
the subject deems it necessary.
During an Unscheduled Visit the assessments will be performed as applicable as judged by 
the Investigator
8.6
Open-label extension study (EP0073)
Subjects who experience substantial benefit from UCB0942 with acceptable tolerability may 
have the option to continue taking UCB0942 during an OLE study. The decision to enter the 
OLE study must be made by the subject in consultation with the Investigator and/or the 
subject’s caregiver. This decision must take into account the benefit experienced, the 
potential risks of long-term exposure to UCB0942, and the potential benefit and risks of other 
treatment options available. Subjects who enter the OLE study will have echocardiographic 
follow up as scheduled in the OLE study protocol and will therefore not participate in the
echocardiographic follow up described in Section 8.3.4.
9
ASSESSMENT OF EFFICACY
The efficacy variables are described in detail in Section 4.1.
9.1
Seizure frequency
At the Screening Visit, seizure count will be based on Investigator assessment of subjects’ 
reports during the 4 weeks prior to the Screening Visit, which will determine the subject’s
eligibility for the study. The minimum required historic seizure count during the 4 weeks
REDACTED 
sit
sit
COPY 
This document
follo
ollo
ech
ech
cannot
ial ris
al ri
atment
tmen
ow
ow
be
careg
care
used
n to c
to c
must b
ust b
to
erien
erie
co
support 
label
abe
ence
nc
any
the a
the 
marketing 
n unsch
unsc
as
as
authorization application and 
ysis)
is)
any extensions 
m shou
m shou
s (±1 
(±1 
or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 54 of 125
prior to Screening is 4 partial-onset seizures (IA1, IB, or IC according to the International 
Classification of Epileptic Seizures, 1981) per week on average with no seizure-free period 
longer than 3 days (based on Investigator assessment of subject report). During the study, 
subjects will keep diaries to record daily seizure activity from the Screening Visit until the 
end of study participation. Subjects should be reminded to bring their diaries with them to 
each clinic visit. 
The written information will be discussed with the subjects at each visit in order to ensure 
completeness and accuracy. As a result of the discussion, the Investigator will assess the 
seizures according to the ILAE codes and record the seizure types and frequency in the 
eCRF; he/she will also confirm the presence of AEs if applicable.
Subjects should be educated to complete their diary entries after each seizure or at least once 
a day (eg, when taking evening tablets). A caregiver can assist in completing the diary if 
necessary. Substantial noncompliance with diary completion (seizure recording) may result in 
subject discontinuation from the study at any time by the Investigator or the Sponsor; see 
Section 6.3.
The following seizure information will be recorded in the diary:
!
Seizure type
!
Seizure frequency
9.1.1
Video monitoring
At the discretion of the Investigator, sites may or may not perform video or video-EEG 
monitoring during part of the Inpatient Period or during the whole Inpatient Period,
depending on the infrastructure of each site, to allow exploratory analysis of seizure type, 
severity, and duration, and of the duration of the postictal period.
9.2
Seizure Severity Questionnaire
The SSQ (Cramer et al, 2002) is a review of various aspects of seizures. The person who has 
seizures may ask people who have observed the seizures (family, friends) to help answer 
some of the questions asking about events, but not about feelings. There are 10 questions in 3
sections asking about events before, during, and after typical seizures.
The subject should describe their most common type of seizure when answering the 
questions. If subjects are unsure about how to answer a question, they should give the best 
answer they can and write a comment or explanation on the side of the page. 
The Baseline SSQ will be completed according to the tabular schedule of study procedures, 
Table 5-4. The Baseline version of the SSQ will be used for all visits during which the SSQ is 
to be completed. For this study the recall period will be set to 1 week rather than the original 
4 weeks. At the very beginning of the visit, the SSQ will be provided to all subjects. The 
subject will be asked to complete the questionnaire on his/her own. Once completed, the 
subject will return the completed questionnaire to the Investigator or designee, who will 
verify that all questions have been answered. Further details about the SSQ will be covered in 
the Study Manual.
9.3
Quality of Life Inventory in Epilepsy-31-P
The QOLIE-31-P assesses subject functioning and health-related quality of life.
The QOLIE-31-P (Cramer et al, 2003) is an adaptation of the original QOLIE-31 instrument 
(Cramer et al, 1998) that includes 30 items grouped into 7 multi-item subscales (Seizure 
REDACTED
y
od or
od o
site,
ite, tot
ation o
ation o
y Q
COPY 
or m
or m
This document
subj
subj
su
su
cannot 
4.
comp
comp
weeks
eeks
be 
ne
Th
Th
used
n and
an
SS
SS
to
cts 
cts 
nd
support
ents b
nts b
escribe
scrib
s are
ar
any
abou
abo
bef
b
marketing
Quest
Ques
review
revie
ve ob
ve ob
authorization
may
may no
no
y
r durin
durin
o allo
allo
of the
of the
application 
t
and any extensions
diary
diary
g) ma
g) ma
e Spon
Spon
or
ast o
st o
variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 55 of 125
Worry [5 items], Overall Quality of Life [2 items], Emotional Well-being [5 items], 
Energy/Fatigue [4 items], Cognitive Functioning [6 items], Medication Effects [3 items], and 
Daily Activities/Social Functioning [5 items]) and 1 health status item.
In addition to the 31 items of the QOLIE-31, the QOLIE-31-P contains 7 items assessing the 
degree of “distress” associated with the topic of each subscale (ie, distress items) and 1 item 
asking about the relative importance of each subscale topic (ie, prioritization item).
The QOLIE-31-P will be completed according to the tabular schedule of study procedures in
Table 5-4. At the very beginning of the visit, the QOLIE-31-P will be provided to all 
subjects. The subject will be asked to complete the questionnaire on his/her own. Once 
completed, the subject will return the completed questionnaire to the Investigator or designee, 
who will verify that all questions have been answered. Further details about the QOLIE-31-P 
will be covered in the Study Manual.
9.4
Diary Addendum
A Diary Addendum will be completed according to the tabular schedule of study procedures 
in Table 5-4 as well as at the Withdrawal Visit, if applicable. The Diary Addendum will 
consist of a series of open-ended questions including the following: 
!
Why did you agree to take part in this study? 
!
What are your hopes for this new treatment? 
!
What are the biggest impacts of seizures on your life currently? 
!
What was your experience like during the study?
!
Did participating in the study fulfill any of the hopes you had going into the study? 
!
How do you describe the impact of seizures on your life now? Has that changed since the 
beginning of the study? 
Subjects will be instructed to leave any question blank that he/she does not feel comfortable 
answering. 
10
ASSESSMENT OF PK AND EXPLORATORY VARIABLES
10.1
Pharmacokinetic parameters
The PK variables are described in detail in Section 4.2. Calculations of PK parameters will be 
made with Phoenix WinNonlin (version 6.2 or higher) using the actual sampling times and 
are described in Section 13.4.2. The linear trapezoidal method will be used to calculate the 
AUC parameters. 
Detailed information on the collection, storage, preparation, and shipping of samples will be 
presented in a Laboratory Manual.
10.2
Exploratory parameters
Detailed information on the collection, storage, preparation, and shipping of samples for 
DNA, mRNA, lipidomics, and proteomics analysis will be presented in a Laboratory Manual.
Results for the exploratory parameters obtained from DNA, mRNA, lipidomics, and 
proteomics analysis will be described in a separate report.
REDACTED
he stu
e st
any o
y o
t of se
t of se
COPY 
your li
your li
tud
tud
This document 
10.
10.
cannot 
iled in
led in
sente
sent
be
met
met
used
enix
nix
d in S
in S
to
are 
are 
W
support 
M
macok
maco
de
d
any 
MEN
EN
marketing 
eiz
e an
any q
y
authorization 
if
dy?
of the 
f the 
zure
zure
application 
fe cur
e cur
and 
g:
any 
of
o
y Add
Ad
y
xtensions 
f stu
f stu
or
IE
IE-3
-
variations 
sign
igne
3
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 56 of 125
10.3
Sampling procedures
Blood samples for PK and exploratory variables will be obtained at the scheduled time points 
presented in Table 5-4.
Times for PK samplings will be taken with respect to the time of the morning UCB0942 dose 
on the first and last day of the Maintenance-Dose Week, taken as Time 0=0h. Exact sampling 
times will be recorded in the eCRF. 
Predose blood samples for levels of UCB0942 and its major metabolites will be obtained 
after ECGs and vital signs but prior to dosing of the study medication at Visit 4 and Visit 5.
Predose (trough) blood samples for levels of UCB0942 and its major metabolites will be 
obtained at Visits 6 to 15. The Investigator and the subject should make a realistic effort to 
plan the visits during the Outpatient Maintenance Period before the morning or the evening 
dose of UCB0942. If a predose blood sample is not feasible for a specific visit, a postdose 
blood sample should be collected and the actual times of the dosing and sampling recorded.
For the exploratory assessments, the processing of the blood samples will be described in the 
Laboratory Manual. One sample each will be collected for the mRNA, lipidomics, and 
proteomics assay.
For the AED archival samples, processing will be described in the Laboratory Manual.
Preprinted labels will be provided by the analytical laboratory of UCB. Laboratory kits will 
be provided by UCB or a delegate.
10.4
Bioanalytical methods
Plasma concentrations of UCB0942 and metabolites 
 
 will be determined using validated bioanalytical methods.
10.5
Pharmacokinetic/pharmacodynamic relationships 
If appropriate, a population PK analysis will be performed, as described in Section 13.4.2.
If needed, exploratory exposure-response analysis will be performed to describe the 
relationship between the exposure to UCB0942 and the efficacy and/or safety variables.
11
ASSESSMENT OF SAFETY
11.1
Adverse events
11.1.1
Definition of adverse event
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product that does not necessarily have a causal relationship 
with this treatment. An AE can therefore be any unfavorable and unintended sign (including 
an abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal (investigational) product, whether or not related to the medicinal (investigational) 
product.
In order to ensure complete safety data collection, all AEs occurring during the study 
(ie, after the signing of the Informed Consent form), including any pretreatment and 
posttreatment periods required by the protocol, ie, through the end of the Taper/Safety 
Follow-up Period, must be reported in the eCRF even if no IMP was taken but specific study 
procedures were conducted. This includes all AEs not present prior to the initial visit and all 
AEs that recurred or worsened after the initial visit.
REDACTED 
metab
metab
d using
using
ic/p
ic/p
COPY 
lab
a
This document 
n a
n a
med
med
p
cannot
stere
tere
this t
his 
abn
abn
be
any y 
ed
ed
used
Defi
Def
u
to 
ve
ve
support 
p
SSM
SSM
erse
ers
any 
e-r
osure
osur
marketing
pharm
phar
aly
alysis w
sis
resp
res
authorization 
bolite
olite
g vali
vali
application 
n the
n the L
atory
tory o
y
and 
A, 
A,
any
ll be
ll b
lipid
lipid
extensions
he eve
e ev
, a po
a po
mpling
pling
be
be
o
fort 
ort
variations 
e
to
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 57 of 125
Signs or symptoms of the condition/disease for which the investigational product is being 
studied (ie, seizures) should be recorded as AEs only if their nature changes considerably or 
their frequency or intensity increases in a clinically significant manner as compared to the
clinical profile known to the Investigator from the subject’s history or the Baseline Period.
11.1.2
Procedures for reporting and recording adverse events
The subject will be given the opportunity to report AEs spontaneously. A general prompt will 
also be given at each study visit to detect AEs. For example:
“Did you notice anything unusual about your health (since your last visit)?”
In addition, the Investigator should review any self-assessment procedures (eg, diary cards) 
employed in the study.
11.1.3
Description of adverse events
When recording an AE, the Investigator should use the overall diagnosis or syndrome using 
standard medical terminology, rather than recording individual symptoms or signs. The eCRF 
and source documents should be consistent. Any discrepancies between the subject’s own 
words on his/her own records (eg, diary card) and the corresponding medical terminology 
should be clarified in the source documentation.
Details for completion of the Adverse Event eCRF (including judgment of relationship to 
IMP) are described in the eCRF Completion Guidelines.
11.1.4
Follow up of adverse events
An AE should be followed until it has resolved, has a stable sequelae, the Investigator 
determines that it is no longer clinically significant, or the subject is lost to follow up.
If an AE is ongoing at the end of the Taper/Safety Follow-up Period, follow up should be 
provided until resolution/stable level of sequelae is achieved, or until the Investigator no 
longer deems that it is clinically significant, or until the subject is lost to follow up. If no 
follow up is provided, the Investigator must provide a justification. The follow up will 
usually be continued for 30 days after the subject has discontinued his/her IMP.
Adverse events should not be recorded in the eCRF after the end of the Taper/Safety Follow-
up Period.
11.1.5
Rule for repetition of an adverse event
An increase in the intensity of an AE should lead to the repetition of the AE being reported 
with:
!
The outcome date of the first AE that is not related to the natural course of the disease 
being the same as the start date of the repeated AE, and the outcome of “worsening”
!
The AE verbatim term being the same for the first and repeated AE, so that the repeated 
AE can be easily identified as the worsening of the first one
11.1.6
Pregnancy
If an Investigator is notified that a subject has become pregnant after the first intake of any 
IMP, the Investigator must immediately notify UCB’s Drug Safety (DS) department by 
providing the completed Pregnancy Report and Outcome form (for contact details see SAE
reporting information at the beginning of this protocol). The subject should be withdrawn 
from the study as soon as pregnancy is known (by positive pregnancy test), and the following 
should be completed:
REDACTED
ved, 
ved,
signifi
signifi
Taper
Taper
vel of 
vel of
COPY 
n
h
This document cannot 
ou
ou
eing t
eing t
Th
Th
be 
utco
utco
used
the i
he i
to 
e 
in
support 
be
b
for r
for 
any 
ys
e rec
e re
marketing
f sequ
f seq
nificant
nifican
gator m
gator 
afte
aft
authorization 
has a s
as a s
ficant, 
cant,
r/Safe
/Safe
application 
g judg
g jud
and
g me
g m
any
n the 
n the
medi
med
extensions 
sy
syndro
ndro
y
or si
or si
or variations 
ards)
ds) 
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 58 of 125
!
The subject should return for an early discontinuation visit.
!
The subject should immediately stop the intake of the IMP or be tapered as instructed at 
the early discontinuation visit. 
!
A Safety Follow-Up Visit should be scheduled 1 week after the subject has discontinued 
her IMP.
The Investigator must inform the subject of information currently known about potential risks 
and about available treatment alternatives.
The pregnancy will be documented on the Pregnancy Report and Outcome form provided to 
the Investigator. The progression of the pregnancy and the eventual birth (if applicable) must 
be followed up using the Pregnancy Report and Outcome form in which the Investigator has 
to report on the health of the mother and of the child. Every reasonable attempt should be 
made to follow the health of the child for 30 days after birth for any significant medical 
issues. In certain circumstances, UCB may request that follow up is continued for a period 
longer than 30 days. If the subject is lost to follow up and/or refuses to give information, 
written documentation of attempts to contact the subject needs to be provided by the 
Investigator and filed at the site. UCB’s DS department is the primary contact for any 
questions related to the data collection for the pregnancy, eventual birth, and follow up.
In cases where the partner of a male subject enrolled in a clinical study becomes pregnant, the 
Investigator or designee is asked to contact the subject to request consent of the partner via 
the Partner Pregnancy Consent form that has been approved by the responsible IEC and 
should be available in the Investigator site file. In case of questions about the consent 
process, the Investigator may contact the UCB/contract research organization (CRO) contract 
monitor for the study. The Investigator will complete the Pregnancy Report and Outcome 
form and send it to UCB’s DS department (for contact details see Serious Adverse Event 
reporting information at the beginning of this protocol) only after the partner has agreed that 
additional information can be captured and has provided the signed Partner Pregnancy 
Consent form. UCB’s DS department is also the primary contact for any questions related to 
the data collection for the partner pregnancy, eventual birth, and follow up.
A pregnancy becomes a SAE in the following circumstances: miscarriage, abortion (elective 
or spontaneous), unintended pregnancy after hormonal contraceptive failure (if the hormonal 
contraceptive was correctly used), ectopic pregnancy, fetal demise, or any congenital 
anomaly/birth defect of the baby. Those SAEs must be additionally reported using the 
Investigator SAE Report form.
11.1.7
Overdose of investigational medicinal product
Excessive dosing (beyond that prescribed in the protocol and including overdose) should be 
recorded in the Drug Accountability or Study Drug Dosing module of the eCRF. Any SAE or 
nonserious AE associated with excessive dosing must be followed as any other SAE or 
nonserious AE. These events are only considered AEs or SAEs if there are associated clinical 
signs and symptoms or if the act of taking the excess medicine itself is an AE or SAE 
(eg, suicide attempt).
11.1.8
Safety signal detection
Appropriate data from the study will be reviewed on an ongoing basis to detect as early as 
possible any safety concern(s) related to the IMP so that Investigators, clinical study subjects, 
regulatory authorities, and IECs will be informed appropriately and as early as possible.
REDACTED
e. 
UCB/
UCB/c
will c
will c
tment
tment
ning o
ning o
COPY
ect 
ec
en app
n app
In c
In c
This document
nons
ons
non
non
cannot
sive d
ive d
orded
orded
nse
se
be used
AE R
AE R
O
to
ect o
ect 
support
AE 
AE
ended p
nded 
orrectly
rrectly
of
any 
ner
ner
E in 
E in
marketing
of thi
of th
red 
red and
n
ment 
ment isi
r pre
r pr
authorization 
pro
case o
ase o
contra
ontra
compl
ompl
(for c
(for 
hihi
application
ual b
al 
inic
inical s
al
o reque
requ
oved
oved
and
p
mary
ary c
y
l bir
bir
any 
ve
v
rovide
ovid
co
extensions
g
hould
ould
t med
med
ued fo
ed fo
ve in
e in
or
ator 
tor
variations 
toto
 must
mus
h
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 59 of 125
The Study Physician or medically qualified designee/equivalent will conduct an ongoing 
review of AEs and (especially) any SAEs and perform ongoing SAE reconciliations in 
collaboration with the DS representative.
In addition, the SRG will conduct scheduled reviews of appropriate study data for the 
purpose of safety signal detection.
11.1.9
Safety Review Group
An SRG will be established prior to the start of the study, which will comprise, at a 
minimum, the Study Physician(s), clinical pharmacologist, DS representative, biostatistician,
Coordinating Investigator, and the 
 local Coordinating Investigator, with the intention 
of protecting the safety, health, and well-being of each participating subject. Individual 
Principal Investigators (PI, or their delegate) for each participating site will be invited when 
required. The precise membership, scope, and responsibilities of the SRG are described in the 
SRG Charter. 
The SRG will meet once the first 4 subjects have completed the Transition-to-Outpatient 
Week (Visit 6) or withdrawn from the study before Visit 6. Subsequent meetings will occur 
when the first 10 subjects, the first 16 subjects, and the first 22 subjects have completed 
Visit 6 or withdrawn from the study before Visit 6. Thereafter, SRG meetings will be held on 
an as required/ad hoc basis, in response to emerging data, and at the request of any member 
of the SRG.
The SRG will remain blinded through the first database lock (see Section 12.3.3) unless 
emergent safety information requires unblinding of individual drug allocation for optimal 
assessment and response to AEs of concern. At the time of the first database lock, the Study 
Physician(s), clinical pharmacologist, DS representative, biostatistician, and other UCB 
personnel will be unblinded as to all subjects’ treatment allocation at the beginning of the 
Inpatient Period. 
11.2
Serious adverse events
11.2.1
Definition of serious adverse event
Once it is determined that a subject experienced an AE, the seriousness of the AE must be 
determined. An SAE must meet 1 or more of the following criteria:
!
Death
!
Life-threatening
(Life-threatening does not include a reaction that might have caused death had it occurred 
in a more severe form.)
!
Significant or persistent disability/incapacity
!
Congenital anomaly/birth defect (including that occurring in a fetus)
!
Important medical event that, based upon appropriate medical judgment, may jeopardize 
the patient or subject and may require medical or surgical intervention to prevent 1 of the 
other outcomes listed in the definition of serious
(Important medical events may include allergic bronchospasm requiring intensive 
treatment in an emergency room or at home, blood dyscrasias that do not result in 
inpatient hospitalization, or the development of drug dependency or drug abuse.)
REDACTED
n.n. At t
At 
S repr
S repr
subjec
subjec
COPY 
atabas
atabas
ng of 
g of 
This document
!
C
!
cannot 
mo
mo
Signif
Signi
C
be 
hrea
ore 
ore 
used
ening
ning
eaten
aten
to 
g
support
a s
a 
ust me
st me
any 
subje
ubje
marketing 
e even
eve
eriou
erio
authorization
f indiv
indiv
the tim
he tim
resent
resent
cts’ tr
ts’ tr
application 
SRG
d at the
at th
e lock
lock
i
and
jects
ects
RG m
G m
any
mee
me
ha
h
extensions 
ted
ed
escribe
scribe
n-toto
or 
d wh
d w
variations 
n,
ntion
ntion
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 60 of 125
!
Initial inpatient hospitalization or prolongation of hospitalization, except if an extension 
of the Inpatient Period is required to adjust the dose of UCB0942 before discharge
(A patient admitted to a hospital, even if he/she is released on the same day, meets the 
criteria for the initial inpatient hospitalization. An emergency room visit that results in 
admission to the hospital would also qualify for the initial inpatient hospitalization 
criteria. However, emergency room visits that do not result in admission to the hospital 
would not qualify for this criteria and, instead, should be evaluated for 1 of the other 
criteria in the definition of serious [eg, life-threatening adverse experience, important 
medical event].
Hospitalizations for reasons not associated with the occurrence of an AE [eg, preplanned 
surgery or elective surgery for a pre-existing condition that has not worsened or 
manifested in an unusual or uncharacteristic manner] do not qualify for reporting. For 
example, if a subject has a condition recorded on his/her medical history and later has a 
preplanned surgery for this condition, it is not appropriate to record the surgery or 
hospitalization as an SAE, since there is no AE upon which to assess the serious criteria. 
Please note that, if the pre-existing condition has worsened or manifested in an unusual or 
uncharacteristic manner, this would then qualify as an AE and, if necessary, the 
seriousness of the event would need to be determined.)
11.2.2
Procedures for reporting serious adverse events
If an SAE is reported, UCB must be informed within 24 hours of receipt of this information 
by the site (see contact information for SAE reporting listed in the Serious Adverse Event 
Reporting section at the front of the protocol). The Investigator must forward to UCB (or its 
representative) a duly completed “Investigator SAE Report Form for Development Drug” 
(SAE report form) provided by UCB, even if the data are incomplete, or if it is obvious that 
more data will be needed in order to draw any conclusions. Information recorded on this form 
will be entered into the global safety database.
An Investigator SAE report form will be provided to the Investigator. The Investigator SAE 
Report form must be completed in English. 
It is important for the Investigator, when completing the SAE report form, to include the 
assessment as to a causal relationship between the SAE and the IMP administration. This 
insight from the Investigator is very important for UCB to consider in assessing the safety of 
the IMP and in determining whether the SAE requires reporting to the regulatory authorities 
in an expedited manner.
Additional information (eg, autopsy or laboratory reports) received by the Investigator must 
be provided within 24 hours. All documents in the local language must be accompanied by a 
translation in English, or the relevant information included in the same document must be 
summarized in the Investigator SAE report form.
The Investigator is specifically requested to collect and report to UCB (or its representative) 
any SAEs (even if the Investigator is certain that they are in no way associated with the IMP), 
up to 30 days from the end of the study for each subject, and to also inform participating 
subjects of the need to inform the Investigator of any SAE within this period. Serious AEs 
that the Investigator thinks may be associated with the IMP must be reported to UCB 
regardless of the time between the event and the end of the study.
l). T
l). T
gator
gator
even i
even 
o draw
draw
ty d
y d
COPY
hin 2
hin 2
portin
portin
The
Th
This document 
m
The
The
cannot
ided
ded
lation
ation
mmar
mma
be
 inf
nf
ed w
ed
used
d man
man
for
for
to
term
term
support 
stig
ti
al relat
l rel
estigato
stigat
min
mi
any 
d i
gato
gat
marketing 
w 
databa
ataba
will be
will b
in En
in E
authorization
ng lis
g li
he I
e Inve
nv
SAE 
SAE 
if the 
f the 
an
any
application 
erse e
erse 
4 hours
hour
ste
ste
and
 if ne
if ne
any 
thth
ifeste
ifeste
extensions
ting. 
ing. 
nd lat
d lat
surge
surge
he s
he s
or variations 
anned
nned
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 61 of 125
Upon receipt of the SAE report form, UCB will perform an assessment of expectedness of the 
reported SAE. The assessment of the expectedness of the SAE is based on the Investigator’s 
Brochure.
11.2.3
Follow up of serious adverse events
An SAE should be followed until it has resolved, has a stable sequelae, the Investigator 
determines that it is no longer clinically significant, or the subject is lost to follow up. 
Information on SAEs obtained after clinical database lock will be captured through the DS 
database without limitation of time.
11.3
Adverse events of special interest
An AE of special interest is any AE that a regulatory authority has mandated be reported on 
an expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to 
the administration of a UCB product/compound.
Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total bilirubin 
in the absence of ≥2xULN ALP, with no alternative explanation for the biochemical 
abnormality, must ALWAYS be reported to UCB as an AE of special interest (ie, without 
waiting for any additional etiologic investigations to have been concluded). Follow-up 
information should then be reported if an alternative etiology is identified during 
investigation and monitoring of the subject.
11.4
Immediate reporting of adverse events
The following AEs must be reported immediately:
!
SAE: AE that the Investigator classifies as serious by the above definitions regardless of 
causality
!
Suspected transmission of an infectious agent via a medicinal product
11.5
Anticipated serious adverse events
The following list of Anticipated SAEs has been identified, as these SAEs are anticipated to 
occur in the epilepsy population at some frequency that is independent of drug exposure. This 
original list will remain in effect for the duration of the protocol.
This list does not change the Investigator’s obligation to report all SAEs (including 
Anticipated SAEs) as detailed in Section 11.2.2.
Table 11‒1: Anticipated SAEs for the epilepsy population
MedDRA System Organ Class
MedDRA Preferred Term
Congenital, familial and genetic disorders
Teratogenicity
General disorders and administration site 
conditions
Sudden unexplained death in epilepsy
Injury, poisoning, and procedural complication
Fall
a, fracturea, injurya
Nervous system disorders
Cluster seizures, cognitive disorder, convulsion,
incontinencea,b, status epilepticus
Pregnancy, puerperium, and perinatal disorders
Abortion spontaneous
Psychiatric disorders
Abnormal behavior, anxiety, confusional state,
psychotic behavior, sleep disorder
REDACTED
iatel
ate
fies as
ies as
nfect
nfect
COPY 
verse
verse
ely
ely
This document 
Gene
Gene
co
c
t
um
cannot
Me
Me
ngenit
genit
n
c
be 
1
d
be used 
s)s
: An
A
to
) as 
) as
support
at
in effe
n eff
ange t
nge 
d
any
ed 
ed
tion a
ion a
marketing
tious 
tious 
rious 
ious
d SA
S
authorization 
s serio
serio
application 
con
is iden
is ide
 eve
eve
and
ial in
al i
nclu
nclu
any
e bioc
e bio
inte
nt
extensions 
port
or
f the A
the A
xULN
ULN
or
rted
ted
variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 62 of 125
Table 11‒1: Anticipated SAEs for the epilepsy population
MedDRA System Organ Class
MedDRA Preferred Term
Reproductive system and breast disorders
Impotence, menstrual disorder
MedDRA=Medical Dictionary for Regulatory Activities; SAE=serious adverse event; SOC=System Organ Class
a Event is considered to be anticipated when occurring in context of seizure.
b Event is not classified in MedDRA primary SOC.
11.6
Laboratory measurements
Each site will use their own local clinical laboratory. The following laboratory parameters 
will be measured:
Table 11‒2: Laboratory measurements
Hematology
Chemistry
Urinalysis
a
Basophils
ALP
Total protein
Eosinophils
Calcium
Glucose
Lymphocytes
Chloride
pH
Monocytes
Magnesium
RBC
Neutrophils
Potassium
WBC
Hematocrit
Sodium
Hemoglobin
Glucose
MCH
BUN or urea
MCHC
AST
MCV
ALT
Platelet count
Total bilirubin
RBC count
LDH
WBC count
Creatinine
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; 
BUN=blood urea nitrogen; LDH=lactate dehydrogenase; MCH=mean corpuscular hemoglobin; 
MCHC=mean corpuscular hemoglobin concentration; MCV=mean corpuscular volume; RBC=red blood 
cell; WBC=white blood cell
a Dipstick test only
11.6.1
Evaluation of PDILI
The PDILI IMP discontinuation criteria for this study are provided in Section 6.3.1, with the 
accompanying required follow-up investigation and monitoring detailed below. All PDILI 
events must be reported as an AE and reported to the study site and sponsor within 24 hours 
of learning of their occurrence. Any PDILI event that meets the criterion for potential Hy’s 
Law must be reported as an AE of special interest (see Section 11.3), and, if applicable, also 
reported as an SAE (see Section 11.1.1).
Evaluation of PDILI consists of the diagnostic testing and continued monitoring included in 
Table 11‒3 (specific tests dependent on laboratory results and corresponding symptoms) and 
REDACTED 
um
um
Gluco
Gluco
TE
BUN
BU
DA
R
COPY
PY 
CO
This document 
1
The
Th
cannot 
C=w
ick tes
ck tes
.6.1
6.1
be
n co
co
whit
whit
used
spha
pha
ea nitro
a nitr
orp
orp
to
ata
ata
to 
to support 
rt
po
upp
any y marketing 
N 
N 
A
ng
rk
m
authorization 
on
ose
se
riz
or u
or u
ut
application 
at
plic
pp
and 
a
any 
tal
tal p
a
extensions 
alysis
alysi
ns
e
or variations 
ers 
rs 
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 63 of 125
consultation with a local hepatologist (if applicable; discussed in Section 11.6.1.1). The local 
hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist. Additional investigation and monitoring may be required and adapted 
based on the diagnosis after the cause of the liver injury/abnormality is confirmed (details in 
Section 11.6.1.4). 
The results of all monitoring, including laboratory testing and other testing, should be made 
available to the study site and sponsor.
All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but 
appropriate medical action must not be delayed waiting for the repeat result.
If tests are done locally for more rapid results, a concurrent sample should also be sent to the 
central laboratory whenever possible. Medical care decisions are to be made initially using 
the most rapidly available results and a conservative approach must be taken if the results 
from the 2 laboratory tests are significantly different. Data from the local and central 
laboratory are to be recorded on the applicable CRF pages.
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. In these cases, the investigator should also 
consider dose reduction for medically necessary concomitant medication and consider 
changing any medically required concomitant medication known to be hepatotoxic to a 
suitable alternative.
When IMP is stopped due to PDILI (as described in Section 6.3.1), IMP must be permanently 
discontinued unless a subsequent alternative diagnosis fully explains the hepatic findings. If a 
subsequent alternative diagnosis fully explains the hepatic findings, and the requirements 
provided in Section 11.6.1.2.1 are met, rechallenge with IMP may be appropriate. 
Rechallenge with a substance potentially causing drug-induced liver injury is dangerous, may 
be fatal, and must not occur.
The table below summarizes the approach to investigate PDILI.
REDACTED
ve dia
ve dia
xplain
plain
et, rech
et, rec
ntial
ntial
COPY 
ed in
ed in
This document cannot be used to support any marketing
lllly cau
y ca
appr
app
authorization
n Sect
Sec
gnosis
gnosis
ns the 
ns the 
challen
hallen
application 
 thth
medic
med
known
know
i
and
l sup
sup
he in
e i
any 
ppl
extensions
sent
en
tially
ially
if the
f the
and ce
nd ce
or 
nt to
nt to
variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 64 of 125
Table 11‒3: Required investigations and follow up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
≥3xULN
≥2xULN
b
NA
Hepatology consult.c
Medical Monitor 
must be notified 
within 24 hours 
(eg, by laboratory 
alert) and subject 
discussed with 
Medical Monitor 
ASAP.
Immediate, 
permanent IMP 
discontinuation.
Essential: Must 
have repeat liver 
chemistry values 
and additional 
testing completed 
ASAP (see 
Section 11.6.1.3); 
recommended to 
occur at the site 
with HCP.
Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within baseline 
values.d
≥8xULN
NA
NA
≥3xULN
NA
Yes
Immediate, 
temporary or 
permanent, IMP 
discontinuation.
≥3xULN 
(and ≥2x 
baseline) 
and 
<5xULN
<2xULN
No
Discussion with 
Medical Monitor 
required if the 
criterion that allows 
for IMP continuation 
is met.
Further investigation 
– immediate IMP 
discontinuation not 
required (see 
Section 11.6.1.2).
Not required 
unless otherwise 
medically 
indicated (at 
discretion of 
investigator).
≥5xULN 
(and ≥2x 
baseline) 
<2xULN
No
Discussion with 
Medical Monitor 
required.
Immediate, 
permanent IMP 
discontinuation.
Essential: Every 
attempt must be 
made to have 
repeat liver 
chemistry values 
and additional 
testing completed 
within 48 hours 
at the site with 
HCP (see 
Section 11.6.1.3).
Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within baseline 
values.d
REDACTED 
Furthe
Furthe
– im
TE
ED
COPY 
, IMP 
, IMP
nuatio
nuatio
This document 
en cannot be used 
us
to support
w
Moni
Moni
red.
ed.
any 
with 
ith
y marketing 
on
disco
disco
requ
req
S
ke
authorization 
on.
on.
er inv
er inv
mmed
mmed
riz
application 
ad
a
esting 
esting
ASA
ASA
Se
S
pli
and
stry v
try v
dditi
ddit
any 
usts
at liver
t live
al
extensions
valua
alua
te
t
xt
or 
w u
w u
o variations 
on
up
up
ar
thereof. 
10 O
10 O


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 65 of 125
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug-induced liver injury; ULN=upper limit of normal 
a Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia (>5%), 
rash, and fever (without clear alternative cause).
b If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medical Monitor.
c Details provided in Section 11.6.1.1. The local hepatologist is the expert usually consulted by the treating physician for assessment and management of 
potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist.
d Unless an alternative monitoring schedule is agreed by the investigator and UCB responsible physician. Determination of stabilization is at the discretion of the 
investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions 
cal Mo
cal Mo
sessme
essme
n of s
of s
or 
de 
de
variations 
on
practi
practi
e eo
e eo
thereof. 
10 O
10 O


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 66 of 125
11.6.1.1
Consultation with the Medical Monitor and local hepatologist
Potential drug-induced liver injury events require notification of the Medical Monitor within 
24 hours (eg, by laboratory alert), and the subject must be discussed with the Medical 
Monitor as soon as possible. If required, the subject must also be discussed with the local 
hepatologist. The local hepatologist is the expert usually consulted by the treating physician 
for assessment and management of potential hepatic disease. This would usually be a 
hepatologist, but may be a gastroenterologist. If determined necessary, this discussion should 
be followed by a full hepatology assessment (see Section 11.6.1.3) and SAE report (if 
applicable).
11.6.1.2
Immediate action: determination of IMP discontinuation
All PDILI events require immediate action, testing, and monitoring. 
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by immediate investigation) 
to immediate and permanent discontinuation (see Section 6.3.1 and Table 11‒3 for details).
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. The investigator should also consider dose 
reduction for medically necessary concomitant medication and consider changing any 
medically required concomitant medication known to be hepatotoxic to a suitable alternative.
11.6.1.2.1
IMP restart/rechallenge (if applicable)
Rechallenge with a substance potentially causing drug-induced liver injury is dangerous, may 
be fatal, and must not occur.
Subjects who are immediately discontinued from IMP due to having met certain criteria for 
PDILI (as described in Section 6.3.1 and Table 11‒3), but for whom an alternative diagnosis 
is confirmed, can rarely restart IMP. Rechallenge with IMP can occur only if ALL of the 
following requirements are met:
!
The results of additional testing and monitoring described in Section 11.6.1.3 and 
Section 11.6.1.4 confirm a nondrug-related cause for the abnormal hepatic laboratory 
parameters and any associated symptoms (ie, a subsequent alternative diagnosis fully 
explains the hepatic findings). 
!
No alternative treatment options are available to the subject.
!
The subject has shown clear therapeutic benefit from the IMP.
!
Subject’s ALT or AST elevations do not exceed ≥3xULN.
!
Subject’s total bilirubin is <1.5xULN.
!
Subject has no signs or symptoms of hypersensitivity. 
!
The rechallenge is approved by the UCB responsible physician and a hepatologist. The 
hepatologist must be external to UCB. It is recommended that the hepatologist be a local 
hepatology expert or the hepatologist treating the subject.
!
Subject agrees to the investigator-recommended monitoring plan.
11.6.1.3
Testing: identification/exclusion of alternative etiology
The measurements and additional information required for the assessment of PDILI events 
when there is a reasonable possibility that they may have been caused by the IMP are detailed 
REDACTED 
nued f
nued f
and
and T
P. Re
P. Re
COPY
lica
lica
ng dru
ng dr
This document 
!
cannot 
ubject
ubject
Sub
Sub
be
ct’s A
ct’s 
used
ct has
t has
A
to
trea
tre
support
soci
oc
c findin
find
eatm
atm
any
a non
a no
ciate
cia
marketing
echal
echal
ing an
ng a
d
authorization
rug-
ug-inin
from I
from 
Table
able
ll
application
cons
con
patotox
atoto
ble)
le)
nd
and
sup
u
r shou
shou
nsi
any 
pplem
pplem
extensions 
hepati
epati
ate inv
te in
11
11‒3
or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 67 of 125
in Table 11‒4 (laboratory measurements) and Table 11‒5 (additional information). Results of 
the laboratory measurements and information collected are to be submitted to the sponsor on 
the corresponding CRF. If the medical history of the subject indicates a requirement for other 
assessments not included below, these additional assessments should be completed and 
submitted, as applicable.
All blood samples should be stored, if possible. If tests are done locally for more rapid 
results, a concurrent sample must also be sent to the central laboratory.
The following measurements are to be assessed:
Table 11‒4: PDILI laboratory measurements
Virology-
related
Hepatitis A IgM antibody
HBsAg
Hepatitis E IgM antibody
HBcAb-IgM
Hepatitis C RNA
Cytomegalovirus IgM antibody
Epstein-Barr viral capsid antigen IgM antibody (if unavailable, obtain 
heterophile antibody or monospot testing)
Immunology
Anti-nuclear antibody (qualitative and quantitative)
Anti-smooth muscle antibody (qualitative and quantitative)
Type 1 anti-liver kidney microsomal antibodies (qualitative and quantitative)
Hematology
Eosinophil count
Urinalysis
Toxicology screen
Chemistry
Amylase
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct 
bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase 
elevation
Additional
Prothrombin time/INR
a
Serum pregnancy test
PK sample
ALT=alanine aminotransferase; CPK=creatine phosphokinase; HBcAb-IgM=hepatitis B core antibody-IgM; 
HBsAg=hepatitis B surface antigen; IgM=immunoglobulin M; INR=international normalized ratio; 
LDH=lactate dehydrogenase; PDILI=potential drug-induced liver injury; PK=pharmacokinetic; 
RNA=ribonucleic acid; ULN=upper limit of normal
a Measured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative 
cause).
The following additional information is to be collected:
REDACTED
ative
ative
body
ody (q
(q
y
ED
ney
ey mi
m
y
AC
RE
COPY 
M an
M a
testin
testin
e a
e a
CO
This document 
nt
ALT
AL
cannot be 
l
e used
ru
r
eleva
eleva
P
us
to
um 
um 
support
irubin
ubin
n
t
C
su
any 
a
marketing 
ic
g
ke
m
authorization 
ng
and qu
nd qu
n
(qualit
(qualit
za
croso
roso
th
application 
n
bod
ody (
y 
g)
cat
and 
d
a
any y
a
extensions 
ns
en
e
or r variations 
v
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 68 of 125
Table 11‒5: PDILI information to be collected
New or updated information
Concomitant prescription and over-the-counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included.
Pertinent medical history, including the following:
!
History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other “fatty 
liver disease”)
!
Adverse reactions to drugs
!
Allergies
!
Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha-1 antitrypsin 
deficiency)
!
Recent travel 
!
Progression of malignancy involving the liver (Note: Metastatic disease to the liver, by itself, 
should not be used as an explanation for significant AST and/or ALT elevations.)
The appearance or worsening of clinical symptoms of hepatitis or hypersensitivity (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, jaundice, fever, or 
rash)
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function
Alcohol and illicit drug use
Results of liver imaging or liver biopsy, if done
Results of any specialist or hepatology consult, if done
Any postmortem/pathology reports
ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug-induced liver injury
11.6.1.4
Follow-up evaluation
Potential drug-induced liver injury events require follow-up and monitoring as described in 
Table 11‒3. Monitoring should continue until liver chemistry values normalize, stabilize, or 
return to baseline. Determination of stabilization is at the discretion of the investigator in 
consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
11.7
Other safety measurements
11.7.1
Vital signs
Vital signs including pulse rate, systolic BP, diastolic BP, respiratory rate, and body 
temperature (Day T1 before UCB0942 administration) will be measured in supine position, 
after 5 minutes of rest. Any clinically significant abnormality in the view of the Investigator
will be recorded as an AE.
Vital signs will be measured at the scheduled time points presented in Table 5-4.
11.7.2
Electrocardiograms
All ECG recordings will be performed with the subject resting in the supine position for at 
least 5 minutes. The 12-lead ECG recordings will be measured at the scheduled time points 
presented in Table 5-4. ECG will be recorded at a speed of 25mm/s and with a calibration of 
1cm/mV.
REDACTED 
lt, if do
, if d
TE
AC
RE
arta
arta
COPY 
th h
PY
CO
This document
will 
will 
V
cannot 
gns
ns
eratur
ratur
er 5 m
r 5 m
b
be 
s inc
s inc
used 
Oth
th
Vit
Vit
o
her
he
support 
ou
ou
minat
minat
hepato
hepat
any
njury
njur
uld c
uld c
marketing 
g
ate amin
te amin
ation
ation
ry
ry e
y
authorization 
on
one
one
iza
th
application 
bdo
bdo
mpromi
prom
at
pp
and
nsitiv
sitiv
domi
om
any
evati
evat
it
an extensions
titry
try
the l
the l
i
or 
yps
yps
variations 
ns thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 69 of 125
The Investigator should review all ECG recordings and, if there are abnormalities that are 
considered clinically significant for a particular subject, then the Investigator should initiate a 
review by a specialist of all ECG data pertaining to that subject. The following ECG 
parameters will be recorded in the eCRF: heart rate, PR-interval, QRS-duration, QT-interval, 
QTcB or QTcF, and Investigator’s conclusion on ECG profile.
11.7.3
Echocardiograms
Echocardiograms will be performed during Screening, during dosing (Day OP22 ±1 week), 
and after the last dose of IMP (SFU7), as described in Table 5-4. The echocardiogram will be 
repeated at 6 months (±1 month) after the last dose in the following subjects: 
!
Subjects who complete this study but do not enter the OLE study
!
Subjects who withdraw from the Outpatient Period 
!
Subjects who withdraw from the Inpatient Period and have an abnormal SFU7 
echocardiogram
2D Doppler echocardiography will be performed with:
1. Diastolic measurements (mitral forward flow E and A waves and deceleration time)
2. Tissue Doppler on medial and lateral mitral valve annulus (S, E, and A waves)
3. Standardized views for left atrial volume measurements
Images will be recorded and stored digitally and retained if further analysis is needed. A 
complete echocardiography manual will be provided.
11.7.4
Physical examination
Physical examinations will be performed at the scheduled time points presented in Table 5-4. 
The physical examination will include general appearance; ear, nose, and throat; eyes, hair, 
and skin; respiratory; cardiovascular; gastrointestinal; musculoskeletal; hepatic; neurological 
(including limb reflexes); and mental status. Findings that are considered clinically 
significant changes since the physical examination at the Screening Visit will be recorded as 
AEs.
In addition, height will be measured at the Screening Visit with the subject not wearing shoes 
and the outcome will be rounded to the nearest 0.5cm. Body weight will be measured at the 
scheduled time points presented in Table 5-4 . Body weight will be measured with the subject 
in underwear or light clothing and without wearing shoes; the outcome will be rounded to the 
nearest 0.1kg. At the Screening Visit, the BMI will be calculated (weight [kg]/[height (m)]²) 
and will be reported to 1 decimal place.
11.7.5
Assessment of suicidality
Suicidality will be assessed by trained study personnel using the C-SSRS (Posner et al, 2011). 
This scale will be used for screening as well as to assess suicidal ideation and behavior that 
may occur during the study. The C-SSRS will be completed according to the tabular schedule 
of study procedures (Section 5.2). The Investigator’s decision about patient continuation in 
the study or patient withdrawal from the study if the patient has a positive response to the 
CSSRS Question 4, should be based on the Benefit /Risk balance for continuation or 
discontinuation of study treatment in view of the individual patient circumstances, condition, 
attained efficacy, causality, alternative risk management options, etc. Details of the case must 
be documented by the investigator (PI or investigator physician, not site staff conducting the 
CSSRS) and provided to UCB via the SAE reporting process.
REDACTED 
rov
rov
med a
med a
ude g
ude g
COPY 
e
d retain
reta
vide
vid
This document
Suic
uic
Thi
Th
cannot 
be
.5
cid
cid
be
kg
e rep
e rep
used
or ligh
lig
g. At
. At
to
ints
ints
h
support 
be me
be m
 be ro
be ro
s pr
any 
hy
hy
marketing
gener
gene
r; gastr
r; gast
ental st
ntal s
ysica
sic
authorization 
ned
ne
ed.
ed.
at the 
t the 
application
s (S, E
(S, E
ts
ed if 
d if
and
and de
nd de
any extensions 
SFU7 
FU7 
or variations 
e
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 70 of 125
11.7.6
Psychiatric and cognitive assessments
The overall psychiatric condition of the subjects will be assessed at screening using the BPRS 
and the MINI questionnaire. The BPRS is a questionnaire consisting of 16 questions which 
captures the psychiatric condition of the subject. 
The MINI is a widely used psychiatric structured diagnostic interview instrument. The MINI 
is divided into modules identified by letters corresponding to diagnostic categories. Rating is 
done to the right of each question by circling either Yes or No.
The MMSE is a sensitive, valid, and reliable 30-point questionnaire that is used extensively 
in clinical and research settings to measure cognitive impairment.
Further details about all questionnaires used in this study will be covered in the Study 
Manual.
11.7.7
Withdrawal monitoring
Any symptoms of withdrawal reactions will be monitored using the CIWA-B questionnaire. 
The CIWA-B questionnaire contains 22 questions which are selected to distinguish 
withdrawal symptoms from other symptoms. Further details about this questionnaire will be 
covered in the Study Manual.
12
STUDY MANAGEMENT AND ADMINISTRATION 
12.1
Adherence to protocol
The Investigator should not deviate from the protocol. In medical emergencies, the 
Investigator may use his/her medical judgment and may remove a study participant from 
immediate hazard before notifying UCB (or its representative) and the IEC in writing 
regarding the type of emergency and the course of action taken.
12.2
Monitoring
PRA will monitor the study to meet PRA’s monitoring Standard Operating Procedures 
(SOPs), ICH-GCP guideline, and applicable regulatory requirements, and to ensure that study 
initiation, conduct, and closure are adequate. Monitoring of the study may be delegated by 
UCB to a CRO or a contract monitor.
The Investigator and his/her staff are expected to cooperate with PRA and to be available 
during the monitoring visits to answer questions sufficiently and to provide any missing 
information. The Investigators/institutions will permit direct access to source data/documents 
for study-related monitoring, audits, IEC review, and regulatory inspection(s).
The Investigator will allow PRA to periodically review all eCRFs and corresponding source 
documents (eg, hospital and laboratory records for each study participant). Monitoring visits 
will provide the CRO with the opportunity to evaluate the progress of the study, verify the 
accuracy and completeness of eCRFs, ensure that all protocol requirements, applicable 
authorities regulations, and Investigator’s obligations are being fulfilled, and resolve any 
inconsistencies in the study records.
12.2.1
Definition of source data 
All source documents must be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some permanent form of recording (ink, typing, printing, 
optical disc). They should not be obscured by correction fluid or have temporary attachments 
(such as removable self-stick notes).
p
ment a
ment 
(or it
(or it
he co
he co
COPY 
rotoco
otoc
This document
accu
accu
au
au
cannot 
estst
ments
ments
l prov
l pro
be 
tigat
tiga
used
he In
e In
ated m
ted m
to
ring
ring
nv
nv
support 
act m
ct m
his/her
his/he
g vi
g v
any
re are
re ar
mo
m
marketing 
et PRA
PRA
d app
d app
authorization
col. I
ol. In
and ma
and m
ts repr
ts repr
ourse 
urse 
application 
MINIS
INIS
and
this 
his 
any
o dist
o dis
que
qu
extensions 
A-B q
B q
or 
y
variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 71 of 125
Source documents are original records in which raw data are first recorded. These may 
include hospital/clinic/general practitioner records, charts, diaries, x-rays, laboratory results, 
printouts, pharmacy records, care records, ECG or other printouts, completed scales, or 
quality of life questionnaires, for example. Source documents should be kept in a secure, 
limited access area.
Source documents that are computer generated and stored electronically must be printed for 
review by the monitor (eg, ECG reports). Once printed, these copies should be signed and 
dated by the Investigator and become a permanent part of the subject’s source documents. 
The Investigator will facilitate the process for enabling the monitor to compare the content of 
the printout and the data stored in the computer to ensure all data are consistent.
Electronic data records, such as echocardiogram results, must be saved and stored as 
instructed by UCB (or designee).
12.2.2
Source data verification
Source data verification ensures accuracy and credibility of the data obtained. During 
monitoring visits, reported data are reviewed with regard to being accurate, complete, and 
verifiable from source documents (eg, subject files, recordings from automated instruments, 
tracings [ECG], x-ray films, laboratory notes). All data reported on the eCRF should be 
supported by source documents, unless otherwise specified in Section 12.2.1.
12.3
Data handling
12.3.1
Case Report form completion
This study is performed using remote data capture. The Investigator is responsible for prompt 
reporting of accurate, complete, and legible data in the eCRFs and in all required reports.
Any change or correction to the eCRF after saving must be accompanied by a reason for the 
change.
Corrections made after the Investigator’s review and approval (by means of a 
password/electronic signature) will be reapproved by the Investigator.
The Investigator should maintain a list of personnel authorized to enter data into the eCRF.
Detailed instructions will be provided in the eCRF Completion Guidelines.
12.3.2
Database entry and reconciliation
Case Report forms/external electronic data will be entered/loaded into a validated electronic 
database using a clinical data management system (CDMS). Computerized data cleaning 
checks will be used in addition to manual review to check for discrepancies and to ensure 
consistency of the data. The data are entered into the eCRF once and are subsequently 
verified.
An electronic audit trail system will be maintained within the CDMS to track all data changes 
in the database once the data have been saved initially into the system or electronically 
loaded. Regular backups of the electronic data will be performed.
12.3.3
Database lock
The database lock and unblinding may occur in a tiered approach. 
Details regarding the tiered database lock will be described in the Data Management Plan. 
Plans for analysis of data and production of tables, figures and listings will be described in 
the Statistical Analysis Plan (SAP).
REDACTED
captu
captu
ble da
ble da
RF afte
RF aft
COPY 
on
on
This document
An e
An e
inin
cannot
stency
ency
ified.
fied.
be
ll be
ll be
used
orms/
ms/
ng a c
g a c
to 
ab
support 
ill be p
ll be 
base
base
any 
ntain 
ntain
marketing 
gator’s
gator’
will be
will b
authorization 
rere. T
. Th
ata in 
ata in 
er sav
r sav
application 
on
o
n Secti
Sect
and
m aut
m au
n th
n th
any
urate, 
rate,
tom
t
extensions 
ned. 
ed. 
or variations 
of 
of 
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 72 of 125
12.3.4
Subject Screening and Enrollment log/Subject Identification Code 
list
The subject’s screening and enrollment will be recorded in the Subject Screening and 
Enrollment Log.
The Investigator will keep a Subject Identification Code list. This list remains with the 
Investigator and is used for unambiguous identification of each subject.
The subject’s consent and enrollment in the study must be recorded in the subject’s medical 
record. These data should identify the study and document the dates of the subject’s 
participation.
12.4
Termination of the study
UCB reserves the right to temporarily suspend or prematurely discontinue this study either at 
a single site, multiple sites, or at all sites at any time for reasons including, but not limited to, 
safety or ethical issues, inaccurate or incomplete data recording, noncompliance, or 
unsatisfactory enrollment with respect to quality or quantity.
If the study is prematurely terminated or suspended, UCB (or its representative) will inform 
the Investigators/institutions and the regulatory authority(ies) of the termination or 
suspension and the reason(s) for the termination or suspension, in accordance with applicable 
regulatory requirement(s). The IEC should also be informed and provided with reason(s) for 
the termination or suspension by the Sponsor or by the Investigator/institution, as specified 
by the applicable regulatory requirement(s). In addition, arrangements will be made for the 
return of all unused IMP and other material in accordance with UCB procedures for the 
study.
12.5
Archiving and data retention
The Investigator will maintain adequate records for the study, including eCRFs, medical 
records, laboratory results, Informed Consent documents, drug dispensing and disposition 
records, safety reports, information regarding participants who discontinued, and other 
pertinent data.
All essential documents are to be retained by the Investigator until at least 2 years after the 
last approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region, or at least 2 years have elapsed since 
the formal discontinuation of clinical development of the IMP. These documents should be 
retained for a longer period, however, if required by the applicable regulatory requirement(s) 
or by an agreement with UCB (CPMP/ICH/135/95, 2002 [Section 4.9.5]). The Investigator 
will contact UCB for authorization prior to the destruction of any study records or in the 
event of accidental loss or destruction of any study records. The Investigator will also notify 
UCB should he/she relocate or move the study-related files to a location other than that 
specified in the Sponsor’s study master file.
12.6
Audit and inspection
The Investigator will permit study-related audits mandated by UCB, after reasonable notice, 
and inspections by domestic or foreign regulatory authorities.
The main purposes of an audit or inspection are to confirm that the rights and well-being of 
the subjects enrolled have been protected, that enrolled subjects (ie, signing consent and 
undergoing study procedures) are appropriate for the study, and that all data relevant for the 
evaluation of the IMP have been processed and reported in compliance with the planned 
REDACTED
in ac
n a
ta ret
ta ret
quat
quat
COPY
y the 
the
y
additi
addit
acco
acc
This document
spec
spec
1
cannot 
ntac
tac
of ac
of ac
CB sh
B sh
be
gree
ee
ct U
ct U
used 
nti
nti
longe
onge
em
em
o
inua
inu
support 
re to
e to
keting 
eting
ting a
ing a
any 
o b
o
marketing
te reco
te rec
d Cons
d Con
ion reg
on reg
authorization
ion, 
on,
cordan
ordan
etenti
tenti
application 
th
n, in a
n, in a
ed and 
d and
nvesti
nvest
, arr
ar
and
pres
res
he te
e te
any 
sent
sen
extensions 
tudy
tudy e
y
ut not 
t not 
liance
iance
or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 73 of 125
arrangements, the protocol, investigational site, and IEC SOPs, ICH GCP, and applicable 
regulatory requirements.
The Investigator will provide direct access to all study documents, source records, and source 
data. If an inspection by a regulatory authority is announced, the Investigator will 
immediately inform UCB (or designee).
12.7
Good Clinical Practice
Noncompliance with the protocol, ICH-GCP, or local regulatory requirements by the 
Investigator, institution, institution staff, or designees of the Sponsor will lead to prompt 
action by UCB to secure compliance. Continued noncompliance may result in the termination 
of the site’s involvement in the study.
13
STATISTICS
A description of statistical methods follows and will be described in more detail in the SAP.
13.1
Definition of analysis sets
Analysis sets will be defined as follows:
∀
The Enrolled Set (ES) will consist of all subjects who signed the ICF.
∀
The Randomized Set (RS) will consist of all enrolled subjects who were randomized.
∀
The Full Analysis Set (FAS) will consist of all randomized subjects who received at 
least 1 dose of IMP and have at least 1 post-Baseline seizure diary.
∀
The Per-Protocol Set (PPS) will consist of all subjects in the FAS Population who do 
not have a major protocol deviation impacting the primary efficacy variable.
∀
The Safety Set (SS) will consist of all randomized subjects who receive at least 1 dose 
of IMP.
All primary and secondary efficacy analyses will be carried out using the FAS.
Selected supportive efficacy analyses will be carried out using the PPS.
Safety analyses will be carried out using the SS.
All analyses will be based on randomized treatment assignment. Incorrectly-treated subjects
will be evaluated during the data evaluation meeting to assess the potential impact of such 
cases and any special analysis considerations.
The periods considered in the definition of efficacy and safety variables are the following:
!
Baseline Period consisting of 2 weeks of prospective subject diary seizure counts during 
the Prospective Outpatient Baseline Period
!
Inpatient Double-Blind Treatment Period
∀
Double-Blind Titration Week (inpatient)
∀
Maintenance-Dose Week (inpatient)
∀
Transition to Outpatient Week (inpatient)
!
Outpatient Maintenance Period
!
Last 4 weeks of Outpatient Maintenance Period
!
Overall: Inpatient and Outpatient Period
REDACTED
nsist
nsist o
ion im
on im
nsist o
nsist o
COPY
f all 
f all
post-
post-B
This document
!
I
cannot
elin
elin
the Pr
he Pr
I
be 
s c
ne
ne
used
peci
peci
cons
ons
to
duri
duri
ial
ial
suppor
arried
rrie
based o
ased 
ring 
ing
any
naly
nal
ed o
ed
marketing 
of 
cy an
an
y
ala
yse
uthorization
Base
ase
of all 
of all 
mpact
mpact
all r
all r
application 
gne
ne
d subje
d subj
random
andom
elin
elin
and 
ed t
ed t
any extensions 
tail in
ail in
or variations 
ation
ation
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 74 of 125
13.2
General statistical considerations
Summary statistics will be provided for all efficacy, safety, and Baseline/demographic 
variables. Summary statistics will consist of frequency tables for categorical variables. For 
continuous variables, descriptive statistics (number of available observations, mean, median, 
standard deviation [SD], minimum, maximum, 25th and 75th percentiles) will be tabulated. 
Unless otherwise mentioned, statistical hypothesis tests will be one-sided at the 5% 
significance level.
13.3
Planned efficacy analyses
The efficacy variables will be analyzed as described below using the FAS.
Total seizure frequency per week (7 days) will be derived from the seizure count information 
recorded on the diary card and is defined as the number of seizures standardized to a 7-day 
period. It is computed as the number of seizures recorded (by category: total, type I, type IA1, 
IB, and IC) over the period, divided by the total number of days in that period, multiplied 
by 7.
13.3.1
Analysis of the primary efficacy variable
The primary outcome measure is the 75%RR. In the active group, this is defined as the 
proportion of subjects with a 75% or greater reduction in focal seizure frequency during the 
last 2 weeks of the Inpatient Period compared to the 2-week Prospective Outpatient Baseline
Period. In the placebo group, the 75%RR is defined as the proportion of subjects with a 75% 
or greater reduction in focal seizure frequency during the first 2 weeks of the Inpatient Period 
(the 2 weeks on placebo) compared to the Prospective Outpatient Baseline Period. The 
75%RR will be analyzed using a logistic regression with effects for treatment, for LEV use 
stratification factor, and log-transformed Baseline seizure frequency as a continuous 
covariate. Odds-ratio of UCB0942 versus placebo groups and its 95% confidence intervals
(CI) will be estimated. The primary analysis will be performed on the FAS but also on the 
PPS.
13.3.2
Secondary efficacy analyses
Median percent reduction in seizures:
The percent reduction in total and partial seizure frequency from Baseline to the 
corresponding Treatment Period will be compared between UCB0942 arm and placebo using 
a Wilcoxon-Mann-Whitney test. The Hodges-Lehmann non-parametric estimator will be used 
to estimate the median percent reduction in seizures between groups and its corresponding 
95% CI will be provided. For secondary efficacy variables using responder rate (75%RR and 
50%RR), the analysis will be conducted similarly to the primary efficacy analysis 
(Section 13.3.1). Different treatment periods will be considered (inpatient as defined in 
Section 13.3.1, outpatient, and overall).
Seizure freedom:
To be considered seizure free, a subject must not report seizures of any type and must 
complete the corresponding treatment period. The seizure freedom rate will be analyzed 
using a logistic regression with effects for treatment and log-transformed Baseline seizure 
frequency as a continuous covariate. Odds-ratio of UCB0942 versus placebo groups and its 
95% CIs will be estimated. The seizure freedom will be evaluated at the following different 
treatment times: Inpatient Period as defined in Section 13.3.1, last 4 weeks of Outpatient 
Maintenance Period.
REDACTED
rosp
rosp
regres
regres
ed Ba
d Ba
versus
versus
y an
an
y
COPY
ed as 
d as
during
durin
pec
pec
This document 
Seiz
Seiz
me
cannot 
), th
, th
ion
on 13
1
ction
tion
be
ll b
l b
the
the
used 
n
e med
med
be p
be p
to
-Wh
W
support 
n n 
t
in tota
tot
ment 
ment
hi
any 
ic
ic
seizu
seizu
a
marketing 
s p
nalalys
ysisis
cacy
cac
uthorization
g the
g th
ctive O
tive 
ssion 
sion 
seline
eline
plac
plac
application 
p,
al seizu
seiz
ek Pros
k Pro
the pro
he pr
he fi
e fi
and 
this
thi
any extensions
o a a 7
type I,
pe I
y
od, m
d, m
or
rma
rm
variations 
t
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 75 of 125
Percentage of seizure-free days:
A descriptive analysis will be performed on the percentage of seizure-free days by treatment 
group and study periods.
13.3.3
Exploratory efficacy analyses
Seizure severity:
Changes in the SSQ and average seizure severity as calculated by the percentage of seizures 
that are type IC from Baseline to the end of the Inpatient Period and the end of the Outpatient 
Maintenance Period will be analyzed.
The QOLIE-31-P (change from Baseline) will be analyzed by descriptive statistics and any 
relevant graphical displays. Relationship between QOLIE-31-P parameters and efficacy 
parameters (seizure reduction, 75%RR) will be evaluated.
Seizure frequency (continuous variable):
An analysis of covariance (ANCOVA) will be performed on the log-transformed weekly 
seizure frequency data. Specifically, ln(1+weekly seizure frequency during the Treatment 
Period) will be modeled with treatment group as factor and ln(1+weekly seizure frequency at 
Baseline) as covariate. Contrasts will be estimated to compare UCB0942 to observed placebo 
results.
All seizure frequency (Type I+II+III) and subtypes of partial seizures (Type IA, IB, IC) per 
week over the Treatment Period will be analyzed in a manner similar to the seizure 
frequency. Transformation of efficacy data could be envisaged given the data distribution. 
Different treatment periods will be considered (inpatient as defined in Section 13.3.1, 
outpatient, and overall).
Box-plots will be also displayed for the change in seizure frequency (absolute and 
percentage).
Exploratory analysis will be performed on the seizure count/SSQ data collected during the 
Tapering/Safety Follow-Up Period.
13.4
Planned safety and population PK analyses
13.4.1
Safety analyses
Adverse events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA®). Adverse events will be summarized by MedDRA System Organ Class and 
Preferred Term. The incidence of SAEs, AEs leading to premature discontinuation or dose 
tapering, and related AEs, and the incidence of AEs by maximum intensity, will also be 
summarized.
Laboratory values, ECG data (ventricular rate, PR, QTc [using Bazett’s and Fridericia’s 
formula], and QRS), vital signs, weight, and changes from Baseline in these measures will be 
summarized by period, visit, and treatment group. Possibly clinically significant treatment-
emergent abnormalities for laboratory values, vital signs, and weight will be listed and 
summarized by period and visit for each treatment group. 
Electrocardiogram abnormalities as well as physical and neurological abnormalities will also 
be listed by period and visit. Quantitative safety parameters will be summarized descriptively 
by time point and treatment group. Categorical safety summaries will provide the number and 
percentage of subjects within each summarized category. Doppler echocardiography results 
REDACTED 
oul
oul
ered
ered (i
r the c
r the c
COPY
of p
of 
d in a 
d in 
uld b
ld
This document
ab
form
form
su
su
cannot
arize
rize
borat
orat
be
er
and r
and 
used
Adve
dve
rm. T
m. T
to
ill b
ll b
support
saf
sa
y anal
ana
y
be c
be
any 
rioi
afet
afe
marketing 
cha
ha
ormed 
rmed
od.
od.
authorization 
m
be env
e env
(inpati
npat
ang
ang
application
UCB
UCB
artial s
rtial 
mann
ann
and 
weekl
eekl
B0
B0
any 
sfo
f
uring 
uring
extensions 
ca
form
orm
or 
acy
cy
variations 
any 
any 
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 76 of 125
at Baseline and during and after treatment, and changes from Baseline, will be listed and 
descriptively summarized.
All C-SSRS data obtained at Baseline and subsequent visits will be reported as a listing 
ordered by subject and visit. Psychiatric and cognitive assessments (MINI, BPRS, and 
MMSE) and CIWA-B data will also be covered using listings. Moreover, hypersensitivity 
reactions data will be summarized and listed.
13.4.2
PK analyses
13.4.2.1
Non-compartmental PK analysis
Plasma concentrations of UCB0942, 
 will be 
determined from blood samples obtained in the study, during the Titration and Maintenance 
Periods in order to investigate the PK of UCB0942 and its major metabolites.
The following PK parameters will be calculated:
! AUCτ:
area under the plasma concentration-time curve over a dosing interval, as 
determined using the linear trapezoidal rule.
! Cmax:
maximum observed plasma concentration.
! tmax:
time of Cmax.
! t½:
apparent terminal elimination half-life, reported in hours, as determined via 
simple linear regression (slope = -λz) of natural log(ln) concentration vs time 
for data points in the terminal phase of the concentration-time curve. t½ is 
calculated as ln(2)/λz.
! Ctrough:
measured concentration at the end of the dosing interval at steady state.
The PK variables will be computed by non-compartmental analysis (NCA) with Phoenix 
WinNonlin (version 6.2 or higher) using the actual sampling times. The linear trapezoidal 
method will be used to calculate AUC parameters.
PK parameters of UCB0942 and its metabolites will be listed and summarized using the 
following descriptive statistics: number of observations, geometric mean, lower and upper 
95% CI, geometric coefficient of variation (CV), arithmetic mean, SD, median, and minimum 
and maximum values. Graphical outputs over time will be produced on the trough plasma 
drug concentrations.
13.4.2.2
Population PK analysis
If appropriate, a population PK analysis will be conducted to characterize the PK of 
UCB0942, including inter-individual variability, and to assess the potential effect of 
concomitant AEDs on the PK of UCB0942. The population PK analysis will be based on 
plasma concentrations obtained during the Maintenance Week of the Inpatient Period, as well 
as samples collected during the Outpatient Maintenance Period. A separate data analysis plan 
(DAP) will describe the analysis, which will be reported in a separate report.
13.4.2.3
Population PK-PD analysis
Exploratory population PK-PD analysis may be performed if needed to characterize the 
relationship between exposure to UCB0942 and the clinical and/or safety clinical outcome. A 
separate DAP will describe the analysis, which will be reported in a separate report.
REDACTED 
p
n at th
at th
d by
d by n
y
usi
us
COPY
ifefe
-λz) o
) o
phase
hase
This document 
las
a
as sa
as sa
(D
(D
anno
942, 
42, 
comita
omita
sma
sma
be
iate,
iate
inin
used
Pop
Pop
a
to 
ns.
ns.
support
ficient
icien
. Grap
Grap
any
nd i
nd 
cs: nu
cs: n
marketing 
on
on
ing the
ng the
AUC pa
UC p
its m
its
authorization
e of th
 of th
he end
e end
-co
co
application 
ported
ported
f natur
natu
h
and any extensions 
sing i
ing i
o
enan
ena
variations 
anc
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 77 of 125
13.5
Handling of protocol deviations
After all lockable data have been verified/entered into a database and prior to the first 
database lock, a data evaluation meeting will take place. The purpose of the data evaluation 
will be to examine all protocol deviations, define the PPS, and to verify the quality of the 
data. The data evaluation will also help in guiding decisions on how to manage data issues on 
a case-by-case basis (eg, withdrawals, dropouts, and protocol deviations).
Accepted deviations from theoretical time points will be described in the appropriate 
documents and included in the Study Master File. After the data review, resolution of all 
issues, and documentation of all decisions, the database will be locked.
13.6
Handling of dropouts or missing data
The methods for handling dropouts will be described in the SAP.
13.7
Planned interim analyses and data monitoring
An interim analysis will be performed if needed for purposes of planning and designing of 
future studies. If performed, this analysis will be conducted when at least 75% of patients 
have been randomized and completed through the Inpatient Period (completed through 
Visit 5).
All subjects who have completed through Visit 5 at the time of the data snapshot will be 
included in the interim analysis.
All statistical analyses will be described in detail in the interim SAP.
For the interim analysis, the primary efficacy variable (75%RR) will be analyzed using the 
methods described for the primary efficacy analysis. In addition, seizure-free rate, 50%RR, 
and percent reduction in focal seizure frequency will be analyzed as described for the 
secondary/exploratory analyses.
The 75%RR, Seizure-free rate, and 50%RR variables may also be analyzed using Bayesian 
logistic regression. If Bayesian analysis is performed, the percent reduction in focal seizure 
frequency from the Baseline will be estimated using Bayesian analysis of variance (ANOVA) 
and/or ANCOVA. For these analyses, posterior medians, 95% credible intervals for the 
treatment effect, and additional posterior probabilities will be presented. Non informative and 
informative priors will be considered, and sensitivity to different prior settings will be 
assessed. Other efficacy variables may also be analyzed in the Bayesian framework.
The following safety data will also be presented: 
!
Treatment emergent AEs
!
AEs leading to drop-out or withdrawal
!
SAEs
!
Laboratory assessments out of normal range
!
BPRS
The study will not be terminated early for either efficacy or futility based on the results of 
this interim analysis and therefore, an alpha penalty of 0.001 to be assessed on the primary 
efficacy analysis is considered appropriate.  
REDACTED
cy
cy va
va
y
acy
cy an
an
y
e frequ
frequ
COPY 
il in th
il in t
This document 
!
cannot 
AEs lea
Es le
SA
SA
be
ment
ment
used
g safet
safet
to
fica
fica
support 
e e
ditiona
dition
ill be c
l be c
acy
acy
any
will b
will 
anal
anal
marketing 
50%R
50%R
anal
nalys
ysis
be
be
authorization 
he i
e 
riable 
riable
naly
nalysis
si
uency
uency
application 
e of the
of th
inte
inte
and
(com
(com
any 
a
ast 75
ast 7
mp
xtensions 
and d
nd 
or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 78 of 125
The study is not expected to be stopped due to safety reasons during this interim analysis, 
since there are ongoing quarterly Safety Review Group meetings already planned for this 
purpose. Therefore, no criteria for evaluation of early stopping due to safety are included.  
An unblinded team will be established at both the Sponsor and CRO and will include the 
following roles (all unblinded): Data Manager, Statistician, Statistical Programmer, and 
Project Lead. All staff involved in the conduct of the study, including staff at UCB, the CRO, 
participating vendors, and the participating sites will remain blinded to individual treatment 
identity and will not be informed of the results of the interim analysis until final unblinding. 
13.8
Determination of sample size
This is an exploratory pilot study to obtain a first evaluation of the efficacy (estimate and 
variability) of UCB0942 in this specific refractory population. The planned sample size was 
evaluated based on placebo results obtained in similar refractory epileptic populations from
BRV and lacosamide Phase 3 studies in add-on partial epilepsy, and the desired effect was 
based on a doubling of the effect of lacosamide and BRV in subjects in the current target 
population.
For the primary efficacy variable, the 75%RR in the placebo group from these historical 
studies was estimated to be less than 5%. The response on UCB0942 was expected to be 
36.5% in order to provide clear differentiation from lacosamide and BRV in this patient 
population. 
Based on a 2-group Fisher's exact one-sided test with a ratio active:placebo of 1:1, the 
required number of subjects is 23 in each arm to detect a significant difference between the 
2 groups with a power of 80% and a false positive rate of 5%.
14
ETHICS AND REGULATORY REQUIREMENTS
14.1
Informed consent
Subject’s informed consent must be obtained and documented in accordance with local 
regulations, ICH-GCP requirements, and the ethical principles that have their origin in the 
principles of the Declaration of Helsinki.
Prior to obtaining informed consent, information should be given in a language and at a level 
of complexity understandable to the subject in both oral and written form by the Investigator 
(or designee). Each subject will have the opportunity to discuss the study and its alternatives 
with the Investigator.
Prior to participation in the study, the written ICF should be signed and personally dated by 
the subject, or his/her legal representative, and by the person who conducted the informed 
consent discussion (Investigator or designee). The subject or his/her legal representative must 
receive a copy of the signed and dated ICF. As part of the consent process, each subject must 
consent to direct access to his/her medical records for study-related monitoring, auditing, IEC 
review, and regulatory inspection.
If the ICF is amended during the study, the Investigator (or the Sponsor, if applicable) must 
follow all applicable regulatory requirements pertaining to the approval of the amended ICF
by the IEC and use of the amended form.
The subject may withdraw his/her consent to participate in the study at any time. A subject is 
considered as enrolled in the study when he/she has signed the Informed Consent form. An
eCRF must not be started, nor may any study specific procedure be performed for a given 
subject, without having obtained his/her written consent to participate in the study.
REDACTED
t
positiv
positi
GULA
GUL
ent
ent
COPY 
with a
with a
o det
o de
This documen
cons
ons
rev
rev
cannot
nt dis
t dis
eive a
eive a
se
se
be
t, or
t, or
used 
gato
ato
cipat
cipat
to 
h su
tor.
tor
support
med co
ed co
andabl
andab
subje
ubje
any
of He
of H
on
marketing 
e obtai
obta
ents, a
ents, 
el
authorization
a 
etect a
tect a
ve rat
ve rat
ATO
TO
application 
094
094
ide and
de an
ratio
ratio
and
p from
from
942
42
any 
m
extensions
e siz
siz
lation
ation
ed ef
ed ef
e curr
curr
or 
and
n
ze
ze
variations 
nd d
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 79 of 125
14.2
Subject identification cards
Upon signing the Informed Consent and Assent form (as applicable), the subject or legal 
representative will be provided with a subject identification card in the language of the 
subject. The Investigator will fill in the subject identifying information and medical 
emergency contact information. The Investigator will instruct the subject to keep the card 
with him/her at all times.
14.3
Subject compensation
In addition to reimbursement of incurred expenses (eg, travel), subjects will be financially 
compensated for the burden and inconvenience of spending time at the inpatient unit as this is 
an unusual requirement for participants in clinical studies. The amount of compensation will 
be country-specific and approved by the local ethics committee.
14.4
Independent Ethics Committees
The study will be conducted under the auspices of an IEC, as defined in local regulations, 
ICH-GCP, and in accordance with the ethical principles that have their origin in the 
Declaration of Helsinki.
The Investigator/UCB will ensure that an appropriately constituted IEC that complies with 
the requirements of the current ICH-GCP version or applicable country-specific regulations 
will be responsible for the initial and continuing review and approval of the clinical study. 
Prior to initiation of the study, the Investigator/UCB will forward copies of the protocol, 
Informed Consent form, Investigator’s Brochure, Investigator’s curriculum vitae (if 
applicable), advertisement (if applicable), and all other subject-related documents to be used 
for the study to the IEC for its review and approval.
Before initiating a study, the Investigator will have written and dated full approval from the 
responsible IEC for the protocol.
The Investigator will also promptly report to the IEC all changes in the study, all 
unanticipated problems involving risks to human subjects or others, and any protocol 
deviations, to eliminate immediate hazards to subjects.
The Investigator will not make any changes in the study or study conduct without IEC 
approval, except where necessary to eliminate apparent immediate hazards to the subjects. 
For minor changes to a previously approved protocol during the period covered by the 
original approval, it may be possible for the Investigator to obtain an expedited review by the 
IEC as allowed.
As part of the IEC requirements for continuing review of approved studies, the Investigator 
will be responsible for submitting periodic progress reports to the IEC (based on IEC 
requirements), at intervals appropriate to the degree of subject risk involved, but no less than 
once per year. The Investigator should provide a final report to the IEC following study 
completion.
UCB (or its representative) will communicate safety information to the appropriate regulatory 
authorities and all active Investigators in accordance with applicable regulatory requirements. 
The appropriate IEC will also be informed by the Investigator or the Sponsor, as specified by 
the applicable regulatory requirements in each concerned country. Where applicable, 
Investigators are to provide the Sponsor (or its representative) with evidence of such IEC 
notification.
REDACTED
nd al
nd a
d appr
d appr
gator w
gator w
COPY
CB w
CB w
e, I
, Inv
nv
llll
This document
once
nce
com
com
cannot
resp
resp
uirem
irem
e p
e p
be 
f the
f the
used 
al, i, i
d.d.
to
to
it m
it m
support
mak
mak
e nece
e nece
o a pr
 a pr
any
diate
diat
ke
k
mark
y
eting 
 report
repo
y
g risks
g risk
te h
te
authorization
vesti
esti
other
other
roval.
oval.
will ha
will h
application 
ted 
ed
ble cou
le cou
nd appr
d app
ill forw
ll forw
iga
ig
and 
d IE
d IE
any
origi
orig
extensions 
cal re
cal re
i
or
on 
on
variations 
this is
his is
n wi
wi
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 80 of 125
14.5
Subject privacy
UCB staff (or designee) will affirm and uphold the subject’s confidentiality. Throughout this 
study, all data forwarded to UCB (or designee) will be identified only by the subject number 
assigned at Screening.
The Investigator agrees that representatives of UCB, its designee, representatives of the 
relevant IEC, or representatives of regulatory authorities will be allowed to review that 
portion of the subject’s primary medical records that directly concerns this study (including, 
but not limited to, laboratory test result reports, ECG reports, admission/discharge summaries 
for hospital admissions occurring during a subject’s study participation, and autopsy reports 
for deaths occurring during the study).
14.6
Protocol amendments
Protocol changes may affect the legal and ethical status of the study and may also affect the 
statistical evaluations of sample size and the likelihood of the study fulfilling its primary 
objective.
Significant changes to the protocol will only be made as an amendment to the protocol and 
must be approved by UCB, the IECs, and the regulatory authorities (if required), prior to 
being implemented.
15
FINANCE, INSURANCE, AND PUBLICATION
Insurance coverage will be handled according to local requirements.
Finance, insurance, and publication rights are addressed in the Investigator and/or CRO 
agreements, as applicable.
REDACTED 
rere ad
ad
COPY 
local
local
ddr
dd
This document cannot be used to support any marketing authorization 
l re
ressed
esse
application 
UBLI
UBL
requir
equir
and 
ment
en
es (if 
s (if 
any 
nt to 
t to
extensions 
lso af
so a
ng its p
g its p
or variations 
s 
rts 
ts
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 81 of 125
16
REFERENCES
Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern nonenzyme-
inducing AEDs for refractory focal epilepsy: systematic review and meta-analysis. Epilepsia.
2012;53(3):512-20.
Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in 
newly diagnosed epilepsy. Neurology. 2012;78(20):1548-54.
Busto UE, Sykora K, Sellers EM. A clinical scale to assess benzodiazepine withdrawal. J 
Clin Psychopharmacol. 1989;9(6):412-6
Chung S, Ben-Menachem E, Sperling MR, Rosenfeld W, Fountain NB, Benbadis S, et al.
Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical 
trials. CNS Drugs. 2010;24(12):1041-54.
Commission on Classification and Terminology of the International League Against 
Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic 
seizures. Epilepsia. 1981;22:489-501.
CPMP/ICH/135/95 Note for guidance on Good Clinical Practice (EMEA) Jul 2002.
Cramer JA, Baker GA, Jacoby A. Development of a new seizure severity questionnaire: 
initial reliability and validity testing. Epilepsy Res. 2002;48:187-97.
Cramer JA, Perrine K, Devinsky O, Bryant-Comstock L, Meador K, Hermann B. 
Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory. 
Epilepsia. 1998;39(1):81-8.
Cramer JA, Van Hammée G, N132 Study Group. Maintenance of improvement in health-
related quality of life during long-term treatment with levetiracetam. Epilepsy Behav. 
2003;4(2):118-23.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading 
the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-98.
Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al.
Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the 
ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069-77.
Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy: response to sequential treatment 
schedules. Eur J Neurol. 2006;13(3):277-82.
Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports.
1962:10:799-812.
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al, The 
Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings 
from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266-77.
Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment 
history. Neurology. 2008;70(1):54-65.
Steinhoff BJ. Efficacy of perampanel: a review of pooled data. Epilepsia. 2014;55 Suppl 1:
9-12.
REDACTED 
y Gro
Gro
y
m trea
m trea
COPY
ock 
ock
a 31
31-i
This document 
o
from
rom
f
cannot 
7
ner K,
er K,
lumb
um
be 
G
99
99-8
sed 
Ne
Ne
Gorh
Gorh
to 
ie M
e M
eur
eur
support
nt ep
t ep
Therap
Thera
MJ. 
MJ
any
erg A
erg A
pile
pil
marketing 
PR. “M
PR. “
r the cli
the c
AT
authorization
item
em
oup. M
up. M
tment
en
application
re se
re se
:187
187-9
, Mea
Mea
m qu
m q
and
EME
ME
e
any 
A)
A
extensions 
Again
Again
ficatio
icatio
or
nica
ica
variations 
alal.
l
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 82 of 125
17
APPENDICES
17.1
Protocol Amendment 1.0
Rationale for the amendment
The addition of an echocardiogram during dosing was made as a result of comments from the 
Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und 
Medizinprodukte). They have requested the addition of an echocardiogram during dosing. 
This echocardiogram has been added at Day OP22. In addition, the following changes were 
made:
-
It has been clarified that either urine or serum pregnancy tests can be used for all 
visits. 
-
It has been pointed out that the decision to continue in the OLE will occur at
Day OP43. 
-
Clarification on the procedure for dose reduction in cases of poor tolerability of 
UCB0942 400mg bid (ie, reduction to UCB0942 200mg bid and in some cases to 
UCB0942 100mg bid).
-
The withdrawal criteria for elevated transaminases have been reworded as the 
previous description was not clear.
Modifications and changes
Specific changes
Change #1
Section 1 SUMMARY, bullet #7
!
An echocardiogram at the end of the study and at 6 months after the final dose
Has been changed to:
!
An echocardiogram during dosing, after the last dose, and at 6 months after the final dose
Change #2
Section 1 SUMMARY, paragraph 6
Titration to UCB0942 400mg bid will occur over the course of 1 week in the clinical unit. For 
subjects in the active arm, doses will be titrated to UCB0942 400mg bid during the first 
inpatient week. For subjects who initially received placebo, doses will be titrated to 
UCB0942 400mg bid during the last week of the Inpatient Period. For subjects in the active 
arm who do not tolerate UCB0942 400mg bid, during the third week of the Inpatient Period, 
the dose can be tapered to UCB0942 200mg bid before starting the Outpatient Maintenance 
Period. Similarly, for subjects in the placebo group the dose can be tapered to a tolerable dose 
during the Outpatient Maintenance Period. All subjects will stay in the clinical unit for a total 
of 3 weeks and will then be discharged for an 8-week Outpatient Maintenance Period.
Has been changed to:
Titration to UCB0942 400mg bid will occur over the course of 1 week in the clinical unit. For 
subjects in the active arm, doses will be titrated to UCB0942 400mg bid during the first 
inpatient week. For subjects who initially received placebo, doses will be titrated to 
UCB0942 400mg bid during the last week of the Inpatient Period. For subjects in the active 
REDACTED 
#7
#7
of th
of th
COPY 
This document
he e
Peri
Peri
d
annot
942 4
42 4
who d
who d
dos
dos
be
week
week
40
40
used 
B09
09
e activ
 activ
k
to 
942
942
support 
ARY
RY
any
g do
g do
marketing 
the stu
he stu
si
authorization application
e bee
bee
and any 
toto
d in s
d in 
extensions 
ur at
ur at
oler
oler
or variations 
l
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 83 of 125
arm who do not tolerate UCB0942 400mg bid, during the third week of the Inpatient Period, 
the dose can be tapered to UCB0942 200mg bid before starting the Outpatient Maintenance 
Period. Similarly, for subjects in the placebo group the dose can be tapered to UCB0942 
200mg bid during the Outpatient Maintenance Period. Dose tapering to UCB0942 100mg bid 
may be permitted after discussion with the Sponsor’s Study Physician. All subjects will stay 
in the clinical unit for a total of 3 weeks and will then be discharged for an 8-week Outpatient 
Maintenance Period.
Change #3
Section 4.1.3 Exploratory efficacy variables, bullet #4
!
Change in time to recovery from Baseline to the end of the Inpatient Period and the end 
of the Outpatient Maintenance Period (derived from the SSQ, see Section 9.2).
Has been deleted
Change #4
Section 4.4 Safety variables, bullet #10
!
Changes in 2-dimensional Doppler echocardiography from Baseline to after treatment 
(end of dosing and 6 months after last dose), with diastolic measurements as well as atrial 
volumes to identify any subtle valvular changes and to assess for pericardial effusions
Has been changed to:
!
Changes in 2-dimensional Doppler echocardiography from Baseline to after Baseline 
(during dosing, after the last dose, and 6 months after last dose), with diastolic 
measurements as well as atrial volumes to identify any subtle valvular changes and to 
assess for pericardial effusions
Change #5
Section 5.1 Study description, bullet #7
!
An echocardiogram at the end of the study and at 6 months after the last dose
Has been changed to:
!
An echocardiogram during dosing, after the last dose, and at 6 months after the last dose
Change #6
Section 5.1 Study description, paragraph 6
If a subject is not tolerating UCB0942 400mg bid well, the dose can be tapered to UCB0942 
200mg bid. The taper from UCB0942 400mg bid to UCB0942 200mg bid will occur over 
3 days (see Table 5‒2) and will require unblinding of the subject if this occurs during the 
Inpatient Period.
Has been changed to:
If a subject is not tolerating UCB0942 400mg bid well, the dose can be tapered to UCB0942 
200mg bid. The taper from UCB0942 400mg bid to UCB0942 200mg bid will occur over 
3 days (see Table 5‒2) and will require unblinding of the subject if this occurs during the 
Inpatient Period. Dose tapering to UCB0942 100mg bid may be permitted after discussion 
with the Sponsor’s Study Physician.
ard
ard
6 mo
6 mo
mes to
mes t
COPY 
diog
dio
This document 
da
da
Inpa
Inp
cannot
bject
ect
mg bi
mg bi
ay
ays
be 
5.1
t i
t i
sed 
1 S
1 S
to support 
to:
to:
am du
am d
any
e end
e end
marketing 
tion
ion
authorization 
graph
graph
onths a
nths 
to iden
o iden
application
c meas
c mea
assess 
assess
and 
aselin
selin
any extensions or
e e
e 
variations 
end
end
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 84 of 125
Change #7
Section 5.1.2 Planned number of subjects and sites
Subjects with highly drug-resistant focal epilepsy will be enrolled at up to 10 
 sites 
in order to provide 46 evaluable subjects, ie, 46 subjects who complete the Inpatient Period.
Subjects who drop out before Visit 6 (eg, during the Inpatient Period) for reasons other than 
safety or tolerability will be replaced. First subject, first visit is planned for Q2 2015.
Has been changed to:
Subjects with highly drug-resistant focal epilepsy will be enrolled at 
 sites in order 
to provide 46 evaluable subjects, ie, 46 subjects who complete the Inpatient Period. Subjects 
who drop out before Visit 6 (eg, during the Inpatient Period) for reasons other than safety or 
tolerability will be replaced. First subject, first visit is planned for Q2 2015.
Change #8
Section 5.2 Schedule of study assessments
In the schedule of study assessments (Table 5-4), an “X” has been added at Day OP22 for 
echocardiogram. 
Change #9
Section 5.2 Schedule of study assessments, Table 5-4, footnote j:
j In addition to the echocardiogram after the last dose, for subjects who do not continue in the 
OLE study, an echocardiogram at 6 months after the last dose will also be performed.
Has been changed to:
j In addition to the echocardiogram during dosing and after the last dose, for subjects who do 
not continue in the OLE study, an echocardiogram at 6 months after the last dose will also be 
performed. Please note that the during dosing time point of Day OP22 for the 
echocardiogram has a time window of ±1 week instead of ±2 days.
Change #10
Section 5.2 Schedule of study assessments, Table 5-4, footnote l:
l Serum pregnancy test at Screening and admission (Day T1); urine pregnancy test at all other 
occasions.
Has been changed to:
l Urine or serum pregnancy test.
Change #11
Section 5.2 Schedule of study assessments, Table 5-5, footnote h:
h Serum pregnancy test, female subject only.
Has been changed to:
h Urine or serum pregnancy test, female subject only.
Change #12
Section 5.3 Schematic diagram
REDACTED
after
afte
during
during
echo
echo
COPY 
ent
en
st dose
t dose
er t
This document
Sec
Sec
h
cannot
or s
or s
hange
ange
be 
 c
seru
ser
used 
cha
cha
to 
te
support 
ule of
ule o
est at 
st at 
any marketing 
ng g
ocardi
ocard
ring do
ng do
ow of 
ow o
uthorization
e, fo
, fo
the la
he la
dos
dos
application 
, Tabl
Tab
or s
or
and 
dde
de
any 
ed a
ed
extensions or
afet
fety
variations 
der 
er 
bjects
jects
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 85 of 125
Has been changed to:
CTED 
REDACT
COPY 
This docume
ment cannot be used to support any marketing 
orization
on 
author
application and any extensions or 
riations 
varia
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 86 of 125
Change #13
Section 6.3 Withdrawal criteria, criterion #1
Subject develops a clinically relevant medical condition (or laboratory abnormality) that, in 
the opinion of the Investigator, compromises the subject’s ability to participate or safety. In 
the case of transaminase (AST, ALT, or both) levels at least 3 times the upper limit of normal 
(ULN) to less than 5 times the ULN, in the presence of normal total bilirubin, the laboratory 
tests will be repeated within a few days. If the repeat testing confirms the abnormality (ie, 
transaminases are at least 3 times the ULN to less than 5 times the ULN with normal 
bilirubin), then weekly monitoring of liver function tests should continue until resolved (ie, 
less than 3 times the ULN or stable condition). The Investigator is to decide whether or not to 
stop the investigational medicinal product (IMP). To monitor for hypersensitivity reactions, 
percent eosinophils >10% or absolute eosinophil count ≥0.5G/L or absolute neutrophil count 
<1.5G/L or absolute platelet count ≤100G/L, if in combination with fever, rash, 
lymphadenopathy, or other symptoms/signs suggestive of internal organ involvement 
(including but not limited to hepatitis, nephritis, pneumonitis, carditis, colitis, encephalitis, 
pancreatitis, myositis, or arthritis) will lead to stopping the IMP.
Has been changed to:
Subject develops a clinically relevant medical condition (or laboratory abnormality) that, in 
the opinion of the Investigator, compromises the subject’s ability to participate or safety. In 
the case of transaminase (AST, ALT, or both) levels at least 3 times the upper limit of normal 
(ULN) in the presence of normal total bilirubin, the laboratory tests will be repeated within a 
few days. If the repeat testing confirms the abnormality, then weekly monitoring of liver 
function tests should continue until resolved (ie, less than 3 times the ULN or stable 
condition). The Investigator is to decide whether or not to stop the investigational medicinal 
product (IMP). To monitor for hypersensitivity reactions, percent eosinophils >10% or 
absolute eosinophil count ≥0.5G/L or absolute neutrophil count <1.5G/L or absolute platelet 
count ≤100G/L, if in combination with fever, rash, lymphadenopathy, or other 
symptoms/signs suggestive of internal organ involvement (including but not limited to 
hepatitis, nephritis, pneumonitis, carditis, colitis, encephalitis, pancreatitis, myositis, or 
arthritis) will lead to stopping the IMP.
Change #14
Section 7.1 Description of investigational medicinal products, Table 7-1, 
Note
For the Inpatient Period, 1 kit per treatment period and per dose will be packaged. Each kit 
will contain blister packs, each covering 1 week of treatment. For the Outpatient Period, 
UCB0942 tablets will be provided in bottles, containing 40 tablets per bottle, either 200mg 
tablets for subjects on UCB0942 400mg bid, or 100mg tablets for subjects who reduce dose 
to UCB0942 200mg bid. The bottles containing 40 UCB0942 100mg tablets will be 
dispensed for the Taper Period.
Has been changed to:
For the Inpatient Period, 1 kit per treatment period and per dose will be packaged. Each kit 
will contain blister packs, each covering 1 week of treatment. For the Outpatient Period, 
UCB0942 tablets will be provided in bottles, containing 37 tablets per bottle, either 200mg 
tablets for subjects on UCB0942 400mg bid, or 100mg tablets for subjects who reduce dose 
REDACTED
abno
abno
ved (i
ved (i
de wh
de wh
ersens
ersen
or
or
COPY
bjej
els at
els a
n, the 
, the 
This document
able
able
to U
to U
d
cannot
ontain
ntain
B0942
B0942
lets
ets
be
patie
pati
used 
De
to
esc
sc
suppor
ping 
ping
ri
any
itis, c
itis, 
g th
g t
marketing
sitiv
iti
r absolu
absolu
with fe
with 
nterna
terna
authorization
labo
labo
rmality
mality
ie, les
e, les
hether
ether
tivit
ivit
application 
laborat
abora
s abilit
abili
least 3
least
ra
and any
olit
oli
extensions
ea
rophi
rophi
h, 
h, 
volve
volve
itis,
tis
or
ctio
ctio
variations 
e,e,
not t
not 
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 87 of 125
to UCB0942 200mg bid. The bottles containing 37 UCB0942 100mg tablets will be 
dispensed for the Taper Period.
Change #15
Section 7.9.1.3 Breaking the treatment blind for taper of dose during the 
study
If the IMP is not tolerated during the Inpatient Period by an individual subject, the dose can 
be tapered to the last tolerated dose. This is only permitted if the subject has great difficulty 
tolerating the IMP and the Investigator does not think that tolerability will improve. When it 
is decided to reduce the dose, the blind will have to be broken, following the procedure 
described in Section 7.9.1.2.
Has been changed to:
If the IMP is not tolerated during the Inpatient Period by an individual subject, the dose can 
be tapered to UCB0942 200mg bid. This is only permitted if the subject has great difficulty 
tolerating the IMP and the Investigator does not think that tolerability will improve. When it 
is decided to reduce the dose, the blind will have to be broken, following the procedure 
described in Section 7.9.1.2.
Change #16
Section 8.1.1 Screening (Visit 1, Day -1), bullet #16
!
Serum pregnancy test (female subjects only)
Has been changed to:
!
Urine or serum pregnancy test (female subjects only)
Change #17
Section 8.2.1 Titration Week (Visit 3, Day T1 to Day T7), bullet #5
!
Serum pregnancy test (female subjects only)
Has been changed to:
!
Urine or serum pregnancy test (female subjects only)
Change #18
Section 8.3.1 Outpatient Maintenance Period (Visit 6 to Visit 15, Day OP1 
to Day OP57), paragraph 4
Further dose tapering may be implemented for each subject during the 8 weeks of treatment 
in the Outpatient Maintenance Period at the discretion of the Investigator in conjunction with 
the wishes of the subject.
Has been changed to:
Dose tapering from UCB0942 400mg bid to UCB0942 200mg bid to increase tolerability 
may be implemented for each subject at any time during the 8 weeks of treatment in the 
Outpatient Maintenance Period at the discretion of the Investigator in conjunction with the 
wishes of the subject. Dose tapering to UCB0942 100mg bid may be permitted after 
discussion with the Sponsor’s Study Physician.
REDACTED 
male s
male s
COPY
 bu
 b
y)
This document
the w
the w
H
cannot 
er dos
er dos
the O
he O
be
OP5
OP5
used 
3.1 O
3.1 O
57
57
to support 
o:
o:
egnanc
egnan
any
ale
ale
marketing 
k (Vis
k (V
e su
e su
authorization 
subjec
ubjec
application 
let #1
et #1
and
win
win
any
will im
will i
ng t
ng
extensions 
ct, the
ct, the
as gre
s gre
or variations 
it 
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 88 of 125
And the following bullet point has been added:
!
Echocardiogram (Day OP22 ±1 week)
Change #19
Section 8.3.1 Outpatient Maintenance Period (Visit 6 to Visit 15, Day OP1 
to Day OP57), BULLET #13
!
Urine pregnancy test (females only; Days OP8, OP36, and OP57)
Has been changed to:
!
Urine or serum pregnancy test (females only; Days OP8, OP36, and OP57)
And the following bullet point has been added:
!
Decision to continue in the OLE study (Day OP43)
Change #20
Section 8.3.3 Safety Follow-Up (Visit 18 to 20, Day SFU7, SFU14, and 
SFU28), BULLET #9
!
Pregnancy test (urine, females only)
Has been changed to:
!
Pregnancy test (urine or serum, females only)
Change #21
Section 8.3.4 Echocardiography follow up
For subjects who do not continue in the OLE study, it is mandatory that they have an 
echocardiogram at 6 months (±1 month) after the last dose of IMP (in addition to the 
echocardiogram at the end of the study). 
Has been changed to:
For subjects who do not continue in the OLE study, it is mandatory that they have an 
echocardiogram at 6 months (±1 month) after the last dose of IMP (in addition to the 
echocardiogram at Screening, during dosing, and after the last dose). 
Change #22
Section 8.4 Withdrawal Visit, bullet #18
!
Pregnancy test (serum, females only)
Has been changed to:
!
Pregnancy test (urine or serum, females only)
Change #23
Section 8.6 Open-label extension study (EP0073)
Subjects who experience substantial benefit from UCB0942 with acceptable tolerability will 
have the option to continue taking UCB0942 during an OLE study. The decision to enter the 
OLE study must be made by the subject in consultation with the Investigator and/or the 
subject’s habitual epilepsy provider (the neurologist who treats the subject outside of the 
study), and this decision must take into account the benefit experienced, the potential risks of 
hy fol
fo
y
n the O
n the 
on
on
COPY 
y)
This document 
!
cannot
egnan
gnan
as be
s be
be 
8.4
.4
used 
4 W
4 W
to support
ontin
nti
months 
onths
creeni
creen
any 
tinu
inu
marketing
OL
OL
nth) aft
th) aft
study
tudy).)
authorization 
ollow 
low
LE
LE
application and 
U
any 
7, SF
7, S
extensions or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 89 of 125
long-term exposure to UCB0942, and the potential benefit and risks of other treatment 
options available that have not been tried. Subjects who enter the OLE study will have 
echocardiographic follow up as scheduled in the OLE study protocol and will therefore not 
participate in the echocardiographic follow up described in Section 8.3.4.
Has been changed to:
Subjects who experience substantial benefit from UCB0942 with acceptable tolerability may 
have the option to continue taking UCB0942 during an OLE study. The decision to enter the 
OLE study must be made by the subject in consultation with the Investigator and/or the 
subject’s caregiver. This decision must take into account the benefit experienced, the 
potential risks of long-term exposure to UCB0942, and the potential benefit and risks of other 
treatment options available. Subjects who enter the OLE study will have echocardiographic 
follow up as scheduled in the OLE study protocol and will therefore not participate in the 
echocardiographic follow up described in Section 8.3.4.
Change #24
Section 9.2 Seizure Severity Questionnaire, paragraph 3
The SSQ will be competed according to the tabular schedule of study procedures, Table 5-4.
For this study the recall period will be set to 1 week rather than the original 4 weeks. At the 
very beginning of the visit, the SSQ will be provided to all subjects. The subject will be asked 
to complete the questionnaire on his/her own. Once completed, the subject will return the 
completed questionnaire to the Investigator or designee, who will verify that all questions 
have been answered. Further details about the SSQ will be covered in the Study Manual.
Has been changed to:
The SSQ will be completed according to the tabular schedule of study procedures, Table 5-4.
For this study the recall period will be set to 1 week rather than the original 4 weeks. At the 
very beginning of the visit, the SSQ will be provided to all subjects. The subject will be asked 
to complete the questionnaire on his/her own. Once completed, the subject will return the 
completed questionnaire to the Investigator or designee, who will verify that all questions 
have been answered. Further details about the SSQ will be covered in the Study Manual.
Change #25
Section 11.7.3 Echocardiograms, paragraph 1
Echocardiograms will be performed during Screening, after the last dose of IMP, and at 
6 months after the last dose of IMP, as described in Table 5-4.
Has been changed to:
Echocardiograms will be performed during Screening, during dosing (Day OP22 ±1 week), 
after the last dose of IMP, and at 6 months after the last dose of IMP, as described in 
Table 5-4.
Change #26
Section 13.3.3 Exploratory efficacy analyses, paragraph 1
Changes in the SSQ, time to recovery, and average seizure severity as calculated by the 
percentage of seizures that are type IC from Baseline to the end of the Inpatient Period and 
the end of the Outpatient Maintenance Period will be analyzed.
REDACTED 
e S
e S
ng to th
g to th
l be s
l be s
COPY
e com
e co
esigne
sign
SSQ
SSQ
This documen
after
fter
Tab
Ta
canno
een
een
hocard
ocard
r t
r t
be 
fte
n
used
ms w
ms w
er th
r th
to 
Ec
Ec
upport 
cho
cho
any 
In
detai
deta
marketing
set to
set to
will be
will b
his/her
his/he
nves
nve
authorization 
ee,
Q will 
will 
he tab
he tab
application
n the 
n the
subjec
subje
mpleted
pleted
e, wh
 wh
and 
ud
udy p
y p
any 
3
extensions
og
ate in 
te in
or
raph
rap
variations 
f othe
f othe
h
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 90 of 125
Has been changed to:
Changes in the SSQ and average seizure severity as calculated by the percentage of seizures 
that are type IC from Baseline to the end of the Inpatient Period and the end of the Outpatient 
Maintenance Period will be analyzed.
Change #27
Section 13.4.1 Safety analyses, paragraph 3
Electrocardiogram abnormalities as well as physical and neurological abnormalities will also 
be listed by period and visit. Quantitative safety parameters will be summarized descriptively 
by time point and treatment group. Categorical safety summaries will provide the number and 
percentage of subjects within each summarized category. Doppler echocardiography results 
at Baseline and after treatment, and changes from Baseline, will be listed and descriptively 
summarized.
Has been changed to:
Electrocardiogram abnormalities as well as physical and neurological abnormalities will also 
be listed by period and visit. Quantitative safety parameters will be summarized descriptively 
by time point and treatment group. Categorical safety summaries will provide the number and 
percentage of subjects within each summarized category. Doppler echocardiography results 
at Baseline and during and after treatment, and changes from Baseline, will be listed and 
descriptively summarized.
REDACTED COPY 
g
This document cannot be used to support any marketing authorization application
es w
s w
ppler e
ppler 
om Ba
om B
and
e sum
sum
will
will
any 
abnor
abno
mm
extensions
y
scripti
cript
or
resu
resu
variations 
vely
ely
ber an
er an
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 91 of 125
17.2
Protocol Amendment 2.0
Rationale for the amendment
The protocol describes the use of video monitoring during the Inpatient Period. The video 
monitoring is an exploratory endpoint, and the data will be used to assess the difference 
between seizure diaries (the primary endpoint) and seizures detected with video. The 
intention of the protocol language was to let sites perform video monitoring according to their 
usual clinical practice; however, the language in the first version was not sufficiently clear to 
convey this flexibility. The purpose of this amendment is to make the video monitoring 
language in the protocol more flexible so that sites/Investigators can perform this according 
to their usual practice. This new language will also allow video-EEG monitoring as some 
sites do not perform video-only monitoring. 
A second change was the wording of the drug misuse exclusion criterion. As is customary in 
most UCB protocols, exclusion for drug misuse is only applicable if the Investigator deems 
that study participation is either a risk to the subject or that the drug misuse could confound 
the outcomes measured in the study. The wording of this exclusion criterion was changed to 
match that of other UCB studies.
In addition, the possibility of rescreening screening failures was added.
Modifications and changes
Specific changes
Change #1
Section 3.3 Exploratory objectives, bullet #2
Use video recordings to explore the effect of UCB0942 on seizure type, seizure severity, 
seizure duration, and duration of the postictal period
Has been changed to:
Use video recordings, when available, to explore the effect of UCB0942 on seizure type, 
seizure severity, seizure duration, and duration of the postictal period
Change #2
Section 4.3, Exploratory variables, paragraph 4
During the Inpatient Period, there will be video monitoring of subjects in their rooms (and in 
other areas depending on the infrastructure of each site) to assess seizure type, severity, 
duration, and the duration of the postictal period.
Has been changed to:
At the discretion of the Investigator, sites may or may not perform video or 
video- electroencephalogram (EEG) monitoring during parts of the Inpatient Period or during 
the whole Inpatient Period, depending on the infrastructure of each site, to assess seizure 
type, severity, duration, and the duration of the postictal period.
Change #3
Section 5.2 Schedule of study assessments, Table 5-4, footnote a:
If a subject fails screening, a rescreening is allowed if deemed appropriate by the 
Investigator.
REDACTED 
ves
es, b
, b
effect 
effect 
he po
he po
COPY 
This document 
At th
At th
vid
vid
cannot 
s bee
bee
the
the
be
de
and t
and 
used
atien
tien
epen
epen
to 
xpl
p
t
support 
lora
lora
any 
aili
ation, 
tion,
marketing
osticta
ostict
ilabl
labl
authorization 
bulle
ulle
of UC
of UC
t
application
s add
ad
and 
dde
dde
any
erion
erion
extensions 
custo
custo
estigat
estigat
e cou
e cou
or variations 
ng
ng
me
me
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 92 of 125
Has been added, subsequent footnotes have been renumbered 
accordingly
Change #4
Section 5.2 Schedule of study assessments, Table 5-4:
Video monitoring in subject rooms
Has been changed to:
Video or video-EEG monitoringm
Change #5
Section 5.2 Schedule of study assessments, Table 5-4:
EEG=electroencephalogram;
Has been added
Change #6
Section 5.2 Schedule of study assessments, Table 5-4, footnote m:
At the discretion of the Investigator, sites may or may not perform video or video-EEG 
monitoring during parts of the Inpatient Period or during the whole Inpatient Period.
Has been added, subsequent footnotes have been renumbered 
accordingly
Change #7
Section 5.2 Schedule of study assessments, Table 5-5:
Video monitoring in subject rooms
Has been changed to:
Video or video-EEG monitoringh
Change #8
Section 5.2 Schedule of study assessments, Table 5-5:
EEG=electroencephalogram;
Has been added
Changes #9
Section 5.2 Schedule of study assessments, Table 5-5, footnote h:
At the discretion of the Investigator, sites may or may not perform video or video-EEG 
monitoring during parts of the Inpatient Period or during the whole Inpatient Period.
Has been added, subsequent footnotes have been renumbered 
accordingly
Change #10
Section 6.2 Exclusion criteria, criterion #18
REDACTED 
dy
dy as
as
y
COPY 
es ha
s ha
This document
At th
At th
m
canno
ges
es
ection
ction
be 
s #
s #
used 
ceph
ep
add
add
to 
phal
pha
support 
edule
edule
any 
ing
ngh
marketing 
h
authorization 
av
sess
sess
application 
rform v
form
the who
he wh
ve be
e b
and 
5-4,
4,
any extensions or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 93 of 125
18. Subject has a history in the last 5 years of drug or alcohol dependency or tests positive for 
drugs of abuse or alcohol during Screening.
Has been changed to:
18. Subject has past or present substance abuse/dependence that in the opinion of the 
Investigator could threaten the subject’s safety within the study, affect the subject’s 
ability to fully participate in the study, or confound study interpretation.
Change #11
Section 8.1.2 Baseline Period (Visit 2, Day BL1 to BL14-21)
If a subject fails screening, a rescreening is allowed if deemed appropriate by the 
Investigator.
Has been added
Change #12
Section 8.2.1 Titration Week (Visit 3, Day T1 to Day T7)
During the Inpatient Period of the study, all subjects will be monitored by video in their 
bedrooms (and at some sites in other areas) to provide objective data on seizure type, 
severity, and duration, and on the duration of the postictal period as an exploratory outcome 
measure.
Has been changed to:
At the discretion of the Investigator, sites may or may not perform video or video-EEG 
monitoring during parts of the Inpatient Period or during the whole Inpatient Period of the 
study, depending on the infrastructure of each site, to provide objective data on seizure type, 
severity, and duration, and on the duration of the postictal period as an exploratory outcome
measure.
Change #13
Section 8.2.1 Titration Week (Visit 3, Day T1 to Day T7)
!
Video seizure monitoring in subject rooms
Has been changed to:
!
Video or video-EEG monitoring (optional)
Change #14
Section 8.2.2 Maintenance-Dose Week (Visit 4, Day MD1 to Day MD7)
At the end of the Titration Week, subjects continue in the Maintenance-Dose Week, during 
which they will continue to record their seizures in subject diaries and will continue to be 
video-monitored in their bedrooms.
Has been changed to:
At the end of the Titration Week, subjects continue in the Maintenance-Dose Week, during 
which they will continue to record their seizures in subject diaries.
Change #15
Section 8.2.2 Maintenance-Dose Week (Visit 4, Day MD1 to Day MD7)
REDACTED 
may
may o
y
Perio
Perio
e of ea
e of e
durati
durati
COPY 
This document
t 
whic
whic
viv
cannot
on 8
on 8
the e
the e
be
#14
#1
used 
deo
deo-
4
to 
ge
g
E
support 
toring 
oring
ed t
ed t
any 
Wee
Wee
marketing 
ion o
on o
authorization 
r may
r ma
od or d
d or d
ach si
ach s
of
application
ve dat
ve da
period a
eriod
and 
)
tored 
ored
any extensions or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 94 of 125
!
Video monitoring in subject rooms
Has been changed to:
!
Video or video-EEG monitoring (optional) 
Change #16
Section 8.2.3
Transition-to-Outpatient Week (Visit 5, Day TTO1 to Day 
TTO7)
!
Video monitoring
Has been changed to:
!
Video or video-EEG monitoring (optional)
Change #17
Section 9.1.1
Video monitoring
During all inpatient periods, there will be continuous video monitoring in subjects’ rooms 
(and at some sites in other areas) to allow exploratory analysis of seizure type, severity, and 
duration, and of the duration of the postictal period.
Has been changed to:
At the discretion of the Investigator, sites may or may not perform video or video-EEG
monitoring during part of the Inpatient Period or during the whole Inpatient Period, 
depending on the infrastructure of each site, to allow exploratory analysis of seizure type, 
severity, and duration, and of the duration of the postictal period.
17.3
Protocol Amendment 3.0
Rationale for the Amendment
The primary reason for Amendment 3 is to add and describe an optional interim analysis for 
purposes of planning and designing of future studies. 
Other reasons for the amendment include the following: 
!
To add an exploratory objective, variable and associated assessment (diary 
addendum). Note that this was already part of the study, but not clearly described in 
the protocol.
!
To clarify procedures for dosing when there is intolerance to study medication during 
the Inpatient Period
!
To allow and specify flexibility in dosing during the Outpatient Maintenance Period
!
To further specify which Subjects require an echocardiogram at 6 months after the 
last dose of study medication
!
To expand the range of BMIs allowed for inclusion in the study
!
To revise procedures for assessment of suicidality using the C-SSRS (specifically, the 
C-SSRS withdrawal criterion) in line with revision to sop-ai-015774, Version 2.0,
which became effective on 01 Apr 2016. 
!
To update the protocol information pertaining to potential drug-induced liver injury 
(exclusion criteria, withdrawal criteria, adverse events of special interest, and 
REDACTED
to a
to a
n of th
n of th
ment
ment
ent
ent
COPY
may
may n
y
or dur
or dur
llll
This document 
!
cannot 
he
To
To
!
be
cla
e I
e Inp
np
used
ocol
col
arify
arify
to 
. N
ol.
ol
support
ndm
ndm
lorator
orato
Note 
Note 
any 
nin
ni
men
men
marketing 
entnt 3 is
3
ing o
ing
authorization
ring 
ring 
low e
ow e
he po
e po
3.0
3.0
application 
not per
ot pe
thth
and
g
eizur
izur
any 
g in su
in s
extensions or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 95 of 125
assessments) based on new standard language which is being applied across all 
protocols at UCB. Note that these additions do not reflect a change in the known 
safety of the compound. 
!
To revise study personnel and make other administrative changes 
Modifications and changes
Specific changes
Change #1
Coordinating Investigator 
Name:
Dr. 
Affiliation:
Address:
Phone:
+
Has been changed to: 
Coordinating Investigator 
Name:
Prof. Dr. 
Affiliation:
Address:
Phone:
Change #2
Study Contact Information, Early Development Lead/New Medicines 
Therapeutic Area Specialist
Name:
Address:
UCB Biopharma SPRL
Chemin du Foriest
B-1420 Braine-l'Alleud
BELGIUM
Phone:
REDACTED
TE
AC ED 
RE
COPY 
CO
C
This document cannot 
ddr
d
ca
be 
dres
dres
e used 
A
ed to
rea
rea
support 
nform
nform
a S
any
any
ny market
ma
ting 
keting
mar
m
authoriza
iza
th
ation 
on
zati
application 
ion and 
nd any extensions 
ns
ns
or variations 
v
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 96 of 125
Has been changed to: 
Name:
, MD
Address:
UCB Biopharma SPRL
Chemin du Foriest
B-1420 Braine-l'Alleud
BELGIUM
Phone:
Change #3
Study Contact Information, Sponsor Study Physician
Name:
Address:
UCB Celltech, UK Registered Branch of UCB Pharma SA
208 Bath Road, Slough
Berkshire, SL1 3WE
UNITED KINGDOM
Phone:
Has been changed to: 
Name:
, MD
Address:
UCB Biopharma SPRL
Chemin du Foriest
B-1420 Braine-l'Alleud
BELGIUM
Phone:
Change #4
Sponsor Contact Information, Clinical Trial Biostatistician
Name:
Address:
UCB Biopharma SPRL
Chemin du Foriest
B-1420 Braine-l'Alleud
BELGIUM
Phone:
REDACTED 
MD
MD
SPRL
SPRL
riest
riest
ine
ine l
TE
COPY 
Y
CO
This document cannot 
ca
be 
s
used 
s:s:
ed to 
o support 
t Info
 Info
s
any
ny
ny marketing
Alleu
Alleu
ar
ma
authorization 
on
riz
application 
tio
pli
and any extensions 
on
arma 
rma 
en
or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 97 of 125
Has been changed to: 
Name:
Address:
UCB BIOSCIENCES Inc.
8010 Arco Corporate Drive
Raleigh, NC  27617
UNITED STATES
Phone:
Change #5
List Of Abbreviations
Have been added: 
ANOVA
analysis of variance
PDILI
potential drug-induced liver injury
SAP
Statistical Analysis Plan
Change #6
Section 1 SUMMARY, bullet #7
!
An echocardiogram during dosing, after the last dose, and at 6 months after the final dose
Has been changed to: 
!
An echocardiogram during dosing and after the last dose (the SFU7 echocardiogram). 
The echocardiogram will be repeated at 6 months (±1 month) after the last dose in the 
following subjects:
∀
Subjects who complete this study but do not enter the OLE study
∀
Subjects who withdraw from the Outpatient Period 
∀
Subjects who withdraw from the Inpatient Period and have an abnormal SFU7 
echocardiogram
Change #7
Section 3.3 Exploratory objectives
Added the following exploratory objective: 
!
To assess motivations, hopes and impact of seizures using a Diary Addendum
Change #8
Section 4.3 Exploratory variables
Added the following exploratory variable: 
!
Responses to open questions in the Diary Addendum, including: 
∀
Reason for participation in the study
∀
Hopes for this new treatment and fulfillment of hopes during the study
∀
Baseline and change from Baseline in the impact of seizures on the patient’s life
REDACTED 
g and 
and 
pe
peated
ated
COPY 
e last 
last 
This document
Cha
Cha
S
cannot 
 th
t
To ass
To as
a
be 
he 
he 
used 
3 Ex
Ex
to support
thdraw
hdraw
am
any
w fro
w fr
marketing 
d ata
his stud
s stu
authorization
dose
dose
after t
fter t
at 6
t 6
application 
e
and any extensions or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 98 of 125
The subject will be instructed to leave any questions blank that he/she does not feel 
comfortable answering.
Change #9
Section 5.1 Study description, bullet #7
!
An echocardiogram during dosing, after the last dose, and at 6 months after the last dose
Has been changed to: 
!
An echocardiogram during dosing and after the last dose (the SFU7 echocardiogram). 
The echocardiogram will be repeated at 6 months (±1 month) after the last dose in the 
following subjects:
∀
Subjects who complete this study but do not enter the OLE study
∀
Subjects who withdraw from the Outpatient Period 
∀
Subjects who withdraw from the Inpatient Period and have an abnormal SFU7 
echocardiogram
Change #10
Section 5.1 Study description, paragraph immediately following bulleted 
list (bolded text has been deleted)
UCB0942 doses for placebo subjects will be titrated to UCB0942 400mg bid during the 
Inpatient Transition-to-Outpatient Week (Day TTO1 to Day TTO7). After the Inpatient 
Period, all subjects will continue in an open-label Outpatient Maintenance Period and a final 
Tapering Period of 2 weeks (Day TOO1 to Day TOO14). Doses for subjects continuing in the 
OLE study will not be tapered but will follow the schedule of safety and efficacy assessments 
as outlined in the OLE study protocol. Safety follow up will consist of 2 required visits, 1 and 
4 weeks after the last dose of IMP (Day SFU7 and Day SFU28), and 1 optional visit 2 weeks 
after the last dose of IMP (Day SFU14). In addition, all subjects who do not enter the 
OLE study will have an echocardiogram 6 months after the last dose of IMP. For details 
of the study assessments, refer to Table 5-4. For a general presentation of the study design 
refer to Figure 5-1.
Has been changed to: 
UCB0942 doses for placebo subjects will be titrated to UCB0942 400mg bid during the 
Inpatient Transition-to-Outpatient Week (Day TTO1 to Day TTO7). After the Inpatient 
Period, all subjects will continue in an open-label Outpatient Maintenance Period and a final 
Tapering Period of 2 weeks (Day TOO1 to Day TOO14). Doses for subjects continuing in the 
OLE study will not be tapered but will follow the schedule of safety and efficacy assessments 
as outlined in the OLE study protocol. Safety follow up will consist of 2 required visits, 1 and 
4 weeks after the last dose of IMP (Day SFU7 and Day SFU28), and 1 optional visit 2 weeks 
after the last dose of IMP (Day SFU14). For details of the study assessments, refer to Table 
5-4. For a general presentation of the study design refer to Figure 5-1.
Change #11
Section 5.1 Study description, starting at second paragraph following 
the bulleted list
During the Titration Week the dose for subjects randomized to UCB0942 will be titrated to 
UCB0942 400mg bid following the schedule in Table 5-1. Subjects randomized to placebo 
REDACTED 
y T
y
n-lab
lab
1 to D
1 to D
ill foll
ill foll
col. S
col. S
COPY 
ated to
ated 
TTO
TTO
This document 
s o
4 w
4 w
a
cannot
ng P
g P
E stud
stud
outl
outl
be
l sub
l sub
erer
used
s for
for
nsitio
nsitio
bjbj
to 
g
or p
or p
support 
e
ed to
ed to
any
car
ca
er to
er to
marketing
Safet
Safet
Day
Day SF
S
y
FU14)
FU14
ardio
rd
authorization 
to U
O1 to 
1 to 
el Ou
el Ou
Day
Day TO
T
y
low th
ow th
t
application 
diatel
diate
UCB
UC
and any 
no
extensions 
orma
rm
or variations 
he
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 99 of 125
will follow the same schedule during the Transition-to-Outpatient Week. The entire Inpatient 
Period will be double-blind.
Table 5-1:
Dose titration to UCB0942 400mg bid
Day T1a
Day T2
Day T3
Day T4
Day T5
Day T6
Day T7
Day MD1
AM
0
100mg
100mg
200mg
200mg
300mg
300mg
400mg
PM
100mg
100mg
200mg
200mg
300mg
300mg
400mg
400mg
AM=morning dose; PM=evening dose 
a In placebo-arm subjects the same schedule is used from Day TTO1 to TTO7.
If a subject is not tolerating UCB0942 400mg bid well, the dose can be tapered to UCB0942 
200mg bid. The taper from UCB0942 400mg bid to UCB0942 200mg bid will occur over 
3 days (see Table 5-1) and will require unblinding of the subject if this occurs during the 
Inpatient Period. Dose tapering to UCB0942 100mg bid may be permitted after discussion 
with the Sponsor’s Study Physician.
Table 5-2:
Taper from UCB0942 400mg bid to UCB0942 200mg bid
Day TTO1
Day TTO2
Day TTO3
Day TTO4 onwards
AM
300mg
300mg
200mg
200mg
PM
400mg
300mg
300mg
200mg
AM=morning dose; PM=evening dose
At the end of the Outpatient Maintenance Period, or at the time a subject is withdrawn from 
the study, UCB0942 will be tapered following the schedule in Table 5-3.
Table 5-3:
Dose taper from UCB0942 400mg bid
Day
TOO1 to TOO4
TOO5 to TOO8
TOO9 to TOO12
TOO13 and TOO14
AM
300mg
200mg
100mg
PM
300mg
200mg
100mg
100mg
AM=morning; PM=evening dose
In order to provide an ongoing assessment of the safety of subjects as the study progresses, a 
Safety Review Group (SRG) comprising appropriate Sponsor study team members and the 
Investigator(s) at each site will meet regularly to review appropriate safety data (see 
Section 11.1.9).
Has been changed to: 
Dosing in the Inpatient Period
Titration Week (first week of the Inpatient Period
The objective of the Titration Week is to achieve the maximum UCB0942 dose of 400mg bid 
in as many of the subjects randomized to UCB0942 as possible while minimizing tolerability 
issues. During the Titration Week the dose for subjects randomized to UCB0942 will be 
titrated to UCB0942 400mg bid following the schedule in Table 5-1. The UCB0942 dose will 
be titrated to 400mg bid in a double-blinded fashion (ie, it will also appear that subjects 
randomized to placebo are being titrated). If, in the opinion of the Investigator, the Subject 
REDACTED 
ce Per
ce Pe
follow
follo
U
COPY
mg
m
300m
300m
PY 
CO
This document 
Ha
Do
Do
m
annot
ato
n 11.
11.
as b
s b
be
ew
or(s)
or(s
used
vide 
ide 
w Gr
w G
to 
e
support 
rtrtrtrtrt
venin
venin
pp
any y marketing 
UCB0
UCB
OO5 
OO5
ark
authorization 
mg
on
eriod, 
riod, 
wing t
ing 
application 
D
n
at
pp
pp
pp
pp
pp
and
942 2
42 2
a
any 
0
extensions 
UC
ccur o
ccur o
s durin
duri
after 
after 
or
CB0
B0
variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 100 of 125
will be unable to titrate to the maximum dose of IMP due to intolerance of a lower dose, the 
Investigator should discuss this immediately with the Sponsor Study Physician, unless the 
subject’s condition warrants immediate unblinding, and time does not allow discussion with 
the Sponsor. Unblinding may be required depending on the plan agreed upon by the 
Investigator and Sponsor Study Physician before dose tapering to UCB0942 200mg bid or 
100mg bid. If unblinding reveals that the Subject is randomized to placebo, then further 
dosing with IMP will cease until the Transition-to-Outpatient Week (third week of the 
Inpatient Period), at which time, the Subject will titrate UCB0942 according to Table 5-1.All 
other assessments will continue as planned.
Table 5-1:
Dose titration to UCB0942 400mg bid
Day T1a
Day T2
Day T3
Day T4
Day T5
Day T6
Day T7
Day MD1
AM
0
100mg
100mg
200mg
200mg
300mg
300mg
400mg
PM
100mg
100mg
200mg
200mg
300mg
300mg
400mg
400mg
AM=morning dose; PM=evening dose 
a In placebo-arm subjects the same schedule is used from Day TTO1 to TTO7.
Maintenance-Dose Week (second week of the Inpatient Period)
If a subject is not tolerating the maximum dose of IMP well during the 
Maintenance-Dose Week such that the Investigator believes a dose reduction is necessary, 
then then the Investigator should contact the Sponsor Study Physician to discuss the situation 
and agree upon a course of action. If a dose reduction is agreed, unblinding will be required. 
If the subject is randomized to UCB0942, the dose can be tapered from UCB0942 400mg bid 
to UCB0942 200mg bid. The taper from UCB0942 400mg bid to UCB0942 200mg bid will 
occur over 3 days (see Table 5-2) Dose tapering to UCB0942 100mg bid may also be 
permitted after discussion with the Sponsor’s Study Physician. If it is revealed that the 
Subject is randomized to placebo, then further dosing with IMP will cease until the 
Transition-to-Outpatient Week (third week of the Inpatient Period), at which time, the 
Subject will titrate UCB0942 according to Table 5-1. All other assessments will continue as 
planned.
Table 5-2:
Taper from UCB0942 400mg bid to UCB0942 200mg bid
Taper Day 1
Taper Day 2
Taper Day 3
Taper Day 4 onwards
AM
300mg
300mg
200mg
200mg
PM
400mg
300mg
300mg
200mg
AM=morning dose; PM=evening dose
Transition-to-Outpatient Week (third week of the Inpatient Period)
The objective of the Transition-to-Outpatient Week is to achieve the maximum UCB0942 
dose of 400mg bid in as many of the subjects randomized to placebo (now switching to 
UCB0942) as possible while minimizing tolerability issues. The UCB0942 dose will be 
titrated to 400mg bid in a double-blinded fashion (ie, it will also appear that subjects 
randomized to UCB0942 are being titrated) following the schedule in Table 5-1. If, in the 
opinion of the Investigator, the Subject will be unable to titrate to the maximum dose of IMP 
due to intolerance of a lower dose, the Investigator should discuss this with the Sponsor 
REDACTED
redu
redu
the d
the d
m UC
m UC
ose ta
ose ta
Spo
Spo
COPY
r bel
r be
onsor
onso
uct
uct
This document
Tran
Tran
T
cannot 
M=mor
M=mo
ot be 
e used 
ed
ed
ed
sed
u
to 
Ta
Ta
support 
er fro
er fro
s
any
acco
acc
marketing
ap
onsor’
onsor
hen fur
hen fu
third w
hird 
ord
or
authorization
r Stu
Stu
tion is
ion is
dose c
ose c
CB094
B094
perin
erin
application 
)
ll durin
ll duri
eves a 
ves a
tudy
udy
and any extensions
Day
Da
o
mg
on
sio
400mg
00mg
en
e
or 
y
or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 101 of 125
Study Physician. Unblinding may be required depending on the plan agreed upon by the 
Investigator and Sponsor Study Physician.
Dosing in the Outpatient Maintenance Period and Tapering Period
During the Outpatient Maintenance Period, Subjects will continue to administer UCB0942 at 
the final Inpatient Period dose. Multiple adjustments (tapering or increase) of the dose are 
allowed during the Outpatient Maintenance Period (minimum 100mg bid and maximum 
400mg bid); however, any change of dose in the Outpatient Maintenance Period should first 
be discussed with the Sponsor Study Physician. 
At the end of the Outpatient Maintenance Period, or at the time a subject is withdrawn from 
the study, UCB0942 will be tapered following the schedule in Table 5-3. If the subject is not 
taking a dose of UCB0942 other than 400mg bid, then the Investigator should contact the 
Sponsor Study Physician to discuss the appropriate tapering schedule.
Table 5-3:
Dose taper from UCB0942 400mg bid
Day
TOO1 to TOO4
TOO5 to TOO8
TOO9 to TOO12
TOO13 and TOO14
AM
300mg
200mg
100mg
PM
300mg
200mg
100mg
100mg
AM=morning; PM=evening dose
In order to provide an ongoing assessment of the safety of subjects as the study progresses, a 
Safety Review Group (SRG) comprising appropriate Sponsor study team members and the 
Investigator(s) at each site will meet regularly to review appropriate safety data (see 
Section 11.1.9).
Change #12
Section 5.2 Schedule of study assessments, Table 5-4
Added the following assessment: 
Diary Addendum has been added. This is completed at V3 and V15. 
Change #13
Section 5.2 Schedule of study assessments, Table 5-4, footnote k
In addition to the echocardiogram during dosing and after the last dose, for subjects who do
not continue in the OLE study, an echocardiogram at 6 months after the last dose will also be 
performed. Please note that the during dosing time point of Day OP22 for the 
echocardiogram has a time window of ±1 week instead of ±2 days.
Has been changed to: 
In addition to the echocardiogram during dosing and after the last dose (SFU7), the 
echocardiogram will be repeated at 6 months (±1 month) after the last dose in the following 
subjects: 1) Subjects who complete this study but do not enter the OLE study, 2) Subjects 
who withdraw from the Outpatient Period, and 3) Subjects who withdraw from the Inpatient 
Period and have an abnormal SFU7 echocardiogram. Please note that the during dosing time 
point of Day OP22 for the echocardiogram has a time window of ±1 week instead of ±2 days
and the Day SFU7 echocardiogram has a time window of ±1 week instead of ±1 day.
REDACTED
prop
rop
larly
arly tot
y
COPY 
e safe
e saf
pria
pri
This document
Has
Has
In 
In
cannot 
ed.d
cardio
ardio
as b
s b
be 
ue in
e i
d. Pl
d. Pl
used
the ec
he ec
in th
in th
to
he
he
support 
ad
a
edu
edu
any 
dded
dded
marketing 
dy
dy as
as
y
essm
ssm
authorization
ety o
y 
ate Sp
ate Sp
to revi
o revi
application 
g
at
y of s
of
and 
d
a
any 
TO
TO
y
a
extensions
act 
ct
e
or 
isi
t thth
variations 
om
om
is no
s no
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 102 of 125
Change #14
Section 5.2 Schedule of study assessments, Table 5-4, new footnote x
Added the following footnote x (pertaining to the Diary Addendum): 
The subject will be instructed to leave any questions blank that he/she does not feel 
comfortable answering
Change #15
Section 5.2 Schedule of study assessments, Table 5-4, new footnote y
Added the following footnote y (pertaining to the Diary Addendum): 
Collect at Day OP57 or at Early Withdrawal.
Change #16
Section 5.2 Schedule of study assessments, Inpatient Period Table 5-5
Added the following assessment: 
Diary Addendum has been added. This is completed at V3, Study Day T1. 
Change #17
Section 5.2 Schedule of study assessments, Inpatient Period Table 5-5, 
new footnote o
Added the following footnote o (pertaining to the Diary Addendum): 
The subject will be instructed to leave any questions blank that he/she does not feel 
comfortable answering. 
Change #18
Section 6.1 Inclusion criteria, Inclusion Criterion #5 (changes bolded)
Subject is of normal weight as determined by a body mass index (BMI) between 18.0 and 
35.0kg/m2 (exclusive), with a body weight of at least 50kg (males) or 45kg (females).
Has been changed to: 
Subject is of normal weight as determined by a body mass index (BMI) between 16.0 and 
40.0kg/m2 (exclusive) and with a body weight of at least 50kg (males) or 45kg (females).
Change #19
Section 6.2 Exclusion criteria, Exclusion Criterion #2
Subject has a history of liver disease, including but not limited to, stable (on repeat testing) 
elevation of liver enzymes (alanine aminotransferase [ALT] or aspartate aminotransferase 
[AST] >1.5 times the upper limit of laboratory reference ranges or alkaline phosphatase 
[ALP] >2 times the upper limit of laboratory reference range).
Has been changed to: 
Subject has either:
∀
>1.5x upper limit of normal (ULN) of any of the following: 
◦
alanine aminotransferase (ALT)
REDACTED
erta
erta
any qu
y qu
COPY 
ent
en
ain
i
This document
ub
elev
elev
[A
[A
cannot
on 6
on 6
bject
ject
be
#1
#19
used
clusiv
lusi
9
to
mal w
al w
support
th a
h a
ed to:
d to
we
any
s det
s de
a bo
a b
marketing 
ria
ia, In
I
ter
t
authorization 
ning
ning
uestion
uestion
application 
y
, Inpa
Inpa
and 
Day
Day
any extensions 
iod T
od T
or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 103 of 125
◦
aspartate aminotransferase (AST)
◦
alkaline phosphatase (ALP)
-OR-
∀
>ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome). 
If subject has elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate 
bilirubin to identify possible undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%). 
For randomized subjects with a baseline result >ULN for ALT, AST, ALP, or total 
bilirubin, a baseline diagnosis and/or the cause of any clinically meaningful elevation 
must be understood and recorded in the Case Report form (CRF). 
If subject has >ULN ALT, AST, or ALP that does not meet the exclusion limit at 
screening, repeat the tests, if possible, prior to dosing to ensure there is no further ongoing 
clinically relevant increase. In case of a clinically relevant increase, inclusion of the 
subject must be discussed with the Medical Monitor. 
Change #20 Exclusion criteria, Exclusion Criterion #14 (changes bolded)
Subject is currently treated with carbamazepine, phenytoin, primidone, or phenobarbital or 
any other drug known to induce CYP3A4 liver enzymes.
Has been changed to: 
Subject is currently treated with carbamazepine, phenytoin, primidone, or phenobarbital or 
any other drug known as a strong inducer of CYP3A4 liver enzymes.
Change #21
Section 6.3 Withdrawal criteria, Withdrawal Criterion #1
Subject develops a clinically relevant medical condition (or laboratory abnormality) that, in 
the opinion of the Investigator, compromises the subject’s ability to participate or safety. In 
the case of transaminase (AST, ALT, or both) levels at least 3 times the upper limit of normal 
(ULN) in the presence of normal total bilirubin, the laboratory tests will be repeated within a 
few days. If the repeat testing confirms the abnormality, then weekly monitoring of liver 
function tests should continue until resolved (ie, less than 3 times the ULN or stable 
condition). The Investigator is to decide whether or not to stop the investigational medicinal 
product (IMP). To monitor for hypersensitivity reactions, percent eosinophils >10% or 
absolute eosinophil count ≥0.5G/L or absolute neutrophil count <1.5G/L or absolute platelet 
count ≤100G/L, if in combination with fever, rash, lymphadenopathy, or other 
symptoms/signs suggestive of internal organ involvement (including but not limited to 
hepatitis, nephritis, pneumonitis, carditis, colitis, encephalitis, pancreatitis, myositis, or 
arthritis) will lead to stopping the IMP.
Has been changed to: 
Subject develops a clinically relevant medical condition (or laboratory abnormality) that, in 
the opinion of the Investigator, compromises the subject’s ability to participate or safety. 
Potential drug-induced liver injury IMP discontinuation criteria are described in Section
6.3.1. To monitor for hypersensitivity reactions, percent eosinophils >10% or absolute 
eosinophil count ≥0.5G/L or absolute neutrophil count <1.5G/L or absolute platelet count 
≤100G/L, if in combination with fever, rash, lymphadenopathy, or other symptoms/signs 
suggestive of internal organ involvement (including but not limited to hepatitis, nephritis, 
REDACTED 
f C
f C
ria
ria, W
ant
ant
COPY 
, phen
 phe
CYP
CY
This document 
Has
Ha
cannot 
ms/
ms
titis, n
tis, n
hritis
hritis
be 
G/
G/
/sig
/sig
used
To
nophil
ophil
/L
/L
to
 mo
mo
support
ting 
ng
ontinue
ntinu
stigato
stiga
any
mal t
mal 
g co
g c
marketing 
medic
medic
mprom
mprom
ALT, 
ALT,
t
authorization 
nyto
yt
P3A4 
3A4
Withd
Withd
application 
mid
toin,
oin
and 
4 
4
done
one
any 
(cha
(ch
extensions 
t at 
at 
further
urthe
usion 
usion 
or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 104 of 125
pneumonitis, carditis, colitis, encephalitis, pancreatitis, myositis, or arthritis) will lead to 
stopping the IMP.
Change #22
Section 6.3 Withdrawal criteria, Withdrawal Criterion #6
Subject has a lifetime history of suicide attempt (including an actual attempt, interrupted 
attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a 
positive response (Yes) to either Question 4 or Question 5 of the C-SSRS at Screening. 
Subjects may be withdrawn from the study if the following event occurs: for subject who did 
not complete a C-SSRS at Screening, subject had actual suicidal ideation prior to study entry 
or since study initiation as indicated by a positive response (Yes) to either Question 4 or 
Question 5 of the “Already Enrolled Subjects” version of the C-SSRS. The Investigator must 
immediately refer the subject to a Mental Healthcare Professional and use clinical judgment 
as to whether to withdraw the subject from the study.
Has been changed to: 
Subject has active suicidal ideation without specific plan as indicated by a positive response 
(“Yes”) to Question 4 of the “Since Last Visit” version of the C-SSRS. The subject should be 
referred immediately to a Mental Healthcare Professional and may be withdrawn from the 
study based upon the Investigator’s judgment of benefit/risk of continuing the subject in the 
study/on study medication. If the Subject has active suicidal ideation with a plan as indicated 
by a positive response (“Yes”) to Question 5 of the “Since Last Visit” version of the C-SSRS, 
the subject should be referred immediately to a Mental Healthcare Professional and must be 
withdrawn from the study.
Change #23
Section 6.3 Withdrawal criteria
Added the following Withdrawal Criterion #7:
Subject has a prolongation or worsening of overall seizure duration, frequency, type, or 
pattern considered by the Investigator as persistent and serious enough to warrant 
discontinuation from the study.
Change #24
Section 6.3 Withdrawal criteria, paragraph immediately above Section 
6.3.1
The Investigator should contact the UCB Study Physician whenever possible to discuss the 
withdrawal of a subject in advance.
Has been changed to:
The Investigator should contact the UCB Study Physician whenever possible to discuss the 
withdrawal of a subject in advance. If this is not possible, the Investigator should contact the 
UCB study physician to inform him/her about the subject withdrawal as soon as possible after 
the withdrawal.
REDACTED 
a a
eria
eria
COPY
e sui
e su
he “S
he “
Me
Me
This document 
Has
a
Th
Th
annot 
estst
rawal
rawal
as b
s b
be 
tigat
tiga
used 
Wit
Wit
to 
thd
thd
support
study
stud
any 
wor
wo
vestig
vestig
marketing 
rawal
awa
orsen
rse
authorization 
Sin
ental H
ntal H
application
may
may b
y
k of co
k of c
idal id
dal id
nce L
nce L
and 
d b
d b
SRS
SRS
b
any 
by a 
y a
extensions
gato
gato
cal jud
al jud
or 
or 
or
tor
or
variations 
id d 
entry
ntry
r
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 105 of 125
Change #25
Section 6.3 Withdrawal criteria
Added Section 6.3.1 Potential drug-induced liver injury IMP 
discontinuation criteria: 
Subjects with potential drug-induced liver injury (PDILI) must be assessed to determine if 
IMP must be discontinued. In addition, all concomitant medications and herbal supplements 
that are not medically necessary should also be discontinued. 
The PDILI criteria below require immediate and permanent discontinuation of IMP: 
!
Subjects with either of the following:
∀
ALT or AST ≥5xULN
∀
ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 
The PDILI criterion below requires immediate discontinuation of IMP:
!
Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without 
clear alternative cause), rash, or eosinophilia (ie, >5%).
If a nondrug-related cause for the symptoms can be confirmed, these subjects may resume 
IMP administration after discussion with the responsible UCB physician, but only when the 
requirements for rechallenge with IMP as provided in Section 11.6.1.2.1 are followed.
The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
investigator. 
!
Subjects with ALT or AST ≥3xULN (and ≥2x baseline) and <5xULN, total bilirubin 
<2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis 
(eg, fatigue, nausea, vomiting, right upper quadrant pain or tenderness).
Evaluation of PDILI must be initiated as described in Section 11.6.1. If subjects are unable to 
comply with the applicable monitoring schedule, IMP must be discontinued immediately.
Investigators should attempt to obtain information on subjects in the case of IMP 
discontinuation to complete the final evaluation. Subjects with PDILI should not be 
withdrawn from the study until investigation and monitoring are complete. All results of 
these evaluations and observations, as well as the reason(s) for IMP discontinuation and 
subject withdrawal (if applicable), must be recorded in the source documents. The CRF must 
document the primary reason for IMP discontinuation.
REDACTED
rovid
rovi
ubjects
bjects
xUL
xUL
COPY
be con
e co
spons
spons
de
d
This document cannot
ment t
ent t
be
thdr
thdr
used
m the
m the
ions 
ions 
to
com
com
e
support
ble m
e m
attemp
attem
mp
mp
any
initia
initi
mon
marketing
LN (an
N (an
ie,e, ≤5%
≤5
g, righ
g, rig
authorization
sible
ible
ed in S
d in S
s to co
s to co
application
g
oms i
oms 
nfirmed
firme
e U
e U
and 
oc
oc
ue, n
ue, n
i
any 
iated
iate
extensions or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 106 of 125
Change #26
Section 7.1 Description of investigational medicinal products, Table 7-1 
(bolded text in Note has been revised)
Table 7-1:
Description of investigational medicinal product
UCB0942
Placebo for UCB0942
Dosage form
Tablets (white, film-coated), in 
2 strengths:
-
100mg
-
200mg
100mg and 200mg tablets have 
the same size and appearance 
Tablets (white, film-coated):
Provided in a size and 
appearance matching UCB0942.
Manufacturer
Batch/lot number
Will be assigned according to GMP
Expiry date
Will be assigned according to GMP
GMP=Good Manufacturing Practice
Note: For the Inpatient Period, 1 kit per treatment period and per dose will be packaged. Each kit will contain 
blister packs, each covering 1 week of treatment. For the Outpatient Period, UCB0942 tablets will be 
provided in bottles, containing 37 tablets per bottle, either 200mg tablets for subjects on 
UCB0942 400mg bid, or 100mg tablets for subjects who reduce dose to UCB0942 200mg bid. The bottles 
containing 37 UCB0942 100mg tablets will be dispensed for the Taper Period.
REDACTED
eriod
erio
For th
For th
bottle, 
bottle, 
r subjec
subjec
will be
will be
COP
d a
d
OPY
e ass
e ass
OP
This document cannot be used to support any marketing 
e disp
disp
authorization 
and pe
nd pe
he Out
e Out
either 
either 
cts wh
ts wh
pe
pe
application 
d accord
acco
ion
gned ac
ned a
lic
ap
and 
a
any extensions 
ext
or variations 
0942.
942.
tio
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 107 of 125
Has been changed to (bolded text in table and in Note has been added): 
Table 7-1:
Description of investigational medicinal product
UCB0942
Placebo for UCB0942
Dosage form
Tablets (white, film-coated), in 
2 strengths:
-
100mg
-
200mg
100mg and 200mg tablets have 
the same size and appearance 
Tablets (white, film-coated):
Provided in a size and 
appearance matching UCB0942.
Manufacturer
Batch/lot number
Will be assigned according to GMP
Expiry date
Will be assigned according to GMP
GMP=Good Manufacturing Practice
Note: For the Inpatient Period, 1 kit per treatment period and per dose will be packaged. Each kit will contain 
blister packs, each covering 1 week of treatment. For the Outpatient Period, UCB0942 tablets will be 
provided in bottles, containing 37 tablets per bottle, either 200mg tablets for subjects on UCB0942 400mg bid
or UCB0942 200mg bid, or 100mg tablets for subjects who reduce dose to UCB0942 100mg bid. The bottles 
containing 37 UCB0942 100mg tablets will be dispensed for the Taper Period.
Change #27
Section 7.9.1.3 Breaking the treatment blind for taper of dose during the 
study
If the IMP is not tolerated during the Inpatient Period by an individual subject, the dose can 
be tapered to UCB0942 200mg bid. This is only permitted if the subject has great difficulty 
tolerating the IMP and the Investigator does not think that tolerability will improve. When it 
is decided to reduce the dose, the blind will have to be broken, following the procedure 
described in Section 7.9.1.2.
Has been changed to: 
When the Investigator and Sponsor Study Physician agree that a subject cannot titrate to the 
maximum dose or that a dose reduction is necessary during the Inpatient Period (See 
Section 5.1, the blind will have to be broken, following the procedure described in 
Section 7.9.1.2.
REDACTED 
Wil
Wil
D
reatme
eatme
eatm
eatm
CT
COPY 
ill be 
ll be 
OP
This document
Has
Has
cannot
g
ided t
ded t
cribed
ribe
be
ththe I
used
ot tol
t to
UCB
UCB
to 
l
support 
reakin
eaki
any marketing
nt
ment. Fo
ent. F
per bott
per bot
blets for
ets fo
ts will
s wi
authorization
assig
assig
ll be a
l be a
ati
t peri
peri
or
app
ap
on 
ation
plicat
ppli
d
and 
an
any extensions 
ns or variations 
tio
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 108 of 125
Change #28
Section 8.2.1 Titration Week (Visit 3, Day T1 to Day T7)
Added the following assessment: 
!
Diary Addendum (T1)
Change #29
Section 8.3.1 Outpatient Maintenance Period (Visit 6 to Visit 15, Day OP1 
to Day OP57)
Added the following assessment:
!
Diary Addendum (OP57)
Change #30
Section 8.3.3 Safety Follow-Up (Visit 18 to 20, Day SFU7, SFU14, and 
SFU28), bullet #8
!
Echocardiogram after last dose and 6 months later (±1 month)
Has been changed to: 
!
Echocardiogram after last dose and 6 months later (±1 month). For subjects who 
withdraw during the Inpatient Period and for subjects who withdraw during the 
Outpatient Period, see Section 8.4 for echocardiogram requirements following 
withdrawal. 
Change #31
Section 8.3.4 Echocardiograph follow up
For subjects who do not continue in the OLE study, it is mandatory that they have an 
echocardiogram at 6 months (±1 month) after the last dose of IMP (in addition to the 
echocardiogram at Screening, during dosing, and after the last dose).
Has been changed to (bolded text added): 
For subjects who complete this study but do not continue in the OLE study, it is mandatory 
that they have an echocardiogram at 6 months (±1 month) after the last dose of IMP (in 
addition to the echocardiogram at Screening, during dosing, and after the last dose). 
Change #32
Section 8.4 Withdrawal Visit, bullet #6
!
Echocardiogram after last dose and 6 months later (±1 month)
Has been changed to: 
!
Echocardiogram
∀
Withdrawal during the Inpatient Period: The SFU7 echocardiogram should be 
performed. If there is no abnormality, the echocardiogram does not need to be 
repeated. If there is an abnormality, the echocardiogram should be repeated at 
6 months (±1 month) after the last dose of IMP. 
REDACTED 
aph 
aph 
COPY 
ter 
er
subjec
subje
cardi
cardi
This document 
Has
Ha
cannot
on 8
Ech
Ech
be 
#3
8
used
echo
cho
32
to
echo
echo
oc
oc
support
to (b
(b
mplete
plete
hoca
oca
any
dur
dur
bo
bo
marketing
fol
fol
n the O
the O
month
mont
ring
rin
authorization
iogram
iogra
ollo
llo
application 
1 mont
mon
cts wh
ts wh
and any extensions 
SFU1
FU
or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 109 of 125
∀
Withdrawal during the Outpatient Period: The SFU7 echocardiogram should be 
performed, and the echocardiogram should be repeated at 6 months (±1 month) after 
the last dose of IMP. 
Change #33
Section 8.4 Withdrawal Visit
Added the following assessment:
!
Diary Addendum
Change #34
Section 9.4 Diary Addendum
This Section has been added: 
A Diary Addendum will be completed according to the tabular schedule of study procedures 
in Table 5-4 as well as at the Withdrawal Visit, if applicable. The Diary Addendum will 
consist of a series of open-ended questions including the following: 
!
Why did you agree to take part in this study? 
!
What are your hopes for this new treatment? 
!
What are the biggest impacts of seizures on your life currently? 
!
What was your experience like during the study?
!
Did participating in the study fulfill any of the hopes you had going into the study? 
!
How do you describe the impact of seizures on your life now? Has that changed since the 
beginning of the study? 
Subjects will be instructed to leave any question blank that he/she does not feel comfortable 
answering. 
Change #35
Section 11.3 Adverse events of special interest
An AE of special interest is any AE that a regulatory authority has mandated be reported on 
an expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to 
the administration of a UCB product/compound.
There are no adverse events of special interest to be reported for UCB0942.
Has been changed to: 
An AE of special interest is any AE that a regulatory authority has mandated be reported on 
an expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to 
the administration of a UCB product/compound.
Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total bilirubin 
in the absence of ≥2xULN ALP, with no alternative explanation for the biochemical 
abnormality, must ALWAYS be reported to UCB as an AE of special interest (ie, without 
waiting for any additional etiologic investigations to have been concluded). Follow-up 
information should then be reported if an alternative etiology is identified during 
investigation and monitoring of the subject.
REDACTED 
y of th
y of t
f seizu
f seiz
COPY
ur lif
ur l
tudy
tudy?
This document
an e
an e
thth
cannot
been
been
AE 
AE 
be
no a
o a
used
ion o
on o
adv
ad
to
, reg
, re
f
support
se ev
e e
erest is
erest i
ga
any 
ve
marketing 
any que
y qu
authorization 
he ho
he ho
ures o
ures o
application 
e curren
curre
and any 
Ad
A
extensions 
study
study
dde
dde
or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 110 of 125
Change #36
Section 11.7.3 Echocardiograms
Echocardiograms will be performed during Screening, during dosing (Day OP22 ±1 week), 
after the last dose of IMP, and at 6 months after the last dose of IMP, as described in
Table 5-4.
2D Doppler echocardiography will be performed with:
1. Diastolic measurements (mitral forward flow E and A waves and deceleration time)
2. Tissue Doppler on medial and lateral mitral valve annulus (S, E, and A waves)
3. Standardized views for left atrial volume measurements
Images will be recorded and stored digitally and retained if further analysis is needed. A 
complete echocardiography manual will be provided.
Has been changed to: 
Echocardiograms will be performed during Screening, during dosing (Day OP22 ±1 week), 
and after the last dose of IMP (SFU7), as described in Table 5-4. The echocardiogram will be 
repeated at 6 months (±1 month) after the last dose in the following subjects: 
!
Subjects who complete this study but do not enter the OLE study
!
Subjects who withdraw from the Outpatient Period 
!
Subjects who withdraw from the Inpatient Period and have an abnormal SFU7 
echocardiogram
2D Doppler echocardiography will be performed with:
1. Diastolic measurements (mitral forward flow E and A waves and deceleration time)
2. Tissue Doppler on medial and lateral mitral valve annulus (S, E, and A waves)
3. Standardized views for left atrial volume measurements
Images will be recorded and stored digitally and retained if further analysis is needed. A
complete echocardiography manual will be provided.
Change #37
Section 11.6 Laboratory assessments
Added Section 11.6.1 Evaluation of PDILI:
The PDILI IMP discontinuation criteria for this study are provided in Section 6.3.1, with the 
accompanying required follow-up investigation and monitoring detailed below. All PDILI 
events must be reported as an AE and reported to the study site and sponsor within 24 hours 
of learning of their occurrence. Any PDILI event that meets the criterion for potential Hy’s 
Law must be reported as an AE of special interest (see Section 11.3), and, if applicable, also 
reported as an SAE (see Section 11.1.1).
Evaluation of PDILI consists of the diagnostic testing and continued monitoring included in 
Table 11-3 (specific tests dependent on laboratory results and corresponding symptoms) and 
consultation with a local hepatologist (if applicable; discussed in Section 11.6.1.1). The local 
hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a 
nt P
nt P
perfo
perfo
l forw
l forw
COPY
Period
Period
Peri
Per
This document
even
ven
of l
of 
cannot
DILI 
DILI 
ompa
ompa
nts
nt
be
ec
ec
used
6 La
La
ctio
cti
to 
b
support 
nd s
d 
aphy
phy m
y
any 
ata
stor
sto
marketing
ward 
ward
lateral 
atera
trial 
tria
authorization 
iod an
od an
ormed
rmed
application 
wing
wing
OLE st
OLE s
and
(
The ec
he e
g s
g s
any 
Day 
Day 
h
extensions 
eded.
ded.
or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 111 of 125
gastroenterologist. Additional investigation and monitoring may be required and adapted 
based on the diagnosis after the cause of the liver injury/abnormality is confirmed (details in 
Section 11.6.1.4). 
The results of all monitoring, including laboratory testing and other testing, should be made 
available to the study site and sponsor.
All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but 
appropriate medical action must not be delayed waiting for the repeat result.
If tests are done locally for more rapid results, a concurrent sample should also be sent to the 
central laboratory whenever possible. Medical care decisions are to be made initially using 
the most rapidly available results and a conservative approach must be taken if the results 
from the 2 laboratory tests are significantly different. Data from the local and central 
laboratory are to be recorded on the applicable CRF pages.
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. In these cases, the investigator should also 
consider dose reduction for medically necessary concomitant medication and consider 
changing any medically required concomitant medication known to be hepatotoxic to a 
suitable alternative.
When IMP is stopped due to PDILI (as described in Section 6.3.1), IMP must be permanently 
discontinued unless a subsequent alternative diagnosis fully explains the hepatic findings. If a 
subsequent alternative diagnosis fully explains the hepatic findings, and the requirements 
provided in Section 11.6.1.2.1 are met, rechallenge with IMP may be appropriate. 
Rechallenge with a substance potentially causing drug-induced liver injury is dangerous, may 
be fatal, and must not occur.
The table below summarizes the approach to investigate PDILI.
REDACTED 
causin
causin
pproac
pproac
COPY 
sisis
he hep
he hep
enge 
nge 
This document cannot be used to support any marketing
ch to
h t
authorization
p
with 
with
ng dru
g dru
toto
application 
6.3.1
6.3.1)
ullyly exp
ex
y
atic fi
tic fi
I
and
o be 
be 
any
on an
on an
he
h
extensions 
ral
ments t
ents 
tigat
igat
or 
ult
ul
variations 
he
ng g 
ltsts
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 112 of 125
Table11-3:
Required investigations and follow up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
≥3xULN
≥2xULN
b
NA
Hepatology consult.c
Medical Monitor 
must be notified 
within 24 hours 
(eg, by laboratory 
alert) and subject 
discussed with 
Medical Monitor 
ASAP.
Immediate, 
permanent IMP 
discontinuation.
Essential: Must 
have repeat liver 
chemistry values 
and additional 
testing completed 
ASAP (see 
Section 11.6.1.3);
recommended to 
occur at the site 
with HCP.
Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within baseline 
values.d
≥8xULN
NA
NA
≥3xULN
NA
Yes
Immediate, 
temporary or 
permanent, IMP 
discontinuation.
≥3xULN 
(and ≥2x 
baseline) 
and 
<5xULN
<2xULN
No
Discussion with 
Medical Monitor 
required if the 
criterion that allows 
for IMP continuation 
is met.
Further investigation 
– immediate IMP 
discontinuation not 
required (see 
Section 11.6.1.2).
Not required 
unless otherwise 
medically 
indicated (at 
discretion of 
investigator).
≥5xULN 
(and ≥2x 
baseline) 
<2xULN
No
Discussion with 
Medical Monitor 
required.
Immediate, 
permanent IMP 
discontinuation.
Essential: Every 
attempt must be 
made to have 
repeat liver 
chemistry values 
and additional 
testing completed 
within 48 hours 
at the site with 
HCP (see 
Section 11.6.1.3).
Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within baseline 
values.d
REDACTED 
Furthe
Furthe
– im
TE
ED
COPY 
, IMP 
, IMP
nuatio
nuatio
This document 
en cannot be used 
us
to support
w
Moni
Moni
red.
ed.
any 
with 
ith
y marketing 
on
disco
disco
requ
req
S
ke
authorization 
on.
on.
er inv
er inv
mmed
mmed
riz
application 
ad
a
esting 
esting
ASA
ASA
Se
S
pli
and
stry v
try v
dditi
ddit
any 
usts
t liver
live
al
extensions
valua
alua
te
t
xt
or 
w u
w u
o variations 
on
up
up
ar
thereof. 
10 O
10 O


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 113 of 125
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug-induced liver injury; ULN=upper limit of normal 
a Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia (>5%), 
rash, and fever (without clear alternative cause).
b If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medical Monitor.
c Details provided in Section 11.6.1.1. The local hepatologist is the expert usually consulted by the treating physician for assessment and management of 
potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist.
d Unless an alternative monitoring schedule is agreed by the investigator and UCB responsible physician. Determination of stabilization is at the discretion of the 
investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed
COPY 
This document cannot be used to support any marketing authorization application and any extensions 
cal Mo
cal Mo
sessme
essme
n of s
of s
or 
de 
de
variations 
on
practi
practi
e eo
e eo
thereof. 
10 O
10 O


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 114 of 125
11.6.1.1
Consultation with the Medical Monitor and local hepatologist
Potential drug-induced liver injury events require notification of the Medical Monitor within 
24 hours (eg, by laboratory alert), and the subject must be discussed with the Medical 
Monitor as soon as possible. If required, the subject must also be discussed with the local 
hepatologist. The local hepatologist is the expert usually consulted by the treating physician 
for assessment and management of potential hepatic disease. This would usually be a 
hepatologist, but may be a gastroenterologist. If determined necessary, this discussion should 
be followed by a full hepatology assessment (see Section 11.6.1.3) and SAE report (if 
applicable).
11.6.1.2
Immediate action: determination of IMP discontinuation
All PDILI events require immediate action, testing, and monitoring. 
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by immediate investigation) 
to immediate and permanent discontinuation (see Section 6.3.1 and Table 11‒3 for details).
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. The investigator should also consider dose 
reduction for medically necessary concomitant medication and consider changing any 
medically required concomitant medication known to be hepatotoxic to a suitable alternative.
11.6.1.2.1
IMP restart/rechallenge (if applicable)
Rechallenge with a substance potentially causing drug-induced liver injury is dangerous, may 
be fatal, and must not occur.
Subjects who are immediately discontinued from IMP due to having met certain criteria for 
PDILI (as described in Section 6.3.1 and Table 11‒3), but for whom an alternative diagnosis 
is confirmed, can rarely restart IMP. Rechallenge with IMP can occur only if ALL of the 
following requirements are met:
!
The results of additional testing and monitoring described in Section 11.6.1.3 and 
Section 11.6.1.4 confirm a nondrug-related cause for the abnormal hepatic laboratory 
parameters and any associated symptoms (ie, a subsequent alternative diagnosis fully 
explains the hepatic findings). 
!
No alternative treatment options are available to the subject.
!
The subject has shown clear therapeutic benefit from the IMP.
!
Subject’s ALT or AST elevations do not exceed ≥3xULN.
!
Subject’s total bilirubin is <1.5xULN.
!
Subject has no signs or symptoms of hypersensitivity. 
!
The rechallenge is approved by the UCB responsible physician and a hepatologist. The 
hepatologist must be external to UCB. It is recommended that the hepatologist be a local 
hepatology expert or the hepatologist treating the subject.
!
Subject agrees to the investigator-recommended monitoring plan.
11.6.1.3
Testing: identification/exclusion of alternative etiology
The measurements and additional information required for the assessment of PDILI events
when there is a reasonable possibility that they may have been caused by the IMP are detailed 
REDACTED 
nued f
nued f
 and
 and T
P. Re
P. Re
COPY
cable
cabl
ng dru
ng dr
This document 
!
cannot 
ubject
ubject
Sub
Su
be
ct’s A
ct’s 
used
ct has
t has
A
to
trea
tre
suppor
ssoci
soc
c findi
 find
eatm
atm
any
a non
a no
ciate
cia
marketing
echal
echal
ing an
ng a
d
authorization
rug
ug-inin
from I
from 
Table
able
l
application
cons
con
patotox
atoto
)
d
and
sup
up
r shou
shou
si
any 
pplem
pplem
extensions 
hepati
epati
ate inv
te in
11
11‒3
or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 115 of 125
in Table 11-4 (laboratory measurements) and Table 11-5 (additional information). Results of 
the laboratory measurements and information collected are to be submitted to the sponsor on 
the corresponding CRF. If the medical history of the subject indicates a requirement for other 
assessments not included below, these additional assessments should be completed and 
submitted, as applicable.
All blood samples should be stored, if possible. If tests are done locally for more rapid 
results, a concurrent sample must also be sent to the central laboratory.
The following measurements are to be assessed:
Table 11-4: PDILI laboratory measurements
Virology-
related
Hepatitis A IgM antibody
HBsAg
Hepatitis E IgM antibody
HBcAb-IgM
Hepatitis C RNA
Cytomegalovirus IgM antibody
Epstein-Barr viral capsid antigen IgM antibody (if unavailable, obtain 
heterophile antibody or monospot testing)
Immunology
Anti-nuclear antibody (qualitative and quantitative)
Anti-smooth muscle antibody (qualitative and quantitative)
Type 1 anti-liver kidney microsomal antibodies (qualitative and quantitative)
Hematology
Eosinophil count
Urinalysis
Toxicology screen
Chemistry
Amylase
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct 
bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase 
elevation
Additional
Prothrombin time/INR
a
Serum pregnancy test
PK sample
ALT=alanine aminotransferase; CPK=creatine phosphokinase; HBcAb-IgM=hepatitis B core antibody-IgM; 
HBsAg=hepatitis B surface antigen; IgM=immunoglobulin M; INR=international normalized ratio; 
LDH=lactate dehydrogenase; PDILI=potential drug-induced liver injury; PK=pharmacokinetic; 
RNA=ribonucleic acid; ULN=upper limit of normal
a Measured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative 
cause).
The following additional information is to be collected:
REDACTED
ative
ative
body
ody (q
(q
y
ED
ney
ey mi
m
y
AC
RE
COPY 
M an
M a
testin
testin
e a
e a
CO
This document 
nt
ALT
AL
cannot be
l
e 
e used
ru
r
eleva
eleva
P
us
to
um 
um 
support
irubin
ubin
n
t
C
su
any 
a
marketing 
ic
g
ke
m
authorization 
ng
and qu
nd qu
n
(qualit
(qualit
za
croso
roso
th
application 
n
bod
ody (
y 
g)
cat
and 
d
a
any y
a
extensions 
ns
en
e
or r variations 
v
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 116 of 125
Table 11-5: PDILI information to be collected
New or updated information
Concomitant prescription and over-the-counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included.
Pertinent medical history, including the following:
!
History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other “fatty 
liver disease”)
!
Adverse reactions to drugs
!
Allergies
!
Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha-1 antitrypsin 
deficiency)
!
Recent travel 
!
Progression of malignancy involving the liver (Note: Metastatic disease to the liver, by itself, 
should not be used as an explanation for significant AST and/or ALT elevations.)
The appearance or worsening of clinical symptoms of hepatitis or hypersensitivity (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, jaundice, fever, or 
rash)
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function
Alcohol and illicit drug use
Results of liver imaging or liver biopsy, if done
Results of any specialist or hepatology consult, if done
Any postmortem/pathology reports
ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug-induced liver injury
11.6.1.4
Follow-up evaluation
Potential drug-induced liver injury events require follow-up and monitoring as described in 
Table 11‒3. Monitoring should continue until liver chemistry values normalize, stabilize, or 
return to baseline. Determination of stabilization is at the discretion of the investigator in 
consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
Change #38
Section 11.7.5 Assessment of suicidality
Suicidality will be assessed by trained study personnel using the C-SSRS (Posner et al, 2011). 
This scale will be used for screening as well as to assess suicidal ideation and behavior that 
may occur during the study. The C-SSRS will be completed according to the tabular schedule 
of study procedures (Section 5.2)
Has been changed to (bolded text added): 
Suicidality will be assessed by trained study personnel using the C-SSRS (Posner et al, 2011). 
This scale will be used for screening as well as to assess suicidal ideation and behavior that 
may occur during the study. The C-SSRS will be completed according to the tabular schedule 
of study procedures (Section 5.2). The Investigator’s decision about patient continuation 
in the study or patient withdrawal from the study if the patient has a positive response 
to the CSSRS Question 4, should be based on the Benefit /Risk balance for continuation 
REDACTED 
lt, if do
, if d
TE
AC
RE
arta
arta
COPY 
th h
PY
CO
This document
of st
of st
H
cannot 
lityty
scale 
cale 
y occ
 oc
y
be 
y wi
wi
y
used 
.7.
.7.5
to support 
ou
ou
minat
minat
hepato
hepat
any
njury
njur
uld c
uld c
marketing 
g
ate amin
te amin
tion
ion
ry
ry e
y
authorization 
on
one
one
iza
th
application 
bdo
bdo
mpromi
prom
at
pp
and
nsitiv
sitiv
domi
om
any
evati
evat
it
an extensions
titry
try
the l
the l
i
or 
yps
yps
variations 
ns thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 117 of 125
or discontinuation of study treatment in view of the individual patient circumstances, 
condition, attained efficacy, causality, alternative risk management options, etc. Details 
of the case must be documented by the investigator (PI or investigator physician, not 
site staff conducting the CSSRS) and provided to UCB via the SAE reporting process.
Change #39
Section 13.7 Planned interim analyses and data monitoring
This Section has been added: 
An interim analysis will be performed if needed for purposes of planning and designing of 
future studies. If performed, this analysis will be conducted when at least 75% of patients 
have been randomized and completed through the Inpatient Period (completed through 
Visit 5).
All subjects who have completed through Visit 5 at the time of the data snapshot will be 
included in the interim analysis.
All statistical analyses will be described in detail in the interim SAP.
For the interim analysis, the primary efficacy variable (75%RR) will be analyzed using the 
methods described for the primary efficacy analysis. In addition, seizure-free rate, 50%RR, 
and percent reduction in focal seizure frequency will be analyzed as described for the 
secondary/exploratory analyses.
The 75%RR, Seizure-free rate, and 50%RR variables may also be analyzed using Bayesian 
logistic regression. If Bayesian analysis is peformed, the percent reduction in focal seizure 
frequency from the Baseline will be estimated using Bayesian analysis of variance (ANOVA) 
and/or ANCOVA. For these analyses, posterior medians, 95% credible intervals for the 
treatment effect, and additional posterior probabilities will be presented. Non informative and 
informative priors will be considered, and sensitivity to different prior settings will be 
assessed. Other efficacy variables may also be analyzed in the Bayesian framework.
The following safety data will also be presented: 
!
Treatment emergent AEs
!
AEs leading to drop-out or withdrawal
!
SAEs
!
Laboratory assessments out of normal range
!
BPRS
The study will not be terminated early for either efficacy or futility based on the results of 
this interim analysis and therefore, an alpha penalty of 0.001 to be assessed on the primary 
efficacy analysis is considered appropriate.  
The study is not expected to be stopped due to safety reasons during this interim analysis, 
since there are ongoing quarterly Safety Review Group meetings already planned for this 
purpose. Therefore, no criteria for evaluation of early stopping due to safety are included.  
An unblinded team will be established at both the Sponsor and CRO and will include the 
following roles (all unblinded): Data Manager, Statistician, Statistical Programmer, and 
Project Lead. All staff involved in the conduct of the study, including staff at UCB, the CRO, 
participating vendors, and the participating sites will remain blinded to individual treatment 
identity and will not be informed of the results of the interim analysis until final unblinding. 
REDACTED
eform
efor
mated u
mated u
poster
oste
terior 
erior 
ed, 
ed, 
COPY 
iables
iable
rme
rm
This document
effic
effic
T
cannot 
study
udy w
y
s inte
inte
be used 
y asse
asse
y
to suppo
op
port 
Es
Es
-out o
out
any marketing
p
and se
and s
may
may als
a
y
so be
so b
authorization
s ma
ma
ed, t
ed, th
using 
using
rior m
ior m
proba
roba
application 
n, s
n, seie
lyz
yzed a
ed
ay
ay
and 
will be
ill be
i
any extensions 
g
shot w
hot w
or 
gh h 
variations 
f f
nts 
ts
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 118 of 125
17.4
Protocol Amendment 4.0
Rationale for the Amendment
The primary reason for Amendment 4.0 is to describe a tiered approach to database lock and 
unblinding. 
Other changes include: 
!
Correction of an inconsistency between the Summary section and the Study Design 
section pertaining to allowable dose changes 
!
Clarification of the reporting period for adverse events
!
Specification that the Baseline version of the SSQ is to be used in all instances where it is 
administered 
!
Correction of the number of questions in the SSQ was from 11 to 10. 
!
Correction of several cross references 
!
Other minor administrative changes 
Modifications and changes
Specific changes
Change #1
Summary (revised for consistency with Section 5, Study Design)
Titration to UCB0942 400mg bid will occur over the course of 1 week in the clinical unit. 
For subjects in the active arm, doses will be titrated to UCB0942 400mg bid during the first 
inpatient week. For subjects who initially received placebo, doses will be titrated to 
UCB0942 400mg bid during the last week of the Inpatient Period. For subjects in the active 
arm who do not tolerate UCB0942 400mg bid, during the third week of the Inpatient Period, 
the dose can be tapered to UCB0942 200mg bid before starting the Outpatient Maintenance 
Period. Similarly, for subjects in the placebo group the dose can be tapered to UCB0942 
200mg bid during the Outpatient Maintenance Period. Dose tapering to UCB0942 100mg bid 
may be permitted after discussion with the Sponsor’s Study Physician. All subjects will stay 
in the clinical unit for a total of 3 weeks and will then be discharged for an 8-week 
Outpatient Maintenance Period.
Has been changed to: 
Titration to UCB0942 400mg bid will occur over the course of 1 week in the clinical unit. 
For subjects in the active arm, doses will be titrated to UCB0942 400mg bid during the first 
inpatient week. For subjects who initially received placebo, doses will be titrated to 
UCB0942 400mg bid during the last week of the Inpatient Period. Dose reductions will be 
allowed during titration and maintenance in the Inpatient Period, but this should be discussed 
with the Sponsor Study Physician unless this is not possible due to the circumstances. 
Multiple adjustments (tapering or increase) of the dose are allowed during the Outpatient 
Maintenance Period (minimum 100mg bid and maximum 400mg bid); however, any change 
of dose in the Outpatient Maintenance Period should first be discussed with the Sponsor 
Study Physician.
REDACTED 
w
ccur ov
ccur ov
will be
will b
nitially
nitially
ast w
ast w
COPY 
ith S
ith 
This document
UC
UC
all
all
cannot
ubjec
bjec
patien
atien
CB
CB
be
to U
to U
used 
chan
han
to
enan
ena
support 
tpat
pat
discus
discu
or a to
r a to
nc
any
s in t
s in
atien
tie
marketing 
y r
y
week o
week 
2 400m
400m
0942 2
0942
tht
uthorization
Sect
Sec
ver th
ver th
e titrat
titra
rece
rece
application and any extensions or
here
her
variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 119 of 125
Change #2
Section 5.1.3 Anticipated regions and countries
The study is planned to be performed in The 
. 
Other countries in the 
 can be added if deemed necessary by the Sponsor.
Has been changed to: 
The study is planned to be performed in The 
 
 
 
 
 
 and 
 
Change #3
Table 5-4, row header, Table 5-5 row header and footnote m, Section 8 – Study Procedures 
by Visit: SSQ has been revised to SSQ (Baseline version) to make it clear that whenever the 
SSQ is administered, the Baseline version is to be used. 
Change #4
Table 5-4, row header had been revised to correct the duration of the Taper and Safety 
Follow-up Periods. The Taper Period is up to 2 weeks, and the Safety Follow-up Period is 
4 weeks.  
Change #5
Section 9.2 Seizure severity questionnaire
The SSQ (Cramer et al, 2002) is a review of various aspects of seizures. The person who has 
seizures may ask people who have observed the seizures (family, friends) to help answer 
some of the questions asking about events, but not about feelings. There are 11 questions in 3 
sections asking about events before, during, and after typical seizures.
The subject should describe their most common type of seizure when answering the 
questions. If subjects are unsure about how to answer a question, they should give the best 
answer they can and write a comment or explanation on the side of the page. 
The SSQ will be completed according to the tabular schedule of study procedures, Table 5-4. 
For this study the recall period will be set to 1 week rather than the original 4 weeks. At the 
very beginning of the visit, the SSQ will be provided to all subjects. The subject will be asked 
to complete the questionnaire on his/her own. Once completed, the subject will return the 
completed questionnaire to the Investigator or designee, who will verify that all questions 
have been answered. Further details about the SSQ will be covered in the Study Manual.
Has been changed to (changes bolded):
The SSQ (Cramer et al, 2002) is a review of various aspects of seizures. The person who has 
seizures may ask people who have observed the seizures (family, friends) to help answer 
some of the questions asking about events, but not about feelings. There are 10 questions in 3 
sections asking about events before, during, and after typical seizures.
The subject should describe their most common type of seizure when answering the 
questions. If subjects are unsure about how to answer a question, they should give the best 
answer they can and write a comment or explanation on the side of the page. 
The Baseline SSQ will be completed according to the tabular schedule of study procedures,
Table 5-4. The Baseline version of the SSQ will be used for all visits during which the SSQ 
is to be completed. For this study the recall period will be set to 1 week rather than the 
original 4 weeks. At the very beginning of the visit, the SSQ will be provided to all subjects. 
REDACTED
va
d the 
d the
nts, bu
ts, bu
during
during
most
most
COPY 
aire
aire
arious
riou
This document
som
som
se
se
cannot 
SSQ (
SQ (
zures
zure
be
en c
en c
used 
ion
on
swere
were
h
to
est
nna
nna
support
period
erio
visit, th
visit, 
tionn
tionn
any
accor
accor
d w
d
marketing
t comm
com
out how
out ho
mment o
ment
authorization
us asp
s asp
seizu
seizu
ut not 
ut not 
g, and
g, and
application and
ety F
y F
any 
Taper 
aper
Fol
F
extensions
henev
enev
or
edur
u
d
variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 120 of 125
The subject will be asked to complete the questionnaire on his/her own. Once completed, the 
subject will return the completed questionnaire to the Investigator or designee, who will 
verify that all questions have been answered. Further details about the SSQ will be covered in 
the Study Manual.
Change #6
Section 11.1.1, Definition of adverse event, paragraph 2
In order to ensure complete safety data collection, all AEs occurring during the study 
(ie, after the signing of the Informed Consent form), including any pretreatment and 
posttreatment periods required by the protocol, must be reported in the eCRF even if no IMP 
was taken but specific study procedures were conducted. This includes all AEs not present 
prior to the initial visit and all AEs that recurred or worsened after the initial visit.
Has been changed to (change bolded): 
In order to ensure complete safety data collection, all AEs occurring during the study 
(ie, after the signing of the Informed Consent form), including any pretreatment and 
posttreatment periods required by the protocol, ie, through the end of the Taper/Safety 
Follow-up Period, must be reported in the eCRF even if no IMP was taken but specific study 
procedures were conducted. This includes all AEs not present prior to the initial visit and all 
AEs that recurred or worsened after the initial visit.
Change #7
Section 11.1.4, Follow up of of adverse events, paragraph 2
If an AE is ongoing at the end of the study for a subject, follow up should be provided until 
resolution/stable level of sequelae is achieved, or until the Investigator no longer deems that 
it is clinically significant, or until the subject is lost to follow up. If no follow up is provided, 
the Investigator must provide a justification. The follow up will usually be continued for 30 
days after the subject has discontinued his/her IMP.
Has been changed to (changes bolded): 
If an AE is ongoing at the end of the Taper/Safety Follow-up Period, follow up should be 
provided until resolution/stable level of sequelae is achieved, or until the Investigator no 
longer deems that it is clinically significant, or until the subject is lost to follow up. If no 
follow up is provided, the Investigator must provide a justification. The follow up will 
usually be continued for 30 days after the subject has discontinued his/her IMP.
Adverse events should not be recorded in the eCRF after the end of the Taper/Safety 
Follow-up Period.
Change #8
Section 11.1.9, Safety Review Group, paragraph 3
The SRG will remain blinded during the study unless emergent safety information requires 
unblinding of individual drug allocation for optimal assessment and response to AEs of 
concern.
Has been changed to: 
The SRG will remain blinded through the first database lock (see Section 12.3.3) unless 
emergent safety information requires unblinding of individual drug allocation for optimal 
assessment and response to AEs of concern. At the time of the first database lock, the Study 
REDACTED 
ers
y for 
y for 
chieve
chiev
he sub
he sub
tific
tific
COPY 
se e
se e
This document
Sec
Sec
cannot
up 
up 
hange
ang
be
ven
en
P
used
tinue
inue
nts
nts
to
ded,
ded
d
support
end
end
n/stab
n/stab
is clini
s clin
tht
any 
ha
ha
d of
d o
marketing 
bjeje
cation
ation
nued hi
ued h
ang
ang
authorization
even
even
a subj
a subj
ed, or
d, or
ect i
ct i
application
prior 
prior
and 
of 
of 
was t
was t
any
reatm
eatm
the
th
extensions 
g the 
g the 
or
ese
ese
variations 
IMP 
MP 
ent
ent
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 121 of 125
Physician(s), clinical pharmacologist, DS representative, biostatistician, and other UCB 
personnel will be unblinded as to all subjects’ treatment allocation at the beginning of the 
Inpatient Period. 
Change #9
Section 11.6.1, Evaluation of PDILI
Several incorrect table and section references have been corrected. 
Change #10
Section 12.3.3, Database lock – section has been added: 
The database lock and unblinding may occur in a tiered approach. 
Details regarding the tiered database lock will be described in the Data Management Plan. 
Plans for analysis of data and production of tables, figures and listings will be described in 
the Statistical Analysis Plan (SAP).
Change #11
Section 13.5, Handling of protocol deviations, paragraph 1
After all data have been verified/entered into a database and prior to database lock, a data 
evaluation meeting will take place. The purpose of the data evaluation will be to examine all 
protocol deviations, define the PPS, and to verify the quality of the data. The data evaluation 
will also help in guiding decisions on how to manage data issues on a case-by-case basis (eg, 
withdrawals, dropouts, and protocol deviations).
Has been changed to (changes bolded): 
After all lockable data have been verified/entered into a database and prior to the first 
database lock, a data evaluation meeting will take place. The purpose of the data evaluation 
will be to examine all protocol deviations, define the PPS, and to verify the quality of the 
data. The data evaluation will also help in guiding decisions on how to manage data issues on 
a case-by-case basis (eg, withdrawals, dropouts, and protocol deviations).
REDACTED
ons).
ons)
bold
bold
rified
rified
eetin
eetin
COPY
the q
the q
manage
anag
)
This document cannot be used to support any
draw
draw
marketing
d/
ng wil
ng wi
iations
ation
so help
o he
wa
w
authorization
e da
 da
ded):
ded):
/ente
ente
application 
g
prior to
rior 
a evalu
a eval
uality
ality o
y
ata
ata
and 
grap
rap
any extensions 
ment P
ment P
e desc
desc
or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 122 of 125
18
DECLARATION AND SIGNATURE OF INVESTIGATOR
I confirm that I have carefully read and understood this protocol and agree to conduct this 
clinical study as outlined in this protocol, according to current Good Clinical Practice and 
local laws and requirements.
I will ensure that all subinvestigators and other staff members read and understand all aspects 
of this protocol.
I have received and read all study-related information provided to me.
The objectives and content of this protocol as well as the results deriving from it will be 
treated confidentially, and will not be made available to third parties without prior 
authorization by UCB.
All rights of publication of the results reside with UCB, unless other agreements were made 
in a separate contract.
Investigator:
Printed name
Date/Signature
REDACTED COPY 
e/S
/
This document cannot be used to support any marketing authorization applicatio
nature
ature
tion 
tio
and any extensions 
s were
were
or variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 123 of 125
19
DECLARATION AND SIGNATURE OF COORDINATING 
INVESTIGATOR (
I confirm that I have carefully read and understood this protocol and agree to conduct this 
clinical study as outlined in this protocol, according to current Good Clinical Practice and 
local laws and requirements.
I will ensure that all subinvestigators and other staff members read and understand all aspects 
of this protocol.
I have received and read all study-related information provided to me.
The objectives and content of this protocol as well as the results deriving from it will be 
treated confidentially, and will not be made available to third parties without prior 
authorization by UCB.
All rights of publication of the results reside with UCB, unless other agreements were made 
in a separate contract.
Coordinating Investigator (
_____________________________
Date/Signature
REDACTED COPY 
This document cannot be used to support any marketing authorization application 
____
___
ature
ature
and any extensions 
ments 
ents 
or 
be
be
variations thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 124 of 125
20
DECLARATION AND SIGNATURE OF COORDINATING 
INVESTIGATOR 
I confirm that I have carefully read and understood this protocol and agree to conduct this 
clinical study as outlined in this protocol, according to current Good Clinical Practice and 
local laws and requirements.
I will ensure that all subinvestigators and other staff members read and understand all aspects 
of this protocol.
I have received and read all study-related information provided to me.
The objectives and content of this protocol as well as the results deriving from it will be 
treated confidentially, and will not be made available to third parties without prior 
authorization by UCB.
All rights of publication of the results reside with UCB, unless other agreements were made 
in a separate contract.
Coordinating Investigator:
_____________________________
Date/Signature
REDACTED COPY 
This document cannot be used to support any marketing authorization application 
__
__
urere
and 
_
any extensions 
ents w
ents w
or variations 
e
thereof. 


UCB
10 Oct 2016
Clinical Study Protocol
UCB0942
EP0069
Confidential
Page 125 of 125
21
SPONSOR DECLARATION
I confirm that I have carefully read and understand this protocol and agree to conduct this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


ELECTRONIC SIGNATURES
Signed by 
Meaning of Signature 
Server Approval Date 
(dd-mon-yyyy
(HH:mm))
(33URWRFRO$PHQGPHQW
&OLQLFDO$SSURYDO
2FW*07
'H
&OLQLFDO$SSURYDO
2FW*07
REDACTED COPY 
DO
This document cannot be used to support any marketing authorization application and 
an
a
y
any 
erve
a y extensions or variations thereof. 

SAP_001.pdf: 
UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 1 of 62
STATISTICAL ANALYSIS PLAN
Study: EP0069
Product: UCB0942
A double-blind, randomized, placebo-controlled study of the efficacy, safety/tolerability, and 
pharmacokinetic profile of UCB0942 in adult patients with highly drug-resistant focal epilepsy.
SAP/Amendment Number
Date
Final SAP
03 Jul 2015
Amendment 1
07 Oct 2016
Confidentiality Statement
Confidential
This document is the property of UCB and may not – in full or in part – be passed on, reproduced, 
published, or otherwise used without the express permission of UCB.
2015
2015
t 2
t 2
COPY 
ts w
s 
This document
This
This
u
cannot 
nn
be used to support any marketing 
016
16
authorization application 
e effica
 effic
h highl
high
and any extensions or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 2 of 62
TABLE OF CONTENTS
LIST OF ABBREVIATIONS....................................................................................................5
1
INTRODUCTION .............................................................................................................8
2
PROTOCOL SUMMARY.................................................................................................8
2.1 Study objectives.................................................................................................................8
2.1.1
Primary objective...................................................................................................8
2.1.2
Secondary objectives .............................................................................................8
2.1.3
Exploratory objectives...........................................................................................8
2.2 Study variables...................................................................................................................9
2.2.1
Efficacy variables ..................................................................................................9
2.2.1.1
Primary efficacy variable ............................................................................9
2.2.1.2
Secondary efficacy variables.......................................................................9
2.2.1.3
Exploratory  efficacy variables....................................................................9
2.2.2
Pharmacokinetic variables...................................................................................10
2.2.3
Other exploratory variables .................................................................................10
2.2.4
Safety variables....................................................................................................11
2.3 Study design and conduct ................................................................................................12
2.4 Determination of sample size...........................................................................................13
3
DATA ANALYSIS CONSIDERATIONS......................................................................13
3.1 General presentation of summaries and analyses ............................................................13
3.2 General study level definitions ........................................................................................15
3.2.1
Analysis timepoints .............................................................................................15
3.2.1.1
Relative day...............................................................................................15
3.2.1.2
Study periods.............................................................................................15
3.3 Definition of Baseline values...........................................................................................16
3.4 Protocol deviations...........................................................................................................17
3.5 Analysis sets.....................................................................................................................17
3.5.1
Enrolled Set .........................................................................................................17
3.5.2
Randomized Set...................................................................................................17
3.5.3
Safety Set.............................................................................................................17
3.5.4
Full Analysis Set..................................................................................................17
3.5.5
Per Protocol Set ...................................................................................................17
3.5.6
Other analysis sets ...............................................................................................17
3.6 Treatment assignment and treatment groups ...................................................................18
3.7 Center pooling strategy....................................................................................................18
3.8 Coding dictionaries ..........................................................................................................18
3.9 Changes to protocol-defined analyses..............................................................................19
3.10 Definition of study-specific derived variables.................................................................19
REDACTED 
....
....
ONS
ONS
s and a
s and a
......
......
COPY 
.....
.........
This document
3.5
3.
3
cannot 
4
.5.5.5
be
Sa
Sa
used 
ollele
Rando
ando
to 
.
ed S
ed S
support 
va
va
.........
......
....
...
any 
ds
ds.....
alues
lue
marketing 
.....
....
.......
...
........
....
authorization 
....
........
......
....
analy
analy
application 
.....
...
.......
....
.......
.....
.....
and 
......
....
any 
......
.....
extensions 
........
.......
......
....
......
....
or
.....
....
variations 
...8
..8
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 3 of 62
3.10.1
Seizure frequency related variables.....................................................................19
3.10.2
Seizure freedom...................................................................................................20
3.10.3
Seizure-free days .................................................................................................20
3.10.4
Patient Weighted Quality of Life in Epilepsy Inventory.....................................20
3.10.5
Medications..........................................................................................................21
4
STATISTICAL/ANALYTICAL ISSUES.......................................................................22
4.1 Adjustments for covariates...............................................................................................22
4.2 Handling of dropouts or missing data..............................................................................22
4.3 Interim analyses and data monitoring..............................................................................23
4.3.1
Safety Review Group...........................................................................................23
4.3.2
Blinded Interim Analysis.....................................................................................23
4.4 Multicenter studies...........................................................................................................24
4.5 Multiple comparisons/multiplicity...................................................................................24
4.6 Use of an efficacy subset of subjects ...............................................................................24
4.7 Active-control studies intended to show equivalence......................................................24
4.8 Examination of subgroups ...............................................................................................24
4.9 End of Study Analyses.....................................................................................................25
5
STUDY POPULATION CHARACTERISTICS.............................................................25
5.1 Subject disposition...........................................................................................................25
5.2 Protocol deviations...........................................................................................................26
6
DEMOGRAPHICS AND OTHER BASELINE CHARACTERISTICS ........................26
6.1 Demographics ..................................................................................................................26
6.2 Medical history and concomitant diseases.......................................................................26
6.2.1
History of epilepsy...............................................................................................26
6.3 Prior and concomitant medications..................................................................................27
6.3.1
Non- Antiepileptic drugs .....................................................................................28
6.3.2
Antiepileptic drugs...............................................................................................28
7
MEASUREMENTS OF TREATMENT COMPLIANCE...............................................29
8
EFFICACY ANALYSES ................................................................................................30
8.1 Statistical analysis of the primary efficacy variable ........................................................30
8.2 Statistical analysis of the secondary efficacy variables ...................................................30
8.3 Analysis of exploratory efficacy variables ......................................................................31
9
PHARMACOKINETICS.................................................................................................33
9.1 Non compartmental PK analysis......................................................................................33
9.2 Population pharmacokinetics...........................................................................................34
9.3 Pharmacokinetic/pharmacodynamic analysis ..................................................................34
10
SAFETY ANALYSES.....................................................................................................34
10.1 Extent of exposure ...........................................................................................................34
REDACTED 
T
......
......
......
.....
ER BA
ER BA
COPY 
......
...
TICS
ICS
This document 
9
9.1
9.1
cannot
atisti
tisti
Anal
Ana
P
be
tical
tical
used 
M
CY AN
Y AN
a
to
ENT
EN
support 
m
pileptic
ilepti
eptic dr
ptic dr
T
any 
.....
edica
edica
marketing 
A
.......
.....
ant dise
nt dis
.....
...
authorization 
......
......
......
....
......
.....
SEL
SEL
application 
.
.......
.....
........
....
......
.....
and 
.......
......
any 
.....
....
...
extensions
......
.....
........
......
.........
.......
or 
......
variations 
22
22
22
2
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 4 of 62
10.2 Adverse events.................................................................................................................34
10.3 Clinical laboratory evaluations ........................................................................................36
10.4 Vital signs, physical findings, and other observations related to safety..........................37
10.4.1
Vital signs ............................................................................................................37
10.4.2
Electrocardiograms..............................................................................................38
10.4.3
Doppler echocardiography...................................................................................38
10.4.4
Physical examination...........................................................................................38
10.4.5
Columbia-Suicide Severity Rating Scale.............................................................38
10.4.6
Neurological examination....................................................................................38
10.4.7
Psychiatric and cognition assessment and withdrawal monitoring .....................38
10.4.8
Other safety variables ..........................................................................................39
11
OTHER ANALYSES ......................................................................................................39
12
REFERENCES ................................................................................................................40
13
APPENDICES .................................................................................................................42
13.1 Treatment groups in TFL outputs ....................................................................................42
13.2 PCST criteria....................................................................................................................43
13.2.1
Hematology..........................................................................................................43
13.2.2
Blood chemistry...................................................................................................44
13.2.3
Urinalysis.............................................................................................................45
13.2.4
Vital signs and body weight ................................................................................46
13.3 QOLIE-31-P total and subscale score calculations..........................................................48
13.4 SSQ Scoring Algorithm ...................................................................................................51
13.5 SAP Amendment 1 ..........................................................................................................53
STATISTICAL ANALYSIS PLAN SIGNATURE PAGE.....................................................62
REDACTED 
......
......
.....
.....
score 
score 
COPY 
......
...
....
....
This document cannot be used to support any 
A
marketing 
c
.......
.....
........
.....
AN SI
N S
authorization 
......
......
......
....
......
.....
alcu
alcu
application 
.
.......
.....
........
....
......
.....
and 
.......
......
any 
.....
....
...
extensions
......
.....
........
......
.........
.......
or 
......
variations 
38
38
3
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 5 of 62
LIST OF ABBREVIATIONS
50%RR
50% responder rate
75%RR
75% responder rate
ADaM
analysis dataset model
AE
adverse event
AED
antiepileptic drug
ALP
alkaline phosphatase
ALT
alanine aminotransferase
ANCOVA
analysis of covariance
AST
aspartate aminotransferase
AUC
area under the concentration-time curve
AUCτ
area under the plasma concentration-time curve over a dosing interval
BMI
body mass index
BPRS
Brief Psychiatric Rating Scale
BRV
brivaracetam
BUN
blood urea nitrogen
CF
correction factor
CI
confidence interval
CIWA-B
Clinical Institute Withdrawal Assessment-Benzodiazepines
Cmax
maximum observed plasma drug concentration
CRF
case report form
CRO
contract research organization
C-SSRS
Columbia Suicide Severity Rating Scale
CSR
clinical study report
Ctrough
measured concentration at the end of a dosing interval at study state
CV
coefficient of variation
DAP
data analysis plan
DBP
Diastolic blood pressure
DNA
Deoxyribonucleic acid
ECG
electrocardiogram
ES
enrolled set
EudraCT
European Union Drug Regulating Authorities Clinical Trials
REDACTED 
nterva
nterva
COPY 
lele
This document
DBP
BP
D
cannot 
P
be used to support 
ontract
ntra
Col
Co
any 
eport f
port 
marketing 
al
ute Wi
ute W
obs
obser
authorization application 
e ov
e ov
and 
over
ver
any extensions or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 6 of 62
FAS
Full Analysis Set
FDA
Food and Drug Administration
HBsAg
hepatitis B surface antigen
HCV-Ab
hepatitis C antibody
HIV-1/2Ab
human immunodeficiency virus-1/2 antibody
ICF
Informed Consent Form
ICH
International Conference on Harmonization
ILAE
International League Against Epilepsy 
IMP
investigational medicinal product
LDH
lactate dehydrogenase
LEV
levetiracetam
MedDRA
Medical Dictionary for Regulatory Activities
MCH
mean corpuscular hemoglobin
MCHC
mean corpuscular hemoglobin concentration
MCV
mean corpuscular volume
MINI
Mini International Neuropsychiatric Interview
MMSE
mini-mental state examination
mRNA
messenger RNA
n
number of observations
NCA
non-compartmental analysis
OLE
Open Label Extension study
PCST
potentially clinical significant treatment-emergent
PK
pharmacokinetic(s)
PK-PPS
Pharmacokinetic Per Protocol Set
PPS
Per Protocol Set
PR
pulse rate
PT
preferred term
QOLIE-31-P
Quality of Life Inventory in Epilepsy-31-P
QTcB
QT interval corrected for heart rate using Bazett’s formula
QTcF
QT interval corrected for heart rate using Fridericia’s formula
RBC
red blood cells
RS
Randomized Set
REDACTED
europ
europ
 exam
exa
RNA
RNA
COPY
n co
n co
e
This document
QOL
OL
Q
cannot 
LI
LI
be used to support 
otentia
tenti
phar
pha
any 
Label
Labe
marketing 
ervatio
ervat
artmen
artme
authorization 
sy
sychia
chi
minati
minat
application 
es
centrat
centra
and any extensions or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 7 of 62
SAE
serious adverse event
SAP
Statistical analysis plan
SBP
systolic blood pressure
SD
standard deviation
SFU
Safety Follow-up
SI
Standard International 
SOC
system organ class
SRG
Safety Review Group
SS
Safety Set
SSQ
seizure severity questionnaire
t1/2
apparent terminal elimination half-life, reported in hours
TFL
table listing figure
tmax
time of occurrence of maximum observed plasma drug concentration
ULN
upper limit of normal
VNS
vagal nerve stimulation
WBC
white blood cell
WHODD
World Health Organization Drug Dictionary
REDACTED 
rganiz
ganiz
COPY 
This document cannot be used to support any marketing authorization 
zation 
ation
application 
ved pla
ed pl
and 
d inin
any 
n ho
n h
extensions or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 8 of 62
1
INTRODUCTION
The purpose of this statistical analysis plan (SAP) is to provide all information that is necessary 
to perform the required statistical analysis of data collected in EP0069. It also defines the 
summary tables, listings, and figures (TFLs) to be included in the final Clinical Study Report 
(CSR) according to the protocol.
This SAP is based upon, and assumes familiarity, with the following study documents:
Protocol Amendment 4: 05 October 2016
Unless specified below, the study will be analyzed as described in the most recent version of the 
protocol (EudraCT-Number: 2014-003330-12).
If a future protocol amendment necessitates a substantial change to the statistical analysis of the 
study data, this SAP will be amended accordingly. If, after database lock, additional analyses are 
required to supplement the planned analyses described in this SAP, those unplanned analyses 
will not be described in the amended SAP but they will be described in a separate analysis plan.
However, if analysis definitions have to be modified or updated, a SAP amendment will be 
required. The content of this SAP is compatible with the International Conference on 
Harmonization (ICH)/ Food and Drug Administration (FDA) E9 Guidance documents (ICH E9, 
1998). 
UCB is the Sponsor and PRA is the Contract Research Organization (CRO) for this study.  
2
PROTOCOL SUMMARY
2.1
Study objectives
2.1.1
Primary objective
The primary objective is to evaluate the efficacy of UCB0942 administered concomitantly with 
each subject’s current, stable antiepileptic drug (AED) regimen in subjects who have 4 or more 
focal seizures with or without secondary generalization per week and who have failed to achieve 
seizure control with ≥4 AED regimens of adequate dose and duration.
2.1.2
Secondary objectives
The secondary objectives are to:
!
Evaluate the safety and tolerability of UCB0942.
!
Evaluate the pharmacokinetics (PK) of UCB0942 and its metabolites.
2.1.3
Exploratory objectives
The exploratory objectives are to:
!
Identify genetic polymorphisms, gene expression patterns, plasma proteins, plasma lipids 
or other plasma substances that predict or are associated with disease etiology, drug
response, or tolerability.
!
Use video recordings to explore the effect of UCB0942 on seizure type, seizure severity, 
seizure duration and duration of the postictal period. 
!
Evaluate the efficacy of UCB0942 using exploratory efficacy variables.
REDACTED 
RY
COPY 
earch 
earch
This document 
!
cannot 
e explo
explo
be 
ua
ua
used
the 
he 
ate t
ate t
to 
ct
sa
support 
ary
ry o
y
b
ives a
ves a
any 
co
co
regim
egim
marketing 
he effi
he eff
pileptic
pilept
onda
ond
authorization
Org
Or
application 
ional
ona
E9 Gu
E9 Gu
rgan
rgan
and 
n a a 
AP am
AP am
l
any
unpl
unp
sepa
sep
extensions 
i
al ana
l ana
dition
dition
lal
or
on o
n o
variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 9 of 62
2.2
Study variables
2.2.1
Efficacy variables
The periods for which the efficacy variables are calculated are described in Section 3.2.1.2.
2.2.1.1
Primary efficacy variable
Seizure frequency will be determined using subject diary cards. The subject will be instructed as 
to how to complete the diary and the procedure for completing the diary will be identical during 
the Inpatient and Outpatient Maintenance Periods.
The primary outcome measure is the 75% responder rate (75%RR). In the active group this is 
defined as the proportion of subjects with a 75% or greater reduction in the focal seizure (IA1, 
IB, IC) frequency during the last 2 weeks of the Inpatient Period compared to the 2-week 
Prospective Outpatient Baseline. In the placebo group the 75%RR is defined as the proportion of 
subjects with a 75% or greater reduction in the focal seizure frequency during the first 2 weeks 
of the Inpatient Period (the 2 weeks on placebo) compared to the Prospective Outpatient Baseline
Period.
2.2.1.2
Secondary efficacy variables
The 2-week Inpatient Period to be considered is the last 2 weeks of the Inpatient Period for the 
active group, and the first 2 weeks of the Inpatient Period for the placebo group (see 
Section 3.2.1.2).
The secondary efficacy variables are:
!
Median percent reduction in focal seizure frequency from the Baseline Period to the 2-week 
Inpatient Period, the Outpatient Maintenance Period and On-UCB0942 Overall.
!
Seizure-free rate during the 2-week Inpatient Period, the last 4 weeks of the Outpatient 
Maintenance Period, and the On-UCB0942 Overall Period (Section 3.10.2 ).
!
The 75%RR during the last 4 weeks of the Outpatient Maintenance Period, and 
On-UCB0942 Overall.
!
Percentage of seizure-free days during the 2-week Inpatient Period and Outpatient
Maintenance Period (Section 3.10.2).
2.2.1.3
Exploratory  efficacy variables
For all the exploratory efficacy variables, the Inpatient Period to be considered for the active 
group is the last 2 weeks and for the placebo group is the first 2 weeks of the Inpatient Period.
Exploratory efficacy variables are as follows:
!
Median seizure frequency by focal seizure type (IA1, IB, IC) per study period: Baseline, 1st 
Inpatient Week, 2nd Inpatient Week, 3rd Inpatient Week, the 2-week Inpatient Period,
Outpatient Maintenance Period, and On-UCB0942 Overall.
!
The 50% responder rate (50%RR) during the 2-week Inpatient Period and during the 
Outpatient Maintenance Period.
!
Seizure Severity Questionnaire score (SSQ, Cramer et al, 2002) change from Baseline to the 
end of the Inpatient Period and the end of the Outpatient Maintenance Period.
REDACTED 
eizure 
eizure
Mainte
Mainte
k
COPY
stst
Period
Perio
This document
M
cannot 
oratory
ratory
Me
Me
be
xp
e las
e las
used
xpl
pl
plora
plora
to 
plor
lor
support 
re-free 
free
od
od (Se
S
any
4 w
4 w
marketing 
en
k Inpat
Inpat
n-UCB
UCB
wee
we
authorization 
frequ
frequ
nance
ance
application 
weeks
eeks o
d for th
for t
and 
pec
ec
any
ing 
ing
ctive 
tive 
extensions
up th
p th
eizure
eizure
e 2-w
as the
as the
g th
g th
or 
his
his
variations 
s s 
ring 
ng 
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 10 of 62
!
Changes in average seizure severity as calculated by the percentage of all seizures that are 
type IC for the 2-week Inpatient and Outpatient Maintenance Periods.
!
Change from Baseline in Quality of Life Inventory in Epilepsy-31-P (QOLIE-31-P, Cramer 
et al, 2003) subscales and total score for the Outpatient Visits 10, 12, 15, 17.
2.2.2
Pharmacokinetic variables
Plasma concentrations of UCB0942, 
 will be used to 
derive PK-population parameters.
The following PK variables will be calculated:
!
AUCτ: area under the plasma concentration-time curve over a dosing interval.
!
Cmax:
maximum observed plasma drug concentration.
!
tmax:
time of occurrence of Cmax.
!
t½:
apparent terminal elimination half-life, reported in hours. 
!
Ctrough: measured concentration at the end of a dosing interval at study state. 
2.2.3
Other exploratory variables
Blood samples for DNA, mRNA, and lipidomics/proteomics/additional blood biomarkers will be 
collected during the study:
!
DNA: One tube for DNA isolation will be collected at the beginning of the Inpatient Period 
of the study. The DNA may be used to assess known variants associated with drug-resistant 
epilepsy or AED resistance and may be used for further genetic analyses relating to epilepsy 
and drug response.
!
mRNA: One tube will be collected on the day before the first dose of UCB0942/placebo, and 
1 tube will be collected on the last day of the Inpatient Maintenance Dose Week. The mRNA 
samples may be used to identify gene expression patterns that are associated with disease 
etiology, that predict (Baseline sample), or that are associated with (post-treatment sample) 
drug response.
!
Lipidomics/proteomics/additional blood biomarkers: One tube will be collected on the 
day before the first dose of UCB0942 or placebo, and 1 tube will be collected on the last day 
of the Inpatient Maintenance Dose Week. These samples may be used for additional blood 
biomarker analysis.
All subjects will be asked to provide specific consent for these samples. Refusal to provide 
consent for the collection of samples for DNA, mRNA, and lipidomics/proteomics will not 
disqualify the subject from participating in the study.
Single archive blood samples (for potential background AED assay) will be collected at the start 
of titration, the end of the Inpatient Period, and at the end of the Outpatient Maintenance Period 
(before last dose of investigational medicinal product [IMP]). These samples will be collected 
just before the morning dose of IMP and stored for up to 1 year after the study ends.
During the Inpatient Period, there will be video monitoring of subjects  in their rooms (and in 
other areas depending on the infrastructure of each site) to allow detection of nocturnal seizures 
REDACTED 
be coll
be col
o asse
ass
ay
ay be u
 be 
y
COPY
roteom
oteo
This document 
isq
sq
Sin
Sin
cannot
jects
cts
ent fo
ent fo
qual
ual
be 
er r
used 
e f
tient M
ient M
r ana
ana
to
first
first
support 
ase
as
eomic
omic
d
any
ntify
ntif
eline
elin
marketing 
ed on t
ed on
 last da
last 
fy
fy g
y
authorization 
lected
ected
ss kn
ss kn
used f
used 
application
l at st
at s
mics/ad
ics/a
and 
stut
any extensions or variations 
o 
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 11 of 62
and seizures not recorded by the subject  and to assess seizure type, severity, duration and the 
duration of the postictal period. The video data will not be used to corroborate or supplement the 
diary data and shall not influence the diary seizure capture by the subject.
2.2.4
Safety variables
The safety of participating subjects will be closely monitored. Psychiatric assessment will be 
performed by a staff member trained in the identification of psychiatric symptoms, and the 
assessments will be performed using the Brief Psychiatric Rating Scale (BPRS; Overall and 
Gorham, 1962), which assesses various psychiatric domains including: 
!
Changes in mood and symptoms of depression or mania.
!
Changes in thinking and perception, and other symptoms of psychosis.
!
Changes in behavior.
Other safety variables are:
!
Adverse events (AEs) reported by the subject and/or caregiver or observed by the 
Investigator or inpatient staff.
!
Serious AE (SAEs).
!
Subject withdrawals or premature UCB0942 tapering due to AEs.
!
Changes in clinical laboratory test parameters.
!
Changes in vital sign parameters – pulse rate (PR), systolic blood pressure (SBP), diastolic 
blood pressure (DBP), and respiratory rate.
!
Changes in 12-lead electrocardiogram (ECG) parameters.
!
Changes in key cardiac structures on 2-dimensional Doppler echocardiography from Baseline 
to after treatment (end of dosing and 6 months after last dose).
!
Changes in physical examination (including body weight) and neurological examination 
findings.
!
Changes in memory or cognition as assessed with the mini-mental state examination 
(MMSE; Folstein et al, 1975).
!
Changes indicative of a hypersensitivity reaction including an AE or laboratory value (as 
defined below) suggestive of internal organ involvement (including but not limited to 
hepatitis, nephritis, pneumonitis, carditis, colitis, encephalitis, pancreatitis, myositis, arthritis, 
or hematologic system involvement) combined with at least 1 of the following: fever, rash, 
lymphadenopathy, or eosinophilia.
∀
Treatment-emergent abnormal laboratory value criteria suggestive of internal organ 
involvement or eosinophilia:
◦
Eosinophils % ≥10%
◦
Eosinophils absolute ≥0.5G/L
◦
Neutrophils absolute <1.5G/L
REDACTED 
ers
ers
se rate
se rate
ory
ory rat
rat
y
ogram
ogram
COPY
pering
perin
s
This document cannot 
titis
ti
hema
hem
lylymp
mp
y
be 
bel
bel
is, n
is, n
used 
ndicati
dicati
elow
low
to
ein e
in e
support 
ry or c
y or c
et a
et
any 
inatio
inatio
marketing
m (EC
m (EC
s on 
on 2
ng and
ng an
authorization 
g
e (PR)
(PR)
e.
C
application 
due to
due 
and 
r obse
obse
any extensions or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 12 of 62
◦
Platelets ≤100G/L
◦
Alanine aminotransferase (ALT) ≥2x upper limit of normal (ULN)
◦
Aspartate aminotransferase (AST) ≥2x ULN
!
Any indication of withdrawal symptoms using the Clinical Institute Withdrawal Assessment-
Benzodiazepines (CIWA-B; Busto et al, 1989).
!
Changes in suicidality using the Columbia-Suicide Severity Rating Scale (C-SSRS).
2.3
Study design and conduct
EP0069 is a Phase 2A, double-blind, randomized, placebo-controlled, multicenter study that will 
test the potential efficacy, safety/tolerability, and PK profile of UCB0942 in adult subjects with 
highly drug-resistant focal epilepsy. 
At least 46 subjects will be randomized 1:1 to receive UCB0942 400mg bid or placebo as add-on 
to each subject’s concomitant AED regimen. Stratified randomization will be used to ensure 
balance in the 2 treatment arms on the levetiracetam (LEV)-use factor (3 strata):
1. LEV prior and current use (concomitant use of LEV at study entry).
2. LEV Prior Use Only=History of prior LEV use and must have discontinued 4 weeks prior to 
study entry.
3. LEV Naïve=No history of prior LEV use, and no use at study entry.
All subjects will stay in the clinical unit for a total of 3 weeks and will then be discharged for an 
8-week Outpatient Period. Titration to UCB0942 400mg bid will occur over the course of 1 week 
in the clinical unit. Subjects in the active arm will be titrated to UCB0942 400mg bid, during the 
first inpatient week. Subjects who initially received placebo will be titrated to UCB0942 400mg 
bid during the last week of the 3-week Inpatient Period. For subjects in the active arm who do 
not tolerate UCB0942 400mg bid, during the third week of the Inpatient Period the dose can be 
tapered to UCB0942 200mg bid before starting the 8-week Outpatient Period. Similarly, for 
subjects in the placebo group the dose can be tapered to a tolerable dose during the Outpatient 
Period. 
For a general presentation of the study design refer to Figure 2‒1.
The total duration of the study after Screening is 20 weeks for each subject, including the 
Prospective Outpatient Baseline Period (2 to 3 weeks), the Inpatient Period (3 weeks), the 
Outpatient Period (8 weeks of treatment and 2 weeks of taper), and a Safety Follow-Up (SFU)
Period (4 weeks). The total duration of exposure to UCB0942 during this study is 13 weeks.
Subjects who drop out prior to their Visit 6 may be replaced.
REDACTED 
nd
r a tota
r a tota
UCB09
CB0
tive ar
ive ar
nitial
nitial
COPY 
d d
d no
d no
This document cannot
4 we
w
jects w
ects 
be
Peri
Per
wee
wee
used
n of
of
Outpati
utpati
ioio
to 
of th
of th
support 
p t
p 
ation o
tion 
any
d be
d be
the d
the d
marketing
rm
lly
lly rec
rec
y
ek Inpa
k Inp
, during
durin
efor
efo
authorization 
o use a
use a
al of 3
al of 3
942 40
42 4
m wi
m wi
application 
y entry
entry
y
st have 
t have
and 
wi
w
or (3 s
r (3 
any 
d or
o
ll be 
ll be 
extensions
tud
udy t
y 
t subj
subj
or p
or p
or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 13 of 62
Figure 2‒1: Study design
Maint. = maintenance; OLE = open-label extension; Sbjs=subjects; Titrat. = titration.
An echocardiogram is planed to be performed 6 months after the last dose. If not all 
echocardiographs are completed by the time of the initial database locks, the database will be 
unlocked so that the echocardiography data will be included and cleaned. These data will be 
reported in an addendum.
2.4
Determination of sample size
This is an exploratory pilot study to obtain a first evaluation of the efficacy (estimate and 
variability) of UCB0942 in this specific refractory population. The planned sample size was 
evaluated based on placebo results obtained in similar refractory epileptic populations from 
brivaracetam (BRV) and lacosamide Phase 3 studies in add-on focal epilepsy and the desired 
effect was based on a doubling of the effect of lacosamide and BRV in patients in the current 
target population.
For the primary efficacy variable, the 75%RR in the placebo group from these historical studies 
was estimated to be less than 5%. The response on UCB0942 was expected to be 36.5% in order 
to provide clear differentiation from lacosamide and BRV in this patient population. Based on a 
two-group Fisher's exact one-sided test with a ratio active:placebo of 1:1, the required number of 
subjects is 23 in each arm to detect a significant difference between the two groups with a power 
of 80% and a false positive rate of 5%.
3
DATA ANALYSIS CONSIDERATIONS
3.1
General presentation of summaries and analyses
Statistical evaluation will be performed by UCB or designee and supervised by the Exploratory
Statistics Department of UCB unless otherwise indicated. Data may be summarized by study 
period and by timepoint, if applicable. 
The analysis datasets will follow the UCB analysis dataset model (ADaM) data specifications.
REDACTED
f the
f th
will b
will b
sam
am
COPY 
cts; 
cts
month
month
he
he i
This document 
3
3
cannot
p
ts is 2
s is 2
0% an
0% a
be
e
Fish
Fish
used
o be 
be 
ar di
ar di
to
ficac
icac
l
support
ubling 
ling
cy
any
lts 
lts
samid
samid
marketing
mple
pl
obtain a
btain 
ecific r
cific
s obt
s ob
authorization
hs afaf
nitial
nitial
be inc
e inc
ple
le
applica
trat. = ti
rat. = 
fter
fter
ication and any extensions or 
ions 
variatio
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 14 of 62
All analysis will be performed using SAS® version 9.3, or higher (SAS Institute, Cary, NC, 
USA). The PK variables will be computed by non-compartmental analysis (NCA) with Phoenix 
WinNonlin® (version 6.2, or higher) using the actual sampling times. 
A glossary of common abbreviations will be provided and will contain abbreviations not 
footnoted in the tables, figures, and listings.
For continuous variables, summary statistics will include number of observations (n), mean, 
median, quartiles, standard deviation (SD), minimum, and maximum, and may also include 95% 
confidence intervals (CI). Categorical endpoints will be summarized using number of subjects, 
frequency, and percentages. Coefficient of variation (CV), geometric mean, and 95% CI will also 
be presented in the descriptive statistics for PK parameters. Missing data will not be imputed
apart from the exceptions as outlined in Section 4.2.
When reporting relative frequencies or other percentage values, the following rules apply:
!
For values where all subjects fulfill certain criteria, the percentage value will be displayed as 
100.
!
For values where the absolute frequency is 0, there will be no percentage presented at all.
!
All other percentage displays will use 1 decimal place. 
When reporting descriptive statistics, the following rules will apply in general:
!
n will be an integer.
!
Mean, SD, and median will use 1 decimal place more than the original data.
!
The CV will be reported as a percentage to 1 decimal place. 
!
Minimum and maximum will be reported using the same number of decimal places as the 
original value.
!
If no subjects have data at a given timepoint, for example, then only n=0 will be presented. 
However, if n<3, present the n, minimum and maximum only. If n=3, n, mean, median, 
minimum and maximum will be presented only. The other descriptive statistics will be left 
blank. 
Details of statistical summaries for safety are described in Section 9.
General statistical and reporting conventions are outlined in UCB Global Statistical Conventions; 
Version 1.0 dated 26 June 2013.
For PK calculations the User guide for Clinical Pharmacokinetics Modeling and Simulation; 
Version 8.0, dated 4 July 2012 of UCB will be considered as guideline.
REDACTED 
mal pl
mal pl
entage
entage
rep
rep
COPY
g rules
g rules
This document canno
calc
alc
ion 8.
on 8.
be 
da
cul
cu
used
ical an
cal an
ated
ated
to 
l su
su
support
um wi
m w
umm
um
any 
giv
gi
he n, 
he n,
will
i
marketing 
ported 
orted
iven 
ven
authorization 
lace m
ace m
 to 1 
to 1 
application
o perc
o per
will a
will 
and any 
lue w
lue w
extensions
C
e impu
imp
g rule
g rule
or
wi
wi
variations 
95%
5% 
ects,
ects,
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 15 of 62
3.2
General study level definitions
3.2.1
Analysis timepoints 
3.2.1.1
Relative day
The relative day of an event will be derived with the start date of first IMP administration as 
reference date, up to and including the last day of the IMP administration:
!
Active group: Date of the first/last UCB0942 administration  (including the tapering period, 
where applicable)
!
Placebo group: Date of the first Placebo administration /last Placebo administration (before 
the first UCB0942 administration).
Relative days for an event or measurement occurring before the reference date are calculated as 
follows:
Relative Day=(Event Date-Reference Date)
Relative days for an event or measurement occurring on or after the reference date to the last day 
of IMP administration are calculated as follows:
Relative Day=(Event Date-Reference Date)+1
For events or measurements occurring after the date of last dosing (as defined above), the 
relative day will be calculated with the date of last IMP administration as reference. Relative day 
in this case will be prefixed with ‘+’ in the data listings and will be calculated as follows:
Relative Day=+(Event Date-Reference Date)
Therefore, for the active group, every relative day post the tapering period will be presented with 
a prefix, and for the placebo group, every day since the first UCB0942 dose (2nd Inpatient Week) 
be presented with a prefix.
There is no relative Day 0. Relative day is not calculated for partial dates in cases where relative 
day is shown in a subject data listing. In such cases, relative day should be presented as ‘--’ in 
the subject data listings.
3.2.1.2
Study periods
The following periods, and their combinations will be considered in the definition of efficacy 
and safety variables:
!
Baseline Period: Prospective Outpatient Baseline Period consisting of 2 to 3 weeks of 
prospective post-screening subject diary seizure counts.
!
Inpatient Period: The Double-Blind Inpatient Treatment Period, with the following sub-
periods.
∀
1st Inpatient Week: Double-Blind Titration Week (active group on UCB0942 titration; 
placebo group on placebo)
∀
2nd Inpatient Week: Double-Blind Maintenance-Dose Week (active group on UCB0942 
maintenance; placebo group on placebo)
REDACTED
a
ata lis
ata li
+(Eve
(Ev
ry
ry rela
rela
y
ve
v
COPY 
te of l
te of l
st I
st IM
This document
p
cannot
spect
pect
Inpat
Inpat
be
ne Pe
ne Pe
i
used 
rioio
iables
ables
to
ods
ods
support 
y perio
perio
any
tive
tiv
listin
listin
marketing
ative
ive
ery
ry day
day
y
ve da
ve d
authorization
las
MP ad
MP ad
stings 
tings
vent D
ent D
ve d
e d
application 
e r
nce Da
nce D
st do
st do
and 
refer
refe
any extensions
on (b
(
e are c
are c
or 
(be
(be
variations 
od
od, , 
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 16 of 62
∀
3nd Inpatient Week: Transition to Outpatient Week (active group on UCB0942 
maintenance; placebo group on UCB0942 titration).
∀
2-week Inpatient Period: For the active treatment group this is the last 2 weeks of the 
Inpatient Treatment Period and for the placebo treatment group this is the first 2 weeks of 
the Inpatient Treatment Period.
!
Outpatient Maintenance Period: 8 week Outpatient open-label (active group on UCB0942 
maintenance; placebo group on UCB0942 maintenance).
!
Last 4 weeks of Outpatient Maintenance Period.
!
On-UCB0942 Overall: This is the whole period while the subjects have been taking 
UCB0942 (from the 1st Week of the Inpatient period for the active group and from the 3rd
week of the Inpatient period for the Placebo group, until the end of Outpatient period or 
Tapering). 
!
Tapering Period.
!
SFU Period.
!
Overall: Whole study duration (start of 1st inpatient week through end of SFU).
3.3
Definition of Baseline values
Baseline for seizure frequency will be based on the seizure frequency over the Baseline Period. 
This calculation is described in detail in Section 3.10.
The Baseline for other efficacy and safety variables will be the last available scheduled or 
unscheduled assessment (see Table 3‒1). 
Table 3‒1:
Measurement-specific Baseline timepoints
Category
Parameter
Baseline
Efficacy
QOLIE-31-P, SSQ
Pre-dose T1
Safety
Clinical laboratory assessments (chemistry, hematology, 
urinalysis), echocardiogram
Screening Day -1
Vital signs (SBP, DBP, PR, and respiratory rate), 
temperature, weight, 12-lead ECG, physical examination
Pre-dose T1, or, if missing, 
the Screening Day -1
C-SSRS, psychiatric and cognitive assessments (BPRS, 
MMSE), neurological examination,
Pre-dose T1, or if missing, 
the Screening Day -1
Other
DNA, mRNA, lipodomics/ proteonomics
Pre-dose T1
BPRS=Brief Psychiatric Rating Scale; C‑SSRS=Columbia Suicide Severity Rating Scale; DBP=diastolic blood 
pressure; ECG=electrocardiogram; MMSE=mini-mental state examination; mRNA=messenger RNA; 
QOLIE-31-P=Quality of Life Inventory in Epilepsy-31-P; SBP=systolic blood pressure; SSQ=seizure severity 
questionnaire; T1 = Titration Day 1.
In addition, the change from the last pre-UCB0942 administration measurement may be 
calculated for the placebo subjects for safety and efficacy variables. 
REDACTED
ion
ion 3
ty vari
vari
y
1). 
). 
cif
cif
COPY 
he se
he se
This document
press
pres
QO
QO
cannot 
er
t
an
RS=B
RS=B
be
M
be
b
used
mper
per
C-
C-SS
S
ed to
sign
sign
erat
erat
support
ratory
atory
), echoc
echo
gns (
ns
up
any 
Q
y a
an marketing 
fic Bas
c Ba
ke
m
authorization
eizure
eizure
10.
ables
ables
application 
throug
throu
and any extensions 
king 
king 
d from
from
tient p
ient p
or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 17 of 62
3.4
Protocol deviations
Important protocol deviations are deviations from the protocol which could potentially have a 
meaningful impact on the study conduct or on the primary efficacy outcome, secondary efficacy 
variables, PK data or key safety data for an individual subject. Important protocol deviations will 
be reviewed as part of the data cleaning process and all important deviations will be identified 
and documented to confirm exclusion from the analysis sets.
After all data have been verified/coded/entered into a database, all protocol deviations will be 
classified according to their impact on study objectives during the database pre-lock data 
evaluation meeting (DEM). The purpose of this meeting will be to check all protocol deviations, 
define the analysis sets, and check the quality of the data. The review will also help decide how 
to manage problems in the subjects’ data (e.g., missing values, withdrawals, dropouts, and 
protocol deviations). After the classification of all deviations, Statistical Programming will then 
incorporate the definition of the analysis populations into the analysis files for statistical 
evaluation. If necessary, appropriate actions will be implemented in the SAP before locking the 
database. After the pre-analysis review, resolution of all issues, and documentation of all 
decisions, the database will be locked.
3.5
Analysis sets
3.5.1
Enrolled Set
The Enrolled Set (ES) will consist of all subjects who have signed the informed consent form 
(ICF).
3.5.2
Randomized Set
The Randomized Set (RS) will consist of all enrolled subjects randomized into the study.
3.5.3
Safety Set
The Safety Set (SS) will consist of all subjects in the RS who have received at least 1 dose of
IMP.
3.5.4
Full Analysis Set
The FAS will consist of all subjects in the RS who received at least 1 dose of IMP, and have at 
least 1 post-Baseline seizure diary.
3.5.5
Per Protocol Set
The Per-Protocol Set (PPS) will consist of subjects in the FAS Population who do not have a 
major protocol deviation impacting the primary efficacy variable.
3.5.6
Other analysis sets
The Pharmacokinetic Per-Protocol Set (PK-PPS) will consist of subjects in the RS who received 
at least 1 dose of IMP who do not have a major protocol deviation impacting the PK variables.
The evaluable population for the PK analysis will consist of those subjects in the PK-PPS for 
whom a sufficient number of samples are available to determine at least 1 PK parameter. At the 
discretion of the pharmacokineticist, a subject may be excluded from this set.
REDACTED 
st of a
st of a
COPY 
who
who
This document
The P
he 
at l
at 
cannot
roto
oto
6
P
be
otoc
toc
oco
oco
used
Per P
er P
col
co
to 
e se
e s
P
support 
ysis 
is
of all su
f all 
seizu
eiz
any 
S
marketing 
all 
ll 
f all su
f all s
authorization
have
hav
l enr
enr
application and
docum
ocum
any 
fo
f
SAP
SAP b
extensions
dev
 decid
 decid
pouts,
outs,
ramm
amm
or st
r st
r
viat
viat
variations 
be
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 18 of 62
3.6
Treatment assignment and treatment groups
Incorrectly-treated subjects will be evaluated during the DEM to assess the potential impact of 
such cases and any special analysis considerations. The treatment assignment for the SS, PK-PPS 
will be according to the actual treatment received, whereas the treatment assignment for the PPS 
and the FAS will be based on the randomized treatment.
Listings and summaries will be presented by the most appropriate treatment group and for the 
most appropriate period and all outputs will use the conventions outlined in Table 3‒2.
Table 3‒2:
Table conventions
Label used in 
outputs
Description
By Arm
Placebo/UCB0942
Subjects randomized to Placebo; period: whole study
UCB0942/UCB0942
Subjects randomized to UCB0942; period: whole study
All UCB0942 
Subjects
All subjects; period: whole study 
By Period
Placebo only
Subjects randomized to Placebo; period: 1st+ 2nd Inpatient week
UCB0942 Titration
Subjects randomized to UCB0942; period: 1st Inpatient week
Subjects randomized to Placebo; period: 3rd Inpatient week
UCB0942 
Maintenance
Subjects randomized to UCB0942; period: 2nd Inpatient week to 
the end of Outpatient Period
Subjects randomized to Placebo; period: whole Outpatient Period
UCB0942 Taper
Subjects randomized to UCB0942; period: 2- week Taper Period 
Subjects randomized to Placebo; period: 2- week Taper Period 
SFU
Subjects randomized to UCB0942; period: SFU
Subjects randomized to Placebo; period: SFU
On-UCB0942 
Overall
Subjects randomized to UCB0942; period: 1st Inpatient week to 
end of the Outpatient Maintenance Period
Subjects randomized to Placebo; period: 3rd Inpatient week to end 
of the Outpatient Maintenance Period
3.7
Center pooling strategy
Subjects with highly drug-resistant focal epilepsy will be enrolled at up to 10 
 clinical 
centers. The data from all centers will be pooled. The data summaries and statistical analyses 
will not be performed by center, unless otherwise is stated.
3.8
Coding dictionaries
Adverse events and medical history will be coded according to the latest available version of the 
Medical Dictionary for Regulatory Activities (MedDRA®). Medications will be coded according 
to the latest available version of the World Health Organization Drug Dictionary (WHODD). 
The medical procedures will not be coded.
REDACTED
omize
omiz
Outpat
Outpat
ts rand
s rand
jects 
jects 
ED
COPY
toto UC
U
zed to 
zed to 
C
This document 
ill
3.8
3.8
cannot
s wit
wit
rs. 
s. Th
Th
l not 
not
be 
ith
ith
used 
ed
Ce
Ce
to support 
2
any
Sub
u
a
marketing
rando
rando
ects ran
cts ra
ubjects
ubjec
bj
rk
authorization
Plac
Plac
d to U
d to U
tient P
ent P
domize
omize
io
au
application 
; period
perio
ion
B0942
B0942
ceb
ceb
lic
and 
d any
whole 
whole
a
extensions s
study
tudy
en
e
or 
o variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 19 of 62
3.9
Changes to protocol-defined analyses
The protocol states that all analyses will be based on the randomized treatment. However, the PK 
and safety analyses will be performed on the actual treatment received. 
The Change in time to recovery (protocol, section 4.1.3) will not be analyzed in this study.
The efficacy endpoints will be reported and analyzed in the periods specified in the protocol, and 
also at additional periods if deemed appropriate.
3.10
Definition of study-specific derived variables
3.10.1
Seizure frequency related variables
!
Seizure frequency
Initial Processing of Diary Data
Each seizure code in the clinical database will be mapped to exactly 1 of the following codes 
based on the 1981 International League Against Epilepsy (ILAE) classification: I, IA, IA1, IA2, 
IA3, IA4, IB, IB1, IB2, IC, II, IIA, IIB, IIC, IID, IIE, IIF, or III. 
With regard to cluster seizures, investigator sites are to report the number of cluster episodes 
rather than reporting the estimated number of individual seizures. Therefore, no imputation will 
be applied for the seizure counts corresponding to reports of cluster seizures.
Calculation of Total Seizure Counts by Study Period
The total number of seizures for seizure types IA1 (not IA2-4), IB (i.e. IB1 and IB2), IC (i.e. 
IC1, IC2, and IC3), and the total number of focal seizures (IA1, IB, IC), and the total number of 
seizures for all seizure types (I+II+III) will be calculated across all diary records over the study 
period being summarized.
Calculation of Adjusted Seizure Frequency
Weekly adjusted seizure frequency for seizure types IA1 (not IA2-4), IB (i.e. IB1 and IB2), IC 
(i.e. IC1, IC2, and IC3), and the total number of focal seizures (IA1, IB, IC) will be calculated 
for the period of interest by dividing the number of seizures for each seizure type by the number 
of days for which the diary was completed for each study period, and multiplying the resulting 
value by 7.
The 28-day adjusted seizure frequency will be calculated in a similar way as above.
Calculation of Log-Transformed Values
The above values for each study period of interest will be transformed using the function 
ln(x+1), where ln represents the natural logarithm function.
!
Percent reduction in seizure frequency
Percent reduction from Baseline in seizure frequency to the corresponding evaluation Period will 
be calculated using the following formulae:
Change from Baseline in the weekly adjusted seizure frequency 
Weekly adjusted seizure frequency during the Baseline period  × 100
REDACTED 
e
D
pes 
pes IA
IA
r of fo
of f
I) will
will
COPY
ala
eport
eport
riod
riod
C
This document
!
P
cannot
ove v
ve v
+1), w
1), w
be
of 
of 
be used
usted
sted
f L
f L
to support
by div
div
diary
iary w
y
any
ncy
ncy
he tot
he to
i
mar
q
keting 
l b
equenc
quenc
ar
y fo
fo
y
authorization 
1 (no
1 (no
ocal s
cal s
be ca
be ca
application 
the num
he nu
zures. 
zures.
s of clu
of cl
and
sific
sific
any
the fo
the f
cati
ca
extensions or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 20 of 62
The change from Baseline is calculated subtracting the weekly adjusted seizure frequency during 
the period of interest from the weekly adjusted seizure frequency during the Baseline period.
The following categories of percent reduction in seizure frequency from Baseline to the
corresponding Treatment Period will be computed: <-25%, -25% to <25%, 25% to <50%, 50% 
to <75%, 75% to <100%, and 100%.
!
XX% Responder Rate in seizure frequency
A subject is defined as a responder if s/he has a reduction in seizure frequency of at least XX% 
from their Baseline seizure frequency. The XX%RRs that will be calculated include, but are not 
limited to 50%, 75%, and will be calculated as follows:
Count of responders during the period
Count of  responders during the period + Count of  non responders during the period × 100
3.10.2
Seizure freedom 
A subject is defined as seizure free over a specific time period if they meet all of the following 
criteria:
1. The subject completed this specific time period.
2. The subject did not have any missing diary days over the time period.
3. The subject did not report any seizure of any type over the time period. Period-specific 
algorithm rules will be added for the seizure freedom evaluation.
!
Seizure-free rate
The seizure-free rate (%) for a specific time period will be calculated using the following 
formula:
Count of seizure free subjects during the period
Count of seizure free subjects during the period + Count of non seizure free subjects during the period × 100
3.10.3
Seizure-free days
The percentage of seizure-free days for a specific time period will be calculated using the 
following formula:
Count of seizure free days during the time interval
Count of days of the time interval will available seizure diary data × 100 
3.10.4
Patient Weighted Quality of Life in Epilepsy Inventory
The Patient Weighted QOLIE-31-P is an adaptation of the original QOLIE-31 (Cramer et al, 
1998). The QOLIE-31-P includes 30 items grouped into 7 multi-item subscales (seizure worry [5 
items], overall quality of life [2 items], emotional well-being [5 items], energy/fatigue [4 items], 
cognitive functioning [6 items], medication effects [3 items], and social function [5 items]) and a 
health status item. The QOLIE-31-P total score, subscale scores, and health status item score are 
calculated according to the scoring algorithm described below, with scores ranging from 0 to 100 
and higher scores indicating better functioning. In addition to these 31 items, the QOLIE-31-P 
includes seven items assessing the degree of “distress” associated with the topic of each subscale 
(ie, distress items) and 1 item asking about the relative importance of each subscale topic (ie, 
prioritization item). 
REDACTED 
e fre
e fr
c time 
c time
COPY 
ver 
er
yp
ype ov
e ov
reed
ree
This document
cogn
cogn
he
he
cannot
ent 
ent 
). The
The
ms], o
ms], o
be 
t W
t W
used 
Coun
oun
Pa
Pa
to 
nt
nt
to support
free 
free 
Cou
C
any
day
days
d
marketing 
re
re free
free
he peri
per
rk
authorization
ver t
er 
dom e
om e
perio
perio
application 
e time p
time
the 
the
and
mee
mee
any 
et al
et a
extensions 
eriod
eriod
ns
×
or
are
ar
variations 
X%
re n
re n
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 21 of 62
Subscale Scores
As a first step to calculating the subscale scores, the individual responses for the 30 subscale 
items are rescaled to a 0 to 100 scale with higher scores reflects better functioning; the rescaled 
values for each item are defined in Section 13.3. Each subscale score is then calculated by 
summing the rescaled responses for that subscale and dividing by the number of items with a 
non-missing response. A subscale score will be calculated only if at least 50% of the items 
within the subscale are present.
Total Score
Total score is calculated as a weighted sum of the subscale scores based on the weighting in
Section 13.3. Total score will be missing if at least 1 subscale score is missing. Total score will 
range from 0 to 100 with a higher score reflecting better functioning. 
Health Status Item
Responses for the health status item are a multiple of 10 ranging from 0 to 100 with a higher 
score corresponding to a better health status. The health status item response is analyzed without 
rescaling.
Distress Items
Each subscale includes 1 distress item. The response for each distress item is an integer ranging 
from 1 to 5. The response for each distress item will be converted to a 0 to 100 scale (ie, 0, 25, 
50, 75, and 100) with a higher score corresponding to greater distress.
Prioritization Item
The response for each subscale for the prioritization item is an integer ranging from 1 to 7. The 
prioritization ranking is analyzed without rescaling.
3.10.5
Medications
Each medication will be classified as either an AED or a non-AED. Medications recorded on the 
Prior and Concomitant AED case report form (CRF) will be classified as AEDs. Medications 
recorded on the Prior and Concomitant Non-AED CRF can be classified as either AEDs or Non-
AEDs based on the following rules and based on manual review of such medications.
Benzodiazepines taken more than once per week for non-epilepsy indications will generally be 
classified as AEDs. Generally, benzodiazepines taken with a frequency of QD, BID, TID, QID, 
5XD, 6XD, QOD, QAM, or QPM will be classified as AEDs. With regard to PRN use, each 
individual intake of a benzodiazepine is to be recorded on the CRF and the classification of such 
benzodiazepines as an AED will generally be assessed on an individual basis. In general, all 
benzodiazepines will be reviewed during pre-lock meeting to ensure the appropriate 
classification as AEDs or non-AEDs.
Other medications which pharmacologically can be classified as an AED but which were taken 
for non-epilepsy indications may also be classified as AEDs. The classification of such 
medications will be determined during the database pre-lock meeting and prior unblinding. 
There may be medications recorded on the Prior and Concomitant Medications CRF which are 
taken for seizure rescue. These medications will be classified as AEDs. The identification of 
such medications will be based on a manual evaluation of the indication and other CRF fields.
REDACTED
ndin
ndin
e prio
e prio
thou
thou
COPY
e for 
e for
will be
will b
g
This document 
lass
as
Ot
Ot
cannot
diazep
iazep
zodiaz
odia
sifi
sifi
be
Q
intak
inta
used
EDs. 
Ds. 
OD,
OD,
to
aken
ken
G
support
Conc
Conc
lowing
owin
n m
any 
ed
case r
ase r
marketing
ori
ut resc
ut resc
d as e
as
authorization
e con
e co
to gre
to gre
itizat
tiza
application 
each d
ach 
nv
and
0 t
0 t
respon
espon
any 
to 10
o 10
extensions
hting
ting
tal sco
al sco
or 
g ini
variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 22 of 62
4
STATISTICAL/ANALYTICAL ISSUES
4.1
Adjustments for covariates
The primary analysis will be conducted using adjustment for the stratification variable; the 
LEV-use factor (3 strata):
1. LEV prior and current use (concomitant use of LEV at study entry).
2. LEV Prior Use Only=History of prior LEV use and must have discontinued 4 weeks prior to 
study entry.
3. LEV Naïve=No history of prior LEV use, and no use at study entry.
4.2
Handling of dropouts or missing data
Missing data will not be imputed with the following exceptions:
Seizure diary:
Seizure frequency will be computed over non-missing diary days as described in Section 3.10; 
missing seizure diary days will not be considered in the calculation of seizure frequency.
Generally, compliance with the daily seizure diary is expected to be high in a refractory 
population and, therefore, the impact of missing diary data is expected to be minimal. However, 
the impact of missing diary data cannot be ruled out, and missing data will be assessed as part of 
the database pre-lock meeting to ensure an acceptable level of compliance with the seizure diary 
across the study population.
For subjects who prematurely discontinue, or have missing diary days, the calculation of the
seizure frequency over a specified period will be based on available seizure diary up to the last
diary entry. This effectively imputes the unobserved seizures after discontinuation with the 
seizure frequency observed prior to discontinuation. 
Times and Dates:
Times and partial dates may be imputed for statistical analyses for specific outcomes according 
to the following rules. Imputed times and dates should not be shown in the listing.
Imputation of Start Times and Partial Start Dates:
!
If only the date is specified and it is the date of the first dose, then use the time of the first 
dose, otherwise, use 00:00.
!
If only the month and year are specified and the month and year of first dose is not the same 
as the month and year of the start date, then use the 1st of the month and 00:00.
!
If only the month and year are specified and the month and year of first dose is the same as 
the month and year of the start date, then use the date and time of first dose.
!
If only the year is specified, and the year of first dose is not the same as the year of the start 
date, then use January 1st and 00:00 of the year of the start date.
!
If only the year is specified, and the year of first dose is the same as the year of the start date,
then use the date and time of the first dose.
REDACTED 
e, or h
, or h
iod
iod wi
wi
s the u
s the 
i
COPY
da
d
ut, and
ut, and
table
table
This document
thth
!
cannot
he m
e m
If onl
If onl
the
h
be
the m
the 
mo
mo
used
e 
wise, 
wise, 
m
to
is s
is s
support
puted
uted
mes an
es a
any
e imp
e imp
d tit
marketing
unob
unob
iscontin
iscont
authorization
e leve
 leve
have m
have m
ill be 
ll be 
b
application 
on of
n of
to be h
o be
is expe
s exp
missi
miss
l
and
descr
descr
f s
f
any extensions or variations 
or to 
r to 
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 23 of 62
!
If the start date is completely unknown and end date is unknown or not prior to first dose, 
then use the date and time of first dose.
!
If the start date is completely unknown and end date is known to be prior to first dose, then 
set start date equal to end date.
Imputation of End Times and Partial End Dates:
!
If only the date is specified, then use 23:59 as end time.
!
If only the month and year are specified, then use the last day of the month.
!
If only the year is specified, then use December 31 of that year.
!
If the stop date is completely unknown, do not impute the stop date.
4.3
Interim analyses and data monitoring
4.3.1
Safety Review Group
In order to monitor the safety data, a Safety Review Group (SRG) will be established prior to the 
start of the study with the intention of protecting the safety, health, and wellbeing of each 
participating subject. The precise membership, scope, and responsibilities of the SRG are 
described in the SRG Charter. 
The SRG will meet once the first 4 subjects have completed the Transition-to-Outpatient Period 
(Visit 6) or withdrawn from the study before Visit 6. Subsequent meetings will occur when the 
first 10 subjects, the first 16 subjects, and the first 22 subjects have completed Visit 6 or 
withdrawn from the study before Visit 6. Thereafter, SRG meetings will be held on an as 
required/ad hoc basis, in response to emerging data, and at the request of any member of the 
SRG.
The SRG will remain blinded through the first database lock (see Protocol; Section 12.3.3) 
unless emergent safety information requires unblinding of individual drug allocation for optimal 
assessment and response to AEs of concern. At the time of the first database lock, the Study 
Physician(s), clinical pharmacologist, DS representative, biostatistician, and other UCB 
personnel will be unblinded as to all subjects’ treatment allocation at the beginning of the 
Inpatient Period.
4.3.2
Blinded Interim Analysis
An interim analysis will be performed if needed for purposes of planning and designing of future 
studies. If performed, this analysis will be conducted when at least 75% of patients have been 
randomized and completed through the Inpatient Period (completed through Visit 5).
All subjects who have completed through Visit 5 at the time of the data snapshot will be included 
in the interim analysis.
All statistical analyses will be described in detail in a separate interim SAP or appropriate charter 
document.
For the interim analysis, the primary efficacy variable (75%RR) will be analyzed using the 
methods described for the primary efficacy analysis. In addition, seizure-free rate, 50%RR, and 
percent reduction in focal seizure frequency will be analyzed as described for the 
secondary/exploratory analyses.
REDACTED 
Visit
Visi
he first
he first
There
Ther
emergi
mergi
COPY 
compl
comp
it 6.
it 6
This document
in th
n th
A
cannot
ized
zed
subje
subje
e
be
perfo
perf
used 
n
alys
ysisi
to
nde
nde
support 
maco
ac
ded as 
ed a
d
any
s of 
s of
colog
olo
marketing 
gh the f
h the 
on requ
n req
f co
f
authorization 
lete
ete
. Subs
Sub
t 22 su
2 s
eafter
eafter
ng da
ng da
application
h, an
h, an
ponsibi
onsib
ted th
ed t
and 
ill be 
ll be
nd
any extensions or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 24 of 62
The 75%RR, Seizure-free rate, and 50%RR variables may also be analyzed using Bayesian 
logistic regression. If Bayesian analysis is peformed, the percent reduction in focal seizure 
frequency from the Baseline will be estimated using Bayesian analysis of variance (ANOVA) 
and/or ANCOVA. For these analyses, posterior medians, 95% credible intervals for the treatment 
effect, and additional posterior probabilities will be presented. Non informative and informative 
priors will be considered, and sensitivity to different prior settings will be assessed. Other  
efficacy variables may also be analyzed in the Bayesian framework.
The following safety data will also be presented:
!
Treatment emergent AEs
!
AEs leading to drop-out or withdrawal
!
SAEs
!
Laboratory assessments out of normal range
!
BPRS
The study will not be terminated early for either efficacy or futility based on the results of this 
interim analysis and therefore, an alpha penalty may not assessed.  At a maximum, an alpha 
penalty of 0.001 may be assessed  on the primary efficacy variable.  
The study is not expected to be stopped due to safety reasons during this interim analysis, since 
there are ongoing quarterly Safety Review Group meetings already planned for this purpose. 
Therefore, no criteria for evaluation of early stopping due to safety are included. 
An unblinded team will be established at both the Sponsor and CRO and will include the 
following roles (all unblinded): Statistician, Statistical Programmer, and Project Lead. All staff 
involved in the conduct of the study, including staff at UCB, the CRO, participating vendors, and 
the participating sites will remain blinded to individual treatment identity and will not be 
informed of the results of the interim analysis until final unblinding.
4.4
Multicenter studies
The data from different centers will be pooled. 
4.5
Multiple comparisons/multiplicity
No adjustments for multiplicity will be made as the statistical analyses will be exploratory in 
nature.
4.6
Use of an efficacy subset of subjects
All efficacy analyses will be performed for the FAS. The primary analysis will be performed for 
the PPS as well. No further efficacy subsets are planned.
4.7
Active-control studies intended to show equivalence
Not applicable.
4.8
Examination of subgroups
Descriptive analysis may be performed by the 3 LEV-use levels for some variables, including, 
but not limited to the primary efficacy variable, and the seizure-freedom.
REDACTED 
oup 
oup
y stopp
y stopp
at both
at both
stician
stician
inc
inc
COPY 
cac
a
fety
fety rer
y
p me
p m
This document 
e e 
4.7
4.7
cannot 
efficac
fficac
PPS
PPS
be used
for m
for m
to 
tip
m
support 
centers
enter
ple c
ple c
any 
stud
tud
marketing 
n, S
n, 
ncludin
cludin
inded t
nded
rim an
im an
authorization
easo
aso
eeting
eeting
ping d
ping d
h the S
h the S
Sta
Sta
application 
tyty ba
ba
y
sed.  A
ed.  A
variabl
ariab
sons 
ons
and any extensions or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 25 of 62
Descriptive analysis will performed for subjects requiring dose reduction from study medication 
at any point during the study prior to the protocol-defined taper.  The following tables will be 
repeated for these subjects:
!
75%, 50% Responder Rate in Focal Seizure Frequency Summary
!
Incidence of TEAEs - Overview 
!
Incidence of TEAEs
4.9
End of Study Analyses
The database lock and unblinding may occur in a tiered approach, as described in the protocol. 
Details regarding the tiered database lock will be described in the Data Management Plan 
(DMP).  
Data analysis and production of TFLs will occur as follows:
After the final subject has completed through Visit 15 (end of Outpatient Maintenance Period) 
and the corresponding database lock has occurred, all TFLs will be produced and analyses of all 
data at time points through Visit 15 will be considered final.  Note that unblinding of the 
placebo-controlled portion of the study (Visits 3-5) will occur prior to this analysis, as described 
in the protocol and DMP.  TFLs will include all study visits as planned in the SAP.  However, 
only those time points through Visit 15 will be considered final.  TFLs will be annotated with a 
header to display which visits are considered final.
After the final subject has completed through Visit 20 (End of Taper and Safety Follow Up 
Period) and the corresponding database lock has occurred, all TFLs will be produced and 
analyses of all data at time points through Visit 20 will be considered final.  
After the final subject has completed the echocardiogram required at 6 months (±1 month) after 
the last dose, and the corresponding database lock has occurred, the echocardiogram TFLs will 
be produced and considered final.  
5
STUDY POPULATION CHARACTERISTICS
5.1
Subject disposition
The number of subjects screened, enrolled into the study, subjects included in each analysis set, 
and subjects who completed or prematurely discontinued the study, as well as the reason for 
discontinuation, will be presented for the RS by treatment group, and for All Subjects using 
frequency counts and percentages. The discontinuations due to AEs will be summarized in a 
separate table. Screen failure reasons will be summarized. 
In addition, the following listings will be provided by treatment group:
!
Subject disposition (ES)
!
Study discontinuation (RS)
!
Subject visit dates (RS)
!
Subject analysis sets (ES)
REDACTED 
gh Vis
gh Vis
ock ha
ock h
ugh V
ugh V
d th
d th
COPY 
viv
sidere
sidere
al.
al.
This document
!
S
!
cannot
tab
tab
ddition
dition
S
be
coun
oun
ble
ble
used 
co
co
n, wil
, wil
unts
nts
to
ec
om
omp
support 
disp
is
cts scr
ts scr
any 
PUL
PUL
marketing 
he echo
e echo
databa
datab
authorization 
sit 20 (
t 20 
as occ
as oc
Visit 2
isit 2
application
te tha
tha
prior t
prior 
s as pla
as p
d fina
d fina
and 
nt 
nt
produ
rodu
t
any 
Mai
Mai
extensions
 pro
pro
ent Pla
nt Pla
or 
oto
oto
variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 26 of 62
5.2
Protocol deviations
A listing of all important protocol deviations identified at the database pre-lock meeting will be 
presented for all subjects in the FAS, and will include the deviation type and description. The 
number and percentage of subjects in the FAS with important protocol deviations will be 
summarized by period and overall if appropriate. The denominator for percentages will be the 
number of subjects in the FAS.
6
DEMOGRAPHICS AND OTHER BASELINE 
CHARACTERISTICS
6.1
Demographics
A by-subject listing of Baseline demographic characteristics will be presented by treatment 
group for the ES. This will include the date of birth, age (in years), sex, race, ethnicity, height (in 
cm), weight (in kg), and body mass index (BMI, in kg/m²). 
All Baseline demographic characteristics obtained at the Screening Visit will be summarized for 
the FAS by treatment group, and for All Subjects (apart from the date of birth). 
BMI (in kg/m²) is calculated based on the following formula:
BMI &kg
m'( = Weight (kg) 
Height (m)'
Body mass index will be reported to 1 decimal place.
The following age groups will be summarized in the same table:
!
12 - <18 years
!
≤18 years
!
18 - <65 years
!
19 - <65 years
!
65 - <85 years
!
≥65 years
!
≥85 years
Childbearing potential will be listed for the RS.
Lifestyle information (alcohol, tobacco, caffeinated beverage, and illicit drug use) will be listed 
and summarized by treatment group and for the RS.
6.2
Medical history and concomitant diseases
Medical history and ongoing medical conditions will be listed and summarized for the SS by 
treatment group and MedDRA® system organ class (SOC) and preferred term (PT). The start 
date (month and year only) and end date (or ongoing if applicable) will also be included in the 
listing. Epilepsy history will not be included in these tables.
Procedure history will be listed separately by the procedure reported term for the SS by treatment 
group. Concomitant medical procedures carried out during the study will be listed for the SS.  
For this listing, concomitant is defined in Section 6.3 as for concomitant medications.
6.2.1
History of epilepsy
The history of epilepsy will be listed for all subjects in the ES.
REDACTED
al pla
al pl
rized i
zed i
!
≤
!
COPY
ight
igh
Heigh
Heig
PY
ac
This document 
Proc
Proc
gr
gr
cannot 
t gr
g
month
month
ng. 
ng. E
be 
tory
or
grou
grou
used
Med
ed
ry
ry a
to 
tr
dic
ic
support 
be 
be
alcohol
lcoho
eatm
eatm
any 
liste
lis
marketing 
≤1
19 
19 
!
authorization 
ht (
ce.e.
in the 
in the
18 y
8 y
application 
at
kg
kg) ) 
(m)
(m)
pp
and
isit w
sit w
te of
e of
any 
wil
wi
extensions 
by trea
trea
ethni
ethni
or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 27 of 62
Etiology of epilepsy
The number and percentage of subjects with each type of etiology as specified in the CRF 
(genetic, congenital, etc) will be summarized for the FAS and listed for the RS.
Epileptic seizure profile
The number and percentage of subjects experiencing each seizure type during the last 4 weeks 
prior to the screening visit will be summarized for the FAS based on the ILAE Seizure 
Classification History CRF.
The overall number and percentage of subjects with a history of type I, II, III seizures will be 
summarized. In addition, the overall number and percentage of subjects with a history of type IA, 
IB, IC will be summarized.
Focus localization
The number and percentage of subjects with each category of focus localization (unknown, 
frontal, temporal, parietal, occipital) will be summarized for the FAS. Subjects may be counted 
in more than 1 category of focal localization.
History of epileptic seizures
History of epileptic seizures, including the number and percentage of subjects with a history of 
status epilepticus, the number and percentage of subjects with a history of withdrawal seizures, 
and quantitative summaries of epilepsy duration, age at onset of first seizure, and percent of life 
with epilepsy, will be summarized for the FAS and listed for the RS.
Historical seizure count
The Historical Seizure Count CRF records the number of seizures experienced by the subject 
during the 4 weeks prior to study entry. These data will only be provided in subject data listing 
for the RS and will not be summarized.
Seizure types experienced during baseline
The number and percentage of subjects experiencing each seizure type during the Baseline 
Period will be summarized for the FAS based on data from the subjects’ seizure diaries. The 
following seizure types will be summarized: I, IA, IB, IC, II, IIA through IIF, III, and clusters.
Subjects will be counted for all higher levels of seizure type categories corresponding to the 
seizure types or seizure sub-types reported on the CRF. For example, subjects with an IA1 
seizure will be counted for types I and IA. 
Baseline focal seizure frequency
Baseline weekly adjusted weight frequency will be summarized with descriptive statistics for the 
FAS. Additionally, baseline weekly adjusted frequency will be summarized for the FAS for 
seizure types IA, IB, and IC.
6.3
Prior and concomitant medications
The medications will be classified as AEDs or non-AEDs based on coded terms. The list of 
coded terms considered AEDs will be finalized prior to database lock and unblinding.  Prior and 
concomitant non-AED medications will be listed for the SS by treatment group and by WHODD
REDACTED
n, ,
AS
AS an
an
ecord
ecord
ry
ry
COPY
nd p
nd 
ubject
ubject
age 
age 
This document
FAS
FAS
sei
sei
cannot
e foc
foc
no
eline
eline
be 
be
be
used 
cou
ou
or seiz
r seiz
e co
e co
to
unte
unte
support
e of 
of
zed for 
ed fo
es will
s will
any
g b
g b
y
f sub
f su
marketing
ds the
th
y. Thes
Thes
zed.
ed.
base
bas
authorization
ts w
e at on
at on
d liste
d liste
he n
he
application 
rcentag
centa
with 
with 
and
Sub
Sub
any
izatio
izatio
bjec
bje
extensions
ry of 
of
y
or
ill b
ill b
variations 
b
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 28 of 62
Anatomical Main Group [Level 1], Therapeutic Subgroup [Level 2], PT and reported term. This 
listing will be repeated for all AED medications.
Any non-coded terms will report Level 1 and Level 2 as UNCODED in the listing.
Prior medications include any medications that started prior to the date of first dose of study 
drug.   Concomitant medications are medications taken at least one day in common with the 
study medication dosing period. Medications may be both prior and concomitant. Past 
medications are a subset of prior medications, and include prior medications with a stop date 
before the date of first study medication administration.  
6.3.1
Non- Antiepileptic drugs
The number and percentage of subjects taking prior non-AED medications will be summarized 
for the SS by WHODD Anatomical Main Group [Level 1], Therapeutic Subgroup [Level 2], and 
PT.
The number and percentage of subjects taking concomitant non-AED medications will be 
summarized separately for the SS by WHODD Anatomical Main Group [Level 1], Therapeutic 
Subgroup [Level 2], and PT, and by treatment group for the whole study period. In the same 
table, the number and percentage of subjects taking concomitant non-AED medications will be 
summarized by the following treatment periods as defined in Section 3.2.1.2: Placebo Only, 
UCB0942 Titration, UCB0942 Maintenance, UCB0942 Taper, and UCB0942 Overall.   
6.3.2
Antiepileptic drugs
Previous AED Medications
The number and percentage of subjects taking prior or concomitant AED medications will be 
summarized for the SS by PT.
Number of previous AEDs
The number of AEDs taken prior to study entry will be summarized for the SS based on the 
following categorization: <4, 4 or 5, 6 or 7, 8-10,>10 AEDs. 
Previous AEDs by reason for AED discontinuation
The number and percentage of subjects by reason for discontinuation of previous AEDs will be 
summarized for the SS. Percentages for each reason for discontinuation will be relative to the 
number of subjects taking each AED.
Since reason for discontinuation is collected as free text field, a medical review will be 
conducted prior to database lock and unblinding to combine like terms.  The combined terms 
only will be presented in the summary table.  Both the reported and combined terms will be 
listed.
Use of vagal nerve stimulation at study entry
The number and percentage of subjects with active vagal nerve stimulation (VNS), and the 
percentage of subjects with no VNS implant or a non-active VNS implant will be summarized 
for the SS.
All other VNS data (eg, use of magnet, VNS settings) will be listed but will not be summarized.
REDACTED 
ects ta
ects ta
COPY
n
define
efin
CB094
B094
This document
listed
sted
U
cannot 
aso
so
ucted p
cted 
y will
will
y
d
be 
on f
on f
used
the 
he 
bjects
jects
to
ercen
rce
S
support 
4, 
4, 4
on for
n fo
up
nta
nt
any
ior to
ior t
4 or
4 o
marketing
aking
king
authorization
42 Ta
42 T
ng p
ng
application
Grou
Gro
hole st
ole s
itant n
tant n
d in
d in Se
S
ap
and
D med
med
ou
ou
any 
g
extensions 
l be su
be s
group
rou
or variations 
te
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 29 of 62
Number of AEDs taken at study entry
The number and percentage of subjects taking 1, 2, and 3, 4, 5, >5 AEDs at the time of study 
entry will be summarized for the SS. The same summary will be reported separately by VNS use 
at study entry (no VNS or VNS not active versus currently active VNS).
Levetiracetam use at study entry
The number and percentage of subjects in each LEV-use category at study entry will be 
summarized for the SS:
1. LEV prior and current use (concomitant use of LEV at study entry).
2. LEV Prior Use Only=History of prior LEV use and must have discontinued 4 weeks prior to 
study entry.
3. LEV Naïve=No history of prior LEV use, and no use at study entry.
Concomitant AED Medications
The number and percentage of subjects taking concomitant AED medications will be 
summarized separately for the SS by PT, and by treatment group for the whole study period. In 
the same table, the number and percentage of subjects taking concomitant non-AED medications 
will be summarized by the following treatment periods as defined in Section 3.2.1.2: Placebo 
Only, UCB0942 Titration, UCB0942, UCB0942 Taper, and UCB0942 Overall.
Changes to Concomitant AEDs
All concomitant AEDs will be listed for subjects requiring a dose change to any concomitant 
AED during the study.  A change is defined as any of the following occurring after 
randomization through the end of the Outpatient Maintenance period:
!
Initiation of a new AED
!
Termination of an existing AED
!
Dose change for an existing AED (increase or decrease)
!
Change in frequency of an existing AED
7
MEASUREMENTS OF TREATMENT COMPLIANCE
Study drug compliance will be assessed from the day of first IMP administration to the day of 
last dose during the taper period, or up to the end of the outpatient period for the subjects who 
will continue to the open label extension (OLE). Compliance will be calculated as 100 times the 
dose (tablets) taken divided by the planned dose (tablets) that should have been taken. If a 
subject withdraws from the study during a treatment period, their compliance will be calculated 
up to the time that they dropped out. After a subject has dropped out, the compliance should not 
be set to zero. Compliance will be listed and summarized for the SS.
Compliance will be included in the study drug administration listing. In addition, the mean 
compliance will be listed for each subject, for each of the following treatment periods: 1st
Inpatient Week, 2nd Inpatient Week, 3rd Inpatient Week, Outpatient Maintenance Period, 
Tapering Period, SFU Period, UCB0942 Overall. 
REDACTED 
bjects 
bjects 
ned as
ned a
Outpa
Outp
COPY
s
aper, a
per, 
This document
p t
be se
be se
C
canno
blets
lets
ect wit
ct wit
to th
o th
be
ue to
e t
s)s)
used
plian
ian
ng the
g the
o t
to 
ance
ance
support
ncy
cy of
 of
y
SUR
SUR
any
sting
sting
marketing 
at
 AED
AED
A
authorization 
s requi
requi
s any
 any
tient
ient
application
for t
or t
oncom
oncom
efined 
fined
and UC
nd U
and
dicati
dicat
the
th
any extensions 
weeks 
weeks 
or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 30 of 62
Compliance will be summarized by treatment group for the following treatment periods: 1st
Inpatient Week, 2nd Inpatient Week, 3rd Inpatient Week, Outpatient Maintenance Period, 
Tapering Period, SFU Period, and UCB0942 Overall. The compliance for the subjects 
randomized to placebo will be summarized separately for the Placebo and UCB0942 compliance. 
Additionally, the number and percentage of subjects with compliance levels <80%, 80% to 
120%, and >120% will be summarized by treatment group for the overall UCB0942 treatment 
period.
8
EFFICACY ANALYSES
All seizure diary data will be listed for the RS. The summaries will include the statistics for 
continuous or categorical variables as specified in Section 3.1.
For the efficacy analyses the term “by treatment group” corresponds to the UCB0942/Placebo 
group, the UCB0942/UCB0942 group, and the All UCB0942 Subjects group. 
8.1
Statistical analysis of the primary efficacy variable
The primary outcome measure is the 75%RR which is defined as the proportion of subjects with 
a 75% or greater reduction in focal seizure frequency during the 2-week Inpatient Period (as 
defined in Section 3.2.1.2) compared to the Baseline Period. 
The 75%RR will be analyzed using a logistic regression with effects for treatment, for the 3 
levels of LEV use, and the log-transformed Baseline seizure frequency as a continuous covariate. 
The frequency and percentage of 75%RR will be reported with the estimated odds-ratios and 
two-sided Wald 95% CI for UCB0942 versus placebo. 
The primary analysis will be performed for the FAS but also for the PPS.
8.2
Statistical analysis of the secondary efficacy variables
All analyses of the secondary efficacy analyses will be done for the FAS.
Median percent reduction in weekly focal seizure frequency
The percent reduction in focal seizure (Type IA1+IB+IC) frequency from Baseline Period to the 
2-week Inpatient Period will be compared between the UCB0942 and placebo arms using a 
Wilcoxon-Mann-Whitney test. The Hodges-Lehmann non-parametric estimator will be used to 
estimate the median percent reduction in seizures between groups and its corresponding 95% CI 
will be provided. 
Percent reduction in focal seizure frequency from the Baseline Period to the Outpatient 
Maintenance Period and On-UCB0942 Overall will be assessed using summary tables by 
treatment group. 
The percent reduction in focal seizure frequency from the Baseline Period to the 2-week 
Inpatient Period, the Outpatient Maintenance Period and the On-UCB0942 Overall period will be 
presented graphically with box-plots.
75%RR on percent reduction in weekly focal seizure frequency
This score will be calculated during the last 4 weeks of the Outpatient Maintenance Period, and 
On-UCB0942 Overall, and will be compared to the Baseline Period by treatment group using 
summary statistics. 
REDACTED
ll be r
l be 
rsus pl
sus pl
ed 
ed for 
for
sis
sis
COPY
sion 
sion
line se
ine s
This documen
The p
he p
Inp
Inp
cannot
anc
anc
ment 
ment 
pe
pe
be
ducti
cti
e
used 
an
an
ed.d.
ioi
to
n pe
n pe
support 
ocal
cal s
d will b
will 
tney
tney t
y
any
ekl
ekly
ny
se
marketing 
s of th
of th
acy
cy ana
an
y
ly f
authorization
eizu
zu
eporte
eport
lacebo
acebo
the FA
he F
application
2-we
-we
with eff
with e
ure f
ure
and 
e prop
prop
any 
riabl
riab
extensions 
cs
B0942
B0942
p. 
or
for
for
variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 31 of 62
Seizure free rate
The seizure free rate for the 2-week Inpatient Period will be analyzed using a logistic regression 
with effects for treatment and log-transformed Baseline seizure frequency as a continuous 
covariate, if applicable. Odds-ratio of UCB0942 versus placebo groups and its 95% CIs will be 
estimated. 
The seizure freedom will also be evaluated by treatment group for the last 4 weeks of the 
Outpatient Period and for the On-UCB0942 Overall period using summary statistics. 
Percentage of seizure free days
The percentage of seizure free days will be assessed during the 2-week Inpatient and the 
Outpatient Maintenance periods using summary statistics by treatment group. 95% Hodges-
Lehmann CIs for the median will be estimated.
8.3
Analysis of exploratory efficacy variables
All analyses of the exploratory efficacy analyses will be done for the FAS.
50%RR on percent reduction in weekly focal seizure frequency 
The 50%RR on percent reduction in weekly focal seizure frequency for the 2-week Inpatient 
Period (see Section 2.2.1.3) will be analyzed only for the FAS using a logistic regression with 
effects for treatment, for the 3 levels of LEV-use, and the log-transformed Baseline seizure 
frequency as a continuous covariate. The 50%RR at the Outpatient Maintenance Period will be 
summarized by treatment group.
Median seizure frequency by focal seizure type
An analysis of covariance (ANCOVA) will be performed on the log-transformed weekly seizure 
frequency during the 2-week Inpatient Period. Specifically, ln(1+weekly seizure frequency 
during the 2-week Inpatient Period) will be modeled with treatment group as factor and 
ln(1+weekly seizure frequency during the Baseline Period) as covariate. Contrasts will be 
estimated to compare UCB0942 to placebo results observed. Transformation of efficacy data 
could be envisaged given the data distribution. This analysis will be repeated for all the subtypes 
of focal seizures (Type IA1, IB, IC, and disabling [IB+ IC]).
The seizure frequency for the focal seizures (Type IA1+ IB +IC) and focal seizure subtypes 
(Type IA1, IB, IC, and disabling [IB+ IC]) will also be summarized by treatment group and 
UCB0942 Overall for the following study periods: Baseline, 1st Inpatient Week, 2nd Inpatient 
Week, 3rd Inpatient Week, 2-week Inpatient, Outpatient Maintenance Period, and On-UCB0942 
Overall.
The mean 28-day adjusted seizure frequency by focal seizure subtype (Type IA1, IB, IC, and 
disabling [IB+ IC]) will be displayed graphically as stacked bar charts for the following study 
periods:  Baseline, 1st Inpatient Week, 2nd Inpatient Week, 3rd Inpatient Week, 2-week Inpatient,
Outpatient Maintenance Period, and On-UCB0942 Overall.  This will also be presented by 
subject.
The mean percent reduction in seizure frequency from baseline to each of the following study 
periods will be presented as a bar chart:  1st Inpatient Week, 2nd Inpatient Week, 3rd Inpatient 
REDACTED 
RR
re ty
typ
y
DA
A) wi
A) wi
ntnt
COPY
r the
r th
and th
and 
R at t
R at t
This document
disab
isab
peri
per
O
cannot 
mean
mean
bli
bl
be
npat
pa
used
C, a
, a
erall
rall f
tie
ti
to 
ncy
cy
and
and
suppor
he d
he d
IA1, IB
I
for 
for
y
any
42 to 
42 to
data
dat
marketing
will be
ll b
Period
Period
) will b
will b
uring t
ring
authorization 
he 
the O
he O
pe
uth
be
be
application 
quency
quenc
FAS us
AS u
e log
log
and
FAS
AS
any 
S
extensions 
d the
the
% Ho
% Ho
or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 32 of 62
Week, 2-week Inpatient, Outpatient Maintenance Period, and On-UCB0942 Overall.    This will 
also be presented by subject
Change in seizure severity
Seizure severity is calculated as the percentage of seizures that are type IC out of the total 
number of focal seizures during a given period. Change from Baseline in seizure severity is the 
seizure severity in the period of interest minus the seizure severity during the 2-week prospective 
baseline period. Seizure severity and its change from baseline will be listed and summarized by 
treatment group for the 2-week Inpatient and Outpatient Maintenance Periods.  For subjects not 
experiencing IC seizures during the observed period, severity is considered to be 0%.
Seizure severity questionnaire
Changes in SSQ will be summarized by treatment group for the Inpatient Period (V3, 4, 5), the 
Outpatient Period (V10, 15) and for the Tapering and SFU periods (V15, 17, 18, 20) using 
summary statistics.  Mean change from baseline in SSQ total and subscores will be presented 
graphically.
The SSQ total score (TS) is derived using the algorithm in Appendix x.
Quality of life
The observed values, and changes from Baseline for the QOLIE-31-P total score and the 
subscales will be listed for all subjects for visits 3, 10, 12, 15, 17. The prioritization item will be 
listed separately.
The QOLIE-31-P change from Baseline will be summarized by treatment group using
descriptive statistics for visits 10, 12, 15, 17.
The QOLIE-31-P mean change from Baseline for the total score and the sub-scores will be 
presented in line plots with 95% Hodges-Lehmann CIs for the whole study period.
Exploratory analyses for efficacy
Median 28-day seizure frequency by focal seizure type: An analysis of covariance (ANCOVA) 
will be performed on the log-transformed weekly seizure frequency during the 2-week Inpatient 
Period. Specifically, ln(1+weekly seizure frequency during the 2-week Inpatient Period) will be 
modeled with treatment group as factor and ln(1+weekly seizure frequency during the Baseline 
Period) as covariate. Contrasts will be estimated to compare UCB0942 to placebo results 
observed. Transformation of efficacy data could be envisaged given the data distribution. This 
analysis will be repeated for all the subtypes of focal seizures (Type IA1, IB, IC, and disabling 
[IB+ IC]).
The seizure frequency for the focal seizures (Type IA1+ IB +IC) and focal seizure subtypes 
(Type IA1, IB, IC, and disabling [IB+ IC]) will also be summarized by treatment group and 
UCB0942 Overall for the following study periods: Baseline, 1st Inpatient Week, 2nd Inpatient 
Week, 3rd Inpatient Week, 2-week Inpatient, Outpatient Maintenance Period, and On-UCB0942 
Overall.
Exploratory analysis will be performed on the seizure count and SSQ data collected during the 
tapering and SFU periods. The focal seizure frequency will be summarized by treatment group
for the tapering and SFU periods.
REDACTED 
will be
ill be
5,5, 17
17
m Ba
m Ba
COPY
r the 
r the
3, 10, 
3, 10, 
This document
Ty
Typ
y
UCB
UC
W
cannot 
]).).
seizu
seizu
pe
pe
be
ill be
ill b
used
iate.
te
nsform
sform
e r
e r
to 
men
e C
e C
support
log
og-tra
tr
n(1+we
1+w
nt gr
nt g
any 
ncy
ncy b
y
marketing
aseline
aselin
dges
ges-Le
L
authorization
 12, 
 12, 
e summ
sum
.
application 
ndix x
dix 
QOLIE
QOLI
15
1
and 
x
any
,
res wi
res w
extensions 
od (V
d (V
18, 
18, 
or variations 
ve
by
by
ts no
s no
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 33 of 62
The relationship between QOLIE-31-P parameters and efficacy parameters will be evaluated
graphically. Plots may include, but are not limited to, scatterplots of the QOLIE-31-P subscales 
and total score versus the focal seizure reduction at the end of the Outpatient Maintenance 
Period. This plot will be repeated for the 75%RR.
All video data recorded in the CRF will be listed.
9
PHARMACOKINETICS 
All PK analyses will be performed for the PK-PPS.
9.1
Non compartmental PK analysis
Plasma concentrations of UCB0942, 
 will be
determined from blood samples obtained in the study, during the Titration and Maintenance 
Periods in order to investigate the population PK of UCB0942 and its major metabolites.
Individual concentrations of UCB0942,
 will be listed 
by treatment group for the FAS and will include the actual and nominal sampling times and the 
deviation between them. All deviations will be calculated relative to the IMP administration.
Individual concentrations will be summarized by treatment group, and sampling times for the 
PK-PPS using n, mean, median, SD, minimum, maximum, geometric mean, and geoCV and 95%
CI (assuming log-normally distributed data). This table will be repeated for UCB0942,
.
The following plots will be produced for UCB0942,
for the PK-PPS:
!
All individual concentration time profiles will be displayed graphically on a linear and semi-
logarithmic scale.
!
Spaghetti plots with the individual plasma concentrations over time profiles for each
treatment group will be displayed for all subjects (linear and semi-logarithmic scale).
!
Geometric mean profiles (with and without corresponding lower and upper limit of the 95%
CI) for the treatment groups will be displayed on the same plot.
The figures will include the LLOQ on the semi-logarithmic plots only.
The following PK parameters will be calculated for UCB0942 and its metabolites:
!
AUCτ:
area under the plasma concentration-time curve over a dosing interval, as
determined using the linear trapezoidal rule.
!
Cmax:
maximum observed plasma concentration.
!
tmax:
time of Cmax.
!
t½:
apparent terminal elimination half-life, reported hours, as determined via simple 
linear regression (slope = -λz) of natural log (ln) concentration vs time for data points in the 
terminal phase of the concentration-time curve. t½ is calculated as ln(2)/λz.
!
Ctrough:
measured concentration at the end of a dosing interval at steady state.
REDACTED COPY 
mu
mu
table w
table w
CB094
CB094
e profi
e prof
This document cannot be used to support any marketing authorization application and a
nal sam
al sam
to the
o the
oup, an
up, a
geome
geom
will be
ill be
42,
42,
files wi
les w
dual pla
ual p
play
ayed f
ed
es (with
(wit
group
grou
ude the
de th
K para
par
area
are
mined 
mined
Cmax
max:
tm
!
y extensions or variations thereof. 
ill be
ll be
Mainte
Maint
metab
metab
d any 
zat


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 34 of 62
The PK parameters will be calculated via NCA methods using Phoenix WinNonlin (version 6.2 
or higher) using the actual sampling times by PRA with UCB’s supervision. Actual sampling 
times relative to dosing rather than nominal times will be used in the calculation of all derived 
PK parameters.
The PK parameters of UCB0942 and its metabolites will be listed and summarized using the 
following descriptive statistics: n, geometric mean, lower and upper 95% CI, geometric CV, 
arithmetic mean, SD, median, and minimum and maximum values. 
Graphical outputs over time will be produced on the trough plasma drug concentrations.
9.2
Population pharmacokinetics
If appropriate, a population PK analysis of UCB0942 and identified active metabolites, will be 
performed using non-linear mixed effects modeling within the population software (NONMEM) 
aimed at identifying relevant covariates (demographic variables, other AEDs). The population 
PK analysis will be performed by UCB and will be described in a separate data analysis plan 
(DAP), and it will be reported in a separate report.
9.3
Pharmacokinetic/pharmacodynamic analysis 
Exploratory population PK-PD analysis may be performed if needed to characterize the 
relationship between exposure to UCB0942 and the clinical and/or safety clinical outcome. A 
separate DAP will describe the analysis, which will be reported in a separate report.
10
SAFETY ANALYSES
10.1
Extent of exposure
All study drug administration information will be listed by treatment group. 
The duration of study drug will be calculated as the date of last dose of study drug minus the date 
of first dose of study drug plus 1 day. The duration will be listed for each subject for the 
following treatment periods: 1st Inpatient Week, 2nd Inpatient Week, 3rd Inpatient Week, 
Outpatient Maintenance Period, Tapering Period, SFU Period, UCB0942 Overall.
The duration of study drug exposure will be calculated as the date of last dose of study drug 
during the Period of interest minus the date of first dose of study drug plus 1 day. 
The duration of study drug exposure (in days) will be summarized by treatment group. The 
exposure for the subjects randomized to placebo will be summarized separately for the Placebo 
and UCB0942 exposure. The number and percentage of subjects with the following categories of 
durations of study drug exposure will also be summarized: ≤1 week, >1 to ≤2 weeks, >2 to ≤4 
weeks; 4 to ≤6 weeks; >6 to ≤8 weeks; >8 to ≤9 weeks; >9 to ≤11 weeks; >11 weeks.
10.2
Adverse events
Adverse events will be recorded from the time informed consent is granted until study 
completion or study termination (end of the SFU period). All AEs will be coded using the latest 
available version of MedDRA and will be categorized by intensity (mild/moderate/severe). 
Listings will be provided for all AEs, SAEs, AEs leading to tapering, AEs leading to withdrawal, 
and AEs leading to death by treatment group for the SS.
REDACTED 
mation 
mation
COPY
clini
clin
ill be r
ill be
This document 
0.2
0.
Ad
Ad
cannot 
s of
o
s; 4 to
 4 to
2
be 
42 
42 
of stu
of stu
used 
u
he subj
e sub
2 ex
ex
to
dy d
y 
support 
ug exp
g ex
nterest 
terest
any 
np
d, Tap
d, Ta
marketing
n wi
wi
lculated
lculate
ay. The
ay. Th
patie
pat
authorization
rep
rep
will b
ill b
application 
naly
nalys
f neede
f need
al and/
and
porte
port
and 
s
any 
s)s
te d
e datat
extensions 
bolites
olites
tware 
ware 
).). Th
T
or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 35 of 62
A treatment-emergent adverse event (TEAE) is defined as any event not present prior to the 
initiation of the first dose of study treatment or any unresolved event already present before 
initiation of the first dose that worsens in intensity following exposure to the treatment.
The number and percentage of subjects who experience TEAEs will be summarized by SOC and 
PT, and by treatment group. In the same table, the number and percentage of subjects will be 
summarized by the following treatment periods as defined in Section 3.2.1.2: Placebo Only, 
UCB0942 Titration, UCB0942 Maintenance, UCB0942 Taper, and On-UCB0942 Overall.
The following tabular summaries will be presented for the SS:
!
Incidence of AEs - Overview 
!
Incidence of TEAEs 
!
Incidence of Serious TEAEs 
!
Incidence of TEAEs by Relationship
!
Incidence of SAEs by Relationship
!
Incidence of Non-Serious TEAEs by Relationship
!
Incidence of Fatal TEAEs by Relationship
!
Incidence of TEAEs by Maximum Relationship 
!
Incidence of TEAEs by Maximum Intensity
!
Incidence of TEAEs leading to Tapering
!
Incidence of TEAEs leading to Withdrawal 
!
Incidence of Non-Serious TEAEs above the Threshold of 5% of Subjects
!
Incidence of Non-Serious TEAEs above the Threshold of 5% of Subjects by Relationship
Where dates are missing or partially missing, AEs will be assumed to be treatment-emergent, 
unless there is clear evidence (through comparison of partial dates, see Section 4.2) to suggest 
that the AE started prior to the first dose of study treatment.
Summary tables will contain counts of subjects, percentages of subjects in parentheses and the 
number of events where applicable. A subject who has multiple events in the same SOC and PT 
will be counted only once in the subject counts but all events will be included.
In summaries including relationship to study treatment, the following relationships will be 
summarized: ‘Not related’, ‘Related’. Subjects who experience the same event multiple times 
will be included in the most related category. Events with missing relationship will be considered 
as ‘Related’ to the last given study product for summary purposes but recorded as missing in the 
listings.
In summaries including intensity, the following intensity categories will be summarized: ‘Mild’, 
‘Moderate’, ‘Severe’. Subjects who experience the same event multiple times will be included in 
the most severe category. Events with missing intensity will be considered as ‘Severe’ events for 
summary purposes but recorded as missing in the listings.
REDACTED 
ty
ring
ing
Withdr
ithdr
COPY 
ipip
This document
as ‘R
s ‘R
listi
list
cannot
ari
arized
rized
l be in
be in
Re
Re
be
ies i
ies i
used
s wh
wh
ed onl
d on
to
ll co
ll c
whe
whe
support
nce (t
ce (
r to the
to th
conta
on
any 
rtiall
rtially
(thr
th
marketing 
aw
above 
abov
AEs ab
AEs a
authorization 
wal
wal
application and any extensions or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 36 of 62
Adverse event summaries will be ordered in terms of decreasing frequency for SOC, and PT 
within SOC, in the UCB0942 overall column.
10.3
Clinical laboratory evaluations
All summaries of laboratory parameters will only summarize parameters planned based on the 
protocol; however, both planned and unplanned laboratory parameters will be provided in 
subject data listings.
Observed laboratory data (chemistry, hematology, urinalysis measurements as listed in Table 8‒
1), and changes from Baseline for numeric parameters will be listed and summarized for the SS
by treatment group. The change from the last pre-UCB0942 administration measurement will be 
listed and summarized for the placebo group. Laboratory values will be grouped according to 
the laboratory function panel shown in Table 8‒1 and flagged as high or low based on the
possibly clinically significant treatment emergent (PCST) criteria, if applicable. The number and 
percentage of subjects with a PCST low or high value will be summarized by treatment group. In 
the same table, the number and percentage of subjects will be summarized by the following 
treatment periods as defined in Section 3.2.1.2: Placebo Only, UCB0942 Titration, UCB0942
Maintenance, UCB0942 Taper, and UCB0942 Overall.
Possibly clinically significant treatment emergent criteria are based on FDA Division of 
Neuropharmacologic Drug Products guidelines with some UCB-defined additions (Section 13.2).
For the laboratory parameters that are identified in Table 8‒1, the change in category (normal 
range: low, normal, high) at the end of Maintenance from Baseline will be presented in shift 
tables. 
Additional laboratory tests (including serology –only at Screening-, drugs and alcohol,
pregnancy) performed will be listed, but will not be summarized. 
REDACTED
enan
enan
serolo
serol
, but 
, but 
COPY
h som
som
in n Ta
Ta
This document cannot be used to support any marketing
will 
will 
authorization
ble
ble 8
e from
fro
ogy
gy –
application 
e based
base
e UCB
UCB
and 
ized
zed
0942 
942 
any 
d by
by t
y
d by
d b
extensions
ment
ent
accord
ccord
sed o
ed o
ble. T
le. T
t
or 
thth
t w
variations 
le 8‒
he S
he S
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 37 of 62
Table 8‒1:
Clinical laboratory measurements
Category
Panel
Variable
Serology
HBsAg, HCV Ab, HIV1 Ab, HIV2 Ab
Hematology
Red blood cell
RBC count, hemoglobina, hematocrit, MCH, MCHC, MCV
White blood cell 
WBC counta, basophils, eosinophils, lymphocytes, monocytes, 
neutrophilsa
Platelet
Platelet count
Clinical 
chemistry
Electrolytes
Sodium, chloride, potassium
Minerals
Calcium, magnesium
Metabolic
Glucose
Liver function
ALPa, ALTa, ASTa, total bilirubina, LDH
Kidney function
BUN or urea
Other
Creatininea
Urinalysis
Dipstick
Total protein, pH, glucose, WBC, RBC  
ALP=alkaline phosphatase, ALT=alanine aminotransferase, AST=aspartate aminotransferase, HBsAg=hepatitis B 
surface antigen, HCV-Ab=hepatitis C virus antibody, HIV=human immunodeficiency virus, LDH=lactate 
dehydrogenase; MCH=mean corpuscular hemoglobin; MCHC=mean corpuscular hemoglobin concentration; 
MCV=mean corpuscular volume; RBC=red blood cell; WBC=white blood cell.
aShift tables will be presented for these variables.
10.4
Vital signs, physical findings, and other observations related to 
safety
10.4.1
Vital signs
A by-subject listing of all observed vital measurements (including SBP, DBP, PR, respiratory 
rate, weight, oral body temperature) and changes from Baseline will be listed. This listing will 
include a flag for measurements identified or as being PCST as calculated by the criteria outlined 
in Section 13.2.
Measured values, and changes from Baseline for all vital sign measurements (excluding weight
and temperature) will be summarized by treatment group and timepoint. The change from the 
last pre-UCB0942 administration measurement will be listed and summarized for the placebo 
group. 
The number and percentage of subjects with a PCST value, PCST low values, and PCST high 
value will be summarized for SBP, DBP, PR, and body weight by treatment group. In the same 
table, the number and percentage of subjects will be summarized by the following treatment 
periods as defined in Section 3.2.1.2: Placebo Only, UCB0942 Titration, UCB0942
Maintenance, UCB0942 Taper, and On-UCB0942 Overall. Percentages will be relative to the 
number of subjects with an assessment within each period.
Potentially clinical significant treatment-emergent criteria are based on FDA Division of 
Neuropharmacologic Drug Products guidelines with some UCB-defined additions.
REDACTED
MCH
MCH
ell; WB
ell; WB
ical
ical f
COPY 
uco
uc
PY
AST=a
AST=a
=hum
=hum
HC
HC
This document 
alulu
table
tabl
p
cannot 
numb
numb
ue w
e w
be 
B0
B0
used 
, an
an
re) wi
) wi
094
94
to
nd c
nd
support
pera
era
rement
emen
any 
rved
ved
ratur
atu
marketing 
find
in
v
authorization
as
an im
an im
C=m
=mea
ea
BC=wh
C=wh
ndi
ndi
application 
n
WBC,
WBC
at
pp
spartat
partat
and 
H
d any y extensions 
io
te
or 
o variations 
at
va
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 38 of 62
10.4.2
Electrocardiograms
Observed ECG data (ventricular rate, PR, QT, QTcB [QT corrected for heart rate using Bazett’s 
formula], and QTcF [QT corrected for heart rate using Fridericia’s formula], and QRS) and 
changes from Baseline will be listed and summarized by treatment group and period. The change 
from the last pre-UCB0942 administration measurement will be listed and summarized for the 
placebo group. A separate listing will report the ECG findings.  QTcB and QTcF will be 
calculated for all subjects as below:
-./0 =
12
345 67
⁄
and -./9 =
12
345/67
;
, where QT is the QT interval as reported in the ECG 
transfer and HR is the heart rate as reported in the ECG transfer.
The number and percentage of subjects with no abnormality, an abnormal but not clinically 
significant finding, and a clinically significant finding will be summarized by treatment group.
The number and percentage of subjects will be summarized by the following treatment periods as 
defined in Section 3.2.1.2: Placebo Only, UCB0942 Titration, UCB0942 Maintenance, 
UCB0942 Taper, and On-UCB0942 Overall. Percentages will be relative to the number of 
subjects with an ECG result at each timepoint. Subjects will be counted at most once within each 
time point based on the worst observed outcome across all abnormalities at that timepoint. 
Summaries of shift from Baseline will also be provided based on the categories normal and 
abnormal by treatment group. In the same table, the number and percentage of subjects will be 
summarized by the following treatment periods as defined in Section 3.2.1.2: Placebo Only, 
UCB0942 Titration, UCB0942 Maintenance, UCB0942 Taper, and On-UCB0942 Overall.
10.4.3
Doppler echocardiography
Doppler echocardiography abnormalities at Baseline and subsequent visits will be listed and 
summarized by treatment group and period. All available echocardiography data will be reported 
in the CSR and its addendum.
10.4.4
Physical examination
A listing of abnormal physical examination findings at will be provided; no summaries of 
physical examination findings are planned.
10.4.5
Columbia-Suicide Severity Rating Scale
All C-SSRS data obtained at Screening and subsequent visits will be listed for the FAS.
10.4.6
Neurological examination
A listing of abnormal neurological examination findings at will be provided for the FAS; no 
summaries of neurological examination findings are planned.
10.4.7
Psychiatric and cognition assessment and withdrawal monitoring
Psychiatric and cognitive assessments (BPRS and MMSE throughout the study) as well as the 
changes from Baseline will be listed. The changes from Baseline will be summarized by
treatment group for the FAS. 
Any symptoms of withdrawal reactions will be monitored using the CIWA-B questionnaire. The
CIWA-B scores will listed and summarized by treatment group.
REDACTED
a
, UCB
, UCB
raphy
aphy
ities
ities
pe
pe
COPY 
ed b
ed
e num
e num
as de
s de
This document 
0.4
0.4
Ps
Ps
cannot
g of 
of 
maries
aries
4 7
4 7
be 
f ab
f ab
used
a obt
ob
Ne
Ne
to 
bta
bta
support 
cal
cal
dings a
dings
mbia-
mbia
any 
n
l exa
l ex
marketing 
at B
t B
eriod
riod. A
natio
ati
authorization
mb
efined
fined
B0942
B0942
y
Bas
Bas
application
ounte
unt
ormalit
ormal
sed on 
ed on
ber an
er an
and
ative 
ive 
ted
ted
any 
ng t
g 
Main
Main
t
extensions 
ot clin
t clin
treatm
treatm
trea
tre
or 
G 
G
variations 
G
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 39 of 62
10.4.8
Other safety variables
Treatment-emergent abnormal laboratory value criteria suggestive of internal organ involvement 
or eosinophilia will be listed by the following treatment periods as defined in Section 3.2.1.2: 
Placebo Only, UCB0942 Titration, UCB0942 Maintenance, UCB0942 Taper, and On-UCB0942 
Overall.
11
OTHER ANALYSES
The analyses for blood samples for DNA, mRNA, and lipidomics/proteomics/additional blood 
biomarkers, and other exploratory variables will be described in a separate DAP.
If there is a high number of missing observations (>15%), due to withdrawals or missing 
measurements, further post-hoc analyses may be performed, for example for the QOLIE-31-P, 
and other questionnaires.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions 
ssing
sing
QOLI
QOLI
or variations 
ood 
ood 
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 40 of 62
12
REFERENCES
Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern nonenzyme-inducing 
AEDs for refractory focal epilepsy: systematic review and meta-analysis. Epilepsia. 2012 
Mar;53(3):512-20.
Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in 
newly diagnosed epilepsy. Neurology. 2012 May;78(20):1548-54.
Busto UE, Sykora K, Sellers EM. A clinical scale to assess benzodiazepine withdrawal. J Clin 
Psychopharmacol. 1989 Dec;9(6):412-6
Chung S, Ben-Menachem E, Sperling MR, Rosenfeld W, Fountain NB, Benbadis S, Hebert D, 
Isojärvi J, Doty P. Examining the clinical utility of lacosamide: pooled analyses of three phase 
II/III clinical trials. CNS Drugs. 2010 Dec;24(12):1041-54.
Commission on Classification and Terminology of the International League Against Epilepsy. 
Proposal for revised clinical and electroencephalographic classification of epileptic seizures. 
Epilepsia. 1981:22:489-501.
CPMP/ICH/135/95 Note for guidance on Good Clinical Practice (EMEA) Jul 2002.
Cramer JA, Perrine K, Devinsky O, Bryant-Comstock L, Meador K, Hermann B. Development 
and cross-cultural translations of a 31-item quality of life in epilepsy inventory. Epilepsia. 
1998:39(1):81-8.
Cramer JA, Baker GA, Jacoby A. Development of a new seizure severity questionnaire: Initial 
reliability and validity testing. Epil Res. 2002:48:187-97.
Cramer JA, Van Hammée G, N132 Study Group. Epilepsy Behav. 2003:4(2):118-23.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the 
cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98.
Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshé SL, Wiebe 
S, French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force 
of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069-77.
Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy: response to sequential treatment 
schedules. Eur J Neurol. 2006 Mar;13(3):277-82.
Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962:10:799-
812
Posner K. 2007. State of the Science: Measurement of Suicidal Adverse Events and The 
Columbia Suicide Severity Rating Scale. NCDEU: Boca Raton, FL.
Posner K, Melvin GA, Stanley B, Oquendo MA, Gould M. 2007b. Factors in the assessment of 
suicidality in youth. CNS Spectr; 12:156-162.
Posner K, Oquendo M, Gould M, Stanley B, Davies M. 2007a. Columbia Classification 
Algorithm of Suicide Assessment (C-CASA): Classification of Suicidal Events in the FDA’s 
Pediatric Suicidal Risk Analysis of Antidepressants. Am J Psychiatry; 165:1035-1043.
REDACTED 
ment o
ment o
2002:4
2002:
Study
Study G
y
R
COPY
L
of life
of lif
This document
Posn
Posn
sui
sui
cannot
K. 2
K. 2
umbia
umbia
be used 
orham
rham
to
euro
euro
support
ug
ug
n on Th
on T
MJ. Di
MJ. D
l
any
g AT
g A
g resi
g resi
marketing 
Gr
G
R. “Min
R. “M
linician
nicia
AT
AT
authorization 
of f a ne
a ne
48:18
48:18
roup
roup
application 
e (EM
 (EM
Meador 
eador
in epi
in ep
and 
n of
o
any
ue A
ue A
f ep
f ep
extensions
, Heb
Heb
of thre
of thre
Ag
A
or variations 
Clin
lin
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 41 of 62
Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment 
history. Neurology. 2008 Jan 1;70(1):54-65.
Steinhoff BJ. Efficacy of perampanel: a review of pooled data. Epilepsia. 2014 Jan;55 Suppl 1:9-
12.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 42 of 62
13
APPENDICES 
13.1
Treatment groups in TFL outputs
TFL Group
By Arm
By Period
Placebo/
UCB0942
UCB0942/
UCB0942
All UCB0942 
Subjects
Placebo 
only
UCB0942 
Titration
UCB0942 
Maintenance
UCB0942 
Taper
On-UCB0942 
Overall
Subject 
disposition
X
X
X
Protocol 
Deviations
X
X
X
Demographics
X
X
X
Epilepsy 
history
X
X
X
Prior
Medications
X
X
X
Concomitant
Medications
X
X
X
X
X
X
X
Study 
Medication 
Exposure / 
Compliance
X
X
X
X
X
X
X
PK
X
X
AEs
X
X
X
X
X
X
X
Labs, Vitals, 
ECG, Other 
Safety
X
X
X
PCST 
Incidence
X
X
X
X
X
X
X
Efficacy
X
X
X
AE=adverse event; ECG=electrocardiogram; PCST=potentially clinical significant treatment-emergent; PK=pharmacokinetics.
REDACTED 
X
ED
DA
ED
COPY 
OP
C
This document cannot 
ot
trocard
rocard
be 
e used 
X
d to 
o
t
support 
ort
s
any 
an marketing 
ke
m
authorization 
iza
ho
au
application 
on
ca
ic
a
and 
d any y
a
extensions 
on
CB094
B094
Tape
Tape
xte
e
or 
o variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 43 of 62
13.2
PCST criteria
13.2.1
Hematology 
Parameter
Conventional Units
SI Units
CF
Hematocrit
For 1 m to < 6 m:  # 25%
For 1 m to < 6 m:  # 025%
1
For 6 m to < 2 y:  # 27%
For 6 m to < 2 y:  # 027%
For 2 y to < 4 y:  
# 29%
For 2 y to < 4 y:  
# 029%
For 4 y to < 12 y:  # 32% (F); # 35% (M)
For 4 y to < 12 y:  # 032% (F); # 035% (M)
For ∃12 y:  
# 32% (F); # 37% (M)
For ∃12 y:  
# 032% (F); # 037% (M)
Hemoglobin
For % 6 m:  
# 9.7 g/dL
For % 6 m:  
# 97 g/L
10
For 6 m to < 12 y:  # 10.0 g/dL
For 6 m to < 12 y:  # 100 g/L
For ∃12 y:  
# 9.5 g/dL (F); # 11.5 g/dL (M)
For ∃12 y:  
# 95 g/L (F); # 115 g/L (M)
Platelets
# 75 x 109/L or ∃700 x 109/L
# 75 x 109/L or ∃700 x 109/L
N/A
WBC
For % 17 y:  
< 3.0 x 109/L or > 20 x 109/L; 
For % 17 y:  
< 3.0 x 109/L or > 20 x 109/L; 
N/A
For ∃17 y:  
< 2.8 x 109/L or > 16 x 109/L;
For ∃17 y:  
< 2.8 x 109/L or > 16 x 109/L;
RBC
For % 17 y:  
< 2.5 x 106/mm3
For % 17 y:  
< 2.5 x 1012/L
1
For ∃17 y:  
< 2.0 x 106/mm3 (F); < 2.5 x 106/mm3 (M)
For ∃17 y:  
< 2.0 x 1012/L (F); < 2.5 x 1012/L (M)
Eosinophils
∃10% or ∃0.7 x 109/L
∃0.10 or ∃0.7 x 109/L
0.01 or N/A
Neutrophils
# 15% or # 1.0 x 109/L
# 0.15 or # 1.0 x 109/L
0.01 or N/A
Basophils
∃5% or ∃0.4 x 109/L
∃0.05 or ∃0.4 x 109/L
0.01 or N/A
Monocytes
∃20% or ∃1.5 x 109/L
∃0.20 or ∃1.5 x 109/L
0.01 or N/A
Lymphocytes
For 1 m to < 6 m:  # 22% or ∃80%
For 1 m to < 6 m:  # 0.22 or ∃0.80 
0.01
# 2.1 x 109/L or ∃8.5 x 109/L
# 2.1 x 109/L or ∃8.5 x 109/L
N/A
For 6 m to < 2 y:  # 15% or ∃80% 
For 6 m to < 2 y:  # 0.15 or ∃0.80 
0.01
# 1.5 x 109/L or ∃7.5 x 109/L
# 1.5 x 109/L or ∃7.5 x 109/L
N/A
For 2 y to < 12 y:  # 12% or ∃80% 
For 2 y to < 12 y:  # 0.12 or ∃0.80 
0.01
# 1.0 x 109/L or ∃7.5 x 109/L
# 1.0 x 109/L or ∃7.5 x 109/L
N/A
For 12 y to % 17 y:  # 10% or ∃80% 
For 12 y to % 17 y:  # 0.10 or ∃0.80 
0.01
# 0.5 x 109/L or ∃5.5 x 109/L
# 0.5 x 109/L or ∃5.5 x 109/L
N/A
For ∃17 y:  
# 10% or ∃80% 
For ∃17 y:  
# 0.10 or ∃0.80 
0.01
# 0.5 x 109/L or ∃4.5 x 109/L
# 0.5 x 109/L or ∃4.5 x 109/L
N/A
REDACTED 
D
(M)
(M)
AC
ED
R
COPY
75 x 1
5 x 
Y
For 
For %
OPY
Fo
Fo
This document cannot t be 
1
# 0.5
0.
b
used
or
or
5 x 10
x 109
0% 
0% 
to 
/L
∃80
8
support 
∃7.5 x 
.5 x 
%
L or 
or ∃
any 
10
109/L
/
marketing 
ng
et
ar
L
authorization
17 y
7 y
r ∃17 
17 
For 
For %
at
Fo
Fo
ho
th
au
application 
# 97
9
2 y:  
y: # 1
/L or 
/L or
pli
y:y:
ap
and 
2%
032
32%
7
a
any 
% (F);
(F)
extensions 
on
ns
or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 44 of 62
13.2.2
Blood chemistry
Parameter
Conventional Units
SI Units
CF
AST (SGOT)
> 3 times of  ULN
> 3 times of  ULN
N/A
ALT (SGPT)
> 3 times of  ULN
> 3 times of  ULN
N/A
ALP
For % 17 y:  
> 2 times of  ULN, if normal range
adjusted to the age range; 
For % 17 y:  
> 2 times of  ULN, if normal range
adjusted to the age range; 
N/A
For ∃17 y:  
> 3 times of  ULN
For ∃17 y:> 3 times of  ULN
GGT
> 3 times of  ULN, if baseline value < 3 times of  ULN
> 3 times of  ULN, if baseline value < 3 times of  ULN
N/A
BUN
> 30 mg/dL
> 10.71 mmol/L
0.357
Urea
> 60 mg/dL
> 10.02 mmol/L
0.167
Creatinine
For % 17 y: 
> 1.5 mg/dL; 
For % 17 y:  
> 132.6 umol/L; 
88.4
For ∃17 y:  
> 2.0 mg/dL
For ∃17 y:  
> 176.8 umol/L
Creatinine 
clearance (calc)
For % 12 y:  
% 70 ml/min (Schwartz)(a)
For % 12 y:  
% 70 ml/min (Schwartz)(a)
N/A
For ∃12 y:  
% 70 ml/min (Cockroft)(b)
For ∃12 y:  
% 70 ml/min (Cockroft)(b)
Total bilirubin
> 2.0 mg/dL
> 34.2 umol/L
17.1
Glucose
# 50 mg/dL or ∃180 mg/dL
# 2.775 mmol/L or ∃9.99 mmol/L
0.0555
Total Protein
For ∃1 m to % 6 m:  # 3.6 g/dL or ∃7.8 g/dL
For ∃1 m to % 6 m:  # 36 g/L or ∃78 g/L
10
For ∃6 m to % 17 y:  # 4.7 g/dL or ∃9.5 g/dL
For ∃6 m to % 17 y:  # 47 g/L or ∃95 g/L
For ∃17 y: 
# 4.5 g/dL or ∃9.0 g/dL
For ∃17 y: 
# 45 g/L or ∃90 g/L
Albumin
For % 17 y:  
# 2.4 g/dL or ∃6.5 g/dL
For % 17 y:  
# 24 g/L or ∃65 g/L
10
For ∃17 y: 
# 2.5 g/dL or ∃6.5 g/dL
For ∃17 y: 
# 25 g/L or ∃65 g/L
Globulin
For % 17 y: 
# 1.2 g/dL or ∃5.0 g/dL
For % 17 y:
# 12 g/L or ∃50 g/L
10
For ∃17 y: 
# 1.5 g/dL or ∃5.0 g/dL
For ∃17 y: 
# 15 g/L or ∃50 g/L
Sodium
For % 17 y:  
# 120 mEq/L or ∃155 mEq/L
For % 17 y:  
# 120 mmol/L or ∃155 mmol/L
1
For ∃17 y: 
# 115 mEq/L or ∃155 mEq/L
For ∃17 y: 
# 115 mmol/L or ∃155 mmol/L
Potassium
For % 17 y:  
# 3.0 mEq/L or ∃6.5 mEq/L
For % 17 y:  
# 3.0 mmol/L or ∃6.5 mmol/L
1
For ∃17 y: 
# 3.0 mEq/L or ∃5.8 mEq/L
For ∃17 y: 
# 3.0 mmol/L or ∃5.8 mmol/L
Calcium
For % 17 y:  
# 7 mg/dL or ∃11.5 mg/dL
For % 17 y:  
# 1.75 mmol/L or ∃2.875 mmol/L
0.25
For ∃17 y:  
# 7 mg/dL or ∃15.5 mg/dL
For ∃17 y:  
# 1.75 mmol/L or ∃3.875 mmol/L
Uric Acid
For < 12 y:  
∃8 mg/dL
For < 12 y:  
∃475.84 umol/L
59.48
For ∃12 y:  
∃8 mg/dL (F); ∃9.5 mg/dL (M)
For ∃12 y:  
∃475.84 umol/L (F); ∃565.06 umol/L (M)
Cholesterol
∃300 mg/dL
∃7.77 mmol/L
0.0259
HDL
# 25 mg/dL
# 0.65 mmol/L
0.0259
LDL
∃200 mg/dL
∃5.18 mmol/L
0.0259
Triglycerides
∃300 mg/dL
∃3.42 mmol/L
0.0114
a Schwartz equation (patients <12): Cr Cl ml/min = [Height (cm) * 0.55] / serum creatinine 
b Cockroft equation (patients >12): Male: Cr Cl ml/min = [(140-age) x body weight (kg)] / (72 x serum creatinine); 
Female: Cr Cl ml/min = [(140-age) x body weight (kg)] / (72 x serum creatinine)] x 0.85
CF=correction factor.
REDACTED 
D
TE
DA
R
COPY
.775 m
.775 
Y
For 
or ∃
PY
For
Fo
This document can
-
nnot 
Cr 
Cr
2):): Mal
Mal
age) x
age) 
be
Cl m
Cl
be 
be used to support
m
5.5 mg
5 mg
po
(F); 
F); ∃9
any 
Eq/L
Eq/L
mg/dL
g/dL
ny
/d
marketing 
ting
L
ar
authorization 
m 
m 
∃6 m 
6 m 
For 
For ∃1
For
For
iz
ho
F
ho
ho
ut
application
>
n
% 70
70
n
%
L
ca
mol/L o
mol/L
pl
toto %
ap
and
32.6 u
2.6 u
d
176.8
76.
a
any 
ny
a
extensions 
normal 
normal 
range;
ange;
ns
< 3 tim
tim
exte
e
or 
or variations 
ari
va
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 45 of 62
13.2.3
Urinalysis
Qualitative urine parameters are generally reported by a descriptive score, which differs among laboratories. For data analysis 
purpose, a four-point scale is used. Five-point, six-point, or seven-point scales will be collapsed into a four-point scale first. A value is 
considered possibly clinically significant treatment-emergent abnormal if an upward shift of at least 2 degrees from the baseline 
occurs under investigational treatment. To collapse the results in a five-point scale into a four-point scale, the lowest 2 positive results 
will be combined (see example below). For results reported with a scale of more than five-point, please consult your study physician 
for how to collapse into four-point scale.
Original Five-point Scale
Four-point Scale
Negative/None
Negative/None
Trace/Rare/Mild/A Few
Trace/1+/Rare/Mild/A Few
1+
2+/Mod
2+/Mod
3+/Sev
3+/Sev
REDACTED 
D COPY 
This document cannot be used to support any marketing authorization application and any extensions
ur
degre
degre
scale
scale
pleas
pleas
or
-po
po
variations 
For 
For d
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 46 of 62
13.2.4
Vital signs and body weight
Pulse rate
For 1 m to % 12 m:  <110 bpm and a decrease of > 20 bpm from baseline or >
180 bpm and an increase of > 20 bpm from baseline
For 12 m to % 3 y:  < 90 bpm and a decrease of > 20 bpm from baseline or >
150 bpm and an increase of > 20 bpm from baseline
For 3 y to % 12 y:  < 65 bpm and a decrease of > 20 bpm from baseline or >
130 bpm and an increase of > 20 bpm from baseline
For 12 y to % 17 y:  < 60 bpm and a decrease of > 20 bpm from baseline or >
120 bpm and an increase of > 20 bpm from baseline
For ∃17 y:  < 50 bpm and a decrease of > 30 bpm from baseline or > 120 
bpm and an increase of > 30 bpm from baseline
Systolic 
blood 
pressure
For 1 m to % 12 m:  < 60 mmHg and a decrease of > 20 mmHg from baseline 
or > 110 mmHg and an increase of 
> 30 mmHg from baseline
For 12 m to % 6 y:  < 70 mmHg and a decrease of > 20 mmHg from baseline 
or > 120 mmHg and an increase of 
> 30 mmHg from baseline
For 6 y to % 13 y:  < 70 mmHg and a decrease of > 20 mmHg from baseline 
or > 130 mmHg and an increase of 
> 30 mmHg from baseline
For 13 y and % 17 y:  < 90 mmHg and a decrease of > 20 mmHg from 
baseline or > 140 mmHg and an increase of 
> 30 mmHg from baseline
For ∃17 y:  < 90 mmHg and a decrease of > 30 mmHg from baseline or > 
180 mmHg and an increase of > 40 mmHg from baseline
REDACTED 
ecrease
creas
COPY 
> 20 m
> 20 
OP
This document cannot 
ot be
nd an
nd a
used 
ase
se
0 mm
mm
to
Hg
elin
elin
support 
0 mmH
mmH
g and
and
any 
of f 
marketing 
a decre
dec
authorization
mmH
mmH
 of >
of >
application 
ne or >
e or >
a
and 
e or 
e or >
any y extensions or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 47 of 62
Diastolic 
blood 
pressure
For 1 m to % 12 m:  < 40 mmHg and a decrease of > 15 mmHg from baseline 
or > 60 mmHg and an increase of 
> 20 mmHg from baseline
For 12 m to % 6 y:  < 45 mmHg and a decrease of > 15 mmHg from baseline 
or > 80 mmHg and an increase of 
> 20 mmHg from baseline
For 6 y to % 13 y:  < 50 mmHg and a decrease of > 15 mmHg from baseline 
or > 85 mmHg and an increase of 
> 20 mmHg from baseline
For 13 y to % 17 y:  < 55 mmHg and a decrease of > 20 mmHg from baseline 
or > 90 mmHg and an increase of 
> 30 mmHg from baseline
For ∃17 y:  < 50 mmHg and a decrease of > 20 mmHg from baseline or > 
105 mmHg and an increase of > 30 mmHg from baseline
Weight
For % 17 y:  < 3% or & 97% of the normal body weight growth curve ranges 
for the age at date of weight assessment (a) and gender;
For ∃17 y:  change of ∃7% of baseline weight
(a) Once the subject reaches 17 years of age use the body curve criteria of a 17 year old regardless of their age in the study.
REDACT
body
ody w
y
)
CTED
m base
m bas
and
and
e w
e w
CT
COPY 
mHg f
mHg 
This document cannot be used to support any 
ge e
marketing 
weight
weight
ma
use t
use
author
weigh
weigh
orization
from 
from
eline
eline
gend
gend
ori
application 
om bas
m ba
b
and any y extensions or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 48 of 62
13.3
QOLIE-31-P total and subscale score calculations
The following outlines the calculation of the subscale scores for the QOLIE 31 P. The rescaled responses are provided for each item. 
The subscale scores are calculated by summing the rescaled responses for that subscale and dividing by the number of items with a 
non-missing response. Note that the divisors shown assume that all items for each subscale have a response; the divisor will differ if 
there are missing responses. A subscale score will be calculated only if at least 50% of the items within the subscale are present.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions
he
ponse
ponse
thin th
hin th
or
e nu
nu
variations 
prov
prov
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 49 of 62
Response
Final Score
Scale/Item Numbers
1
2
3
4
5
6
Subtotal
0-100 point scale 
Seizure Worry
30.
0
20
40
60
80
100
_____
31.
0
33.3
66.7
100
––
––
_____
32.
0
50
100
––
––
_____
33.
0
33.3
66.7
100
––
––
_____
34.
100
75
50
25
0
––
_____
TOTAL :  
_____
÷ 5 = _____
Overall Quality of Life
1.
Multiply each response by 10
_____
36.
100
75
50
25
0
––
_____
TOTAL :
_____
÷ 2 = _____
Emotional Well-Being
7.
0
20
40
60
80
100
_____
8.
0
20
40
60
80
100
_____
9.
100
80
60
40
20
0
_____
10.
0
20
40
60
80
100
_____
11.
100
80
60
40
20
0
_____
TOTAL :
_____
÷ 5 = _____
Energy/Fatigue
2.
100
80
60
40
20
0
_____
3.
100
80
60
40
20
0
_____
4.
0
20
40
60
80
100
_____
5.
0
20
40
60
80
100
_____
TOTAL :
_____
÷ 4 = _____ 
Cognitive Functioning
19.
0
20
40
60
80
100
_____
20.
0
33.3
66.7
100
––
––
_____
21.
0
20
40
60
80
100
_____
22.
0
20
40
60
80
100
_____
23.
0
20
40
60
80
100
_____
24.
100
75
50
25
0
––
_____
TOTAL :
_____
÷ 6 = _____
REDACTED 
_
_
0
0
TO
TO
COPY 
_
__
__
This document cannot
20
20
be
20
20
used 
40
40
66.7
66.7
to 
0
support any 
20
2
80
80
marketing 
OTA
TAL :
L :
0
0
authorization 
_
___
__
____
___
__
_
application 
÷ 2 =
2 =
and any extensions or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 50 of 62
Medication Effects
28.
0
33.3
66.7
100
––
––
_____
26.
100
75
50
25
0
––
_____
27.
100
75
50
25
0
––
_____
                                                                                     
TOTAL :
_____
÷ 3 = _____
Daily Activities/Social Functioning
13.
0
20
40
60
80
100
_____
14.
0
25
50
75
100
––
_____
15.
0
25
50
75
100
––
_____
16.
100
75
50
25
0
––
_____
17.
100
75
50
25
0
––
_____
TOTAL :
_____
÷ 5 = _____
Total score is calculated as a weighted sum of the subscale scores based on the weighting shown below. Total score will be missing if 
at least 1 subscale score is missing. Total score will range from 0 to 100 with a higher score reflecting better functioning.
QOLIE-31-P Scale
Final Scale 
Score
Weight
Subtotal
Seizure worry
(a)
____
∋
0.08
=
____
Overall quality of life
(b)
____
∋
0.14
=
____
Emotional well-being
(c)
____
∋
0.15
=
____
Energy/fatigue
(d)
____
∋
0.12
=
____
Cognitive functioning
(e)
____
∋
0.27
=
____
Medication effects
(f)
____
∋
0.03
=
____
Daily activities/Social functioning
(g)
____
∋
0.21
=
____
TOTAL SCORE : Sum subtotals (a) through (g)
REDACTED
to 
to 
TE
DA
COPY 
ased o
ased o
10
10
This document cannot be used 
als (a)
ls (a)
us
to 
(g
support 
_
g)
any 
_
____
___
marketing 
∋
authorization
on th
n th
00 with
0 with
We
We
iza
au
application 
____
____
at
he w
he w
and any extensions or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 51 of 62
13.4
SSQ Scoring Algorithm
Items
Scoring Algorithm
Label
A. Before Seizures
A. Before Seizures
1. Warning 
Score =1a 
Warning score
1a. Helpful Score 
1-7 
B. During Seizures
B. During Seizures
2. Movements 
Score = 2a+2b÷ 2 or 3a 
(mutually exclusive sections) 
Movement during seizures score
2a. Severe Score 
1-7 
2b. Bothersome Score 
1-7 
3. Altered Consciousness 
Score = 2a+2b÷ 2 or 3a 
(mutually exclusive sections) 
Altered consciousness score
3a. Bothersome Score 
1-7 
C. After Seizures 
C. After Seizures
4. Recover After Seizures 
If no, Component C=0; if yes, 
score q. 5, 6, 7 
Recovery duration score
5. Cognitive Effects 
Recovery Cognitive= Total 5a, 
5b, 5c ÷ 3 
Cognitive effects score
5a. Frequency Score 
1-7 
5b. Severe Score 
1-7 
5c. Bothersome Score 
1-7 
6. Emotional Effects 
Recovery Emotional = Total 6a, 
6b, 6c ÷ 3 
Emotional effects score
6a. Frequency Score 
1-7 
6b. Severe Score 
1-7 
6c. Bothersome Score 
1-7 
7. Physical Effects 
Recovery Physical = Total 7a, 
7b, 7c ÷ 3 
Physical effects score
7a. Frequency Score 
1-7 
7b. Severe Score 
1-7 
REDACTED 
D
0; if y
0; if y
TE
ive= 
ive= 
ED
COPY 
A
OPY
CO
This document 
nt cannot 
no
ca
be used 
1
ed
ed
ed
ed
ed
u
to 
-7
7
to support
ery
ery Em
E
y
t
6b
6
t
7
sup
any 
ny
a
marketing
Tota
Tota
ke
ma
authorization 
n
t
at
at
ati
at
es, 
es, 
riz
l
a
application 
tio
red co
ed co
ica
a
and 
ng g 
a
any 
seiz
sei
ny extensions s
en
ex
or 
o variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 52 of 62
7c. Bothersome Score 
1-7 
Recovery Frequency = 5a +6a + 7a ÷ 3 
Recovery Frequency score
Recovery Severity = 5b +6b +7b ÷ 3 
Recovery Severity score
Recovery Bother = 5c +6c +7c ÷ 3 
Recovery Bother score
Recovery Composite 
Recovery Overall = [mean 
5a,b,c] + [mean 6a,b,c] + [mean 
7a,b,c] ÷ 3 
Recovery composite score
D. Severity & Bother
Severity & Bother score = 8+9 ÷ 
2 
Severity & bother score
8. Severity Score 1-7 
Global Severity score = 8 
Global severity score
9. Bothersome Score 1-7 
Global Bother score = 9 
Global bother score
10. Most Bothersome 
Not scored; calculate proportion 
designating each category 
Total SSQ score
Mean of: (Warning score, 
Movement during 
seizures score OR 
Altered consciousness 
score, Recovery 
composite score, Severity 
& bother score)
Total SSQ score
Note: items 2 and 3 are meant to be mutually exclusive. In case both are present, the worst score (ie the lowest score) will be used to 
calculate composite scores.
REDACTED 
R 
R 
iousn
ousn
overy
overy
e sco
e sco
COPY 
OPY
OP
OP
OP
This document cannot be used to support any marketing
ore, Se
ore, S
core)
core)
rk
ive. I
ve. I
authorizat
ess 
ss 
ation
Tot
Tot
at
ap
tal
application 
ritity
other s
other
n 
at
ap
and 
ty s
y s
nd any 
score
scor
y extensions 
on
e
or 
o variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 53 of 62
13.5
SAP Amendment 1
Rationale for the Amendment
The SAP was amended for consistency wit hProtocol Amendment 4 and for clarity.
Modifications and Changes
Change #1
Section 2.2.1.1. Primary Efficacy Variable
The primary outcome measure is the 75% responder rate (75%RR). In the active group this is 
defined as the proportion of subjects with a 75% or greater reduction in the focal seizure 
frequency during the last 2 weeks of the Inpatient Period compared to the 2-week Prospective 
Outpatient Baseline.
Has been changed to 
The primary outcome measure is the 75% responder rate (75%RR). In the active group this is 
defined as the proportion of subjects with a 75% or greater reduction in the focal seizure (IA1, 
IB, IC) frequency during the last 2 weeks of the Inpatient Period compared to the 2-week 
Prospective Outpatient Baseline.
Change #2
Section 2.2.1.3 Exploratory Efficacy Variables, 4th bullet
!
Changes in average seizure severity as calculated by the percentage of seizures that are type 
IC for the 2-week Inpatient and Outpatient Maintenance Periods.
Has changed to
!
Changes in average seizure severity as calculated by the percentage of all seizures that are 
type IC for the 2-week Inpatient and Outpatient Maintenance Periods.
Change #3
Section 2.3 
Study design and conduct, last paragraph
An echocardiogram is planed to be performed 6 months after the last dose. If not all 
echocardiographs are completed by the time of the database lock, the database will be unlocked 
so that the echocardiography data will be included and cleaned. These data will be reported in an 
addendum.
Has changed to
An echocardiogram is planed to be performed 6 months after the last dose. If not all 
echocardiographs are completed by the time of the initial database locks, the database will be
unlocked so that the echocardiography data will be included and cleaned. These data will be 
reported in an addendum.
Change #4
Section 3.1
General presentation of summaries and analyses
REDACTED 
iables
iables
y as ca
as ca
y
Outpa
Outpa
COPY 
This document
An e
An e
ech
ech
cannot 
m.
m.
chan
chan
be
echo
ch
used 
am
phs ar
hs ar
hoca
oca
to
m is 
m is 
support 
design
design
any
atien
atien
marketing
atien
tien
verity
verit
t
authorization 
s, 4
, 4th
th b
alcula
alcula
ntnt
application 
). In
. In
uction 
uction
eriod c
riod c
and 
In t
n t
any extensions 
roup t
oup t
l seizu
seiz
week P
week P
or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 54 of 62
A glossary of common abbreviations will be provided and will contain abbreviations not 
footnoted in the tables, figures, and listings.
Was added.
Change #5
Section 3.2.1.2 
Study periods, last bullet
!
Overall: Whole study duration 
Was changed to 
!
Overall: Whole study duration (start of 1st inpatient week through end of SFU).
Change #6
Section 4.2
Handling of dropouts or missing data
!
If the start date is completely unknown, then use the date and time of first dose.
Was changed to
!
If the start date is completely unknown and end date is unknown or not prior to first dose, 
then use the date and time of first dose.
!
If the start date is completely unknown and end date is known to be prior to first dose, then 
set start date equal to end date.
Change #7
Section 4.3 
Interim analyses and data monitoring
Was renamed as:
4.3.1 Safety Review Group
Change #8
Section 4.3.1 Safety Review Group
The SRG will remain blinded during the study unless emergent safety information requires 
unblinding of individual drug allocation for optimal assessment and response to AEs of concern.
Was changed to
The SRG will remain blinded through the first database lock (see Protocol; Section 12.3.3) 
unless emergent safety information requires unblinding of individual drug allocation for optimal 
assessment and response to AEs of concern. At the time of the first database lock, the Study 
Physician(s), clinical pharmacologist, DS representative, biostatistician, and other UCB 
personnel will be unblinded as to all subjects’ treatment allocation at the beginning of the 
Inpatient Period.
Change #9
Section 4.3.2 Blinded Interim Analysis
Was added.
Change #10
REDACTED 
data m
data m
COPY 
d date
d date
This document
perso
erso
Inp
Inp
ca
y
nnot
e
ment 
ment 
sician
sician
on
on
be
ll 
ergen
ergen
used 
rem
rem
to support 
w G
w 
linded 
inded
ual dru
ual dr
any 
Gro
Gr
marketing authorization 
i
monito
onito
application 
nown o
nown 
is kno
s kno
and any 
first 
first
extensions or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 55 of 62
Section 4.8  Examination of Subgroups 
Descriptive analysis will performed for subjects requiring dose reduction from study medication 
at any point during the study prior to the protocol-defined taper.  The following tables will be 
repeated for these subjects:
!
75%, 50% Responder Rate in Focal Seizure Frequency Summary
!
Incidence of TEAEs - Overview 
!
Incidence of TEAEs
Was added.
Change #11
Section 4.9 End of Study Analyses
Was added.
Change #12
Section 5.2 Protocol Deviations
A listing of all important protocol deviations identified at the database pre-lock meeting will be 
presented for all subjects in the SS, and will include the deviation type and description. The
number and percentage of subjects in the SS with important protocol deviations will be
summarized by period and overall if appropriate. The denominator for percentages will be the 
number of subjects in the SS.
Was changed to
A listing of all important protocol deviations identified at the database pre-lock meeting will be 
presented for all subjects in the FAS, and will include the deviation type and description. The 
number and percentage of subjects in the FAS with important protocol deviations will be 
summarized by period and overall if appropriate. The denominator for percentages will be the 
number of subjects in the FAS.
Change #13
Section 6.1 Demographics
Childbearing potential and lifestyle will be listed in separate listings
Lifestyle information (alcohol, tobacco, caffeinated beverage, and illicit drug use) will be listed 
and summarized by treatment group and for All Subjects.
Was changed to
Childbearing potential will be listed for the RS.
Lifestyle information (alcohol, tobacco, caffeinated beverage, and illicit drug use) will be listed 
and summarized by treatment group and for the RS.
Change #14
Section 6.2
Medical history and concomitant diseases
For this listing, concomitant is defined in Section 6.3 as for concomitant medications.
REDACTED
ate. T
ate. 
eviat
eviat
COPY
the d
the 
h impo
h impo
Th
Th
This document 
hil
Life
Lif
cannot 
hang
hang
ldbe
dbe
be
arize
arize
used
tenti
ent
rmatio
mati
d
to 
ra
tiaia
support 
aphic
phic
any 
all 
all
S.
marketing
tions 
ions 
an
and wi
d w
s in the
in the
l if a
if
authorization
ortan
rtan
he den
e den
i
application 
e datab
 data
deviatio
eviati
ant p
nt p
and any extensions or variations thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 56 of 62
Was added.
Change #15
Section 6.2.1 History of Epilepsy
Classification of epileptic syndrome
The number and percentage of subjects with each epileptic syndrome will be summarized for the
FAS based on the Classification of Epileptic Syndrome CRF. This summary will include the
number and percentage of subjects within the following categories: localization-related epilepsy;
idiopathic, symptomatic, and cryptogenic localization-related epilepsy; generalized epilepsy;
epilepsies undetermined whether focal or generalized including the sub-categories for both
generalized and focal seizures and without unequivocal generalized or focal seizures; and 
situation-related seizures.
Was removed.
Change #16
Section 6.3
Prior and concomitant medications
The medications will be classified as AEDs or non-AEDs in the CRF, and will be reviewed
during the DEM. Prior and concomitant non-AED medications will be listed for the SS by
treatment group and by WHODD Anatomical Main Group [Level 1], Therapeutic Subgroup
[Level 2], PT and reported term. This listing will be repeated for all AED medications.
Any non-coded terms will report Level 1 and Level 2 as UNCODED in the listing.
Prior medication definition
If a subject takes a medication between the Screening date and before the date of study drug
administration, this medication will be classified as ‘prior medication’. With this definition, any
medication recorded that has been taken for at least 1 day and has been stopped before the
Inpatient Period will be considered as prior.
Concomitant medication definition
Prior medication not stopped before the study drug administration date will be classified as
‘concomitant medication’. Medication will be labeled as ‘concomitant medication’ when the start
date is between the date (including the date) of study drug administration and the final study visit
or, in case of early termination, on the date of the subject’s last visit. With this definition, any
medication that has been taken for at least 1 day during the study period will be considered as
concomitant.
Was changed to
The medications will be classified as AEDs or non-AEDs based on coded terms.  The list of 
coded terms considered AEDs will be finalized prior to database lock and unblinding.  Prior and 
concomitant non-AED medications will be listed for the SS by treatment group and by WHODD
Anatomical Main Group [Level 1], Therapeutic Subgroup [Level 2], PT and reported term. This 
listing will be repeated for all AED medications.
Any non-coded terms will report Level 1 and Level 2 as UNCODED in the listing.
Prior medications include any medications that started prior to the date of first dose of study 
drug.   Concomitant medications are medications taken at least one day in common with the 
study medication dosing period. Medications may be both prior and concomitant. Past 
REDACTED
Lev
Lev
the Sc
he Sc
e clas
e clas
aken 
aken 
COPY
Grou
Gro
be rep
be re
vel
vel
This document 
onc
n
Ana
Ana
lili
cannot
dicat
ica
ed term
d term
com
com
be
ged 
ed 
titi
used 
d to
to
to 
be
support
includ
nclud
minatio
inati
een ta
een ta
any
for
for
edicat
dica
di
marketing
n for a
 for a
s prior.
 prior
n
re th
re t
authorization
peat
peat
2 as U
2 as 
creenin
reenin
ified
fied
application 
e CRF,
CRF
ons wil
ns wi
up [L
p [Lev
e
ated
ted
and any extensions
r bo
bo
es; an
es; an
or 
ps
psy
oth
oth
variations 
lepsy
epsy
sy;y;
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 57 of 62
medications are a subset of prior medications, and include prior medications with a stop date 
before the date of first study medication administration.  
Change #17
Section 6.3.2 Antiepileptic drugs
Since reason for discontinuation is collected as free text field, a medical review will be 
conducted prior to database lock and unblinding to combine like terms.  The combined terms 
only will be presented in the summary table.  Both the reported and combined terms will be 
listed.
Was added.
Change #18
Section 6.3.2 Antiepileptic drugs
Changes to Concomitant AEDs
All concomitant AEDs will be listed for subjects requiring a dose change to any concomitant 
AED during the study.  A change is defined as any of the following occurring after 
randomization through the end of the Outpatient Maintenance period:
!
Initiation of a new AED
!
Termination of an existing AED
!
Dose change for an existing AED (increase or decrease)
!
Change in frequency of an existing AED
Was added.
Change #19
Section 8.3 Analysis of Exploratory Efficacy Variables
Median seizure frequency by focal seizure type
An analysis of covariance (ANCOVA) will be performed on the log-transformed weekly seizure
frequency during the 2-week Inpatient Period. Specifically, ln(1+weekly seizure frequency
during the 2-week Inpatient Period) will be modeled with treatment group as factor and
ln(1+weekly seizure frequency during the Baseline Period) as covariate. Contrasts will be
estimated to compare UCB0942 to placebo results observed. Transformation of efficacy data
could be envisaged given the data distribution. This analysis will be repeated for all the subtypes
of focal seizures (Type IA1, IB, IC).
The seizure frequency for the focal seizures (Type IA1+ IB +IC) and focal seizure subtypes
(Type IA1, IB, IC) will also be summarized by treatment group and UCB0942 Overall for the
following study periods: Baseline, 1st Inpatient Week, 2nd Inpatient Week, 3rd Inpatient Week,
2-week Inpatient, Outpatient Maintenance Period, and On-UCB0942 Overall.
Change in seizure severity
The change in seizure severity is calculated as the change from Baseline in the percentage of
seizures that are type IC out of the total number of focal seizures. It will be listed and
summarized by treatment group for the 2-week Inpatient and Outpatient Maintenance Periods.
REDACTED 
(incre
incre
isting 
sting
COPY 
This document
(Ty
Typ
y
fol
fol
cannot 
env
en
al seiz
al sei
e seizu
seizu
be
o co
co
nvis
nvis
used 
k In
I
eizure
izure
omp
omp
to
e 2
Inpa
Inpa
support
by fo
y f
nce (AN
ce (A
2-wee
we
any
rato
rato
oc
marketing 
A
authorization 
ease o
ease o
AED
AED
application
chan
cha
wing o
wing o
ce peri
ce per
and 
ang
ang
any extensions or variations 
s 
e
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 58 of 62
Seizure severity questionnaire
Changes in SSQ will be summarized by treatment group for the Inpatient Period (V3, 4, 5), the
Outpatient Period (V10, 15) and for the Tapering and SFU periods (V15, 17, 18, 20) using
summary statistics.
Quality of life
The observed values, and changes from Baseline for the QOLIE-31-P total score and the
subscales will be listed for all subjects for visits 3, 10, 12, 15, 17. The prioritization item will be
listed separately.
The QOLIE-31-P change from Baseline will be summarized by treatment group using
descriptive statistics for visits 10, 12, 15, 17.
The QOLIE-31-P mean change from Baseline for the total score and the sub-scores will be
presented in line plots with 95% CIs for the whole study period.
Exploratory analyses for efficacy
Median 28-day seizure frequency by focal seizure type: An analysis of covariance (ANCOVA)
will be performed on the log-transformed weekly seizure frequency during the 2-week Inpatient
Period. Specifically, ln(1+weekly seizure frequency during the 2-week Inpatient Period) will be
modeled with treatment group as factor and ln(1+weekly seizure frequency during the Baseline
Period) as covariate. Contrasts will be estimated to compare UCB0942 to placebo results
observed. Transformation of efficacy data could be envisaged given the data distribution. This
analysis will be repeated for all the subtypes of focal seizures (Type IA1, IB, IC).
The seizure frequency for the focal seizures (Type IA1+ IB +IC) and focal seizure subtypes
(Type IA1, IB, IC) will also be summarized by treatment group and UCB0942 Overall for the
following study periods: Baseline, 1st Inpatient Week, 2nd Inpatient Week, 3rd Inpatient Week, 2-
week Inpatient, Outpatient Maintenance Period, and On-UCB0942 Overall.
Exploratory analysis will be performed on the seizure count and SSQ data collected during the
tapering and SFU periods. The focal seizure frequency will be summarized by treatment group
for the tapering and SFU periods.
The relationship between QOLIE-31-P parameters and efficacy parameters will be evaluated
graphically. Plots may include, but are not limited to, scatterplots of the QOLIE-31-P subscales
and total score versus the focal seizure reduction at the end of the Outpatient Maintenance
Period. This plot will be repeated for the 75%RR.
All video data recorded in the CRF will be listed.
Was changed to 
Median seizure frequency by focal seizure type
An analysis of covariance (ANCOVA) will be performed on the log-transformed weekly seizure 
frequency during the 2-week Inpatient Period. Specifically, ln(1+weekly seizure frequency 
during the 2-week Inpatient Period) will be modeled with treatment group as factor and 
ln(1+weekly seizure frequency during the Baseline Period) as covariate. Contrasts will be 
estimated to compare UCB0942 to placebo results observed. Transformation of efficacy data 
could be envisaged given the data distribution. This analysis will be repeated for all the subtypes 
of focal seizures (Type IA1, IB, IC, and disabling [IB+ IC]).
The seizure frequency for the focal seizures (Type IA1+ IB +IC) and focal seizure subtypes 
(Type IA1, IB, IC, and disabling [IB+ IC]) will also be summarized by treatment group and 
UCB0942 Overall for the following study periods: Baseline, 1st Inpatient Week, 2nd Inpatient 
REDACTED 
y tre
tre
y
ent W
ent W
Period
Period
d on t
d on 
l seiz
l seiz
COPY
l seiz
l sei
e IA1+
e IA1
reatm
eat
This document 
(1
(1
estim
estim
co
co
cannot
cy d
ng the
g the
1+we
+we
be
s of 
s of 
dur
dur
used
e frequ
frequ
se
c
to support
epeat
peat
in the
in th
any 
but
bu
l seiz
l seiz
ted
marketing
zure f
zure f
31-
1-P pa
P p
ut are
t ar
authorization 
+ I
tment 
ment 
Week, 2
eek, 2
d, and
d, and
he sei
he sei
f
application 
freq
eq
CB094
B0942
d given
d give
ures (T
res (T
IB +
B +
and
ek Inp
k In
quen
que
any 
arir
ng the
ng th
pa
extensions
will b
will b
rianc
anc
or variations 
e
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 59 of 62
Week, 3rd Inpatient Week, 2-week Inpatient, Outpatient Maintenance Period, and On-UCB0942 
Overall.
The mean 28-day adjusted seizure frequency by focal seizure subtype (Type IA1, IB, IC, and 
disabling [IB+ IC]) will be displayed graphically as stacked bar charts for the following study 
periods:  Baseline, 1st Inpatient Week, 2nd Inpatient Week, 3rd Inpatient Week, 2-week Inpatient,
Outpatient Maintenance Period, and On-UCB0942 Overall. This will also be presented by
subject.
The mean percent reduction in seizure frequency from baseline to each of the following study 
periods will be presented as a bar chart:  1st Inpatient Week, 2nd Inpatient Week, 3rd Inpatient 
Week, 2-week Inpatient, Outpatient Maintenance Period, and On-UCB0942 Overall.    This will 
also be presented by subject
Change in seizure severity
Seizure severity is calculated as the percentage of seizures that are type IC out of the total 
number of focal seizures during a given period. Change from Baseline in seizure severity is the 
seizure severity in the period of interest minus the seizure severity during the 2-week prospective 
baseline period. Seizure severity and its change from baseline will be listed and summarized by 
treatment group for the 2-week Inpatient and Outpatient Maintenance Periods.  For subjects not 
experiencing IC seizures during the observed period, severity is considered to be 0%.
Seizure severity questionnaire
Changes in SSQ will be summarized by treatment group for the Inpatient Period (V3, 4, 5), the 
Outpatient Period (V10, 15) and for the Tapering and SFU periods (V15, 17, 18, 20) using 
summary statistics.  Mean change from baseline in SSQ total and subscores will be presented 
graphically.
The SSQ total score (TS) is derived using the algorithm in Appendix x.
Quality of life
The observed values, and changes from Baseline for the QOLIE-31-P total score and the 
subscales will be listed for all subjects for visits 3, 10, 12, 15, 17. The prioritization item will be 
listed separately.
The QOLIE-31-P change from Baseline will be summarized by treatment group using
descriptive statistics for visits 10, 12, 15, 17. 
The QOLIE-31-P mean change from Baseline for the total score and the sub-scores will be 
presented in line plots with 95% Hodges-Lehmann CIs for the whole study period.
Exploratory analyses for efficacy
Median 28-day seizure frequency by focal seizure type: An analysis of covariance (ANCOVA) 
will be performed on the log-transformed weekly seizure frequency during the 2-week Inpatient 
Period. Specifically, ln(1+weekly seizure frequency during the 2-week Inpatient Period) will be 
modeled with treatment group as factor and ln(1+weekly seizure frequency during the Baseline 
Period) as covariate. Contrasts will be estimated to compare UCB0942 to placebo results 
observed. Transformation of efficacy data could be envisaged given the data distribution. This 
REDACTED 
atment
atment
Taperi
Taperi
m base
m base
COPY
, sev
, sev
This document
Med
Med
wi
wi
cannot
ed in
d in
lorato
orato
ca
be
E-31
31
n li
n l
used
istics
stics
1 P
to
han
han
support
han
a
or all s
r all s
ge
any 
nges 
nges 
marketing 
using t
using 
authorization 
t grou
grou
ing an
ng an
eline i
line i
application 
du
will be 
ill be
intenan
ntena
eritity is 
y is
and
e in 
e in 
urin
urin
any
C out
ou
sei
extensions
pa
.    Th
   T
or
atien
tien
variations 
udy
udy
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 60 of 62
analysis will be repeated for all the subtypes of focal seizures (Type IA1, IB, IC, and disabling 
[IB+ IC]).
The seizure frequency for the focal seizures (Type IA1+ IB +IC) and focal seizure subtypes 
(Type IA1, IB, IC, and disabling [IB+ IC]) will also be summarized by treatment group and 
UCB0942 Overall for the following study periods: Baseline, 1st Inpatient Week, 2nd Inpatient 
Week, 3rd Inpatient Week, 2-week Inpatient, Outpatient Maintenance Period, and On-UCB0942 
Overall.
Exploratory analysis will be performed on the seizure count and SSQ data collected during the 
tapering and SFU periods. The focal seizure frequency will be summarized by treatment group 
for the tapering and SFU periods. 
The relationship between QOLIE-31-P parameters and efficacy parameters will be evaluated 
graphically. Plots may include, but are not limited to, scatterplots of the QOLIE-31-P subscales 
and total score versus the focal seizure reduction at the end of the Outpatient Maintenance 
Period. This plot will be repeated for the 75%RR.
All video data recorded in the CRF will be listed.
Change #20
Section 10.2 Adverse Events
Adverse events will be recorded from the time informed consent is granted until study
completion or study termination. All AEs will be coded using the latest available version of 
MedDRA and will be categorized by intensity (mild/moderate/severe). 
Has changed to
Adverse events will be recorded from the time informed consent is granted until study 
completion or study termination (end of the SFU period). All AEs will be coded using the latest 
available version of MedDRA and will be categorized by intensity (mild/moderate/severe). 
Change #21
REDACTED
l be c
l be 
sitity (m
y (m
m th
m th
COPY 
nforme
forme
co
This document cannot be used to support any marketing
he tim
he tim
d of the
of th
d will b
will 
authorization
ed co
ed c
oded u
oded u
mild/m
mild/m
application 
on
and any
ent M
ent M
extensions 
nt
be ev
be ev
LIE
IE-3
-3
M
or
g
gro
gr
variations 
g the
 the
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 61 of 62
Section 10.4.2 Electrocardiograms
Formulas for QTcB and QTcF have been added.
Change #22
Section 10.4.3 Dopper Echocardiography
Doppler echocardiography results at Baseline and subsequent visits, and changes from baseline
will be listed and summarized by treatment group and period. All available echocardiography
data will be reported in the CSR and its addendum.
Has changed to
Doppler echocardiography abnormalities at Baseline and subsequent visits will be listed and 
summarized by treatment group and period. All available echocardiography data will be reported 
in the CSR and its addendum. 
Change #23
Appendix 13.4 SSQ Scoring Algorithm
Has been added.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions 
be list
e list
data w
ata w
or variations 
y
thereof. 


UCB
03 Jul 2015 
Statistical Analysis Plan
UCB0942
EP0069
Confidential
Page 62 of 62
STATISTICAL ANALYSIS PLAN SIGNATURE PAGE
This document has been reviewed and approved per the Review and Approval of Clinical 
Documents Standard Operating Procedures. Signatures indicate that the final version of the 
Statistical Analysis Plan (SAP) or amended SAP is released for execution.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


ELECTRONIC SIGNATURES
Signed by 
Meaning of Signature 
Server Approval Date 
(dd-mon-yyyy
(HH:mm))
(36$3$PHQGPHQW
&OLQLFDO$SSURYDO
2FW*07
&OLQLFDO$SSURYDO
2FW*07
REDACTED COPY 
DO
This document cannot be used to support any marketing authorization application and 
an
a
y
any 
erve
a y extensions or variations thereof.